ME T H O D S
IN
MO L E C U L A R BI O L O G Y
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For other titles published in this series, go to www.springer.com/series/7651
TM
Metabolic Profiling Methods and Protocols
Edited by
Thomas O. Metz Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
Editor Thomas O. Metz Pacific Northwest National Laboratory Biological Sciences Division P.O. Box 999, MS K8-98 Richland, WA 99352 USA
[email protected]
ISSN 1064-3745 ISBN 978-1-61737-984-0 DOI 10.1007/978-1-61737-985-7 Springer New York Dordrecht Heidelberg London © Springer Science+Business Media, LLC 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Preface After accepting the task to edit a volume of Methods in Molecular Biology devoted to metabolic profiling, I began to contemplate the definition of the term. Fiehn referred to “metabolic profiling” as the identification and quantification of a select number of metabolites in an entire metabolic pathway or intersecting pathways (1). Closely related disciplines were targeted metabolite analysis, metabolic fingerprinting, and metabolomics, the latter of which was defined as the quantitative measurement of perturbations in the metabolite complement of a biological system (2). These four terms are often used interchangeably; indeed, in reviewing the literature over the past 40 years, it is evident that these various disciplines of metabolite analysis are related via an evolution of methods and technology. For example, while the field of metabolomics is now 10 years old, the protocols and instrumentation that form the foundation for the myriad approaches of this discipline are based on those originally established for the diagnosis of inborn errors of metabolism and drug metabolite analysis. Thus, in compiling this volume, I have made an attempt to incorporate protocols that are illustrative of the evolution of metabolic profiling from single molecule analysis to global metabolome profiling. The constraints of this volume necessitate that its contents will be perspective based, rather than comprehensive. However, it is my hope that the methods contained herein will be a resource for both established and new investigators in the field of metabolic profiling. Thomas O. Metz
References 1. Fiehn, O. (2002) Metabolomics – the link between genotypes and phenotypes. Plant Mol Biol 48, 155–171.
metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181–1189.
2. Nicholson, J. K., Lindon, J. C., Holmes, E. (1999) ‘Metabonomics’: understanding the
v
Contents Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
v
Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ix
1.
Origins of Metabolic Profiling . . . . . . . . . . . . . . . . . . . . . . . . . . . Arthur B. Robinson and Noah E. Robinson
1
2.
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism . . . . . Monique Piraud, Séverine Ruet, Sylvie Boyer, Cécile Acquaviva, Pascale Clerc-Renaud, David Cheillan, and Christine Vianey-Saban
25
3.
Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . David S. Millington and Robert D. Stevens
55
Analysis of Organic Acids and Acylglycines for the Diagnosis of Related Inborn Errors of Metabolism by GC- and HPLC-MS . . . . . . . . . . . . . . Giancarlo la Marca and Cristiano Rizzo
73
4.
5.
HPLC Analysis for the Clinical–Biochemical Diagnosis of Inborn Errors of Metabolism of Purines and Pyrimidines . . . . . . . . . . . . . . . . . . . . Giuseppe Lazzarino, Angela Maria Amorini, Valentina Di Pietro, and Barbara Tavazzi
99
6.
Bile Acid Analysis in Various Biological Samples Using Ultra Performance Liquid Chromatography/Electrospray Ionization-Mass Spectrometry (UPLC/ESI-MS) . . . . . . . . . . . . . . . . . . . . . . . . . . 119 Masahito Hagio, Megumi Matsumoto, and Satoshi Ishizuka
7.
Analysis of Glycolytic Intermediates with Ion Chromatography- and Gas Chromatography-Mass Spectrometry . . . . . . . . . . . . . . . . . . . . . . . 131 Jan C. van Dam, Cor Ras, and Angela ten Pierick
8.
Analysis of the Citric Acid Cycle Intermediates Using Gas Chromatography-Mass Spectrometry . . . . . . . . . . . . . . . . . . . . . . . 147 Rajan S. Kombu, Henri Brunengraber, and Michelle A. Puchowicz
9.
Quantification of Pentose Phosphate Pathway (PPP) Metabolites by Liquid Chromatography-Mass Spectrometry (LC-MS) . . . . . . . . . . . . 159 Amber Jannasch, Miroslav Sedlak, and Jiri Adamec
10.
High-Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS)-Based Drug Metabolite Profiling . . . . . . . . . . . . . . . . . . 173 Ian D. Wilson
vii
viii
Contents
11.
Gas Chromatography-Mass Spectrometry (GC-MS)-Based Metabolomics . . . . 191 Antonia Garcia and Coral Barbas
12.
The Use of Two-Dimensional Gas Chromatography–Time-of-Flight Mass Spectrometry (GC×GC–TOF-MS) for Metabolomic Analysis of Polar Metabolites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205 Kimberly Ralston-Hooper, Amber Jannasch, Jiri Adamec, and Maria Sepúlveda
13.
LC-MS-Based Metabolomics . . . . . . . . . . . . . . . . . . . . . . . . . . . 213 Sunil Bajad and Vladimir Shulaev
14.
Capillary Electrophoresis–Electrospray Ionization-Mass Spectrometry (CE–ESI-MS)-Based Metabolomics . . . . . . . . . . . . . . . . . . . . . . . . 229 Philip Britz-McKibbin
15.
Liquid Chromatography-Mass Spectrometry (LC-MS)-Based Lipidomics for Studies of Body Fluids and Tissues . . . . . . . . . . . . . . . . . . . . . . 247 Heli Nygren, Tuulikki Seppänen-Laakso, Sandra Castillo, Tuulia Hyötyläinen, and Matej Orešiˇc
16.
Electrospray Ionization Tandem Mass Spectrometry (ESI-MS/MS)Based Shotgun Lipidomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259 Giorgis Isaac
17.
Processing and Analysis of GC/LC-MS-Based Metabolomics Data . . . . . . . . 277 Elizabeth Want and Perrine Masson
18.
Nuclear Magnetic Resonance (NMR)-Based Drug Metabolite Profiling . . . . . 299 Eva M. Lenz
19.
Nuclear Magnetic Resonance (NMR)-Based Metabolomics . . . . . . . . . . . . 321 Hector C. Keun and Toby J. Athersuch
20.
Slow Magic Angle Sample Spinning: A Non- or Minimally Invasive Method for High-Resolution 1 H Nuclear Magnetic Resonance (NMR) Metabolic Profiling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335 Jian Zhi Hu
21.
Processing and Modeling of Nuclear Magnetic Resonance (NMR) Metabolic Profiles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 365 Timothy M.D. Ebbels, John C. Lindon, and Muireann Coen
Subject Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389
Contributors CÉCILE ACQUAVIVA • Laboratoire des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Hospices Civils de Lyon, Centre de Biologie Est, Bron, France JIRI ADAMEC • Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA ANGELA MARIA AMORINI • Institute of Biochemistry and Clinical Biochemistry, Catholic University of Rome, Rome, Italy TOBY J. ATHERSUCH • Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, South Kensington, London, UK SUNIL BAJAD • Sutro Biopharma Inc., South San Francisco, CA, USA CORAL BARBAS • Faculty of Pharmacy, San Pablo-CEU, Campus Monteprincipe, Madrid, Spain SYLVIE BOYER • Laboratoire des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Hospices Civils de Lyon, Centre de Biologie Est, Bron, France PHILIP BRITZ-MCKIBBIN • Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada HENRI BRUNENGRABER • Department of Nutrition, Mouse Metabolic Phenotyping Center, Case Western Reserve University, Cleveland, OH, USA SANDRA CASTILLO • VTT Technical Research Centre of Finland, Espoo, Finland DAVID CHEILLAN • Laboratoire des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Hospices Civils de Lyon, Centre de Biologie Est, Bron, France PASCALE CLERC-RENAUD • Laboratoire des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Hospices Civils de Lyon, Centre de Biologie Est, Bron, France MUIREANN COEN • Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK VALENTINA DI PIETRO • Institute of Biochemistry and Clinical Biochemistry, Catholic University of Rome, Rome, Italy TIMOTHY M.D. EBBELS • Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK ANTONIA GARCIA • Faculty of Pharmacy, San Pablo-CEU, Campus Monteprincipe, Madrid, Spain MASAHITO HAGIO • Division of Applied Bioscience, Research Faculty of Agriculture, Hokkaido University, Sapporo, Japan JIAN ZHI HU • Pacific Northwest National Laboratory, Richland, WA, USA TUULIA HYÖTYLÄINEN • VTT Technical Research Centre of Finland, Espoo, Finland GIORGIS ISAAC • Bio Separation and Mass Spectrometry, Pacific Northwest National Laboratory, Richland, WA, USA; Water corporation, Mulford, MA SATOSHI ISHIZUKA • Division of Applied Bioscience, Research Faculty of Agriculture, Hokkaido University, Sapporo, Japan AMBER JANNASCH • Bindley Bioscience Center, Purdue University, West Lafayette, IN, USA HECTOR C. KEUN • Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, South Kensington, London, UK
ix
x
Contributors
RAJAN S. KOMBU • Department of Nutrition, Mouse Metabolic Phenotyping Center, Case Western Reserve University, Cleveland, OH, USA GIUSEPPE LAZZARINO • Division of Biochemistry and Molecular Biology, Department of Chemical Sciences, University of Catania, Catania, Italy EVA M. LENZ • AstraZeneca Pharmaceuticals, Mereside, Macclesfield, UK JOHN C. LINDON • Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK GIANCARLO LA MARCA • Mass Spectrometry, Clinical Chemistry and Pharmacology Laboratory, Department of Pharmacology, University of Florence, Meyer Children’s Hospital, Florence, Italy PERRINE MASSON • Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK MEGUMI MATSUMOTO • Meiji Dairies Research Chair, Creative Research Institution Sousei (CRIS), Hokkaido University, Sapporo, Japan D AVID S. MILLINGTON • DUMC Biochemical Genetics Laboratory, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA HELI NYGREN • VTT Technical Research Centre of Finland, Espoo, Finland MATEJ OREŠI Cˇ • VTT Technical Research Centre of Finland, Espoo, Finland MONIQUE P IRAUD • Laboratoire des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Hospices Civils de Lyon, Centre de Biologie Est, Bron, France MICHELLE A. PUCHOWICZ • Department of Nutrition, Mouse Metabolic Phenotyping Center, Case Western Reserve University, Cleveland, OH, USA K IMBERLY RALSTON-HOOPER • Ecosystem Research Division, National Research Council Post-Doctoral Fellow, United States Environmental Protection Agency, Athens, GA, USA COR RAS • Department of Biotechnology, Delft University of Technology, Delft, The Netherlands CRISTIANO RIZZO • Metabolic Unit and Laboratories, Bambino Gesù Children’s Hospital, Rome, Italy ARTHUR B. ROBINSON • Oregon Institute of Science and Medicine, Oregon, OR, USA NOAH E. ROBINSON • Oregon Institute of Science and Medicine, Oregon, OR, USA SÉVERINE RUET • Laboratoire des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Hospices Civils de Lyon, Centre de Biologie Est, Bron, France MIROSLAV SEDLAK • Laboratory of Renewable Resources Engineering, Purdue University, West Lafayette, IN, USA; Department of Agricultural and Biological Engineering, Purdue University, West Lafayette, IN, USA TUULIKKI SEPPÄNEN-L AAKSO • VTT Technical Research Centre of Finland, Espoo, Finland M ARIA SEPÚLVEDA • Department of Natural Resources, Purdue University, West Lafayette, IN, USA VLADIMIR SHULAEV • Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA ROBERT D. STEVENS • Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC, USA BARBARA TAVAZZI • Institute of Biochemistry and Clinical Biochemistry, Catholic University of Rome, Rome, Italy
Contributors
xi
ANGELA TEN PIERICK • Department of Biotechnology, Delft University of Technology, Delft, The Netherlands JAN C. VAN DAM • Department of Biotechnology, Delft University of Technology, Delft, The Netherlands CHRISTINE VIANEY-SABAN • Laboratoire des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Hospices Civils de Lyon, Centre de Biologie Est, Bron, France ELIZABETH WANT • Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK IAN D. WILSON • AstraZeneca, Macclesfield, UK
Chapter 1 Origins of Metabolic Profiling Arthur B. Robinson and Noah E. Robinson Abstract Quantitative metabolic profiling originated as a 10-year project carried out between 1968 and 1978 in California. It was hypothesized and then demonstrated that quantitative analysis of a large number of metabolites – selected by analytical convenience and evaluated by computerized pattern recognition – could serve as a useful method for the quantitative measurement of human health. Using chromatographic and mass spectrometric methods to measure between 50 and 200 metabolites in more than 15,000 human specimens, statistically significant and diagnostically useful profiles for several human diseases and for other systematic variables including age, diet, fasting, sex, and other variables were demonstrated. It was also shown that genetically distinct metabolic profiles for each individual are present in both newborn infants and adults. In the course of this work, the many practical and conceptual problems involved in sampling, analysis, evaluation of results, and medical use of quantitative metabolic profiling were considered and, for the most part, solved. This article is an account of that research project. Key words: Metabolic profiling, metabolomics, urine, breath, chromatography, mass spectrometry, aging, diagnostic medicine, preventive medicine.
1. Introduction Since the dawn of the age of modern chemistry, biochemistry has been of great interest. When molecular structure became established as an exact discipline, the minds of scientists naturally turned toward those molecules of which they themselves are made. Extensive cataloging and structure determination of these substances followed. As the role of proteins in catalyzing the chemical reactions of metabolism was revealed, progress was made in understanding the metabolites – the smaller molecules required for life that protein
T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_1, © Springer Science+Business Media, LLC 2011
1
2
Robinson and Robinson
catalysts select from the many atomic combinations available and produce to make life possible. Detailed understanding of metabolism was not, however, possible until the discovery of carbon 14 (1) and the development of tracer methodology (2), which now includes both radioactive and stable isotopes. When it became possible to label the atoms of metabolites and trace their paths through living systems, a thorough understanding of metabolism was achievable. This understanding and the rapid advance of protein chemistry then led to explanations for some of the simplest metabolic diseases – genetic errors that cause well-defined inborn errors of metabolism. As analytical technology advanced, the list of known genetic illnesses expanded to include a large number of such diseases which, while individually rare, together cause much suffering. This work was further accelerated by findings that, in some cases such as phenylketonuria, understanding of the disease could lead to effective therapy. Simultaneously, improvements in analytical chemistry led to a search for single metabolites that are diagnostic of more prevalent diseases – including those with non-genetic components. An extensive armament of single-substance measurements entered the inventory of clinical laboratories – tests for both inborn errors and other illnesses. Businesses arose to measure these substances, primarily in blood and urine, which have now grown in the United States alone into a $100 billion industry. This work usually involved the correlation of one substance with a condition of interest in human health. Scientists searched for metabolites and proteins, the quantities of which contained sufficient information about health and disease to warrant their measurement. A few such measurements became standard in health screening of ordinary patients, while a much larger number were made available in clinical laboratories, available upon request by physicians for specific patients. While the many substances measureable in human samples were increasingly evident as analytical methods improved, no practical efforts were made to test the possibility that the simultaneous quantitative analysis of large numbers of metabolites followed by computerized pattern recognition could yield health information of significant value. Forty years ago, however, there arose in California an experimental project with the potential to cause a paradigm shift toward the use of simultaneous measurement of large numbers of metabolites for the quantitative measurement of human health. This effort was ahead of its time and, therefore, faced daunting challenges in the construction of analytical and computational capabilities. This work was known in the 1970s as “quantitative metabolic profiling.” It is now a growing part of “metabolomics.” While
Origins of Metabolic Profiling
3
metabolomics still contains substantial single-substance components, extraordinary advances in analytical and computational technology are rapidly moving this field toward metabolic profiling – a continuation of that 1970s’ effort with greatly superior modern analytical equipment and computers. The California work was funded by private donors, NIH grants, and the personal savings of some of the scientists themselves. This effort proved the enormous analytical power of metabolic profiling as applied to human tissues and developed new analytical and computational tools. It had its origin in a collaboration beginning in 1968 between Linus Pauling and Art Robinson at the University of California at San Diego (UCSD). Later, it continued at Stanford University and the Institute of Orthomolecular Medicine (later renamed the Linus Pauling Institute of Science and Medicine), which Pauling and Robinson cofounded in Menlo Park, California, in 1973.
2. Orthomolecular Psychiatry
Pauling hypothesized (3) that the distribution functions of optimum human nutritional requirements are very wide, leading to nutritional deficiencies and illness, especially mental illness, in many people. He invented the term “orthomolecular psychiatry” – meaning right molecule in the right amount for mental health – to designate the treatment of mental illness by means of megavitamin therapy. Later this was designated “orthomolecular medicine” to include treatment of other illnesses in a similar way. Having worked together at Caltech in 1962–1963 on the chemical basis of general anesthesia (4), both Pauling and Robinson were faculty members at UCSD when Pauling made this proposal. At the time, Pauling was developing a theory of the structure of the atomic nucleus, and Robinson and his students were studying the deamidation of asparginyl and glutaminyl residues in peptides and proteins. In addition to this ongoing work, in 1968 the two men began a collaboration to test Pauling’s ideas about orthomolecular psychiatry, with Robinson directing the experimental work and Pauling extending the theoretical aspects, which led eventually to his widely known hypotheses concerning the role of vitamin C in health and disease. Pauling initially proposed an experimental program using vitamin-loading tests, in which large doses of vitamins were given to experimental subjects – those having mental illnesses and control subjects – and the urinary excretion of the vitamins measured. It was postulated that those individuals with greater needs for the substances would retain more, excreting lesser amounts in
4
Robinson and Robinson
their urine. Robinson assembled a small research group and set up a laboratory for this purpose, while continuing to direct his own laboratory – the size of which was increased by UCSD to accommodate the new work. The initial experiments emphasized loading tests with ascorbic acid, niacin, and pyridoxine, and some interesting results were obtained. It soon became evident, however, that this approach was of less value than hoped. The experiments gave very limited information, and the necessary analytical procedures of that day were laborious, time consuming, and expensive, which diminished their practical value.
3. Origin of the Profiling Hypothesis
4. Scientists Who Tested the Hypothesis
In the course of this work, Robinson utilized a method for measurement of pyridoxine in chemically derivatized urine by means of packed-column gas chromatography, which involved resolution of the pyridoxine peak from the large number of metabolic products that are present in urine. During these experiments, Robinson began to think that the information they needed might be more readily available in the many metabolic constituents evident in the chromatograms rather than in the pyridoxine peak itself. He reasoned as follows. The fundamental need was for a method to measure health vs. the amounts of ingested nutrients, as is illustrated in Fig. 1.1. This required, however, a means of measuring metabolic health quantitatively. He hypothesized that the needed values might be obtained by measuring the amounts of a large sampling of urinary metabolites and statistically correlating the patterns in these profiles with various states of human health and disease. Robinson, therefore, initiated an experimental program, with Pauling’s support, to test the hypothesis that quantitative metabolic profiles contained sufficient information for this purpose. As this work progressed, he assembled a skilled group of co-workers for this project.
These included Roy Teranishi, Dick Mon, and Robert Flath – highly skilled experts in gas chromatography; Martin Turner and Carl Boehme – engineers who built and maintained the PDP-11 vintage computer hardware used for lab automation and data collection; Laurelee Robinson – who wrote the computer software
Origins of Metabolic Profiling
5
Fig. 1.1. Diagrammatic representation of the nutritional problem that led to the development of metabolic profiling. The goal was to measure health as a function of nutrition quantitatively for (a) a single individual and (b) groups of individuals. It was hypothesized – and then demonstrated – that quantitative analyses of a large set of easily measurable metabolites contained sufficient information to determine the numbers needed for the vertical axis in (a) and that the same set could be used for a wide variety of human conditions. Reprinted with permission from the Proceedings of the 8th Annual Conference of the National Society for Autistic Children (15).
used for lab automation, data calculation, and profile evaluation; Fred Westall – Salk Institute chemist who provided samples for multiple sclerosis, muscular dystrophy, and Huntington’s disease work and helped organize the sample bank project; Bill Aberth – physicist who built the molecular ion mass spectrometers; Robert Melville – National Institutes of Health Administrator who arranged for and supervised the NIH support; glassblower Paul
6
Robinson and Robinson
Yeager; chemists Henri Dirren, Kent Matsumoto, and Lowell Brenneman; and biochemist Milton Winitz – who invented the synthetic diet Vivonex 100 and supplied it to the project in large quantities without charge, making possible the diet control studies. These people were aided by several technicians, including Sue Oxley, Maida Bergeson, Janet Tussey, Betsy Dore, Mark Weiss, and Walter Reynolds. Additionally helped by their own students and former students, Pauling’s – John Cheronis and Ian Keaveny – and Robinson’s – Fred Westall, Paul Cary, David Partridge, and Alan Sheets – and by other colleagues from UCSD, Stanford, Kaiser Permanente, and other institutions, a remarkable laboratory was built. Human samples were obtained from many institutions and physicians, including especially Drs. John Mann and George Ellison. Key to the laboratory’s success – from its completely automated, custom-made analytical equipment to its advanced computerized fund-raising systems (donations were obtained from more than 50,000 private individuals) – were four PDP-11 computer systems, utilizing machine language and Fortran programs that Art Robinson’s chemist and systems programmer wife Laurelee wrote in the 8-year period between 1971 and 1978. This group of people gradually built the finest physiological fluid analysis laboratory of its time – fully automated and designed for analysis of large numbers of samples. Ultimately, this laboratory measured, during a period of 8 years, more than 15,000 metabolic profiles – each profile including quantitative measurement of between 50 and 200 substances, primarily in human urine.
5. Accomplishments of the 10-Year Project
Most of the analytical work was by automated gas and ion exchange chromatography, with molecular ion mass spectrometry added during the later years and fragmentation mass spectrometry used for chemical characterizations of chromatographically resolved constituents. The early gas chromatographic work utilized 6-ft-long packed columns. These were replaced by 1000ft-long open-bore stainless steel columns, which were used for analysis of urine vapor and breath. The ion exchange system utilized the ninhydrin-positive physiological fluid analytical procedures developed by Dionex, with added PDP-11 automation. The identification work was carried out with a Finnegan gas chromatograph–fragmentation analysis mass spectrometer.
Origins of Metabolic Profiling
7
Between its beginning in 1969 and the end of the work in 1978, this research effort definitively showed the advantages of metabolic profiling – demonstrating unique statistically significant metabolic profiles for aging, multiple sclerosis, Duchenne dystrophy, Huntington’s disease, breast cancer, fasting, sex, diurnal variation, and chemical birth control use. The numbers of correlating metabolites found in these profiles ranged between 10 and 60, depending upon analytical technique and sample type (5–24). Reference 5 provides a review of much of this work, and References 25 and 26 provide more recent perspective. They also demonstrated, in experiments on 1,000 newborn infants, that the ninhydrin-positive metabolites in human urine are not unimodally distributed at birth. About half of these compounds are bimodally and trimodally distributed, apparently reflecting distinct genetic variations. In addition, they showed that the urinary profiles of adult humans are individually unique so that people can be identified by their urinary profiles just as with fingerprints. In experiments on themselves, they discovered the simplification of urinary profiles that occurs with strict chemical diet control but additionally showed that useful metabolic profiles can be obtained in most instances without diet control. Also demonstrated were metabolic profiles for physiological age in fruit flies (22), mice (21), and men (25), with the finding that about one-third of the metabolites in human urine are age correlated. This discovery opened the way toward quantitative evaluation of dietary and other measures that may decrease the degenerative diseases of aging. Some human conditions show no profiles. For example, their experiments on Stanford students failed to find a urinary metabolic pattern correlating with grade point average (5) – a useful comparison to the patterns that were found in other groups. The work of these scientists and engineers included the following: 1. Building the first fully automated metabolic profiling laboratory. Using PDP-11 computer technology, all of the chromatography and the later molecular ion mass spectrometry equipment that they built were entirely computer controlled and all of the data produced were computer collected and analyzed with very little manual intervention. 2. Building the first chromatographic breath and urine vapor metabolic analyzer (9). This machine contained four 1000ft-long stainless steel open-bore capillary columns. Each column was capable of resolution and quantitative analysis of about 200 volatile substances in a urine or a breath sample with a 6-h cycle time. In routine operation, it could analyze 16 samples per day.
8
Robinson and Robinson
3. The conceptual development and computerized implementation of mathematical tools that produced baselinecorrected integration of the chromatograms; corrected for chromatographic drift and automatically matched all metabolites within sets of chromatograms; normalized the experimental values to correct for variable physiological dilution and other systematic variables; computed nonparametric probabilities of significance for all metabolites in an experiment; corrected these probabilities for random correlation; tabulated and plotted cumulative probability distribution functions to determine the numbers of significant correlating substances; and, by means of a conceptually unique method (13, 25), computed the “diagnostic power” of any discovered metabolic pattern. 4. Origination and implementation of the concept of metabolic profiling by means of molecular ion mass spectrometric separation and quantitative analysis, without prior sample preparation or subdivision. This was done before the invention of the electrospray or laser ionization methods commonly in use today. In 1971, Stanford Research Institute experimental physicists William Aberth and Cap Spindt suggested a new way of producing ions for mass spectrometry without fragmentation, which made use of an array of hollow volcano-shaped structures with a grid registered above it, and Robinson suggested that this be used as a profiling device. With the help of Robert Melville at NIH, Aberth, Robinson, and Pauling received funding to build this device. Aberth ultimately built two such mass spectrometers – one at SRI with this NIH funding and one, later, at the Institute of Orthomolecular Medicine, with the second machine fully automated by Walter Reynolds, Carl Boehme, and Laurelee Robinson. These spectrometers had an initial resolution of 1 mass unit, with a design potential of 0.1 mass units in the mass range from about 50 to 1000. 5. Use of metabolic profiling in urine, breath, and cultured human cells. Similar profiling techniques can, of course, be applied to blood, saliva, and other sources of metabolites. The cultured cell work was undertaken to test the hypothesis that cell cultures from single individuals, monitored by metabolic profiles, might serve as individualized experimental systems in which therapeutic procedures for single individuals such as dietary requirements could be tested.
Origins of Metabolic Profiling
6. Goals and Requirements for Quantitative Metabolic Profiling
9
While the advance of technology during the past 30 years now makes a wonderful amount of fundamental biochemical knowledge available through metabolic profiling, these early workers were motivated almost entirely by a practical, empirical goal – in Robinson’s words, “improvement of the quality, length, and quantity of human life,” or, in Pauling’s, “diminution of the amount of human suffering.” Figure 1.2 summarizes these goals. In order to achieve these objectives, practical empirical metabolic profiling requires several things: 1. Suitable reproducible, quantitative, and low-cost analytical methods. 2. Control and experimental sample sets for test and calibration that are sufficiently free of uncontrolled systematic variables to allow reliable characterization of the differences under consideration. 3. Computerized mathematical methods that allow objective evaluation of the experimental results, without, through unnecessary complexity, separating the experimenters and their scientific intuitions from their data and results. During the 10-year duration of this project, these three problems were successfully addressed. The emphasis of the single-substance-orientated clinical chemistry industry of the 1970s was then, as it is today, primarily upon diagnosis of overt disease by technologically obsolete methods. Physicians are offered the amounts of single substances in human samples and comparisons with so-called normal values, typically two-standard-deviation ranges for the general population. Measurements of a couple of dozen such substances are included in ordinary analyses, and single substances beyond the normal range are noted and considered in patient evaluation. A large suite of additional single-substance measurements is available in industrial laboratories, which the physician can order to extend or confirm his diagnosis. This paradigm is expensive, so the number of substances measured is low and the application is limited to patients already exhibiting disease symptoms. Moreover, it entirely misses the metabolic patterns available from groups of substances that have values within the normal ranges – patterns that require computer analysis to discover. Quantitative metabolic profiling of analytically convenient metabolites allows a single analytical procedure, measuring a single large set of metabolites, to diagnose essentially all disease
10
Robinson and Robinson
Fig. 1.2. The primary health goal of “metabolic profiling” or, now, “metabolomics.” The gradually sloping curve of human survival, beginning to decrease at early ages, represents great amounts of suffering and lost years of human life, as illustrated here by the lifespan distribution of men in the United States in 1974 (a). The first goal of metabolomics should be the “squaring” of this curve (b) so that most people live a long, disease-free life during their intrinsic lifespan of about 90 years. A second goal should be extension of the healthful human lifespan (c). Reprinted with permission from (23).
Origins of Metabolic Profiling
11
conditions with one inexpensive procedure. Moreover, by including computerized pattern recognition, metabolic profiling extracts far more complete and valuable medical information than does the traditional method. The low cost and much greater information content of metabolic profiling permits its use in preventive medicine, allowing the individual to combat the probability of disease rather than overt disease itself. It also provides a convenient and inexpensive means of quantitative measurement of illness so that therapeutic procedures can be evaluated in real time – a capability almost entirely absent from current therapeutic medicine. Moreover, the finding that physiological age can be quantitatively measured by metabolic profiling opens the way toward the conduct of objective research for the evaluation of the effects of various adjustable nutritional and other parameters on aging and, when refined in the future, will allow single individuals to monitor their own rate of aging and probabilities of disease as a function of time and their own habits. The low cost and therefore increased availability of health evaluation that metabolic profiling makes possible can save the lives of many people that are now lost because current methods – imbedded in an expensive, inconvenient health system and providing inferior information – fail to diagnose their illnesses in time. “Health” is a concept that varies with individual objectives. Optimum health means different things to an athlete, to an artist, to a mathematician, or to a soldier. Each seeks to optimize different aspects of his abilities. The quantitative measurement of health that quantitative health profiling should eventually make possible will allow each person to optimize those abilities that he considers most valuable. It was these possibilities and other similar objectives that motivated Art Robinson and his colleagues in the 1970s to develop the techniques of quantitative metabolic profiling.
7. Analytical Methods Requirement 1, the choice of analytical methods is simplified by the fact that the many substances in a living metabolism are interlinked in synthesis and function, with each substance providing information about some of the others. When a large subset of these substances are quantitatively analyzed, the metabolites measured can be chosen by analytical convenience and economy rather than maximum information content per metabolite. Instead of seeking, as had been historically customary, one or two
12
Robinson and Robinson
high-information-content substances that are diagnostic of a disease or useful for some other practical health purpose, metabolic profiling combines the information in a large number of substances with lesser information content per substance. The profiler asks, “How many metabolic substances can be measured for a practical cost?” instead of “How can a single diagnostic substance be found?” This markedly reduces overall cost, an especially important goal for preventive medicine. A single cost-selected multi-substance profile is much less expensive than separate analyses of hundreds of singly selected substances. Thus, the same set of substances – between 50 and 200 during the original work in the 1970s and potentially thousands with current technology – can be used for many purposes, such as diagnosing disease, monitoring disease therapy, measuring optimum health as a function of diet, and other health goals. Quantitative measurement of a large number of metabolic substances, appropriate normalization, and computerized pattern recognition combine to make many new things possible. For example, quantitative measurement of individual human physiological age allows the graphing of physiological age vs. time. With this capability, the effect on physiological age of diet, exercise, and other adjustable parameters can be objectively monitored – both for groups and for single individuals. In the case of disease, metabolic profiling makes possible the quantitative measurement of the probability of a specific illness by comparing the profile of an individual with that of diseased individuals and those who will later become ill. During disease therapy, an individual can be measured as he moves along this probability axis, allowing the objective evaluation of therapy. Moreover, assessment of disease probabilities rather than overt symptoms opens the option of fighting the probability of disease rather than disease itself. While these and other similar health goals have become a part of our custom and culture, they have remained largely in the realm of qualitative discussion and guesswork, without the benefit of objective science and technology. The reason for this has been the lack of a means for measuring health quantitatively. Metabolic profiling provides this means. In the 1970s, chromatography was a slow but inexpensive method, while mass spectrometry was fast but expensive. Chromatography linked to mass spectrometry was, therefore, slow and expensive. Robinson imposed a condition upon the analytical methods chosen by that research group that no profiling tool would be used that could not, in industrial application, be offered to the general public at a cost of $5–$10 or less. This was necessary to the health goals of the project and is still a useful limitation.
Origins of Metabolic Profiling
13
8. Sampling Requirement 2, sampling has always been and still remains the weak link in the development of metabolic profiling. Even the simplest experiment – comparison of profiles of individuals known to be sick with a specific illness to those of well individuals – suffers from the danger of systematic error. There is always a possibility that the two groups also differ in ways not fundamental to the illness such as lifestyle, diet, therapeutic drugs, and other factors – differences that may exhibit profiles that are mistaken for those of interest. Moreover, comparison of profiles of individuals to those of groups of other individuals markedly decreases the information content of the profiles because it introduces biological variation into the observations. Longitudinal measurements wherein an individual serves as his own control and differences in his own profile with time are measured with reference to known population profiles contain far more information. Metabolic profiling – as a result of the enormous amount of information that it makes available – provides, for the first time, an objective means of fighting the probability of disease rather than disease itself. By reducing the data to a linear probability axis extending between sick and well, the probability of illness can be measured and the individual’s position on the axis determined – and moved empirically toward the well end of the axis by means of preventive measures before disease symptoms are evident. This cannot be done, however, unless the techniques can be calibrated by means of longitudinal samples obtained from people before they became ill. Realizing this need for sample sets from people that include serial samples from the same individuals before illness was evident, Robinson, Westall, and Pauling, in collaboration with colleagues at Kaiser Permanente, proposed in 1976 that a sample bank be created in which blood and urine samples were collected at 6-month intervals from 50,000 people in ordinary health and stored at –80◦ C. After 5 years, with current disease incidences, this bank would have provided statistically significant prospective sample sets for all diseases with incidences equal to or greater than multiple sclerosis. If collection continued beyond 5 years, suitable sample sets from more rare conditions would be available. Kaiser Permanente agreed to pay the costs of this project if their contribution were matched by $5 million from the National Institutes of Health. After 2 years of lobbying by Robinson, NIH decided in 1978 to fund an initial project with 10,000 subjects, with the possibility of later expansion to 50,000. Unfortunately, just after
14
Robinson and Robinson
this approval, work on profiling at the Pauling Institute collapsed, so this sample bank was not built. The sampling problem is today still the greatest impediment to progress in metabolomics. This sample bank should be built – with urine, breath, saliva, blood, and culturable human tissue collected from at least 100,000 ordinary people at regular intervals and stored at –80◦ C. After a few years, with such a bank in hand, a great increase in progress in the application of metabolic profiling for the improvement of human health would become possible.
9. Computation Requirement 3, computation was more difficult with the PDP11s of the 1970s, which were primitive computers by today’s standards. They were slow, expensive, and required continual repair. They were, however, a great advance over the mainframe computer systems that then existed at most research centers. The PDP-11s permitted dedicated computer systems for specific purposes, and they were not subject to the frequent outages and other limitations that rendered institutional mainframe systems unsuitable for metabolic profiling work. For real-time automation and data collection, the PDP-11s required programming in machine language in order to meet time requirements. For data analysis, Fortran programming was sufficient because time was not a constraint. Most of the multivariate computational methods in use today were available in the 1970s. These, however, proved less than ideal for the profiling work. First, although designed to give attractive displays such as pseudo two-dimensional plots of metabolically similar groupings, the outputs of these systems did not lend themselves to practical, medically useful decision making. Second, especially during research and development, computer procedures that move beyond the intuition of the experimentalists pose great risks of error. The danger of false positives in profile detection through the use of too many adjustable parameters, improper, uncorrected statistical analysis, introduction of systematic errors, and other factors must always be avoided – avoidance that becomes more difficult if “trust” is placed in computer calculations that are beyond checking by simple manual methods or mental calculations. Since there is a large amount of data to be collected and much repetitive calculation required, computers are essential for metabolic work, but they must not be allowed to become experimental variables in the research itself. For this reason, Laurelee and Art Robinson developed specialized
Origins of Metabolic Profiling
15
calculation procedures for this work (Fig. 1.3). These included the following: 1. Fully automatic baseline fitting, integration, and peak matching software to extract the necessary data from the chromatograms. While today, online mass spectrometry can do this, in the 1970s, automatic peak matching in highresolution chromatograms was an especially difficult problem, which they successfully solved. 2. After normalization to weighted averages of the measured values – a procedure they introduced to eliminate systematic errors that affect all of the values such as urine volume – probabilities of correlation with the phenomenon under study were calculated for each metabolite with nonparametric statistics. Since the distribution functions of most metabolites are not Gaussian and many are multi-modally distributed, parametric statistics is unsuitable. So, a method based on modified Wilcoxon statistics was employed. Cumulative distribution functions of these probabilities were then constructed to correct for random correlations and to test for the existence of metabolic profiles in the experiments, as illustrated in Fig. 1.4. 3. After measuring a set of n substances that correlate with a condition of interest, the values from this set were compressed to one dimension because most actions that would be based upon the analysis – for example, medical therapy – are one dimensional. So, simple mathematical means for making this compression were devised as diagrammatically represented in Fig. 1.5. 4. Since experiments to discover metabolic profiles do not inherently contain information about how these profiles will be used, a general method for evaluating profile strength is also needed. In medical practice, the detection of a deadly disease that will be treated by a safe therapy requires that false positives be risked at the expense of avoiding false negatives. Conversely, a mild disease with a relatively dangerous therapy requires the opposite bias. These and other similar interpretive biases are not, however, inherently a part of a metabolic profile. Therefore, a pattern strength methodology was invented, which averages all possible uses, as illustrated in Fig. 1.6. With the correlation indices of individual subjects for the n correlating metabolites compressed on a linear axis extending between the averaged profiles for the two groups being compared, that axis is divided at all possible points and the results graphed as shown. If no diagnostic power is present in the profiles, the values will lie along the diagonal line. If the diagnostic power of the metabolic profile is perfect, the values comprise
16
Robinson and Robinson
Fig. 1.3. The highest resolution metabolic profiler utilized in the 1970s (a). In 6 h, this device performed completely automated quantitative measurement of about 200 volatile compounds (b) in four different urine or breath samples. The equipment was completely automated with PDP-11 computers. All data analysis was also automated in another PDP-11 system, pictured here with Laurelee Robinson, who wrote the software for the 10-year project. Laurelee died in 1988 at the age of 43 – a death that could have been prevented had the metabolic profiling that she helped to develop been in routine medical use. Personal photographs – Art Robinson.
Origins of Metabolic Profiling
17
Fig. 1.4. Cumulative distribution functions of nonparametric probabilities of correlation. In this example of 72 ninhydrin-positive urinary metabolites as a function of sex in 71 male and 77 female Stanford students (a), the diagonal line corrects for random correlation. About 30 of the 72 substances correlate with sex, as is shown by deviation from the diagonal line of random correlation. A similar experiment with 57 male Stanford students (b) shows that, since no profile is present for grade point average, the measured values fall along the diagonal line. Alternatively, a tabular presentation of number of substances below each probability vs. the number expected below that probability can be used. Reprinted with permission from Clinical Chemistry (5). In ordinary singlesubstance clinical chemistry, it is more difficult to rigorously evaluate the significance of a reported correlation because there is no suitable way to correct for the unknown number of unreported experiments that have failed to detect a correlation. Metabolic profiling, in which each experiment evaluates a statistically significant number of potential correlations, has the advantage that correction for random correlation can be made from the experimental data itself.
18
Robinson and Robinson
Fig. 1.5. Diagrammatic representation of three important uses of metabolic profiling. The n-dimensional profiles of substances that correlate with physiological age, probability of illness, and severity of illness are computationally compressed onto one-dimensional axes suitable for empirical evaluation of interventions for preventive and diagnostic medicine and for therapeutic monitoring. This one dimensional compression is also used in the calculation of profile “diagnostic power” as illustrated in Fig. 1.6. Reprinted with permission from Mechanisms of Ageing and Development (23).
Fig. 1.6. Diagnostic power of the sex-correlated ninhydrin-positive compounds illustrated in Fig. 1.4a. The n correlates are computationally compressed to one dimension. The one-dimensional axis extending between the male profile and the female profile as diagrammatically illustrated in Fig. 1.5 has one value for each of the 148 students. In the computation of these values, the profile of the student being calculated is always omitted from the calculation of the profiles to which he is being compared. Reprinted with permission from Clinical Chemistry (5). The resulting linear axis is divided at all of the 149 possible places between and beyond the 148 values and the errors plotted as shown. If there were no diagnostic power, the values would lie along the diagonal line. If the diagnosis is perfect, the graph is reduced to a point in the origin. The fraction of the area between the diagonal and perfect correlation that has been successfully eliminated is the “diagnostic power,” in this case 0.93. This quantitative experimental endpoint is useful in evaluating the strength of a profile, in comparing the relative values of alternative profiling techniques, and in optimizing experimental and computational parameters, such as the coefficients used to normalize the data.
Origins of Metabolic Profiling
19
a point at the origin. The “diagnostic power” is defined as the percentage of the area between the diagonal line and the origin that has been successfully eliminated by the technique. If the data are from more than one replicated experiment or from groups of subjects that are fundamentally impossible to completely separate into unique groups, the probability and diagnostic power distributions are non-linear, so appropriately curved expected distributions are used (13, 24) rather than the linear ones illustrated in Figs. 1.4 and 1.6. The invention of this method (13) permitted further optimization of the metabolic profiling experiments and calculation methods because it provided a quantitative score for the entire experiment and calculation. For example, data normalization coefficients could be optimized by iterative calculations to maximize diagnostic power. This “diagnostic power” method has proved to be generally useful in many unexpected ways. For example, it was recently used to optimize the parameters involved in predicting the deamidation rates in asparginyl residues for proteins of known threedimensional structure (27–30).
10. Summary of the Project In 1978, after 10 years of effort, the initial hypothesis about metabolic profiling had been verified. In every case in which the profiling laboratory completed an experiment intended to detect a profile distinctive of human disease and in many other experiments on variables of interest, a distinctive, diagnostically useful profile had been found. A set of 1000 humans had been profiled at birth with the goal of correlating their genetically unique urinary profiles with their health in later life. Analytical methods using chromatography and direct injection molecular ion mass spectrometry had been refined and automated, and suitable computational tools developed. Moreover, funding had been obtained for the regular sampling of 10,000 humans and permanent storage of the samples at –80◦ C so that profiling technologies could be tested and calibrated with longitudinal controls. Also, the various metabolic profiles discovered over the 10 years of work had been correlated with a single database.
11. Termination of the Project During the 10 years, all of the conceptual and computational questions that arose had been answered. So, the discipline of
20
Robinson and Robinson
metabolic profiling was firmly established. One metabolic profiling laboratory was well funded, equipped, and staffed with welltrained and experienced scientists and engineers and was ready to move forward. Robinson, 36 years old, was then research professor and president of the Pauling Institute and Pauling, 77 years old, was research professor and chairman of the board. Unfortunately, a disagreement arose between these two men regarding a series of experiments on nutrition and the growth rate of squamous cell carcinoma in hairless mice that had been carried out under Robinson’s direction. Involving experiments with about 2,000 mice, these experiments showed that sub-optimum nutrition decreased the cancer growth rate, while better nutrition increased it. The growth rate of squamous cell carcinoma in these mice was varied over a range of 20-fold by means of diet alone, an important finding that may have importance in the management of human cancer (30). General dietary restriction or provision of single nutritional components such as protein in amounts above or below those providing optimum overall health decreased the cancer growth rate, a finding that included vitamin C. With a supplement of the human equivalent of about 3 g/d (a dose Pauling was recommending to the public), vitamin C increased the cancer growth rate by twofold as compared with no supplement – a result that, unfortunately, Pauling believed harmful to his personal campaign to promote vitamin C. Exacerbated by several individuals who sought to gain from this disagreement, this controversy caused the Institute’s research to collapse, and all further work on metabolic profiling ended. Pauling and his attorneys who gained control of the Institute succeeded in prohibiting Robinson and his colleagues access to their equipment and research data, and the very high cost of rebuilding the necessary technology elsewhere prevented them from continuing the work. Accounts of a large part of their work in the 1970s have, however, been published (refs. 5–24 are a complete listing) and should prove useful to those in the field of metabolomics who are now rapidly advancing by means of the wonderful new analytical technology that is available today.
12. Some Thoughts About the Future
In the 1970s, the goal of metabolic profiling was to obtain as much quantitative health information as conveniently and economically as possible. At that time, urine analysis in central laboratories was the best path to this goal. Recognizing that other tissues and fluids were potentially complimentary or superior
Origins of Metabolic Profiling
21
sources, small forays into breath, saliva, blood, and cultured tissue were also undertaken. With regard to the substances analyzed, volatile compounds were easiest with the technology of that day, but non-volatile compounds appeared to contain more information per substance. While nucleic acids, proteins, and metabolites are all now of interest as a result of technological advance, only metabolites were within realistic analytical reach in the 1970s. Even today, it is likely that metabolites are still superior for these purposes. Nucleic acids and proteins are the blueprints for the biological structure and the machines that comprise and operate it. Quantitative health determination based on these molecules is, however, still in its infancy. Metabolites provide immediate real-time access to biochemical information reflected in the chemical output of basic processes in the living system. This profiling is becoming especially valuable, since the computer revolution now makes possible the transfer of diagnostic technology away from centralized laboratories and into each individual’s personal environment (25, 26). This transfer will markedly lower cost and increase convenience and, thereby, make possible a continuous flow of very useful information to each individual. We are not far from a time when each person’s personal computer will constantly acquire data about his health and submit that data for interpretation to the free-enterprise entrepreneurs of his choice – anywhere in the world. Which technologies will be ascendant in the future? All relevant health measurement technologies as applied to a wide variety of samples will obviously compete among research laboratories and in the marketplace. Only this competitive environment can sort out which approaches will provide the greatest health benefits for the greatest numbers of people. Many human factors as well as scientific factors will be important, such as the crucial issue of human compliance. Miraculous machines may arise for the analysis of drops of urine or blood, for example, but how many people would routinely utilize them? While we surely do not know the answers to these questions, breath metabolite analysis seems especially promising. On the basis of information content and ease of analysis, current techniques of breath analysis are much inferior to, for example, urine or blood analysis, but the human compliance problem is fundamentally much easier. Miniaturized mass spectrometers or other devices, for example, purchased as computer peripherals or perhaps routinely included on ordinary personal computer motherboards could continuously sample the breath of a single computer user or the air in a room frequented by a few people, without distraction of the people being monitored. During its birth in the 1970s, metabolic profiling required custom-built, slow, and expensive analytical machines coupled to
22
Robinson and Robinson
primitive, costly, and temperamental computer systems. Still, even then, it could have been incorporated as a very useful tool in centralized clinical laboratories. It is tragic that this was not done. Now, the advance of technology has removed these limitations. Analytical technology is greatly improved and is becoming less expensive and more reliable, while powerful interlinked computers have brought the computational requirements of metabolic profiling within reach of virtually every individual in the developed world. The applications of this new technology to increase the quality, quantity, and length of human life during the coming decades should be spectacular indeed. References 1. Kamen, M. D., Ruben, S. (1940) Production and properties of carbon 14. Phys Rev 58, 194. 2. Kamen, M. D. (1957) Isotopic Tracers in Biology: An Introduction to Tracer Methodology, Academic Press, New York, NY. 3. Pauling, L. (1968) Orthomolecular psychiatry. Science 160, 265–271. 4. Robinson, A. B., Manly, K. F., Anthony, M. P., Catchpool, J. F., Pauling, L. C. (1965) Anesthesia of artemia larvae: method for quantitative study. Science 149, 1255–1258. 5. Robinson, A. B., Pauling, L. C. (1974) Techniques of orthomolecular diagnosis. Clin Chem 20, 961–965. 6. Teranishi, R., Mon, T. R., Robinson, A. B., Cary, P., Pauling, L. C. (1972) Gas chromatography of volatiles from breath and urine. Anal Chem 44, 18–20. 7. Pauling, L. C., Robinson, A. B., Teranishi, R., Cary, P. (1971) Quantitative analysis of urine vapor and breath by gas– liquid partition chromatography. Proc Natl Acad Sci USA 68, 2374–2376. 8. Robinson, A. B., Pauling, L. C. (1973) Quantitative chromatographic analysis in orthomolecular medicine, in W H Freeman & Co (Hawkins, D., ed.), Orthomolecular Psychiatry, pp 35–53. 9. Robinson, A. B., Partridge, D., Turner, M., Teranishi, R., Pauling, L. C. (1973) An apparatus for the quantitative analysis of volatile compounds in urine. J Chromatogr 85, 19–29. 10. Matsumoto, K. E., Partridge, D. H., Robinson, A. B., Pauling, L. C., Flath, R. A., Mon, T. R., Teranishi, R. (1973) The identification of volatile compounds in human urine. J Chromatogr 85, 31–34. 11. Pauling, L. C., Robinson, A. B. (1973) Techniques of orthomolecular medicine. In First
12.
13.
14.
15.
16.
17.
18.
19.
20.
Conference on the Analysis of Multicomponent Mixtures and Their Application to HealthRelated Problems 1, 1–7. Robinson, A. B., Cary, P., Dore, B., Keaveny, I., Brenneman, L., Turner, M., Pauling, L. (1973) Orthomolecular diagnosis of mental retardation and diurnal variation in normal subjects by low-resolution gas–liquid chromatography of urine. Int Res Commun Syst 70, 3. Robinson, A. B., Westall, F. C. (1974) The use of urinary amine measurement for orthomolecular diagnosis of multiple sclerosis. J Orth Psychol 3, 1–10. Robinson, A. B., Westall, F. C., Ellison, G. W. (1974) Multiple sclerosis: urinary amine measurement for orthomolecular diagnosis. Life Sci 14, 1747–1753. Robinson, A. B. (1974) Orthomolecular medicine – diagnosis and therapy. In Proceedings of the 8th Annual Conference National Society for Autistic Children, 1–8. Robinson, A. B. (1975) Looking for optimum health: A guided tour through the Linus Pauling Institute. Prevention 89–96. Robinson, A. B., Weiss, M., Reynolds, W. E., Robinson, L. R. (1975) Use of mass spectrometry for Orthomolecular diagnosis. In Proceedings Twenty-Third Annual Conference on Mass Spectrometry and Allied Topics, 182–184. Dirren, H., Robinson, A. B., Pauling, L. C. (1975) Sex-related patterns in the profiles of human urinary amino acids. Clin Chem 21, 1970–1975. Rosenberg, R. N., Robinson, A. B., Partridge, D. (1975) Urine vapor pattern for olivopontocerebellar degeneration. Clin Biochem 8, 365–368. Robinson, A. B., Dirren, H., And Sheets, A., Miquel, J., Lundgren, P. R. (1976) Quanti-
Origins of Metabolic Profiling
21.
22. 23.
24.
25.
tative aging pattern in mouse urine vapor as measured by gas–liquid chromatography. Exp Gerontol 11, 11–16. Robinson, A. B., Willoughby, R., Robinson, L. R. (1976) Age dependent amines, amides, and amino acid residues in Drosophila melanogaster. Exp Gerontol 11, 113–120. Robinson, A. B., Pauling, L. C., Aberth, W. (1977) A controversy: diagnosis of infectious hepatitis. Clin Chem 23, 908–910. Robinson, A. B. (1979) Molecular clocks, molecular profiles, and optimum diets: three approaches to the problem of aging. Mech Ageing Dev 9, 225–236. Robinson, A. B., Robinson, L. R. (1991) Quantitative measurement of human physiological age by profiling of body fluids and pattern recognition. Mech Ageing Dev 59, 47–67. Robinson, A. B. (2007) Revolutionizing 21st century medicine with consumer-based
26. 27.
28.
29. 30.
23
diagnostics and the internet. J Am Phys Surg 12(1), 14–21. Robinson, A. B. (2007) Human health in the Telecosm. Gilder/Forbes Telecosm 10. Available at www.oism.org/health Robinson, N. E., Robinson, A. B. (2001) Prediction of protein deamidation rates from primary structure and three-dimensional structure. Proc Natl Acad Sci USA 98, 4367–4372. Robinson, N. E., Robinson, A. B. (2001) Deamidation of human proteins. Proc Natl Acad Sci USA 98, 12409–12413. Robinson, N. E. (2002) Protein deamidation. Proc Natl Acad Sci USA 99, 5283–5288. Robinson, A. B., Hunsberger, A., Westall., F. C. (1994) Suppression of squamous cell carcinoma in hairless mice by dietary nutrient variation. Mech Ageing Dev 76, 210–214.
Chapter 2 Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism Monique Piraud, Séverine Ruet, Sylvie Boyer, Cécile Acquaviva, Pascale Clerc-Renaud, David Cheillan, and Christine Vianey-Saban Abstract The diagnosis of inherited metabolic disorders of amino acid (AA) metabolism is based on the qualitative and/or the quantitative analysis of AAs, mainly in blood and urine. For years, the most widespread technique in use was ion-exchange chromatography followed by post-column derivatization with ninhydrin, a method which is the basis of numerous automated AA analyzers with a throughput of about eight samples/day. The emergence of tandem mass spectrometry (MS/MS) coupled to liquid chromatography (LC) has made possible the measurement of many metabolites for the diagnosis of inborn errors of metabolism. The LC-MS/MS method described here allows the clinical diagnosis of AA disorders by analysis of underivatized AAs and derivative molecules in various biological samples prepared by methanol precipitation. AAs are separated by ion-pairing reversed-phase LC, using perfluorocarboxylic acid as an ion-pairing agent. Each AA is detected in MS/MS-positive ionization mode by its specific transition. The method allows the analysis of about 40 biological samples/day. Key words: Amino acids, inborn errors of metabolism, tandem mass spectrometry, liquid chromatography.
1. Introduction The diagnosis of inherited metabolic disorders of amino acid (AA) metabolism is based on the qualitative and/or the quantitative investigation of about 80 AAs or derivative molecules in biological fluids, mainly blood and urine, but also cerebrospinal fluid (CSF), leukocytes, and amniotic fluid (AF). For years, the most T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_2, © Springer Science+Business Media, LLC 2011
25
26
Piraud et al.
widespread technique for this purpose was ion-exchange chromatography followed by post-column derivatization with ninhydrin, a method which is the basis of numerous automated AA analyzers with a throughput of about eight samples/day (1). Tandem mass spectrometry (MS/MS) coupled to liquid chromatography (LC) is still a developing technology capable of replacing classical methods in clinical biology (2) for the diagnosis of inborn errors of metabolism (3–5). Indeed, LC-MS/MS has been applied to newborn screening and other numerous metabolic conditions (6). An LC-MS/MS method has been developed allowing for the analysis of underivatized AAs in various biological samples for clinical diagnosis (7–9). The samples (plasma, urine, CSF, leukocytes, AF) are prepared by methanol precipitation. AAs are separated by ion-pairing reversed-phase liquid chromatography, using perfluorocarboxylic acid as an ion-pairing agent. Each AA is detected in MS/MS-positive ionization mode by its specific transition. The method allows a much higher throughput (about 40 biological samples/day) compared to traditional methods, and the technique can be adapted to other kinds of samples.
2. Materials Reagents used for daily analysis of AAs are underlined. All of them are made ready for analysis. 2.1. Common Reagents
1. Acetonitrile. 2. HPLC-grade methanol. 3. Sterile deionized water.
2.2. LC
1. Solvent A: 0.5 mM Tridecafluoroheptanoic acid (TDFHA). Store at room temperature. For preparation of the stock solution, see Note 1. 2. Solvent B: Acetonitrile. Store at room temperature. 3. Octadecyl-bonded silica gel LC column: Modulo-cart QS Uptisphere, 120 Å, 3 μm BP2, 50 mm × 2 mm (Interchrom; Interchim, Montluçon, France) (see Note 2). 4. Pre-columns of the same stationary phase (Interchim): 10 mm × 2 mm. 5. On-line filters (Interchim): 2 μm. 6. Direct connectors for 10-mm pre-column (Interchim). 7. Two Series 200 micropumps (Perkin-Elmer, Norwalk, CT, USA) (see Note 3).
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
27
8. Series 200 autosampler (Perkin–Elmer) (see Note 3). 9. The temperature of the LC column is controlled with a Croco-Cil (Cluzeau Info Labo, Sainte-Foy-la-Grande, France). 2.3. MS/MS
1. API 2000 triple-quadrupole mass spectrometer (AB Sciex, Toronto, Canada) equipped with a TurboIonSpray source. 2. Balston generator (Parker Hannifin International Ltd, Milan, Italy) to produce nitrogen from compressed (8 bars) air for desolvation and collision. 3. Analyst 1.3.1 software (AB Sciex).
2.4. Amino Acids and AA Qualitative Standards
Beside the individual stock solution for each molecule, a solution containing 26 common AAs is prepared for daily checking of the chromatographic separation. 1. Investigated AAs and other derivative molecules and their manufacturers are listed in Table 2.1, with abbreviations used. 2. Stock solutions of each molecule (5 mM in water (see Note 4)). Store in aliquots at –20◦ C for a maximum of 1 year. 3. L-Cysteine-L-homocysteine disulfide (Cys-Hcy) is not commercially available (see Note 5). 4. Anhydrides of L-argininosuccinic acid (ASA anhydrides) are not commercially available (see Note 6). 5. 50 μM stock solution (26 AAs): Combine 1 mL of each 5 mM AA solution (see list in Table 2.2) and complete to 100 mL with water. Store in 1 mL aliquots at –20◦ C for a maximum of 1 year. 6. 25 μM solution (26 AAs): Dilute 1 mL of the 50 μM stock solution with 1 mL of 1.25 mM TDFHA in a 2-mL injection vial. This solution should be prepared every other week. 7. S-2-Aminoethylcysteine (S2AE, see Note 7) 1 mM stock solution in methanol: prepare in a glass flask with grinded cap by dissolving 20.1 mg of S2AE in 100 mL methanol. Store in a glass flask with grinded cap tightly closed at 4◦ C (maximum 6 months, see Note 8). Do not let the flask open longer than necessary when preparing the deproteinization reagent (see Note 8).
28
Piraud et al.
Table 2.1 List of amino acids and derivative molecules of biological interest for the diagnosis of inherited disorders of amino acids metabolism Name
Abbreviation MM
Manufacturer Biological interest
Sample
Ethanolamine, HCl
EA
61
Calbiochem
Hypoxia
P,U
Glycine
Gly
75
Merck
Nonketotic hyperglycinemia, organic acidurias
P,U,CSF
L -Alanine
Ala
89
Calbiochem
Hyperlactacidemia
P,U
Sarcosine
Sar
89
Sigma
MAD (ETF or ETF-QO deficiency)
P,U
β-Alanine
β-Ala
89
Merck
Hyper-β-alaninemia
U
L -α-Amino-n-
Abu
103
Calbiochem
Protein intake
P
N,NDimethylglycine
(Me)2 -Gly
103
Sigma
MAD (ETF or ETF-QO deficiency)
P,U
β-Aminoisobutyric acid
β-AIB
103
Sigma
Neoplasia, excessive breakdown
γ-Aminobutyric acid L -Serine
GABA
103
Calbiochem
Ser
105
Calbiochem
CNS disorders, neurotrans- P,U,CSF mitter disorders Vitamin B6 deficiency, B6 P,U, CSF synthesis deficiency, serine deficiency disorders
1 -Pyrroline5-carboxylic acid
PC
113
Sigma
Hyperprolinemia (type II)
L -Proline
Pro
115
Calbiochem
Hyperprolinemia (types I, II) P,U
butyric acid
tissue U
U
L -Valine
Val
117
Merck
Maple syrup urine disease
L -Homoserine
Hse
119
Sigma
Interference (neuroblastoma) P, U
L -Threonine
Thr
119
Calbiochem
Hepatic failure
P,U
Taurine
Tau
125
Sigma
Sulfite oxidase deficiency
P,U
Pip
129
Sigma
Peroxisomal disorders
P,U
Pyro-L-glutamic acid
pGlu
129
Fluka
Pyroglutamic aciduria
P,U
ε-Aminocaproic acid
eCap
131
Calbiochem
Interference (therapeutic agent)
δ-Aminolevulinic acid
dALA
131
Sigma
Tyrosinemia type I, porphyrias
U
4-Hydroxy- Lproline
Hyp
131
Calbiochem
Hydroxyprolinemia
P,U
L -Leucine
Leu
131
Calbiochem
Maple syrup urine disease
P,U
L -allo-Isoleucine
aIle
131
Sigma
Maple syrup urine disease
P,U
L -Pipecolic
acid
P,U
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
Table 2.1 (continued) Name
Abbreviation MM
Manufacturer Biological interest
Sample
L -Isoleucine
Ile
131
Calbiochem
Maple syrup urine disease
P,U
Orn
132
Merck
Urea cycle disorders, HHH, P,U hyperornithinemia
L -Asparagine
Asn
132
Fluka
Asparaginase treatment (leukemia)
P,U
L -Aspartic
Asp
133
Merck
Asparaginase treatment (leukemia)
P,U
L -Homocysteine
Hcy
135
Sigma
Homocystinuria, Cbl C/D P,U deficiency
L -Glutamine
Gln
146
Merck
Hyperammonemia, urea cycle disorders
L -Lysine,
Lys
146
Calbiochem
Hyperlysinemia, cystinuria– P,U lysinuria
Glu
147
Calbiochem
Urea cycle disorders
P,U
L -Methionine
Met
149
Calbiochem
Homocystinuria, hypermethioninemia
P,U
L -Histidine,
HCl
His
155
Calbiochem
Histidinemia
P,U
L -α-Aminoadipic
Aad
161
Sigma
α-Aminoadipic aciduria
P,U
5-Hydroxy-L-lysine, HCl
Hyl
162
Sigma
Hydroxylysinuria
U
N-Acetyl-L-cysteine
NAcCys
163
Merck
Interference (therapeutic agent)
P,U
L -Phenylalanine
Phe
165
Merck
Phenylketonuria, hyperphenylalaninemia
P,U
N3 -Methyl-Lhistidine
His-1Me
169
Calbiochem
Renal insufficiency
P,U
N1 -Methyl-Lhistidine
His-3Me
169
Calbiochem
Renal insufficiency, denutri- P,U tion, starvation
Glycyl-L-proline
Gly-Pro
171
Sigma
Iminodipeptiduria
L -Ornithine,
HCl
acid
HCl
L -Glutamic
acid
P,U
acid
U
L -Arginine
Arg
174
Merck
Urea cycle disorders
P,U
Formimino-Lglutamic acid
FIGLU
174
Sigma
FIGLU aciduria
U
N-Acetyl-Lornithine
NAcOrn
174
Sigma
Interference (hyperornithinemia)
L -Citrulline
Cit
175
Merck
Urea cycle disorders
P,U
L -Tyrosine◦
Tyr
181
Calbiochem
Tyrosinemia type I or II
P,U
L -Homocitrulline
Hci
189
ICN
HHH
P,U
L -3-(3,4-
Dopa
197
Sigma
Tyrosinemia, neurotrans- U mitter disorders
Dihydroxyphenyl)alanine◦
29
30
Piraud et al.
Table 2.1 (continued) Name
Abbreviation MM
Manufacturer Biological interest
Sample
S-Sulfo-L-cysteine
S-Cys
201
Sigma
Sulfite oxidase deficiency
P,U
N G ,N G Dimethylarginine, HCl
asym(Me)2 Arg
202
Sigma
Physiological
U
L -Tryptophan◦
Trp
204
Calbiochem
Hartnup disease
P,U
L -Kynurenine
Kyn
208
Sigma
Vitamin B6 deficiency
U
5-Hydroxy-Ltryptophan
Hyt
220
Sigma
Therapeutic agent, neuro- U transmitter disorders
Hcy(Ala)
222
Sigma
Cystathioninuria, neuroblastoma
P,U
3-Hydroxy-Lkynurenine
Hyk
224
Sigma
Vitamin B6 deficiency
U
L -Carnosine
Car
226
Calbiochem
Carnosinemia, physiological U (meat)
L -Anserine
Ans
240
Sigma
Carnosinemia, physiological U (meat)
L -Cystine
(Cys)2
240
Merck
Cystinuria, cystinuria– P,U lysinuria, homocystinuria, sulfite oxidase deficiency
L -Cysteine- L-
Cys-Hcy
254
∗
Cystinosis Homocystinuria, cystinuria
L P,U
(Hcy)2
268
Sigma
Homocystinuria
P,U
ASA anh
272
∗
Urea cycle disorders (AS aciduria)
P,U
L -Saccharopine
Sac
276
Sigma
Saccharopinuria
P,U
L -Argininosuccinic
ASA
290
Sigma
Urea cycle disorders (AS aciduria)
P,U
Glutathione (reduced form)
GSH
307
Sigma
γGT deficiency, GSH synthase deficiency
P,U
β-Aspartylglucosamine
GlcNAcAsn
335
Sigma
Aspartylglucosaminuria
U
L -Cystathionine◦
homocysteine disulfide L -Homocystine L -Argininosuccinic
anhydrides
acid
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
31
Table 2.1 (continued) Name
Abbreviation MM
Manufacturer Biological interest
Sample
S-Adenosyl-L homocysteine
Ad-Hcy
384
Sigma
Homocystinuria, hyperme- P,U thioninemia
S-Adenosyl-L methionine
Ad-Met
398
Sigma
Homocystinuria, hyperme- P,U thioninemia
Glutathione (oxidized form)
GSSG
612
Sigma
γGT deficiency, GSH syn- P,U thase deficiency
∗ : for preparation, see text. ◦ : molecules for which 2 drops of 37% HCl are added per 10 mL of 5 mM stock solution
for dissolution. MM, molecular mass; MAD, multiple acyl-CoA dehydrogenase deficiency; ETF, electron transfer flavoprotein; ETF-QO, ETF-ubiquinone oxidoreductase; CNS, central nervous system; Cbl, cobalamine; HHH, hyperammonemia, hyperornithinemia, homocitrullinuria; P, plasma; U, urine; CSF, cerebrospinal fluid; L, leukocytes. Reproduced with permission from ref. (7).
2.5. Stable Isotope-Labeled AAs (Internal Standards, AAs∗ )
1. Stable isotope-labeled standards for MS/MS are listed in Table 2.3, along with their abbreviations (see Note 9). 2. Stock solutions of each molecule (25 mM for Gly∗ , 15 mM for Gln∗ , 10 mM for Ala∗ and Pro∗ ; 5 mM for others) in water (see Note 4). Store in aliquots at –20◦ C for a maximum of 1 year. 3. Working solutions: 17 AAs∗ at 200 μM (except Pro∗ and Ala∗ at 400 μM, Gln∗ at 600 μM, and Gly∗ at 1 mM). In a 50-mL flask, add 2 mL of each AA∗ stock solution. Complete to 50 mL with water, mix, and store in aliquots at – 20◦ C for a maximum of 1 year.
2.6. AA Quantification Standards
Two quantitative standards are used daily for quantification: one is prepared from a commercially available AA standard supplemented in order to obtain a standard with all the most commonly measured physiological AAs for the diagnosis of inborn errors of metabolism (100 and 50 μM AAs standards) and one is homemade and contains all the molecules to be quantified that are not present in the other standard (supplemental AAs standard). 1. “Amino acid standards, physiological acidics, neutrals and basics for calibrating amino acid analyzers” (Sigma-Aldrich) containing several AAs at 500 μM. 2. AA additional stock solution: Gln 6.25 mM, Gly 5 mM, Asn 1.25 mM. Store in single-use aliquots at –20◦ C for a maximum of 6 months.
β-Ala
Abu
β-Alanine
L -α-Amino-n-
(Me)2 Gly
β-AIB
GABA
N,NDimethylglycine
β-Aminoisobutyric acid (1)
γ-Aminobutyric acid
butyric acid
Ala
Sar
L -Alanine
Gly
Glycine
Sarcosine
EA
Ethanolamine
Abbreviation
20 20
104 > 87
20
20
20
20
20
20
10
20
DP
104 > 86
104 > 86
104 > 58
104 > 58
90 > 72
90 > 44
90 > 44
76 > 30
62 > 44
Monitored transition
14
14
14
18
18
12
20
20
16
16
CE
x
9.5 9.5
Lys∗ Lys∗
3.7
Pro∗
1.3
8.0
Val∗
Gly∗
1.6
Ala∗ x
1.8
x
Ala∗ 2.4
8.8
Expected RT
Gly∗
26 AAs
Leu∗
AA∗
100
100
100
100
100
100
500
100
200
200
Conc. in Conc. in 100 Supplemental µM AA stan- AA standard dard (in µM) (in µM)
3
3
3
1
1–2
2–3
1
1
1
3
Monitoring period
Table 2.2 List of unlabeled AAs and derivative molecules of biological interest for the diagnosis of inherited disorders of amino acid metabolism. Corresponding specific transitions used for the identification of AAs in MS/MS positive ionization mode are given with their specific declustering potential (DP, in V) and collision energy (CE, in eV). Concentrations (in µM) of analytes in the 100 µM AA standard solution and in the supplemental standard solution are indicated, as well as AAs present in the 25 µM solution (26 AAs). Transitions are monitored either in period 1 (0–3.5 min of the chromatogram), in period 2 (3.5–9 min), and/or in period 3 (9–20 min). #: transition 132 > 86 is common to Hyp, Leu, Ile, aIle and dALA; transition 175 > 130 is common to Arg and FIGLU; RT: retention time; In italics: molecules for which quantitation could not be validated. Reproduced with permission from ref. (9)
32 Piraud et al.
Pip
pGlu
eCap
dALA
Hyp
Leu
aIle
Ile
Pyroglutamic acid
ε-Aminocaproic acid
δ-Aminolevulinic acid
4-Hydroxy-L-proline
L -Leucine
L -allo-isoleucine
L -Isoleucine
acid
L -Pipecolic
Hse
L -Homoserine
Thr
Val
L -Valine
Tau
Pro
L -Proline
L -Threonine
PC
1-Pyrroline-5carboxylic acid
Taurine
Ser
Abbreviation
L -Serine
Table 2.2 (continued)
20
16
132 > 86# (2) 25
26
36
30
26
25
30
30
16
16
24
20
20
16
32
32
32
16
20
20
14
CE
25
132 > 69
132 > 69
132 > 43
132 > 68
20
132 > 114 132 > 114
30
30
30
40
132 > 79
130 > 84
130 > 84
126 > 108
20
20
120 > 74 120 > 74
20
25
20
25
10
DP
120 > 44
118 > 72
116 > 70
114 > 68
106 > 60
Monitored transition
1.1
Glu∗
1.3
x x x x
Asp∗ Leu∗ Leu∗ Leu∗
9.8
9.2
10.4
9.6
Leu∗
11.2
5.2
Val∗
1.9 0.77
x
1.9
Ala∗
Ala∗
x
Val∗ 6.0
2.3
x
Pro∗
1.6 2.0
x
Ser∗
Expected RT
Val∗
26 AAs
AA∗
100
100
100
100
100
100
100
100
200
200
200
200
Conc. in Conc. in 100 Supplemental µM AA stan- AA standard dard (in µM) (in µM)
2–3
2–3
3
1
3
3
1
2
1
1
1
1
2
1
1
1
Monitoring period
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism 33
Asn
Asp
L -Asparagine
L -Aspartic
Gln
Lys
Glu
L -Glutamine
L -Lysine
L -Glutamic
His
Aad
L -Histidine
L -α-Aminoadipic
Hyl
Phe
His-3Me
His-1Me
Gly-Pro
Arg
FIGLU
5-Hydroxy-L-lysine
L -Phenylalanine
N1 -Methylhistidine
N3 -Methylhistidine
Glycyl-L-proline
L -Arginine
Formimino-Lglutamic acid
acid
Met
L -Methionine
acid
Hcy
L -Homocysteine
acid
Orn
Abbreviation
L -Ornithine
Table 2.2 (continued)
22
175 > 130# 20
32
16
20
20
20
18
24
18
14
32
20
15
30
30
30
5
20
20
10
24
36
24
24
16
18
18
22
CE
25
175 > 84
175 > 70
173 > 116
170 > 126
170 > 124
166 > 120
163 > 128
162 > 98
156 > 110
150 > 104
15
20
147 > 67
148 > 84
20
20
10
25
25
10
DP
147 > 84
147 > 84
136 > 90
134 > 74
133 > 74
133 > 70
Monitored transition
x x
Met∗ Lys∗
x
Lys∗
Glu∗
3.5
9.7 12.7
Arg∗
11.9
Leu∗ x
x
Lys∗
12.0
12.4 11.2
x
Phe∗
3.9
12.0
6.5
2.0
12.6
1.74
4.3
1.3
1.5
12.1
Expected RT
Lys∗
Pro∗
x
Glu∗
x
x
Asp∗
Lys∗
x
Asp∗
x
x
Orn∗
Gln∗
26 AAs
AA∗
100
100
100
100
100
100
100
100
100
500
100
100
100
200
200
Conc. in Conc. in 100 Supplemental µM AA stan- AA standard dard (in µM) (in µM)
2
2
3
2–3
3
3
3
3
1–2
3
2
1
3
3
1
2
1
1
3
Monitoring period
34 Piraud et al.
Tyr
Hci
Dopa
L -Tyrosine
L -Homocitrulline
L -3-(3,4-
asym(Me)2 Arg 203 > 70
Trp
Kyn
Hyt
Hcy(Ala)
Hyk
Car
Ans
NG ,NG Dimethylarginine
L -Tryptophan
L -Kynurenine
5-Hydroxy-Ltryptophan
L -Cystathionine
3-Hydroxy-Lkynurenine
L -Carnosine
L -Anserine
241 > 109
227 > 110
225 > 208
223 > 88
221 > 204
209 > 192
205 > 188
S-Cys
202 > 120
198 > 152
190 > 173
182 > 165
176 > 159
Monitored transition
S-Sulfo-l-cysteine
Dihydroxyphenyl)alanine
Cit
Abbreviation
L -Citrulline
Table 2.2 (continued)
30
30
20
15
20
20
10
20
15
10
20
25
10
DP
35
30
14
40
10
14
18
42
18
20
16
12
14
CE
12.4 11.9
Lys∗ Lys∗
3.5 10.0 14.0 13.8
Ala∗ Lys∗ Lys∗ Lys∗
10.4
0.6 12.8
Lys∗
7.0
Ala∗
4.5
8.5
2.6
Expected RT
Met∗
x
x
26 AAs
Val∗
Tyr∗
Ala∗ , Pro∗
AA∗
100
100
100
100
100
200
200
200
200
200
200
200
Conc. in Conc. in 100 Supplemental µM AA stan- AA standard dard (in µM) (in µM)
3
3
3
1–2
3
3
3
3
1
2
2
2–3
1–2
Monitoring period
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism 35
acid
GlcNAc-Asn
Ad-Hcy
Ad-Met
GSSG
S2AE
β-Aspartylglucosamine
S-Adenosyl-lhomocysteine
S-Adenosyl-Lmethionine
Glutathione (oxidized form)
S-2-Aminoethylcysteine
165 > 120
613 > 355
399 > 250
385 > 88
336 > 126
308 > 179
291 > 70
277 > 84
273 > 70
269 > 136
241 > 74 255 > 134
Monitored transition
8
20
15
30
15
25
30
25
20
10
25 100
DP
18
30
20
64
24
18
48
36
55
12
40 18
CE
1.6 12.7 15.3 8.7 11.1
Lys∗ Val∗ Lys∗
4.1
Lys∗
11.5
Val∗ Asp∗
5.3
Lys∗
12.4
Val∗
11.8
2.1 5.0
Expected RT
Lys∗
x
26 AAs
(Hcy)2 ∗
(Cys)2 ∗ (Cys)2 ∗
AA∗
100
100
200
200
200
200
Conc. in Conc. in 100 Supplemental µM AA stan- AA standard dard (in µM) (in µM)
(1) BAIB is not measurable when GABA is detectable. (2) Common transition to Leu, Ile, aIle, dALA, and Hyp. It cannot be used for Ile quantification when dALA is present.
GSH
ASA
Glutathione (reduced form)
L -Argininosuccinic
L -Saccharopine
Sac
ASA anh
L -Argininosuccinic
anhydrides
(Hcy)2
(Cys)2 Cys-Hcy
Abbreviation
L -Homocystine
homocysteine disulfide
L -Cysteine- L-
L -Cystine
Table 2.2 (continued)
2
3
3
1
2
3
2
3
3
1 2
Monitoring period
36 Piraud et al.
(5,5-D2 ), 2HCl
(3,3,3’,3’-D4 )
DL -Cystine
151 > 87 151 > 88 152 > 88 153 > 107 171 > 125 177 > 70 184 > 167 245 > 74 277 > 140
Gln∗ Met∗ Phe∗ Arg∗ Tyr∗ (Cys)2 ∗ (Hcy)2 ∗
10
25
25
20
30
10
20
20
15
25
10
25
20
10
20
12
40
12
32
20
14
24
24
24
18
22
36
16
16
20
14
20
16
CE
CIL
CIL
CIL
CIL
CIL
Euriso-top
CIL
Euriso-top
CIL
Euriso-top
CIL
Euriso-top
CIL
CIL
CIL
CIL
CIL
Manufacturer
5
5
5
5
5
5
15
5
5
5
5
5
5
5
10
5
10
25
Stock solution (mM)
Corresponding specific transitions used for their identification in MS/MS positive ionization mode are given with their specific declustering potential (DP, in V) and collision energy (CE, in eV). CIL, Cambridge Isotope Laboratories. Reproduced with permission from ref. (8).
(3,3,3’,3’,4,4,4’,4’-D8 )
(ring 3,5-D2 )
L -Tyrosine
DL -Homocystine
(guanido-15 N2 ), HCl
L -Arginine
(ring-D5 )
(methyl-D3 )
L -Phenylalanine
L -Methionine
(2,3,3,4,4-D5 )
(4,4,5,5-D4 ), 2HCl
L -Glutamine
DL -Lysine
acid (2,4,4-D3 )
acid (2,3,3-D3 )
DL -Glutamic
L -Aspartic
L -Ornithine
Lys∗
135 > 46
(5,5,5-D3 )
Glu∗
135 > 89
Leu∗
L -Leucine
DL -Valine-D8
(2,3,3,4,4,5,5-D7 )
137 > 75
126 > 80
Val∗
DL -Proline
135 > 72
123 > 77
Pro∗
Asp∗
30
109 > 63
Orn∗
25
94 > 48
Ser∗
(2,3,3- D3 )
(2,3,3,3-D4 )
DL -Alanine
DL -Serine
Ala∗
10
78 > 32
Gly∗
Glycine (2,2-D2 )
DP
Monitored transition
Abbreviation
Table 2.3 List of the 17 stable isotope-labeled standards (AA∗ ) Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism 37
38
Piraud et al.
3. AA diluted solution: Gln 625 μM, Gly 500 μM, Asn 125 μM. Add 1 mL AA additional stock solution to 9 mL of water. Use this solution within the day of preparation. 4. 100 μM AA standard (see list in Table 2.2): all AAs at 100 μM (except Gly and Gln at 500 μM). Add 300 μL of the Sigma standard (“amino acid standards, physiological acidics, neutrals, and basics for calibrating amino acid analyzers”) to 1200 μL of AA diluted solution. Store in aliquots at –20◦ C for a maximum of 1 month. When thawed, store at 4◦ C for a maximum of 1 week. 5. 50 μM AA standard: Dilute the 100 μM AA solution. Prepare weekly and use for a maximum of 1 week with storage at 4◦ C. 6. Supplemental AA standard (see list in Table 2.2): several molecules at 200 μM, which are not present in the 100 μM standard. Combine 1 mL of each 5 mM stock solution and complete to 25 mL. Store in 1 mL aliquots at –20◦ C for a maximum of 2 years. When thawed, store at 4◦ C for a maximum of 1 week. 7. 0 μM standard is a water blank. 2.7. Materials for Preparation of Standards and Samples
1. 2-mL injection vials with screw-top caps (Interchim). 2. 9-mm silicone/PTFE slit screw caps (Interchim). 3. Microtest tube rack (Brand, Wertheim, Germany). 4. Microtubes PP 1.5 mL with attached PP safety cap (Sarstedt France, Marnay, France). 5. Deproteinization reagent: 20 μM S2AE in methanol (see Note 7). Dilute the S2AE stock solution 1:49 with methanol in a 50-mL glass flask with grinded cap. Store tightly closed at 4◦ C for a maximum of 1 month. This reagent can be aliquoted to small glass flasks with grinded caps. Open only when used and close immediately after use (see Note 8). 6. 1.25 mM TDFHA working solution (for preparation of the stock solution, see Note 1) 7. Plasma: Sample blood with heparin, then centrifuge 10 min at 5000×g at 4◦ C. Transfer plasma (200 μL minimum) in a tube. Deproteinize immediately or store at –80◦ C. 8. Urine: Determine creatinine concentration for each urine sample with any classical creatinine determination method for this purpose (e.g., Jaffé reaction) and freeze one aliquot at –20◦ C for AA determination (1 mL minimum). 9. Cerebrospinal fluid (CSF) and amniotic fluid (AF): Freeze the sample (300 μL minimum) at –20◦ C immediately.
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
39
10. Leukocytes: Isolate the leukocytes pellet from 15–20 mL of blood as soon as possible (maximum 48 h) after sampling with citric acid–citrate–dextrose as anticlotting agent, according to usual procedures currently in use in the laboratory for leukocytes isolation. For preparation of the leukocyte mixture and analysis, see Note 10. 2.8. Quality Control Samples
1. External QAP (Quality Assurance Program): ERNDIM amino acid scheme (www.erndimqa.nl). 2. External QAP: ERNDIM cystine in white blood cell scheme (www.erndimqa.nl). 3. Internal QAP: SKML control material amino acids (www.erndimqa.nl).
3. Methods Samples for AA analysis are first deproteinized with methanol containing a known quantity of S2AE for control of the correct dilution/precipitation of the sample. Ion-pairing reversed-phase liquid chromatography is used for separation of AAs, and the use of volatile mobile phases (ACN, TDFHA, water) allows MS/MS detection, particularly with the TurboIonSpray source adapted to evaporation of water containing mobile phases. This chromatographic system must be used in stable conditions as described (with respect to rinsing periods) in order to obtain repeatability of the amino acid retention times and of the quantification results. As necessary for MS/MS quantitative analysis, 17 stable isotope-labeled AAs are used as IS. Quantification of the 17 corresponding AAs has been validated in these conditions. Validation of quantification has been obtained for many other AAs but not all. Several AAs for which quantitative validation has not been obtained are described anyway as qualitative markers useful for the diagnosis of some inherited disorders of AA metabolism. 3.1. Sample Preparation
1. Push 1.5-mL microtubes firmly onto the microtube rack. 2. AA standards (0, 50, and 100 μM, AA Suppl. STD 200 μM), plasma, CSF, AF, and quality control samples are used undiluted. For leukocytes, see Note 10. 3. Do not dilute urine samples if the creatinine concentration is below 4 mM. If the creatinine concentration exceeds 4 mM, then dilute urine with water as follows: a. 4–8 mM creatinine, dilute 1:1. b. 8–12 mM creatinine, dilute 1:2.
40
Piraud et al.
c. 12–16 mM creatinine, dilute 1:3. d. 16–20 mM creatinine, dilute 1:4. e. ≥20 mM creatinine, dilute 1:9. 4. Mix 150 μL of each sample (standards, plasma, CSF, AF, controls or adequately diluted urine) with 600 μL of deproteinization reagent, close the cap, and mix thoroughly for 2 min. 5. Store the samples at room temperature for 5 min. 6. Centrifuge the samples at 17,500×g for 5 min at +4◦ C, then transfer the supernatants to new 1.5-mL microtubes, and store at –80◦ C until used. 7. Prior to analysis, thaw and homogenize the deproteinized samples and standards. 8. Combine 200 μL of each supernatant with 40 μL of AA∗ working solution and 160 μL of 1.25 mM TDFHA in an injection vial and mix. 3.2. Liquid Chromatography
1. Assemble the column and the pre-column using the connectors and add a pre-filter. 2. Maintain the column at 26◦ C. 3. Before the first use, rinse the column with ACN at 200 μL/min for 2 h. 4. Separations are carried out at a flow rate of 200 μL/min. 5. Inject 5 μL of sample or standard. 6. Gradient elution is as follows: from 0 to 15% B in 1 min; maintain 15% B for 5 min; from 15 to 25% B in 3 min; maintain 25% B for 6 min; from 25 to 0% B in 1 min; maintain 0% B for 15 min to re-equilibrate the column before a new injection. 7. The sample throughput of the method is 2 samples/h. The LC effluent is directed to the mass spectrometer for the first 20 min of the separation, after which it can be directed to waste.
3.3. Tandem Mass Spectrometry
1. Set the ionization source to positive ionization mode. 2. Set the TurboIonSpray source to 450◦ C. 3. Set the curtain gas (CUR) to 20. 4. Set the collision gas to 2. 5. Set the ion source nebulization gas (GS1) to 25 (arbitrary units are given by the manufacturer). 6. Set the auxiliary gas (GS2) to 40. 7. Set Q1 and Q3 to unit resolution. 8. Set the ion spray voltage (IS) to 5000 V.
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
41
9. Set the focusing potential (FP) to 200 V. 10. Set the entrance potential (EP) to –10 V. 11. Specific transitions optimized for each unlabeled (Table 2.2) or labeled (Table 2.3) compound are listed (see Note 11) with their specific declustering potential (DP, in V) and collision energy (CE, in eV) parameters (see Note 12). 12. For each sample, acquisition of data is performed during the first 20 min of the gradient analysis, according to the chosen transitions in positive ionization mode and specific parameters (Tables 2.2 and 2.3). During the re-equilibration time, the flow can be diverted to waste. 13. The predicted retention time for each molecule is indicated (see Table 2.2). 14. For qualitative analysis (25 μM solution (26 AAs)), the acquisition method contains all the involved transitions in a single period with a dwell time of 25 ms each. 15. For quantification using the Analyst 1.3.1 software, the acquisition time is divided into three periods (period 1 is from 0 to 3.5 min; period 2 is from 3.5 to 9 min; period 3 is from 9 to 20 min), during which only the relevant molecules are managed with their own transition (for the corresponding period, see Table 2.2). For each transition, the dwell time is 25 ms, except for Gly and Gly∗ (100 ms). 16. Some molecules are monitored over two periods in case there is a slight shift in RT (see Table 2.2). 3.4. LC-MS/MS Analysis
1. After rinsing the LC column, inject samples in the following order (see Note 13): a. One 0.5 mM TDFHA sample (not usable). b. One 25 μM solution (26 AAs) (for checking the quality of the analysis). c. 12–14 standards or samples (for quantification). d. Rinse the column on line 1 h with ACN at 200 μL/min. 2. The same sequence (from a to d) can be repeated two more times. Modifying or avoiding the rinsing periods may alter the chromatogram and cause shift in retention times. 3. The 0 and 100 μM AA standards are analyzed in each sequence. 4. The 50 μM and supplemental AA standards are analyzed at least two times every 24 h. 5. After each use (maximum 24 h, three sequences, 36–42 samples), rinse the column (out-line, reverse flow) with methanol/water (85:15) for 16 h at 100 μL/min.
42
Piraud et al.
Fig. 2.1. Overall chromatogram obtained with the 26 AA sample, with an MS/MS method integrating the transitions of each molecule during all the analysis time (20 min). Column: Uptisphere 50 mm × 2 mm ID 3 μm. Elution gradient: solvent A: 0.5 mM TDFHA in water and solvent B: acetonitrile; from 0 to 15% B in 1 min, 1–6 min 15% B maintained, 6–9 min linear gradient to 25% B, 9–15 min 25% B maintained, 15–16 min gradient back to 0% B, then 16–31 min 0% B to equilibrate the column before a new injection. Injection volume, 5 μL; concentration of molecules in mixtures, 25 μM each.
6. Check the quality of the chromatography based on the 25 μM solution (26 AAs) (see Fig. 2.1). 7. Identify each AA based on its transition and its retention time. 8. The overall aspect of the chromatogram and the elution order of the AA must remain the same. The observed retention time for each AA must correspond to the expected value (Table 2.2 and Fig. 2.2; see Note 14). 9. Visually inspect the separation of the critical pairs of AAs (see Fig. 2.2), i.e., mainly Glu and Gln (see Fig. 2.2c), Asp and Asn (see Fig. 2.2d), aIle, Ile, and Leu (see Fig. 2.2g; see Note 15). 10. Verify the sensitivity of the system daily by comparing peak intensities of AAs with those of the previous days.
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
(a)
Fig. 2.2. (continued)
(b)
Fig. 2.2. (continued)
43
44
Piraud et al.
(c)
Fig. 2.2. (continued)
(d)
Fig. 2.2. (continued)
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
(e)
Fig. 2.2. (continued)
(f)
Fig. 2.2. (continued)
45
46
Piraud et al.
(g)
Fig. 2.2. Extracted ion current (XIC) chromatograms of the amino acid pairs that have similar MS/MS characteristics. Column: Uptisphere 50 mm × 2 mm ID, 3 μm. Elution gradient: solvent A: 0.5 mM TDFHA in water and solvent B: acetonitrile; from 0 to 15% B in 1 min, 1–6 min 15% B maintained, 6–9 min linear gradient to 25% B, 9–15 min 25% B maintained, 15–16 min gradient back to 0% B, then 16–31 min 0% B to equilibrate the column before a new injection. Injection volume, 5 μL; concentration of molecules in mixtures, 25 μM each. (a) Ala, Sar (90 > 44); N-acetyl-L-ornithine (NAcOrn), Arg (175 > 70). (b) Abu, (Me)2 Gly (104 > 58). (c) Gln (147 > 84), Glu, Lys (148 > 84). (d) Asn (133 > 74), Asp (134 > 74). (e) Pip, pGlu (130 > 84). (f) Cys (122 > 76), Hcy (136 > 90), (Cys)2 (241 > 74), (Hcy)2 (269 > 136), Cys-Hcy (255 > 134). (g) Isobar molecules giving a parent ion at m/z 132: Leu, Ile, aIle, dALA, Hyp, and εCap. Reproduced with permission from ref. (8).
3.5. Quantification
1. Perform quantification of AA after acquisition of all the samples in the three sequences using Analyst 1.3.1 software. 2. Use the corresponding AAs∗ as internal standards (see Table 2.2, Note 16) (peak area ratio), and the 0 and 100 μM AA standards (or 200 μM supplemental AA standard) as external standards according to a linear calibration curve. 3. The 50 μM AA standard is used as a control sample. 4. The retention times of AAs and AAs∗ are noted, and the AA retention time/AA∗ retention time ratio (ratio of retention times) is calculated. 5. Confirm the quality of the peak integrations manually (see Note 17). 6. Quantitative validation has been obtained for most AAs measured by this method (see Note 17). However, quantita-
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
47
tive validation could not be obtained for some of them (Table 2.2). Therefore, their analysis is only qualitative (see Note 18). 7. In several cases, qualitative identification of the disease marker is sufficient for a diagnosis (e.g., ASA, pGlu, FIGLU, S-Cys, Cys-Hcy). Using the stable isotope-labeled IS analogues of the compounds when available will improve the results. 8. Direct quantification of Cys-Hcy and ASA is not possible because of the lack of quantitative standards (see Notes 19 and 20). 9. Validation of the series is achieved if quantitative results match with the calculated consensus values of the internal control SKML amino acids.
4. Notes 1. Preparation of the 13.73 mM Tridecafluoroheptanoic acid (TDFHA) stock solution: Prepare by dissolving 5 g of TDFHA in 1 L water and store at room temperature (maximum 6 months). 2. Other ultrapure octadecyl-bonded silica gel columns of the same characteristics could be used with no or slight modifications to the gradient shape, provided that the separation of critical pairs of AAs is obtained (see 7, Section 3.4, Fig. 2.2 and Notes 14 and 15). 3. Any other HPLC pumps/autosampler can be used for solvent delivery and automated sample introduction, if adapted to the given flow/sample introduction volume. 4. When necessary, stock solutions are acidified with 2 drops of 37% HCl per 10 mL, in order to enhance the solubility of the compound (see Table 2.1). 5. A qualitative standard solution containing Cys-Hcy can be obtained by heating a solution containing 0.5 M Cys and 0.5 M Hcy at 50◦ C for 2 h. 6. A 0.5 mM ASA anhydrides solution can be obtained by heating a 0.5 M argininosuccinic acid solution at 100◦ C for 60 min. 7. S2AE is used as an internal standard for the control of the correct dilution/precipitation of samples.
48
Piraud et al.
8. Methanol is an efficient reagent for protein precipitation. Its use limits ion suppression that can occur with other precipitating reagents. This solution is used as a standard for deproteinization. Methanol is highly volatile. If evaporation occurs, the concentration may be altered. If the solution stays open longer than necessary, then it will be best to discard the flask and use a new one. 9. The use of stable isotope-labeled ISs of AAs to be quantified corrects the ion suppression phenomenon occurring when several molecules co-elute, assuming that the signal modification present in each sample is the same for the analyte and its corresponding IS. Due to their cost, the number of AAs∗ has been limited to 17, and they have been chosen according to the necessity of a precise quantification of the AAs for the diagnosis of metabolic disorders. For the remaining AAs, one of the 17 nonhomologous AAs∗ has been used as a surrogate IS after careful validation of their quantification in these conditions. In some cases, the quantification could not be validated, but the method can be used for qualitative analysis of the marker. If necessary, other AAs∗ can be easily added to the method (e.g., Cit∗ ), in order to improve quantification results and/or to extend the linear dynamic range of the measurement. 10. Preparation and analysis of leukocyte samples for cystine measurements are slightly modified when compared to those for other samples, in order to enhance the sensitivity of the method for this purpose. The method is modified as follows: a. A leukocyte mixture is prepared by mixing the leukocyte pellet with 250 μL water and sonicating according to usual procedures currently in use in the laboratory for this purpose. b. Protein concentration is determined. c. The 10, 5, and 2.5 μM AA standards for cystine measurement in leukocytes are prepared by diluting adequately the 100 μM AA standard (see Step 4 of Section 2.6) in water. d. Leukocytes extracts, standards, and controls (ERNDIM external QAP for cystine in white blood cells and SKML internal QAP) are immediately deproteinized in 1.5-mL microtubes, as described in Step 4 of Section 3.1, with the exception that 200 μL of leukocyte extracts, standard (0, 2.5, 5, and 10 μM), or controls are mixed with 600 μL of deproteinization reagent.
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
49
e. After deproteinization, the supernatant is kept frozen at –80◦ C. f. Samples for injection are prepared by mixing 200 μL of each supernatant with 50 μL of AA∗ working solution in an injection vial. g. 5 μL is injected. h. The injection sequence is similar to that described in Step 1 of Section 3.4, with the exception that adequate standards and control samples are used. As leukocyte samples are usually very few, these samples can be included in another sample series, provided the leukocyte standards are also included in the same series. i. Quantification (see Section 3.5) involves only the corresponding transitions for Cys and Cys∗ and can be done with a specific quantification method. 11. Transitions are pairs of [M+H]+ precursor ion > fragment ion obtained before (precursor) and after (fragment) fragmentation of the AA and specific of it, e.g., 132 > 86 corresponds to the precursor ion (m/z = 132) and fragment ion (m/z = 86) produced by leucine. For each AA, the most sensitive/specific transition has been chosen. In some cases, the monitoring of two transitions for one AA is necessary to ensure the confident identification/quantification of the AA to be measured. Every molecule that can give the same fragmentation as another is a potential interference when these two molecules are present in the same mixture. This interference phenomenon is mainly due either to isobaric molecules, arising from in-source, collision-induced fragmentation, or to natural isotopic contributions (i.e., mainly 1.1% 13 C and 4.5% 34 S). Interference occurring between molecules analyzed in this method is reported in (7), but most of them have been separated from the AA of interest in the described chromatographic system. 12. Specific transitions have been determined with the API 2000 triple-quadrupole mass spectrometer. However, these transitions can be used in any triple-quadrupole mass spectrometer. DP and CE reported here are specific to the API 2000. The use of another triple-quadrupole mass spectrometer will necessitate the preliminary study of the specific parameters of the new apparatus for each AA. Various parameters (e.g., dwell time) for the data processing should be adapted to the software. Contact the manufacturer for any questions concerning this technology transfer. 13. This method uses ion-pairing, reversed-phase liquid chromatography, a technique which must be run in strictly standardized conditions. Repeatability of the retention time is obtained only when the system is equilibrated with a few
50
Piraud et al.
gradients. Frequent rinsing is necessary in order to limit the fouling of the column (by samples and ion-pairing agent) and thus the peak drift. In a series, the shape of the gradient must not be modified nor the duration of the L re-equilibration time. The first sample injected after rinsing the column cannot be used for analysis. The second sample (25 μM solution (26 AAs) is used to check the quality of the chromatography in the sequence. No more than three sequences must be analyzed in a series. When the column has to be maintained on-line for more than 24 h, it is possible to rinse the column on-line (10 h with 100 μL/min ACN) and use it again for a 24-h period (three sequences, 36–42 samples). 14. Retention times can be slightly different if the conditions of the chromatography are slightly different than those described (HPLC pumps, column, etc.). Calculating the ratios of the retention time of the analyte to that of the IS is helpful. For example, in instances of slight shifts of the retention times after several runs or on some samples, this ratio has been found to be very stable and allows correct identification of the peaks (see Note 15). 15. Gln/Glu (see Fig. 2.2c) and Asn/Asp (see Fig. 2.2d) present interference due to the 13 C isotope contribution and must present as separated peaks. Asp and Glu may be overestimated if they are not baseline separated from Asn and Gln, respectively (mainly Glu, due to the important concentration of Gln in biological fluids). aIle, Ile and Leu share a common 132 > 86 transition and must give three clear peaks with baseline separation (see Figs. 2.1 and 2.2 g). dALA coelutes with Ile. Thus, the common 132 > 86 transition cannot be used for the measurement of Ile when dALA is detectable. GABA and β-AIB cannot be separated by this method. β-AIB is measurable only if GABA is undetectable in the sample. Hse and Thr cannot be separated by this method. Thr is measurable only if Hse is undetectable in the sample. However, in our experience, no Hse has been detected among more than 10,000 analyzed biological samples. 16. When the homologous labeled AA is not available, another AA∗ , as close as possible to the target AA in terms of retention time and structure, is used (see Table 2.2). 17. For every series, the following parameters must be systematically checked: a. Each peak of each AA must be correctly integrated by the software. If not, manually correct the integration. b. The AA retention time/AA∗ retention time ratio must be 100% for each AA for which the corresponding AA∗ is
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism
51
present. For other molecules, the AA retention time/IS retention time ratio is the same in the standards and in the samples. c. The surface of the S2AE peak should be stable among all the standards and samples. If not, then repeat the preparation for injection and analysis. d. The identification of Leu, Ile, and aIle peaks must be correct: Leu/Leu∗ retention time ratio is 100%; Ile/Leu∗ retention time ratio is about 95%, and aIle/Leu∗ retention time ratio is about 90%. All of these can be quantified using the 132 > 86 common transition (135 > 89 for Leu∗ ) except for Ile when dALA is present. The 132 > 43 specific transition can be used for Leu quantification (135 > 46 for Leu∗ ). The 132 > 69 specific transition can be used for Ile and aIle quantification (135 > 46 for Leu∗ ). e. Hyp can be quantified either with the common 132 > 86 or with the 132 > 68 specific transition. f. The Asn/Asp∗ retention time ratio must be about 123%. g. The Gln/Gln∗ retention time ratio must be 100%. h. The Gln/Glu retention time ratio must be about 88%. Because of the prominent concentration of Gln in biological fluids (mainly plasma), Glu may be present as a double peak, with one peak at 100% of Glu∗ (corresponding to Glu) and one peak at 88% of Glu∗ (corresponding to Gln interference). Check that only the Glu part (as well as the Glu∗ part) is integrated for Glu quantification. i. The Sar/Ala∗ retention time ratio must be about 68%. j. The 76 > 30 transition used for Gly is the most sensitive of those characteristic for this AA, but it is not as sensitive relative to transitions for other AA. However, Gly concentrations are elevated in biological fluids, allowing for its accurate quantification. In CSF, the concentration of Gly is reduced, but elevated concentrations found in nonketotic hyperglycinemia can be detected. k. The His-3Me/Lys∗ retention time ratio is about 93%. An interfering peak is present at 88%, which may not be considered as His-3Me. l. The basic AA Arg, His, Lys, Orn elute late in the chromatographic system; a small interfering peak is present in the blank (0 μM AA standard) which must be taken into account in blanks for their measurement.
52
Piraud et al.
18. Quantitative validation, including the determination of the limit of quantification (LOQ), linear dynamic range, intra-day and inter-day precision, and accuracy (correlation and/or recovery experiments) have been obtained for all the AAs for which the corresponding AAs∗ are available (8). It has also been obtained for many AAs for which the corresponding AAs∗ are not used (9) (see Table 2.2). LOQs given in (7) are those determined with the API 2000. LOQs are highly instrument dependent, and a linearity limit has been found up to 3 mM for AAs for which the corresponding AAs∗ are used in the method. For other AAs for which AAs∗ were not used, the linearity limit was found up to 1 mM (9). For some AAs, the quantitative validation could not be obtained (9) (Table 2.2). 19. Cys-Hcy can be qualitatively evaluated by the presence/absence of the peak. A semi-quantitative estimation is possible using (Cys)2 as external standard and (Cys)2 ∗ as IS for the management of patients affected with homocystinuria. 20. The dual form of ASA (acid and anhydrides) is the cause of poor quantitative results for ASA and ASA anhydride by this method. Complete transformation of ASA to ASA anhydride is obtained by heating standards and samples at 100◦ C for 60 min. Total ASA anhydride can thus be measured and allow for the management of patients affected with argininosuccinic aciduria.
Acknowledgments The authors would like to thank Luc Anselmini for reading over this manuscript. The authors thank the journal Rapid Communication in Mass Spectrometry and Wiley Publishing for authorization to reproduce tables and figures from refs.(7–9). References 1. Moore, S., Spackman, D. H., Stein, W. H. (1958) Automatic recording apparatus for use in the chromatography of amino acids. Anal Chem 30, 1190–1206. 2. Vogeser, M., Seger, C. (2008) A decade of HPLC-MS/MS in the routine clinical laboratory – goals for further developments. Clin Biochem 9, 649–662.
3. Dooley, K. C. (2003) Tandem mass spectrometry in the clinical chemistry laboratory. Clin Biochem 36, 471–481. 4. Rashed, M. S. (2001) Clinical applications of tandem mass spectrometry: ten years of diagnosis and screening for inherited metabolic diseases. J Chromatogr B Biomed Sci Appl 758, 27–48.
Amino Acid Profiling for the Diagnosis of Inborn Errors of Metabolism 5. Gelb, M. H., Turecek, F., Scott, C. R., Chamoles, N. A. (2006) Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 29, 397–404. 6. Dietzen, D. J., Rinaldo, P., Whitley, R. J., Rhead, W. J., Hannon, W. H., Garg, U. C., et al. (2009) National academy of clinical biochemistry laboratory medicine practice guidelines: follow-up testing for metabolic disease identified by expanded newborn screening using tandem mass spectrometry executive summary. Clin Chem 55, 1615–1626. 7. Piraud, M., Vianey-Saban, C., Petritis, K., Elfakir, C., Steghens, J. P., Morla, A., Bouchu, D. (2003) ESI-MS/MS analysis of underivatised amino acids: a new tool for the diagnosis of inherited disorders of amino acid metabolism. Fragmentation study of 79
53
molecules of biological interest in positive and negative ionisation mode. Rapid Commun Mass Spectrom 17, 1297–1311. 8. Piraud, M., Vianey-Saban, C., Petritis, K., Elfakir, C., Steghens, J. P., Bouchu, D.. (2005) Ion-pairing reversed-phase liquid chromatography/electrospray ionization mass spectrometric analysis of 76 underivatized amino acids of biological interest: a new tool for the diagnosis of inherited disorders of amino acid metabolism. Rapid Commun Mass Spectrom 19, 1587–1602. 9. Piraud, M., Vianey-Saban, C., Bourdin, C., Acquaviva-Bourdain, C., Boyer, S., Elfakir, C., Bouchu, D. (2005) A new reversed-phase liquid chromatographic/tandem mass spectrometric method for analysis of underivatised amino acids: evaluation for the diagnosis and the management of inherited disorders of amino acid metabolism. Rapid Commun Mass Spectrom 19, 3287–3297.
Chapter 3 Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry David S. Millington and Robert D. Stevens Abstract The acylcarnitine profile is a diagnostic test for inherited disorders of fatty acid and branched-chain amino acid catabolism. Patients with this type of metabolic disorder accumulate disease-specific acylcarnitines that correlate with the acyl coenzyme A compounds in the affected mitochondrial metabolic pathways. For example, propionylcarnitine accumulates in patients with both propionic and methylmalonic acidemias. The test identifies and quantifies the species of acylcarnitines in the whole blood or blood plasma of patients at risk for or suspected of having such a disorder. The acylcarnitines are analyzed using electrospray ionization–tandem mass spectrometry. The instrument is used in the precursor ion scan mode to record the molecular species giving rise to fragment ions at m/z 99, derived specifically from the methylated acylcarnitines within the specimen. Quantification is based on the principle of stable isotope dilution, whereby concentrations are derived from the response ratio of each acylcarnitine species to that of a deuterium-labeled acylcarnitine standard. Interpretation of the acylcarnitine profile requires recognition of abnormal concentrations of specific analytes or patterns of analytes and knowledge of their metabolic origin. Key words: Acylcarnitines, tandem mass spectrometry, inherited metabolic disease, metabolomics, fatty acid oxidation.
1. Introduction Acylcarnitines are the catabolic end products of fatty acids and several branched-chain amino acids that are utilized to generate cellular energy. They are derived from their corresponding acyl coenzyme A (acyl-CoA) analogs through exchange of acyl groups between coenzyme A and L-carnitine by the action of a series of carnitine acyl-transferases. These transferases have overlapping T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_3, © Springer Science+Business Media, LLC 2011
55
56
Millington and Stevens
chain length specificity for the various acyl groups, ranging from 2 carbons (acetyl) to over 18 carbons (stearoyl) in length. Unlike their corresponding acyl-CoA analogs, acylcarnitines can cross mitochondrial and cell membranes, and are readily detectable in plasma. The plasma acylcarnitine profile is thus a fair reflection of the intramitochondrial acyl-CoA status at the time of analysis (1). Under normal metabolic circumstances, the acylcarnitine pattern in fasting plasma or serum is relatively stable and consists primarily of acetylcarnitine, plus relatively minor amounts of species derived from the branched-chain amino acids (C3–C5 acylcarnitines) and still lower concentrations of fatty acid intermediates (2) (Fig. 3.1a). Whole blood also exhibits significant concentrations of long-chain acylcarnitines in proportion to their corresponding dietary precursors (2) (C16, C18:1, C18:2, etc.; Fig. 3.1b). The presence of a block in the catabolic pathway of either the fatty acids or branched-chain amino acids results in the accumulation of one or more acyl-CoA intermediates. This in turn elevates the corresponding acylcarnitine concentrations. Analysis of plasma acylcarnitines can detect more than 25 metabolic disorders of fatty acid and branched-chain catabolism (3, 4), and it has become a frontline diagnostic test for these
100
C2
(a)
%
*
* *
*
*
* C14:1 C16
C18:1
0 m/z 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500
100
(b)
C2
%
* *
*
*
*
C16
*
C18:1
C14
0 m/z 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500
Fig. 3.1. (a) Mass spectrum of plasma acylcarnitines derivatized as their methyl esters, generated from a precursor ion scan of m/z 99 (sum of approximately 50 individual scans) after baseline subtraction, peak smoothing, and centroiding. Internal standard signals are indicated by (∗ ). Note the unit mass resolution at all points in the mass scale. (b) Mass spectrum of blood acylcarnitines derivatized as their methyl esters, generated from a precursor ion scan of m/z 99 (sum of approximately 50 individual scans).
Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry
57
types of disorders. The value of this test has gained international recognition as the basis for the so-called expanded newborn screening panel (5). All babies born in the United States, most European, and several other countries are now routinely screened by analysis of acylcarnitines and amino acids in dried blood spots on filter paper. Those detected as at risk for an inherited metabolic disorder are referred for confirmatory metabolic testing that includes analysis of plasma acylcarnitines (6, 7). Thus the acylcarnitine profile is widely used as a follow-up test to an abnormal newborn screen, as well as for the evaluation and monitoring of patients suspected of having a metabolic disorder (4). Results from the test are usually correlated with urine organic acid analysis performed at the same time. In vitro tests based on the investigation of defects in pathways using metabolic probes with cultured cell lines, particularly fibroblasts, also employ acylcarnitine analysis by tandem mass spectrometry (8, 9). More recently, acylcarnitine analysis has become integrated into targeted metabolomics platforms that have aided the discovery of animal models of human disease and the discovery of new mechanisms of insulin resistance (10, 11). Here we describe a popular method for the analysis of acylcarnitines as their methyl esters using tandem mass spectrometry. Although the preferred specimen type is plasma (or serum), satisfactory (though less accurate) results can also be achieved from dried blood or plasma spots on filter paper. The method is straightforward, robust, highly sensitive to changes in acylcarnitine concentration outside the control range and has a rapid turnaround time. It relies on the molecular specificity of the tandem mass spectrometer and the reproducibility of the analytical procedure. Six isotope-labeled internal standards are used to enable pseudo-quantitative analysis of the acylcarnitines. It should be noted that free carnitine cannot be reliably quantified by this method because the derivatization step partially hydrolyzes acylcarnitines to free carnitine. A separate procedure is required for accurate analysis of free and total carnitine by tandem mass spectrometry (12).
2. Materials 2.1. Standards and Internal Standards
1. Acetyl-L -carnitine and palmitoyl-L-carnitine hydrochloride salts (Sigma Chemical Co, St. Louis, MO) and octanoyl- Lcarnitine (Larodan, Malmo, Sweden). These standards are stored in airtight screw-cap vials within a sealed container with self-indicating desiccant at a temperature of –70◦ C or below. Storage time is 5 years.
58
Millington and Stevens
2. D3-L -Acetylcarnitine, D3-L-propionylcarnitine, D3-L D3-L butyrylcarnitine, D9-L-isovalerylcarnitine, octanoylcarnitine, and D3-L-palmitoylcarnitine hydrochloride salts (Cambridge Isotope Laboratories, Andover, MA). These standards are stored in airtight screw-cap vials within a sealed container with selfindicating desiccant at a temperature of –70◦ C (see Note 1). Storage time is 5 years. 3. Stock solutions of each standard and internal standard (except for C16) are prepared in deionized water by rapidly weighing approximately 25–50 mg of each and making up to a concentration of 0.1 M by addition of the exact volume of deionized water (DI-H2 O) required (see Note 1). The palmitoylcarnitine (C16) standard and internal standard solutions are prepared in MeOH:DI-H2 O (75:25 v/v). Stock solutions are stored at –20◦ C for up to 1 year. 4. Quality control stock solutions for the plasma assay are prepared by first mixing the standard solutions in correct proportion and diluting the mixture in MeOH:DI-H2 O (1:1, v/v) to provide a stock solution (5 mL) with final concentrations of 3 mM acetylcarnitine, 1 mM octanoylcarnitine, and 2 mM of palmitoylcarnitine. This quality control stock solution is stored at –20◦ C for up to 1 year. 5. Working quality control solution for the plasma assay is made first by a 1:5 dilution of the stock solution with MeOH:DI-H2 O (1:1, v/v) to make the working mixture (0.1 mL). Then 0.06 mL of the working mixture is equilibrated with 12 mL bovine adult serum (BAS) in a-15 mL centrifuge tube by agitating for 30 min on a sample rocker at ambient temperature. 6. 100 μL aliquots of the working quality control solution, containing final concentrations of 3 μM acetylcarnitine, 1 μM octanoylcarnitine, and 2 μM palmitoylcarnitine, are stored at –20◦ C. QC samples are analyzed at least in duplicate within each batch of samples. A “patient QC” is also selected to be analyzed within each sample run. This is a sample selected at random from a previously analyzed batch of patient samples. 7. Quality controls for the blood spot assay are prepared from a fresh specimen of whole blood (10 mL, heparinized). This whole blood specimen can be spiked with octanoyl-L carnitine at a concentration of 1 μM for comparison with the plasma QC standard. Then 50 μL aliquots are pipetted onto the pre-defined circles on newborn screening specimen cards. The spots are allowed to air-dry for at least 6 h and are then stored in paper envelopes within a sealed
Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry
59
plastic bag in the presence of self-indicating desiccant at –70◦ C. 8. Stock internal standard mixture is prepared by first mixing the internal standard solutions and diluting the mixture in MeOH:DI-H2 O (1:1, v/v) to provide final concentrations of 10 mM D3-acetylcarnitine, 4 mM D3palmitoylcarnitine, and 2 mM of each of the other internal standards. The stock internal standard solution is stored at –20◦ C for up to 1 year. 9. Working internal standard solution for the plasma assay is prepared from stock by serial dilution in MeOH:DIH2 O (1:1, v/v) to provide final concentrations of 0.1 mM D3-acetylcarnitine, 0.04 mM D3-palmitoylcarnitine, and 0.02 mM of each of the other internal standards (see Note 2). The working internal standard solution is stored for up to 1 month at 0–4◦ C. 10. Working internal standard solution for the dried blood spot assay is prepared from stock by serial dilution in MeOH:H2 O (1:1, v/v) to provide final concentrations of 12 μM D3-acetylcarnitine, 4.8 μM D3-palmitoylcarnitine, and 2.4 μM of each of the other internal standards. The working internal standard solution is stored for up to 1 month at 0–4◦ C. 11. A mass spectrometry tuning solution is prepared from the internal standard stock solution as follows. 30 μL of stock (containing 1 mM D3-acetyl-, 0.2 mM D3-octanoyl-, and 0.4 mM D3-palmitoyl-carnitines) is pipetted into a 5-mL glass vial. Evaporate to dryness under nitrogen. Add 100 μL of 3 M HCl in MeOH, cap and vortex mix, then incubate for 15 min at 50◦ C. Uncap the vial, evaporate to dryness, and reconstitute in 2 mL of final matrix (MeOH:H2 O, 85:15, v/v). Store at 0–4◦ C for up to 2 weeks. 2.2. Solvents and Reagents
1. Anhydrous methanolic hydrogen chloride (Supelco, Bellefonte, PA): 3 M. It is advisable to aliquot this reagent as rapidly as possible upon receipt into small screw-cap glass vials intended for single use (1–2 mL), wrap with parafilm, and store with desiccant in a sealed plastic bag at –20◦ C (see Note 3). 2. Anhydrous butanolic hydrogen chloride (Supelco): 3 M. It is advisable to aliquot this reagent as rapidly as possible upon receipt into small screw-cap glass vials intended for single use (1–2 mL), wrap with parafilm, and store with desiccant in a sealed plastic bag at –20◦ C (see Note 3). 3. HPLC-grade methanol.
60
Millington and Stevens
4. Deionized water (resistivity >17 M/cm). 5. Mobile phase: MeOH:DI-H2 O (15:85, v/v). This should be filtered prior to use through a 0.2-μm nylon membrane (Grace, Deerfield, IL). 2.3. Equipment and Other Materials
1. Tandem quadrupole mass spectrometer (Quattro Micro, Waters Associates, Milford, MA) equipped with ESI source, solvent delivery, and autosampler systems (Acquity, Waters). Equivalent systems from other vendors are acceptable. 2. Plate dryer, 96-well (Biotage, CA), preferably equipped R -coated stainless steel head. with Teflon 3. Harvard pump model HA11 (Instech Labs, Inc., Plymouth Meeting, MA). 4. A set of high-quality variable pipettes (0.5–10; 5–50, 20–200; 100–1000 μL; e.g., from Finnpipette or Eppendorf) are required, plus appropriate disposable pipette tips. 5. Microtiter plates (96-well; Evergreen, Los Angeles, CA). 6. A good quality steel hole puncher, 3/16 in. diameter. 7. Aluminum foil (7.5-cm-wide roll; Fisher Scientific, Pittsburgh, PA) and adhesive film (microadhesive film; USA Scientific, Ocala, FL), used to cover 96-well plates. 8. Plastic microcentrifuge and centrifuge tubes of 1.5, 2, and 15 mL capacity. 9. Laboratory benchtop centrifuge (e.g., Fisher model 235C from Fisher Scientific, Pittsburgh, PA or equivalent). 10. Vortex mixer. 11. Orbital shaker. 12. Incubator/oven.
3. Methods The general objective of this method is to generate a report showing the concentrations of up to 30 acylcarnitine species relative to the upper limits, and for a few analytes the lower limits, of a control range for each of them. It is not a rigorous quantitative analysis. The general principles are as follows. Isotope-labeled internal standards are added to the specimen as early as possible during the sample preparation procedure to establish a fixed ratio of their concentrations to those of the target analytes. When the sample is a dried blood spot (DBS), the internal standards are added to an extract from the DBS. Thus, the accuracy of the
Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry
61
method is inherently lower for DBSs than for plasma, which is compounded by the fact that the volume of blood in a DBS is estimated from the diameter of the punch and by the variable hematocrit. Similarly, dried plasma spots on filter paper, although facilitating specimen collection and transfer from remote or challenging locations, do not provide the most accurate results. For these reasons, liquid plasma (or serum) is regarded as the best and preferred specimen for this test. DBSs collected by the heelstick method are widely used to screen newborns using a method similar to that described here (6). The errors inherent in this approach are minimized in the diagnostic laboratory by using a larger sample quantity and a more rigorous analytical technique. The amounts of the added internal standards are designed to provide high sensitivity at the upper limits of the normal analyte concentration ranges, thus enhancing the discrimination between normal individuals and those at risk for a metabolic disorder. After precipitation of proteins, the acylcarnitines are converted to methyl esters to enhance sensitivity, which is especially important for dicarboxylic species (see Note 4). Their analysis is performed by flow injection of the derivatized sample directly into the electrospray ion source of a tandem quadrupole mass spectrometer operated at unit mass resolution, using a precursor ion scan of m/z 99. The precursor ions are recorded as a single accumulated spectrum from m/z 200 to 500 (Fig. 3.1a). After baseline subtraction, peak smoothing, and centroiding, the signal ratios for the analytes and their respective internal standards (see Table 3.1) are generated, converted to an approximate concentration by multiplying by the final concentration of internal standard added to the aliquot of sample, and inserted into a final report (see examples in Tables 3.2 and 3.3). In some cases, in order to distinguish between isomers (Section 3.4), samples may be reanalyzed as their butyl esters, in which case the precursor ion scan of m/z 85 is used and the precursor ions are recorded from m/z 250 to 550 (6).
Table 3.1 Pseudo-molecular ion masses of the target analytes and their respective internal standards (in bold characters) as methyl esters and butyl esters Species
Methyl ester
Butyl ester
C2
218
260
C2–IS
221
263
C3
232
274
C3–IS
235
277
C4
246
288
62
Millington and Stevens
Table 3.1 (continued) Species
Methyl ester
Butyl ester
C4–IS
249
291
C5:1
258
300
C5
260
302
C4–OH
262
304
C5–IS
269
311
C6
274
316
C5–OH
276
318
C3–DC
276
360
C4–DC
290
374
C8:1
300
342
C8
302
344
C5–DC
304
388
C8–IS
305
347
C6–DC
318
402
C10:2
326
368
C10:1
328
370
C10
330
372
C8–DC
346
430
C12:1
356
398
C12
358
400
C14:2
382
424
C14:1
384
426
C14
386
428
C14:1–OH
400
442
C14–OH
402
444
C16
414
456
C16–IS
417
459
C16–OH
430
472
C18:2
438
480
C18:1
440
482
C18
442
484
C18:2–OH
454
496
C18:1–OH
456
498
C16–DC
458
542
C18:1–DC
484
568
Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry
63
Table 3.2 Example of a final report from the acylcarnitine profile analysis of a plasma specimen, showing comparison of patient results (bold characters) with control values and interpretation Nanoliter range (nmol/mL)
Result (nmol/mL)
Status
21.48
NL
2.41
NL
<0.41
0.28
NL
(Tiglyl/Me-crotonyl)
<0.03
(BQL)
NL
(Isovaleryl/2Me-butyryl)
<0.35
0.22
NL
∗ <0.24
0.11
NL
<0.03
0.12
Elevated
Species
(Acyl group)
C2
(Acetyl)
C3
(Propionyl)
<2.57
C4
(Butyryl/isobutyryl)
C5:1 C5 OH–C4
(3-OH-butyryl)
C6
(Hexanoyl)
2.0–28.3
OH–C5
(3-OH-isovaleryl/malonyl)
∗ <0.19
0.13
NL
BZL
(Benzoyl)
∗ <0.01
(BQL)
NL
(Methylmalonyl/succinyl)
∗ <0.62
0.29
NL
C4–DC C8:1
(Octenoyl)
<0.24
0.23
NL
C8
(Octanoyl)
<0.11
0.10
NL
C5–DC
(Glutaryl)
∗ <0.02
(BQL)
NL
C6–DC
(Adipoyl/Me-glutaryl)
∗ <0.05
0.10
Elevated
C10:2
(Decadienoyl)
∗∗ <0.02
0.03
Elevated
C10:1
(Cis-4-decenoyl)
<0.14
0.08
NL
C10
(Decanoyl)
<0.20
0.13
NL
∗ <0.05
0.09
Elevated
C8–DC
(Suberyl)
C12:1
(Dodecenoyl)
<0.08
0.03
NL
C12
(Dodecanoyl)
<0.14
0.10
NL
C14:2
(Tetradecadienoyl)
<0.07
0.06
NL
C14:1
(Tetradecenoyl)
<0.14
0.05
NL
C14
(Tetradecanoyl)
<0.30
0.25
NL
0.04
Elevated
(BQL)
OH–C14:1
(3-OH-C14:1)
∗ <0.03
OH–C14
(3-OH-C14)
∗ <0.02
C16
(Palmitoyl)
OH–C16
(3-OH-palmitoyl)
C18:2
(Linoleoyl)
0.3–2.4 ∗ <0.02
<1.33 0.4–2.7
NL
1.83
NL
(BQL)
NL
1.48
Elevated
C18:1
(Oleoyl)
1.30
NL
OH–C18:2
(3-OH-linoleoyl)
∗ <0.03
(BQL)
NL
OH–C18:1
(3-OH-oleoyl)
∗ <0.02
(BQL)
NL
C16–DC
(C16-dicarboxylic)
∗ <0.01
(BQL)
NL
C18:1–DC
(C18:1-dicarboxylic)
∗ <0.01
(BQL)
NL
Comments: several mildly elevated values – pattern is nonspecific. BQL, Below quantitation limit; NL, normal. ∗ These values are ratios to internal standard; not nmol/mL. ∗∗ New analyte added to report.
64
Millington and Stevens
Table 3.3 Example of a final report from the acylcarnitine profile analysis of a blood spot specimen, showing comparison of patient results (bold characters) with control values and interpretation Nanoliter range (nmol/mL)
Result (nmol/mL)
Status
1.07
Low
0.06
NL
<0.47
0.09
NL
(Tiglyl/Me-crotonyl)
<0.07
(BQL)
NL
(Isovaleryl/2Me-butyryl)
<0.44
0.05
NL
∗ <0.18
(BQL)
NL
<0.13
(BQL)
NL
(3-OH-isovaleryl/malonyl)
∗ <0.04
(BQL)
NL
(BQL)
NL
(BQL)
NL
<0.55
0.06
NL
Species
(Acyl group)
C2
(Acetyl)
C3
(Propionyl)
<0.90
C4
(Butyryl/isobutyryl)
C5:1 C5 OH–C4
(3-OH-butyryl)
C6
(Hexanoyl)
OH–C5
2.1–15.7
BZL
(Benzoyl)
∗ <0.03
C4–DC
(Methylmalonyl/succinyl)
∗ <0.07
C8:1
(Octenoyl)
C8
(Octanoyl)
<0.25
(BQL)
NL
C5–DC
(Glutaryl)
∗ <0.06
(BQL)
NL
C6–DC
(Adipoyl/Me-glutaryl)
∗ <0.15
C10:2
(Decadienoyl)
C10:1 C10 C8–DC
0.03
NL
∗∗ <0.07
(BQL)
NL
(Cis-4-decenoyl)
<0.37
(BQL)
NL
(Decanoyl)
<0.50
(BQL)
NL
0.03
NL
(Suberyl)
∗ <0.15
C12:1
(Dodecenoyl)
<0.17
(BQL)
NL
C12
(Dodecanoyl)
<0.21
0.04
NL
C14:2
(Tetradecadienoyl)
<0.14
0.20
Elevated
C14:1
(Tetradecenoyl)
<0.23
0.66
Elevated
C14
(Tetradecanoyl)
<0.09
0.22
Elevated
0.03
NL
(BQL)
NL
0.21
NL
OH–C14:1
(3-OH-C14:1)
∗ <0.03
OH–C14
(3-OH-C14)
∗ <0.03
C16
(Palmitoyl)
OH–C16
(3-OH-palmitoyl)
C18:2
(Linoleoyl)
C18:1
(Oleoyl)
OH–C18:2
(3-OH-linoleoyl)
<0.23 ∗ <0.03
(BQL)
NL
<0.21
0.06
NL
<0.33
0.12
NL
(BQL)
NL
∗ <0.03
Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry
65
Table 3.3 (continued) Result (nmol/mL)
Status
∗ <0.03
(BQL)
NL
(C16-dicarboxylic)
∗ <0.03
(BQL)
NL
(C18:1-dicarboxylic)
∗ <0.03
(BQL)
NL
Species
(Acyl group)
OH–C18:1
(3-OH-oleoyl)
C16–DC C18:1–DC
Nanoliter range (nmol/mL)
Comments: modest elevations of C14:1, C14:2, C14 species. Elevated C14:1/C12:1 ratio Low acetyl signal Pattern is consistent with VLCADD and possible carnitine insufficiency BQL, Below quantitation limit; NL, normal ∗ These values are ratios to internal standard; not nmol/mL. ∗∗ New analyte added to report.
3.1. Sample Preparation for Plasma/Serum
1. Allow all specimens, reagents, quality controls, and the working internal standard mixture to equilibrate to ambient laboratory temperature for at least 30 min. This is especially true for the methanolic HCl, for which it is imperative that exposure to moisture is limited. 2. Vortex each specimen tube, quality control, and internal standard vial for at least 10 s to ensure homogeneity. 3. Pipette 100 μL of each sample into a numbered plastic microcentrifuge tube (2.0 mL capacity with snap-top cap) containing 5 μL of the plasma working internal standard solution, then gently vortex mix each tube for 5 s. Treat the pre-aliquoted quality controls in the same manner. 4. Add methanol (800 μL) to each tube, cap, and vortex mix vigorously for 30 s, then centrifuge for 5 min in order to pellet the protein precipitate. 5. Remove and uncap each tube in turn and transfer 200 μL of supernatant liquid to a pre-assigned well of a microtiter plate. 6. Cap the sample tubes and store at 0–4◦ C for possible repeat or reflex tests. Steps 7–11 below must be performed under a fume hood. 7. Transfer the microtiter plate to a 96-well plate dryer/incubator and evaporate the solvent under nitrogen flow at 50◦ C for 20 min. Then remove the plate and allow it to cool for 2 min. 8. Open a vial of reagent (3 M HCl-MeOH) and transfer 100 μL to each well as rapidly as possible, then place an
66
Millington and Stevens
adhesive film over the plate, and carefully seal. Discard unused reagent. 9. Place the plate in an incubator oven pre-heated to 50◦ C for 15 min. Use a timer, and do not exceed the specified time. 10. Allow the plate to cool for 2 min, then carefully remove the cover, and without delay evaporate the samples to dryness on the 96-well plate dryer (20 min at 50◦ C). If for any reason the samples cannot be analyzed within 1 h, cover and seal the plate with adhesive film and store at 0–4◦ C for up to 48 h. 11. Add final matrix (200 μL) to each sample well, then cover, and seal the plate with aluminum foil. Transfer the plate to the autosampler of the tandem mass spectrometer system for analysis. Typically, 20 μL of the sample is injected directly via a loop injector. 3.2. Sample Preparation for Dried Blood Spots (DBSs)
1. For each DBS sample and quality control, use a hole puncher to punch out two discs of 3/16 in. diameter from a single blood spot (equivalent to 15.2 μL whole blood) into a numbered microcentrifuge tube (1.5 mL capacity with snap-top cap). Punch a circle from a clean area of the filter paper to clean the hole puncher between sampling each specimen. 2. To the inside wall of each sample tube, pipette 6 μL of the DBS internal standard working solution, then add methanol (400 μL) to each tube, and vortex mix for 5 s. 3. Agitate the sample tubes on an orbital shaker for a timed 30 min at ambient temperature. Do not exceed the extraction time. 4. Centrifuge the sample tubes for 5 min and then transfer 200 μL aliquots of the supernatants to pre-assigned wells of a microtiter plate. 5. Finally, follow Steps 7–11 in Section 3.1 with the exception that 60 μL of reagent is required for derivatization instead of 100 μL. Note that plasma and DBS extracts can be prepared on the same microtiter plate.
3.3. Sample Preparation for Dried Plasma Spots (DPSs)
1. For each DPS sample, use a hole puncher to punch out four circles of 3/16 in. diameter from the plasma spots (equivalent to 15.2 μL whole blood) into a numbered microcentrifuge tube (1.5 mL capacity with snaptop cap). Punch a circle from a clean area of the filter paper to clean the hole puncher between sampling each specimen. 2. Follow Steps 2–5 in Section 3.2.
Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry
67
3.4. Sample Preparation with Modification to Form Butyl Esters
This procedure is used at the laboratory director’s discretion to distinguish between isomeric hydroxylated and dicarboxylic acylcarnitine species with two fewer carbon atoms when such species are elevated. It is used reflexively to retest all specimens (except from previously diagnosed patients) with elevated C5–OH/ C3–DC species (precursor m/z 276) and on occasion to distinguish between long-chain dicarboxylic species (C12–DC to C18:1–DC) and isomeric long-chain hydroxylated species (C14–OH to C20–OH). In such cases, the same procedures are followed in Sections 3.1, 3.2, and 3.3, depending on the specimen type, on stored residual extracts when available. The only modifications required in the sample preparation are to substitute butanolic HCl (3 M) for methanolic HCl as the reagent and to incubate at 65◦ C for 15 min instead of 50◦ C.
3.5. Analysis of Prepared Samples by Tandem Mass Spectrometry (MS/MS)
There is no specific recommendation as to the equipment manufacturer for the major item equipment required for the assay. The important requirements are that the mass analyzer is a triple-quadrupole equipped with ESI source and a minimum mass range of 0–1000 amu and there is an integrated solvent delivery system (at least a single HPLC pump) and an autosampler that can accommodate 96-well microtiter plates. The software package must enable a full precursor ion scan and be able to generate a summed spectrum. It must also generate ion ratios and either export them to a spreadsheet or incorporate software to perform the necessary calculations. There is no LC column; however, an inline filter is recommended to remove particulate matter. 1. Tune the mass spectrometer for optimal performance for acylcarnitine analysis using the tuning solution (Step 11 of Section 2.1). Ideally, this solution should be delivered continuously to the ion source via a syringe infusion pump. 2. Set up a run sequence in the order QC#1, blank, patient QC, patient specimens, QC#2 and analyze the first three samples prior to running any other sample. Generate reports from these analyses and review the acceptance criteria. These criteria must at a minimum address mass resolution and accuracy, absolute sensitivity, carryover, quantitative accuracy (for at least three analytes), and signal-to-noise ratio (see Note 5). The run is terminated if QC criteria are not met, and the problem must be corrected. 3. Generate and print the raw mass spectra (precursors of m/z 99) from each patient sample, acquiring data for about 1 min during the elution of the injected sample (Fig. 3.1a, b) and review each for overall quality. Generate the final reports (Tables 3.2 and 3.3) and add interpretative comments as appropriate (see Note 6).
68
Millington and Stevens
4. In order to establish initial analyte control ranges, it is necessary to analyze at least 50–100 specimens from age-matched patients considered at risk for an underlying metabolic disorder, but in whom no underlying disorder is clearly manifest in the acylcarnitine or the urine organic acid profile, if available. All the absolute analyte “levels” (i.e., the ratios of the analyte signals to their respective internal standards) are tabulated into a single spreadsheet and valid statistical methods applied to establish the upper limits for each analyte (also referred to as the “cutoffs”). Typically, the distribution of levels for each analyte is skewed and should be normalized by taking the logarithms of the ion ratios. Lognormal distributions, after removing outliers, allow for an accurate calculation of the upper limit (mean + 2SD). In plasma, it is helpful to establish a lower control limit (mean – 2SD) for acetylcarnitine (Table 3.2). Values below the low cutoff indicate either low flux through the mitochondrial oxidative pathways or carnitine insufficiency. In the DBS, acetyl-, C16and C18:1-acylcarnitines are provided with both upper and lower limits (mean ± 2SD) (Table 3.3). 5. In addition to the analytes, certain biochemically rational analyte ratios have been found helpful in assigning risk for a metabolic disorder. It is recommended that control ranges for C3/C2, C8/C10, and C14:1/C12:1 be compiled alongside the analyte ranges because their elevation, in combination with elevation of the primary analytes C3, C8, C14:1, is an added risk factor for metabolic disease (2, 4, Millington DS, unpublished). Mild isolated elevations of C3, C8, and C14:1 are rather commonly observed and are often unrelated to metabolic disease. 6. The control ranges generally stabilize after about 250 results are compiled and remain stable unless there is a significant change in either the sample population or the assay conditions (see Note 7). It is advisable to monitor these ranges by continuously compiling results and recalculating control ranges at 6-month intervals. 3.6. Interpretation
Providing interpretation and recommendations for the referring physician is an integral part of the analysis. This requires considerable experience and knowledge of the biochemistry of inherited metabolic disorders of fatty acid and amino acid catabolism, and continual review of the literature. In the authors’ laboratory, salient comments are initially made on the acylcarnitine report by a trained analyst, noting any significant findings. Then a final interpretation is provided by a professional (PhD or MD, PhD) who specializes and is certified in biochemical and/or medical genetics. Comments on the final report may
Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry
69
include recommendations for further testing or treatment, taking into consideration other test results, if applicable, plus any clinical and dietary information provided with the specimen. The acylcarnitine profile as performed by this method is not a complete analysis because it does not resolve isomeric or isobaric species, such as isobutyryl and butyryl (C4), isovaleryl and 2-methylbutyryl (C5), tiglyl and 3-methylcrotonyl (C5:1), methylmalonyl and succinyl (C4DC), and 30H-isovaleryl and 2-methyl-3OH-isobutyryl (C5OH). Although methods exist for separation of these isomers using chromatography in combination with tandem mass spectrometry (13), the added complexity, time, and validation required are not rewarded by the added information they provide because the acylcarnitine analysis is almost always part of a more extensive biochemical workup that includes, at a minimum, urine organic acid analysis. All known potential diagnostic conflicts arising from isomerism in the acylcarnitine profile are resolved by concomitant urine organic acid analysis. Although a comprehensive guide to interpretation is outside the scope of this report, the following general guidelines, plus comments elsewhere (2, 4), may be helpful. 1. The cutoffs in the diagnostic laboratory (mean + 2SD) are more aggressive than those used in newborn screening (typically mean + 4SD). Therefore, it is typical to observe abnormalities in more than 10% of all profiles. Most of these are mild and are typically the result of either random statistical variation or dietary artifacts. The interpreter’s challenge is to assess the biochemical significance of these abnormalities and make recommendations, often without the benefit of clinical information. 2. Review the report and note any elevated signals from the primary analytes. The primary analytes are those having potential diagnostic significance and include C3, C4, C5, C5:1, C5–OH/C3–DC, C5–DC, C8, C10:2, C14:1, C16, and C16–OH. Isolated elevations of analytes other than the primaries are not diagnostically significant. 3. Isolated elevations of primary analytes greater than the upper limit of the control range may be of potential diagnostic significance. The possible diagnoses should be mentioned, as well as recommendations for further diagnostic evaluation. 4. In addition to the primary analytes, certain secondary analytes and biochemically rational analyte ratios, such as the ratio of C3/C2 and C8/C10, are noted, since they add an element of risk for an underlying metabolic disorder. These ratios are computed within the same spreadsheet and compared with control ratios but are not normally reported.
70
Millington and Stevens
5. Literature review on a continuous basis is necessary because new discoveries continue to add to the scope of metabolic disorders detectable by the acylcarnitine profile. Examples of recent discoveries include the detection of peroxisomal disorders (14).
4. Notes 1. Standards and internal standards are supplied as solid hydrochloride salts. They are inherently chemically unstable and spontaneously decompose to carnitine hydrochloride and the corresponding fatty acid, both in the dry state and in solution. The rate of decomposition is increased by temperature and the presence of moisture. Hence precautions to avoid ingress of moisture during weighings, including equilibration to room temperature, rapid transfer to the weighing balance, immediate recapping, and freezing of the stock, and dry storage conditions are essential. 2. When the stock internal standards or solutions thereof expire or degrade and have to be replaced, their absolute concentrations may not be the same as in the original mixture. New internal standard mixtures must be rigorously checked alongside the previous lot using a standard mixture of acylcarnitine standards and quality controls before they are placed in service. To avoid re-establishing the control ranges from scratch, it is acceptable to initially adjust the response factors based on these comparisons. 3. The derivatizing reagents are extremely hygroscopic and very corrosive. They must be purchased from a reputable supplier, kept under anhydrous conditions to avoid premature loss of potency, and used under a fume hood. The stock should be stored in a refrigerator designed for storage of flammables. 4. Alternative methods for acylcarnitine analysis include butylation, which in the authors’ experience is less sensitive than methylation and offers no significant advantage except to differentiate between isomers when necessary, as described. Analysis of free acylcarnitines without derivatization is possible but not recommended. The esterification of acylcarnitine carboxyl groups enhances sensitivity both by producing preformed cations (analogous to surfactants) and by avoiding multiple cationization (from sodium, potassium, protium, ammonium ions in solution) that dilutes the signal of the targeted protonated form. This is particularly important for
Acylcarnitines: Analysis in Plasma and Whole Blood Using Tandem Mass Spectrometry
71
the dicarboxylic species such as glutarylcarnitine, a marker for glutaryl-CoA dehydrogenase deficiency that may be only slightly elevated above background in affected patients (15). 5. Use of multiple reaction monitoring (MRM) for acylcarnitine analysis is unacceptable. The quality of each recorded precursor ion mass spectrum (after processing the raw data) must be individually reviewed and assessed. Although there are few known interfering substances in this assay, occasionally spurious signals occur in the profile, possibly from unusual intravenous fluids, medications, or dietary additives (2, 4), and their impact on the assay can be assessed only in the full scan mode. The isotope peaks at adjacent masses must be completely resolved, and the signal-to-noise ratio calculated for every analysis. Degradation of the signal-tonoise ratio can lead to spurious elevations of analytes and misinterpretation (see Note 7). 6. The ion ratios used to generate the pseudo-concentration values are those of the target analytes and their corresponding internal standards (usually the nearest m/z value). Thus several analytes may “share” the same internal standard (e.g., C6 to C12, C5–DC to C8–DC, and C5–OH all use D3–C8 as the internal standard; all analytes higher in m/z value than the C12 acylcarnitine species share the D3–C16 internal standard). 7. The method is semi-quantitative and relies heavily upon the reproducibility of the analytical procedure. In the authors’ experience, the addition of more internal standards than the six recommended here does not significantly add to the analytical precision. Because several analytes of diagnostic significance (including C3–DC, C5–DC, and C16–OH) are undetectable in normal individuals, and there are no commercially available standards or internal standards available to establish quantitative parameters, the control limits for such analytes are merely a reflection of baseline electronic “noise” of the instrument. Hence the need to avoid spurious signal elevations by rigorous adherence to quality control procedures.
References 1. Kler, R. S., Jackson, S., Bartlett, K., Bindoff, L. A., Eaton, S., Pourfarzam, M., Frerman, F. E., Goodman, S. I., Watmough, N. J., Turnbull, D. M. (1991) Quantitation of acyl-coA and acylcarnitine esters accumulated during abnormal mitochondrial fatty acid oxidation. J Biol Chem 266, 22932–22939.
2. Millington, D. S. (2003) Tandem mass spectrometry in clinical diagnosis, in (Blau, N., Duran, M., Blaskovics, M. E., Gibson, M., eds.), Physician’s Guide to the Laboratory Diagnosis of Metabolic Diseases, 2nd edn, pp. E57–75. Springer, Berlin.
72
Millington and Stevens
3. Millington, D. S., Chace, D. H. (1992) Carnitine and acylcarnitines in metabolic disease diagnosis and management, in (Desiderio, D. M., ed.), Mass Spectrometry: Clinical and Biomedical Applications, Vol. 1, pp. 199–219. Plenum Press, New York, NY. 4. Rinaldo, P., Cowan, T. M., Matern, D. (2008) Acylcarnitine profile analysis. Genet Med 10, 151–156. 5. Sweetman, L., Millington, D. S., Therrell, B. L., Hannon, W. H., Popovich, B., Watson, M. S., Mann, M. Y., Loyd-Puryear, M. A. (2006) Naming and counting disorders (conditions) included in newborn screening panels. Pediatrics 117, S308–S314. 6. Chace, D. H., Kalas, T. A., Naylor, E. W. (2003) Use of tandem mass spectrometry for multianalyte screening of dried blood spot specimens from newborns. Clin Chem 49, 1797–1817. 7. Frazier, D. M., Millington, D. S., McCandless, S. E., Koeberl, D. D., Weavil, S. D., Chaing, S. H., Muenzer, J. (2006) The tandem mass spectrometry newborn screening experience in North Carolina: 1997– 2005. J Inherit Metab Dis 29, 76–85. 8. Ventura, F. V., Costa, C. G., Struys, E. A., Ruiter, J., Allers, P., Ijlst, L., Tavares de Almeida, I., Duran, M., Jakobs, C., Wanders, R. J. (1999) Quantitative acylcarnitine profiling in fibroblasts using [U-13C] palmitic acid: an improved tool for the diagnosis of fatty acid oxidation defects. Clin Chim Acta 281, 1–17. 9. Roe, C. R., Roe, D. S. (2000) Detection of gene defects in branched-chain amino acid metabolism by tandem mass spectrometry of carnitine esters produced by cultured fibroblasts. Methods Enzymol 324, 424–431. 10. Kao, H.-J., Cheng, C.-F., Chen, Y.-H., Hung, S.-I., Huang, C.-C., Millington, D.,
11.
12.
13.
14.
15.
Kikuchi, T., Wu, J.-Y., Chen, Y.-T. (2006) ENU mutagenesis identifies mice with cardiac fibrosis and hepatic steatosis caused by a mutation in the mitochondrial trifunctional protein beta-subunit. Hum Mol Genet 15, 3569–3577. Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., Rochon, J., Gallup, D., Ilkayeva, O., Wenner, B. R., Yancey, W. S. Jr., Eisenson, H., Musante, G., Surwit, R., Millington, D. S., Butler, M. D., Svetkey, L. P. (2009) A branched-chain amino acidrelated metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9, 311–326. Stevens, R. D., Hillman, S., Worthy, L. S., Sanders, D., Millington, D. S. (2000) Assay for free and total carnitine in human plasma using tandem mass spectrometry. Clin Chem 46, 727–729. Minkler, P. E., Stoll, M. S., Ingalls, S. T., Yang, S., Kerner, J., Hoppel, C. L. (2008) Quantification of carnitine and acylcarnitines in biological matrices by HPLC electrospray ionization–mass spectrometry. Clin Chem 54, 1451–1462. Rizzo, C., Boenzi, S., Wanders, R. J., Duran, M., Caruso, U., Dionisi-Vici, C. (2003) Characteristic acylcarnitine profiles in inherited defects of peroxisome biogenesis: a novel tool for screening diagnosis using tandem mass spectrometry. Pediatr Res 53, 1013–1018. Gallaher, R. C., Cowan, T. M., Goodman, S. I., Enns, G. M. (2005) Glutaryl-CoA dehydrogenase deficiency and newborn screening: retrospective analysis of a low excretor provides further evidence that some cases may be missed. Mol Genet Metab 86, 417–420.
Chapter 4 Analysis of Organic Acids and Acylglycines for the Diagnosis of Related Inborn Errors of Metabolism by GC- and HPLC-MS Giancarlo la Marca and Cristiano Rizzo Abstract The analysis of organic acids in urine is commonly included in routine procedures for detecting many inborn errors of metabolism. Many analytical methods allow for both qualitative and quantitative determination of organic acids, mainly in urine but also in plasma, serum, whole blood, amniotic fluid, and cerebrospinal fluid. Liquid–liquid extraction and solid-phase extraction using anion exchange or silica columns are commonly employed approaches for sample treatment. Before analysis can be carried out using gas chromatography-mass spectrometry, organic acids must be converted into more thermally stable, volatile, and chemically inert forms, mainly trimethylsilyl ethers, esters, or methyl esters. Key words: Organic acids, inborn errors of metabolism, gas chromatography-mass spectrometry, organic acidurias.
1. Introduction Organic acids are small molecules continuously produced, metabolized, and excreted by healthy individuals, as well as by those in abnormal states. Their origins include the metabolic pathways of amino acids, carbohydrates, lipids, and steroids, as well as drug metabolism, bacterial decomposition of food in the intestine, artifacts due to storage, sample preparation, and analysis of the sample (see Note 1). A list of the most characteristic diagnostic organic acids and their associated disorders is reported in Table 4.1. To date, by the analytical methodologies available, more than 250 different compounds (mainly organic acids) and glycine conjugates can be identified in the urine of a normal T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_4, © Springer Science+Business Media, LLC 2011
73
74
la Marca and Rizzo
Table 4.1 Characteristic organic acids profile in metabolic disorders Disorders
Metabolites
Amino acid disorders Maple syrup urine disease
2-Keto-isocaproic acid 2-Keto-isovaleric acid 2-Keto-3-methylvaleric acid 2-Hydroxy-isocaproic acid 2-Hydroxy-isovaleric acid 2-Hydroxy-3-methylvaleric acid
Tyrosinemia type I
4-Hydroxy-phenyllactic acid Succinylacetone 4-Hydroxy-phenylpyruvic acid
Tyrosinemia type II
4 Hydroxy-phenyllactic acid 4-Hydroxy-phenylpyruvic acid
Phenylketonuria
Phenyllactic acid Phenylpyruvic acid Mandelic acid di-TMS
Organic acidurias Isovaleric acidemia
3-Hydroxy-isovaleric acid Isovalerylglycine Isovalerylglutamic acid
3-Methylcrotonyl-CoA carboxylase deficiency
3-Hydroxy-isovaleric acid 3-Methylcrotonylglycine
Multiple carboxylase deficiency
3-Hydroxy-isovaleric acid Lactic acid Methylcitric acid 3-Hydroxy-propionic acid 3-Methylcrotonylglycine
3-Hydroxy-3-methylglutaric aciduria
3-Hydroxy-3-methylglutaric acid 3-Methylglutaconic acid 3-Methylglutaric acid 3-Hydroxy-isovaleric acid 3-Methylcrotonylglycine
3-Methylglutaconic aciduria
3-Methylglutaconic acid 3-Methylglutaric acid
3-Ketothiolase deficiency
2-Methyl-3-hydroxy-butyric acid 2-Methyl-acetoacetic acid 3-Hydroxy-butyric acid Tiglylglycine
2-Methylbutyryl-CoA dehydrogenase deficiency
2-Methylbutyrylglycine
2-Methyl-3-hydroxy-butyryl-CoA dehydrogenase deficiency
2-Methyl-3-hydroxy-butyric acid Tiglylglycine
Propionic acidemia
3-Hydroxy-propionic acid Methylcitric acid Propionylglycine Tiglylglycine
Analysis of Organic Acids and Acylglycines
Table 4.1 (continued) Disorders
Metabolites
Methylmalonic aciduria
Methylmalonic acid 3-Hydroxy-propionic acid Methylcitric acid
Glutaric aciduria type I
Glutaric acid 3-Hydroxy-glutaric acid Glutaconic acid
Beta-oxidation fatty acid defects Glutaric aciduria type II
Glutaric acid Ethylmalonic acid Adipic acid Suberic acid 2-Hydroxy-glutaric acid Isovalerylglycine Isobutyrylglycine 2-Methylbutyrylglycine
Short chain acyl-CoA dehydrogenase deficiency
Ethylmalonic acid Butyrylglycine Methylsuccinic acid Adipic acid Suberic acid Sebacic acid
Medium chain acyl-CoA dehydrogenase deficiency
5-Hydroxy-hexanoic acid 7-Hydroxy-octanoic acid Adipic acid Suberic acid Sebacic acid Octanedioic acid Decanedioic acid Hexanoylglycine Phenylpropionylglicine Suberylglycine
Very long-chain acyl-CoA dehydrogenase deficiency
Suberic acid Sebacic acid
Long-chain 3-hydroxy-acyl-CoA dehydrogenase deficiency
Adipic acid
Mitochondrial trifunctional protein deficiency
Suberic acid Sebacic acid 2-Hydroxy-adipic acid 3-Hydroxy-adipic acid 3-Hydroxy-octenedioic acid 3-Hydroxy-suberic acid 3-Hydroxy-decanedioic acid 3-Hydroxy-sebacic acid 3-Hydroxy-dodecenedioic acid 3-Hydroxy-dodecanedioic acid 3-Hydroxy-tetradecenedioic acid 3-Hydroxy-tetradecanedioic acid
Short-chain 3-hydroxy-acyl-CoA dehydrogenase deficiency
3,4-Dihydroxy-butyric acid 3-Hydroxy-glutaric acid
75
76
la Marca and Rizzo
Table 4.1 (continued) Disorders
Metabolites
Translocase deficiency
Adipic acid Suberic acid Sebacic acid Dodecanedioic aid Tetradecanedioic acid
Urea cycle defects HHH syndrome, OTCD, argininemia
Orotic acid
Citrullinemia, argininosuccinic aciduria
Uracil
Carbamoyl phosphate synthetase deficiency
3-Methylglutaconic acid
Carbohydrate metabolism Fructose 1,6-bisphosphatase deficiency
Lactic acid Glycerol Glycerol 3-phosphate
Glycogenosis type I
Lactic acid 3-Methylglutaconic acid 3-Metylglutaric acid
Galactosemia
4-Hydroxy-phenyl-lactic acid
Hereditary fructose intolerance
4-Hydroxy-phenyl-lactic acid
Pyruvate dehydrogenase (subunit E3) deficiency
Lactic acid 2-Ketoglutaric acid Succinic acid Malic acid 2-Keto-isocaproic acid 2-Keto-isovaleric acid 2-Keto-3-methylvaleric acid 2-Hydroxy-isocaproic acid 2-Hydroxy-isovaleric acid 2-Hydroxy-3-methylvaleric acid
Pyruvate carboxylase deficiency
Lactic acid Pyruvic acid Succinic acid Malic acid Fumaric acid
Miscellaneous Lactic acidosis
Lactic acid Pyruvic acid 2-Hydroxy-butyric acid 2-Hydroxy-isobutyric acid 4-Hydroxy-phenyl-lactic acid
Hyperoxaluria type I
Glycolic acid Oxalic acid
Hyperoxaluria type II
Oxalic acid Glyceric acid
D -glyceric
D -glyceric
aciduria
acid
Analysis of Organic Acids and Acylglycines
77
Table 4.1 (continued) Disorders
Metabolites
Glycerol kinase deficiency
Glycerol
3-Hydroxy-isobutyric aciduria
3-Hydroxy-isobutyric acid
Fumaric aciduria Malonic aciduria
Fumaric acid Malonic acid Methylmalonic acid Succinic acid
Mevalonic aciduria
Mevalonic acid
Alkaptonuria
Homogentisic acid
Canavan disease
N-acetylaspartic acid
Acylase I deficiency
N-acetyl-alanine N-acetylaspartic acid N-acetylglutamic acid N-acetyl-isoleucine N-acetyl-methionine N-acetyl-serine N-acetyl-valine
Pyroglutamic aciduria
Pyroglutamic acid
Xanthurenic aciduria
Xanthurenic acid
Peroxisomal biogenesis disorders
3,6-Epoxyoctanedioc acid 3,6-Epoxydecanedioc acid 3,6-Epoxydodecanedioc acid 3,6-Epoxytetradecanedioc acid 2-Hydroxy-sebacic acid 4-Hydroxy-phenyllactic acid Adipic acid Suberic acid Sebacic acid
Formiminoglutamic aciduria
Hydantoin-3-hydroxy-propionic acid
2-Hydroxy-glutaric aciduria
2-Hydroxy-glutaric acid
Aromatic L-amino acid decarboxylase deficiency
Vanyllactic acid
Dihydropyrimidine dehydrogenase deficiency
Thymine Uracil
Molybdenum cofactor deficiency
Xanthine
individual (1), although a great variability due to age and diet occurs (2). More than 70 inborn errors of metabolism are known to yield a characteristic urinary organic acids pattern, which is essential for diagnosis and follow-up (3). Organic acids can be detected in many biological matrices (e.g., blood, plasma, serum, amniotic fluid, and cerebrospinal fluid), but urine is the best fluid. This is mainly due to the fact that organic acids are concentrated in the urine by the kidneys, and this matrix contains very small quantities of proteins, reducing potential drawbacks during sample analysis.
78
la Marca and Rizzo
There are three main steps for the determination of urinary organic acids: (1) oximation; (2) extraction procedures: liquid– liquid extraction or ion-exchange chromatography or solid-phase extraction; (3) derivatization (usually silylation) followed by gas chromatography with mass detection in scan and/or single ion monitoring modes data acquisition. In 2002, Pitt and colleagues (4) reported a new tandem mass spectrometry (MS/MS)-based method to detect some organic acids and acylglycines in urine with a simple dilution of sample by mobile phase followed by direct injection into the mass spectrometer. In 2006, Rebollido and colleagues proposed a modified Pitt method as a neonatal screening tool for the detection of organic acids, acylglycines, acylcarnitines, and amino acids from urine spotted on filter paper (5). Herein, we describe in detail how to perform the analysis of organic acids and acylglycines in urine for the biochemical diagnosis of organic acidemias.
2. Materials
2.1. Reagent Preparation for Picrate Determination of Creatinine
All reagents (Siemens Healthcare Diagnostics Inc., Newark, NJ) are dissolved in water and ready to use and are of reagent grade unless stated otherwise. Their storage temperature is 2–8◦ C. These reagents are delivered and mixed automatically by the Dimension Chemistry System during the determination of creatinine. 1. Lithium picrate 25 mM. 2. Sodium hydroxide 100 mM. 3. Potassium ferricyanide 0.13 mM.
2.2. Solvents, Standards, and Reagents (See Note 1)
All solvents are high-purity chromatography grade. 1. Ethyl acetate. 2. Pyridine. 3 Hydroxyl chloride acid, 30%. 4. Methanol. 5. N-butanol. 6. Formic acid. 7. Acetic acid. 8. Diethyl ether. 9. Ba(OH)2 . 10. H2 SO4 .
Analysis of Organic Acids and Acylglycines
79
11. Hydroxylamine hydroxychloride (25 g/L), dissolved in pyridine. 12. Stock solutions (10 mM) of each organic acid (SigmaAldrich, St. Louis, MO) are prepared in water or methanol. a. Glycolic acid. b. Lactic acid. c. 3-Hydroxy-propionic acid. d. 3-Hydroxy-butyric acid. e. 4-Hydroxy-butyric acid. f. 2-Hydroxy-butyric acid. g. Glyceric acid. h. Fumaric acid. i. Maleic acid. j. 3-Hydroxy-isovaleric acid. k. 2-Hydroxy-isovaleric acid. l. Succinic acid. m. Methylmalonic acid. n. Glutaric acid. o. Ethylmalonic acid. p. Methylsuccinic acid. q. Phosphoethanolamine. r. 3-Methylglutaconic acid. s. 2-Ketoglutaric acid. t. 3-Methylglutaric acid. u. Adipic acid. v. 2-Hydroxy-glutaric acid. w. Mevalonic acid. x. 3-Hydroxy-glutaric acid. y. 4-Hydroxy-phenylacetic acid. z. Succinylacetone. aa. 3-Hydroxy-3-methylglutaric acid. bb. Homogentisic acid. cc. Suberic acid. dd. N-acetylaspartic acid. ee. Homovanillic acid. ff. 4-Hydroxy-phenylacetic acid. gg. Sulfocysteine. hh. Sialic acid.
80
la Marca and Rizzo
ii. Uracil. jj. Thymine. kk. Xanthine. ll. Orotic acid. mm. Uric acid. 13. Acylglycines were synthesized and purchased from Dr. H. Ten Brink (Academic Medical Hospital, the Netherlands). Stock solutions (10 mM) of acylglycines are prepared in water or methanol. a. Propionylglycine. b. Butyrylglycine. c. Isobutyrylglycine. d. 3-Methylcrotonylglycine. e. Tiglylglycine. f. Methylbutyrylglycine. g. Isovalerylglycine. h. Hexanoylglycine. i. 3-Phenylpropionylglycine. j. Suberylglycine. 14. Stock solutions (10 mM) of isotopically labeled and unlabeled internal standards are prepared in water or methanol. The storage temperature of the internal standards is –20◦ C. Under these conditions, the stability of the standard solutions is at least 6 months. a. Tricarballylic acid (TCA) (Sigma-Aldrich). b. 2-Oxocaproic acid (OA) (Sigma-Aldrich). c. 2-Phenylbutyric acid (PBA) (Sigma-Aldrich). d. Dimethylmalonic acid (DMMA) (Sigma-Aldrich). e. Tropic acid (TPA) (Sigma-Aldrich). f. Pentadecanoic acid (PDA) (Sigma-Aldrich). g. 2 H3 -methylmalonic acid (Cambridge Isotopes Laboratories, Andover, MA). h. 2 H3 -3-hydroxy-isovaleric acid (C.D.N. Pointe-Claire, Quebec, Canada). i. j.
Isotopes,
13 C -adipic acid (Cambridge Isotopes Laboratories). 6 2 H -3-hydroxy-3-methylglutaric acid (C.D.N. Iso3
topes). k. 2 H3 -acetylaspartic acid (C.D.N. Isotopes). l. 1,3 15 N2 -uric acid (Cambridge Isotopes Laboratories). m.
15 N -uracil 2
(C.D.N. Isotopes).
Analysis of Organic Acids and Acylglycines
81
n. 2 H4 -thymine (C.D.N. Isotopes). o. p.
15 N
2 -orotic acid (C.D.N. Isotopes). 2 H -propionylglycine (Dr. H. Ten 3
Brink, Academic
Medical Hospital, the Netherlands). q. 2 H3 -hexanoylglycine (Dr. H. Ten Brink, Academic Medical Hospital, the Netherlands). 15. Silylating reagents. a. N,O-bis-(trimethylsilyl)trifluoroacetamide (Supelco, Bellefonte, PA).
(BSTFA)
b. N-methyl-N-trifluoroacetamide (MSTFA) (Supelco). c. N,O-bis-(trimethylsilyl)acetamide (BSA) (Supelco). d. N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetimide (MTBSTFA) (Supelco). 2.3. Glassware
1. Extraction tubes (see Note 1): 8 mL screw-capped pyrex glass tubes (14 × 100 mm) with Teflon-lined caps (Barcorword Scientific, Ltd., Stone Staff, UK). 2. GC-MS 2 mL glass vials (9 mm) and caps with siliconized rubber septa (Chromacol, Ltd. Welwyn Garden City, UK) (see Note 1).
2.4. Columns
2.5. Internal Standards for Semiquantitative and Quantitative Determination of Organic Acids and Acylglycines in Urine by GC-MS
1. Gas chromatography separation column: Agilent J&W ULTRA2 (methyl siloxane 5% phenyl), 25 m × 0.20 mm × 0.33 μm fused silica capillary column or an HP-5 ms (methyl siloxane 5% phenyl), 25 m × 0.25 mm × 0.25 μm fused silica capillary column. A stock calibration solution containing 100 mg/L of each internal standard in ethanol/water (1:1, v/v) is made and stored at 4◦ C or less (see Note 2).The final makeup volume of the working calibration solution is 50 μL; therefore, the concentration of the working calibration solution is 1 μg/mol creatinine when the added internal standard volume is 10 μL and 2 μg/mol creatinine when the added internal standard volume is 20 μL. 1. Dimethylmalonic acid (DMMA). Working calibration solution contains 10 μL of DMMA (100 mg/L) in ethanol/water (1:1, v/v). Store at 4◦ C or less. 2. Tropic acid (TA). Working calibration solution contains 20 μL of TA (100 mg/L) in aqueous solution. Store at 4◦ C or less. 3. Pentadecanoic acid (PDA). Working calibration solution contains 20 μL of PDA (100 mg/L) in ethanol. Store at 4◦ C or less.
82
la Marca and Rizzo
4. Tricarballylic acid (propane-1,2,3-tricarboxylic acid). Working calibration solution contains 10 μL of tricarballylic acid (100 mg/L) in aqueous solution. Store at 4◦ C or less. 5. 2-Phenylbutyric acid. Working calibration solution contains 10 μL of a 2-phenylbutyric acid (100 mg/L) in aqueous solution. Store at 4◦ C or less. 6. 2-Oxocaproic acid (2-oxohexanoic acid). Working calibration solution contains 10 μL of a 2-oxocaproic acid (100 mg/L) in aqueous solution. Store at 4◦ C or less. 7. 2 H3 -methylmalonic acid. Working calibration solution contains 10 μL of 2 H3 -methylmalonic acid (100 mg/L) in ethanol. Store at 4◦ C or less. 8. 2 H3 -3-hydroxy-isovaleric acid. Working calibration solution contains 10 μL of 2 H3 -3-hydroxy-isovaleric acid (100 mg/L) in ethanol. Store at 4◦ C or less. 9.
13 C -adipic acid. Working calibration 6 μL of 13 C6 -adipic acid (100 mg/L) 4◦ C or less.
solution contains 10 in ethanol. Store at
10. 2 H3 -3-hydroxy-3-methylglutaric acid. Working calibration solution contains 10 μL of 2 H3 -3-hydroxy-3methylglutaric acid (100 mg/L) in ethanol. Store at 4◦ C or less. 11. 2 H3 -acetylaspartic acid. Working calibration solution contains 10 μL of 2 H3 -acetylaspartic acid (100 mg/L) in ethanol. Store at 4◦ C or less. 12. 2 H3 -propionylglycine. Working calibration solution contains 20 μL of 2 H3 -propionylglycine (100 mg/L) in ethanol. Store at 4◦ C or less. 13. 2 H3 -hexanoylglycine. Working calibration solution contains 20 μL of 2 H3 -hexanoylglycine (100 mg/L) in ethanol. Store at 4◦ C or less. 2.6. Internal Standards and Calibrators for Semiquantitative and Quantitative Determination of Organic Acids and Acylglycines in Urine by HPLC-MS/MS
A stock calibration solution containing 100 mg/L of each internal standard in ethanol is made and stored at 4◦ C or less (see Note 2). The final makeup volume of the working calibration solution is 200 μL; therefore, the concentration of the working calibration solution is 5 μg/mol creatinine when the added internal standard volume is 10 μL and 10 μg/mol creatinine when the added internal standard volume is 20 μL. 1. 2 H3 -methylmalonic acid. Working calibration solution contains 10 μL of 2 H3 -methylmalonic acid (100 mg/L) in ethanol. Store at 4◦ C or less.
Analysis of Organic Acids and Acylglycines
83
2. 2 H3 -3-hydroxy-isovaleric acid. Working calibration solution contains 10 μL of 2 H3 -3-hydroxy-isovaleric acid (100 mg/L) in ethanol. Store at 4◦ C or less. 3.
13 C
6 -adipic acid. Working calibration solution contains 10 μL of 13 C6 -adipic acid (100 mg/L) in ethanol. Store at 4◦ C or less.
4. 2 H3 -3-hydroxy-3-methylglutaric acid. Working calibration solution contains 10 μL of 2 H3 -3-hydroxy-3methylglutaric acid (100 mg/L) in ethanol. Store at 4◦ C or less. 5. 2 H3 -acetylaspartic acid. Working calibration solution contains 10 μL of 2 H3 -acetylaspartic acid (100 mg/L) in ethanol. Store at 4◦ C or less. 6. 2 H3 -propionylglycine. Working calibration solution contains 20 μL of 2 H3 -propionylglycine (100 mg/L) in ethanol. Store at 4◦ C or less. 7. 2 H3 -hexanoylglycine. Working calibration solution contains 20 μL of 2 H3 -hexanoylglycine (100 mg/L) in ethanol. Store at 4◦ C or less. 8. 1,3-15 N2 -uric acid. Working calibration solution contains 10 μL of 1,3 15 N2 -uric acid (100 mg/L) in ethanol. Store at 4◦ C or less. 9.
2 -uracil. Working calibration solution contains 10 μL of 15 N2 -uracil (100 mg/L) in water. Store at 4◦ C or less. 15 N
10. 2 H4 thymine. Working calibration solution contains 10 μL of 2 H4 thymine (100 mg/L) in water. Store at 4◦ C or less. 11.
15 N
2 -orotic acid. Working calibration solution contains 10 μL of 15 N2 -orotic acid (100 mg/L) in water. Store at 4◦ C or less.
12. Calibration solutions are prepared in an aqueous matrix to simulate the composition of urine samples. The aqueous matrix is composed of the following: a. 30 mM urea (Sigma-Aldrich). b. 11.4 mM sodium chloride (Sigma-Aldrich). c. 7.8 mM potassium chloride (Sigma-Aldrich). d. 1.5 mM potassium dihydrogen orthophosphate (SigmaAldrich). e. 7.6 mg/L bovine serum albumin (Sigma-Aldrich). 13. For monitoring recoveries and for quality control purposes, a pooled urine sample is prepared and diluted to a creatinine concentration of 1.0 mM. Two enriched urine samples are prepared by diluting the same pooled urine sample to a creatinine concentration of 1.0 mM and adding abnormal amounts of metabolites.
84
la Marca and Rizzo
2.7. Instruments
1. Dimension RxL Max Integrated Chemistry System (Siemens Healthcare Diagnostics Inc., Newark, NJ). 2. Gas chromatograph 6890 N with a single-quadrupole mass spectrometer (5975) as detector (Agilent Technologies, Palo Alto, CA). 3. 1100 Series Cap Pump HPLC (Agilent Technologies, Waldbronn, Germany) coupled to an Agilent Micro ALS Autosampler. 4. API 4000 bench-top triple-quadrupole mass spectrometer equipped with the TurboIonSpray source (AB–Sciex, Toronto, Canada).
3. Methods 3.1. Sample Collection
1. Urine samples should be collected over 24 h when possible. However, considering that prolonged urine collections are quite difficult, especially for newborns or very young babies, a random sample, preferably the first morning voiding, is acceptable. Thus, it is possible to obtain results similar to those obtained in a 1-day collection (6), although the amount of many organic acids, excreted per milligram of creatinine, varies considerably according to age. Newborns and small babies have not yet developed complete renal tubular function, so they normally excrete a larger amount of aliphatic acids. 2. Any urine samples must be accompanied by a form containing information about clinical history, therapy, and diet details over the last 48 h. This is a critical point for a correct interpretation of data (see Note 1). 3. Urine should be collected in clean glass containers to avoid contamination by plastic compounds (e.g., phthalates) (7), and the containers should be preferably sterile. 4. Collect 24-h urine samples by freezing each single sampling. Other protein-free physiological fluids should be collected in the same way (see Note 1). Considering that most patients are acutely ill, this procedure is almost impractical.
3.2. Storage
1. Analyze urine samples immediately or freeze at –70◦ C until analysis. 2. If a –70◦ C freezer is not available, freeze the urine samples at –20◦ C. Indeed, if containers are not sterile, prolonged exposure at room temperature leads to bacterial growth, production of artifacts, and the formation of new organic acids (8) or loss of volatile acids (see Note 1). Urine samples should
Analysis of Organic Acids and Acylglycines
85
be transported in a deeply frozen state, preferably packed in solid carbon dioxide at –70◦ C. 3. Some authors suggested adding 2 mL of chloroform or merthiolate [o-(carboxyphenyl)thioethylmercury] sodium salt to urine sample as a preservative (see Note 1). Merthiolate is toxic by inhalation, ingestion, and contact with skin (EC hazard symbol T+), and it has cumulative effects. It is also very toxic to aquatic organisms and may cause longterm adverse effects in aquatic environments. Therefore, the addition of choloroform or merthiolate as a preservative is very seldom used. 3.3. Creatinine Assay
Creatinine (2-imino-1-methyl-4-imidazolidinone) concentration is the reference to which each organic acid concentration is typically normalized for quantitative purposes. However, this molecule is often declared unsuitable as a reference standard (8), due to its increasing excretion with age (9) and wide variation between individuals, especially small babies and newborns (10). Moreover many differences between males and females have been reported (9). Thus, the accurate determination of creatinine prior to urinary organic acid analysis is extremely important. The alkaline picrate-based method (a modified Jaffe method) has been reported to be less susceptible than conventional methods to interference from non-creatinine Jaffe-positive compounds (11). Sampling, reagent delivery, mixing, and processing of the analysis are automatically carried out by the Dimension Chemistry System. 1. Add about 100 μL of urine to a cuvette. Creatinine reacts with picrate (lithium picrate 25 mM) in presence of a strong base, like sodium hydroxide (NaOH 100 mM), forming a red chromophore (λ 510 nm). The rate of increasing absorption is directly proportional to the creatinine concentration in the sample. 2. Read the value of creatinine. It is measured by using a bichromatic (absorption wavelengths: λ 510 and λ 600 nm) rate technique (Dimension Chemistry System or similar) (see Note 3).
3.4. Oximation
1. Dilute urine sample corresponding to 0.5 or 1 mmol of creatinine with distilled water to 1,500 mL. 2. Adjust the pH to 14 with 5 M NaOH. 3. Add 0.5 mL of aqueous hydroxylamine solution. 4. Heat the urine and hydroxylamine mixture at 60◦ C for 30 min, then cool the solution to room temperature, and acidify to pH 1 with 6 M HCl. 5. After acidification, proceed with extraction as described below.
86
la Marca and Rizzo
3.5. Extraction Procedure
In our experience, samples capped well with silicon caps are stable about 1 week at 4◦ C, prior to the derivatization step (12). The solvent extraction procedure described below is widely used even if polar acids are not efficiently extracted. Moreover, many non-acid compounds are extracted, such as urea and alcohols, and these compounds can interfere with the chromatographic separation. Great attention also must be paid to the contaminants potentially present in the organic extraction solvent (see Note 1). a. Place a volume of urine corresponding to 0.5 or 1 mmol of creatinine in a 14 × 100-mm screw-cap culture tube. b. Dilute the sample with deionized water to 1.5 mL and adjust the pH to 1 by dropwise addition of 6 M HC1 or 2.5 M H2 SO4 . c. Add internal standards: 10 μL of DMMA (100 mg/L) in ethanol/water (1:1, v/v); 20 μL of TA (100 mg/L) in water; and 20 μL of PDA (100 mg/L) in ethanol. d. Extract the acidified sample three or four times with 2-mL aliquots of ethyl acetate (or diethyl ether), shaking the tube vigorously. The extraction efficiency has been measured by Tanaka and colleagues (13) who reported that hydroxy acids and low molecular weight dicarboxylic acids were recovered with much higher yields with ethyl acetate than with diethyl ether. e. After shaking, centrifuge the mixture at 1,620×g for 10 min. f. Combine the organic layers in a second tube (see Note 4) and then dry the combined extract over about 1–1.5 g of anhydrous Na2 SO4 for 45–60 min. g. Wash the Na2 SO4 twice with 1-mL portions of ethyl acetate. Optionally, the sample can be filtered with filter paper into a third tube prior to washing the Na2 SO4 . h. Dry the extract under a nitrogen stream at 60◦ C. When the volume is about 1–1.5 mL, transfer the solution to a 2-mL GC-MS glass vial and dry the remaining solvent.
3.6. Derivatization Procedures
After extraction procedures, in order to make the acids more volatile and stable for gas chromatography, a derivatization step is performed. Most laboratories use trimethylsilylation. 1. Add 50 μL of bis-trimethylsilyl-trifluoroacetamide (BSTFA) to the evaporated sample in a 2-mL GC-MS glass vial, vortex-mix, and incubate at 60◦ C for 30 min. It is also possible to use N-methyl-N-trifluoroacetamide (MSTFA), N,O-bis[trimethylsilyl]acetamide (BSA), or N-methyl-N[tert-butyldimethyl-silyl]trifluoroacetimide (MTBSTFA) as alternative derivatization reagents. All of these agents can be used at full strength or diluted with a suitable solvent such as pyridine.
Analysis of Organic Acids and Acylglycines
3.7. Gas Chromatography/Mass Spectrometry Analysis
87
1. The vialed samples should be kept at room temperature until analysis and analyzed no later than 24 h after preparation. 2. Generally, the GC analyses are performed on a gas chromatograph coupled to a single-quadrupole mass spectrometer as analyzer. 3. The capillary column is typically a nonpolar column such as an HP-5 ms or J&W ULTRA2 or similar. 4. The carrier gas is helium at 1 mL/min. 5. The column oven initial temperature is 70◦ C; the temperature gradient is 10◦ C/min to 280◦ C, followed by 280◦ C for 5 min. 6. The injection volume is 1 μL (see Note 5) with a split ratio of 10:1, and the front inlet temperature is 280◦ C. 7. The detector temperature is typically about 280–300◦ C. 8. The mass spectra are recorded both in selected ion monitoring (SIM) and in scan mode over a mass range of 40– 550 m/z. A list containing the most characteristic ions and molecular weights of the main organic acids is reported in Table 4.2. Table 4.3 contains the most diagnostic acylglycines molecular ions and characteristic fragments. 9. The retention times are obtained using chemical organic acid standards. Both standards and urine samples are analyzed under the same chromatographic conditions. 10. Mass calibration (see Note 6) of the instrument by using a mixture containing the target compounds at different concentrations is a critical step. The authors calibrated the mass spectrometer using a mixture containing about 100 different organic acids using a 5-point curve containing 10, 25, 50, 100, and 250 μM of each. 11. The calibration must be performed monthly or more frequently (see Note 6). 12. For quantitation purposes, a mixture containing 50 μM of standards is analyzed weekly, and if the quantitation report differs from the expected values by more than 25%, a new calibration curve is made. 13. The GC-MS system must have a regular maintenance schedule to avoid artifacts and generation of new compounds in the organic acids profile (see Note 7). 14. Many labs choose to perform a semiquantitative determination of urinary organic acids using non-labeled internal standards. These standards are non-physiological compounds that elute in proximity to the organic acids to be quantified. In our own experience, dimethylmalonic
88
la Marca and Rizzo
Table 4.2 The most characteristic ions and molecular weights of the main organic acids Characteristic urinary organic acid
MW
M-15
Ion 1
Ion 2
2-Keto-isovaleric acid (oxime) di-TMS
275
260
232
158
2-Keto-isocaproic acid (oxime) di-TMS
289
274
200
172
2-Keto-3-methylvaleric acid (oxime) di-TMS
289
274
200
172
2-Ketoglutaric acid (oxime) di-TMS
377
362
260
2-Hydroxy-3-methylvaleric acid
276
261
159
2-Hydroxy-adipic acid
378
363
2-Hydroxy-butyric acid di-TMS
248
233
131
2-Hydroxy-glutaric acid
364
349
247
2-Hydroxy-isobutyric acid di-TMS
248
233
95
2-Hydroxy-isocaproic acid di-TMS
276
261
159
103
2-Hydroxy-isovaleric acid di-TMS
262
247
219
145
203
2-Hydroxy-sebacic acid tri-TMS
419
391
317
2-Methyl-3-hydroxy-butyric acid di-TMS
262
247
117
2-Methyl-acetoacetic acid di-TMS
260
245
3-Hydroxy-3-methylglutaric acid
378
363
273
3-Hydroxy-adipic acid
378
363
247
3-Hydroxy-butyric acid
248
233
191
117
3-Hydroxy-isobutyric acid
248
233
177
103
3-Hydroxy-decanedioic acid
432
417
233
3-Hydroxy-dodecanedioic acid
462
447
233
3-Hydroxy-dodecanedioic acid
460
445
233
3-Hydroxy-glutaric acid
364
349
259
185
3-Hydroxy-isovaleric acid
262
247
205
131
3-Hydroxy-octanedioic acid
404
389
233
217
3-Hydroxy-propionic acid di-TMS
234
219
204
177
3-Hydroxy-sebacic acid tri-TMS
434
419
233
217
3-Hydroxy-suberic acid tri-TMS
406
391
233
217
3-Hydroxy-tetradecanedioic acid tri-TMS
490
475
233
217
3-Hydroxy-tetradecanedioic acid tri-TMS
488
473
233
217
247
3-Methylglutaconic acid di-TMS
288
273
198
183
3-Methylglutaric acid di-TMS
290
275
204
69
3,4-Dihydroxy-butyric acid tri-TMS
336
233
189
3,6-Epoxyoctanedioc acid di-TMS
332
317
201
174
3,6-Epoxydecanedioc acid di-TMS
360
345
201
174
3,6-Epoxydodecanedioc acid di-TMS
388
372
201
174
3,6-Epoxytetradecanedioc acid di-TMS
416
401
201
174
4-Hydroxy-butyric acid di-TMS
248
233
204
117
Analysis of Organic Acids and Acylglycines
89
Table 4.2 (continued) Characteristic urinary organic acid
MW
M-15
Ion 1
Ion 2
4-Hydroxy-phenyllactic acid tri-TMS
398
383
308
179
4-Hydroxy-phenylpyruvic acid tri-TMS
396
381
325
4-Hydroxy-phenylpyruvic acid (oxime) tri-TMS
412
396
277
190
4,5-Dihydroxy-hexanoic tri-TMS (erythro and threo)
364
349
247
129
4,5-Dihydroxy-hexanoic lactone (erythro and threo)
202
187
158
143
5-Hydroxy-hexanoic acid di-TMS
276
261
204
171
7-Hydroxy-octanoic acid di-TMS
304
289
260
Adipic acid di-TMS
290
275
172
111 119
Decanedioic acid di-TMS
344
329
164
Dodecanedioic aid
374
359
243
Ethylmalonic acid di-TMS
276
261
217
Fumaric acid di-TMS
260
245
147
Glutaconic acid di-TMS
274
259
217
Glutaric acid di-TMS
276
261
158
Glycerol tri-TMS
308
293
218
205
Glycerol 3-phosphate tetra-TMS
460
445
357
299
Glyceric acid tri-TMS
322
307
292
205
Hydantoin-3-hydroxy-propionic acid tri-TMS
388
373
257
230
Homogentisic acid tri-TMS
384
341
252
Isovaleryl-glutamic acid di-TMS
375
360
258
156
Lactic acid di-TMS
234
219
190
117
Malic acid tri-TMS
350
319
245
233
Malonic acid di-TMS
248
233
133
Mandelic acid di-TMS
296
281
253
179
Methylcitric acid tetra-TMS
494
479
389
361
Methylmalonic acid di-TMS
262
247
218
157
Methylsuccinic acid di-TMS
276
261
217
Mevalonic acid tri-TMS
364
349
247
233
Mevalonic lactone mono-TMS
202
187
145
115
Mevalonic lactone di-TMS
274
259
187
175
N-acetyl-alanine di-TMS
275
260
232
158
N-acetylaspartic acid tri-TMS
391
376
274
230
N-acetylaspartic acid di-TMS
319
304
202
158
N-acetylglutamic di-TMS
333
318
216
158
N-acetyl-isoleucine tri-TMS
245
230
128
86
N-acetyl-methionine di-TMS
335
320
274
261
N-acetyl-serine di-TMS
291
276
261
186
90
la Marca and Rizzo
Table 4.2 (continued) Characteristic urinary organic acid
MW
M-15
Ion 1
Ion 2
N-acetyl-valine di-TMS
303
288
260
186 137
Octanedioic acid di-TMS
316
301
136
Orotic acid tri-TMS
372
357
254
Oxalic acid di-TMS
234
219
190
Phenyllactic acid di-TMS
310
295
220
Phenylpyruvic acid (oxime)
323
308
189
Pyroglutamic acid di-TMS
273
258
156
Pyruvic acid (oxime) di-TMS
247
232
204
Sebacic acid di-TMS
346
331
345
Suberic acid di-TMS
318
303
169
Succinic acid di-TMS
262
247
172
Succinylacetone (oxime)
227
212
182
Tetradecanedioic acid di-TMS
402
387
271
Uracil di-TMS
256
241
99
Vanillactic acid tri-TMS
428
413
338
Xanthurenic acid tri-TMS
420
406
318
193
138
209
acid, tropic acid, pentadecanoic acid, tricarballylic acid, 2-oxocaproic acid, and 2-phenylbutyrric acid can be used as internal standards. Their use is advantageous only in terms of cost per analysis (see Note 8). 15. Quantitation is performed according to either Internal Standard Method or the Absolute Calibration Curve Method, generally using the peak height or peak area. 16. Internal Standard Method a. Prepare several standard solutions containing a constant amount of the specified labeled or unlabeled internal standard and known graded amounts of the compound to be quantified. b. With each of the chromatograms obtained by injecting a constant volume of each standard solution, calculate the ratio of the peak height or peak area of the compound to be quantified to that of the internal standard. c. Prepare a calibration curve by plotting these ratios on the ordinate and the ratios of each amount of the compound to be quantified to the amount of the internal standard, or simply the amount of the compound to be quantified, on the abscissa. The calibration curve is usually a straight line through the origin.
Analysis of Organic Acids and Acylglycines
91
Table 4.3 The most diagnostic acylglycines molecular ions and characteristic fragments Acylglycine mono-TMS derivatives
[M]+
[M-15]+
[M-117]+ [M-146]+ [M-59]+
[M-45]+ [M-44]+
2-Methylbutyrylglycine
231
216
114
85
172
186
187
3-Methylcrotonylglycine
229
214
112
83
170
184
185
Butyrylglycine
217
202
100
71
158
172
173
Hexanoylglycine
245
230
128
99
186
200
201
Isobutyrylglycine
217
202
100
71
158
172
173
Isovalerylglycine
231
216
114
85
172
186
187
Phenylpropionylglycine
270
255
86
57
144
158
159
Propionylglycine
203
188
86
57
144
158
159
Tiglylglycine
229
214
112
83
170
184
185
Suberylglycine
300
285
183
154
241
255
256
Aclglycine di-TMS derivatives
[M]+
[M-15]+
[M-117]+ [M-131]+ [M-218]+
2-Methylbutyrylglycine
303
288
186
172
85
3-Methylcrotonylglycine
301
286
184
170
83
Butyrylglycine
289
274
172
158
71
Hexanoylglycine
317
302
200
186
99
Isobutyrylglycine
289
274
172
158
71
Isovalerylglycine
303
288
186
172
85
Phenylpropionylglycine
343
328
226
212
125
Propionylglycine
275
260
158
144
57
Tiglylglycine
301
286
184
170
83
Suberylglycine
375
360
256
242
155
[M-15]+ =[M-CH3 ]+ [M-117]+ =[M-COOSi(CH3 )3 ]+ [M-146]+ =[RCO]+ R=alkyl radical [M-59]+ =[M-CH2 COOH]+ [M-45]+ =[M-COOH]+ [M-44]+ =[M-COO]+ [M-131]+ =[M-CH2 COOSi(CH3 )3 ]+ [M-218]+ =[RCO]+ R=alkyl radical
d. Prepare the urine sample containing the same amount of the internal standard as directed in the individual monograph. e. Record a chromatogram under the same conditions as for the preparation of the calibration curve. f. Calculate the ratio of the peak height or peak area of the compound to be quantified to that of the internal standard.
92
la Marca and Rizzo
g. Perform the quantitation using the calibration curve. 17. Absolute Calibration Curve Method a. Prepare standard solutions containing a graded amount of the compound to be quantified and inject a constant volume of each standard solution. b. With the chromatograms obtained, prepare a calibration curve by plotting the peak heights or peak areas of the compound to be quantified on the ordinate and the amounts of the compound to be quantified on the abscissa. The calibration curve is usually a straight line through the origin. c. Prepare the urine sample as directed in the individual monograph. d. Record a chromatogram under the same conditions used for the preparation of the calibration curve. e. Measure the peak height or peak area of the compound to be quantified. f. Perform the quantitation using the calibration curve. 3.8. Liquid Chromatography/Mass Spectrometry Analysis
1. Loop injections (20 μL) are made via a HPLC autosampler into a mobile phase of acetonitrile–water (1:1 by volume). 2. The mobile phase and sample are infused at a flow rate of 30 μL/min by an HPLC pumping system into the electrospray ion source of a triple-quadrupole mass spectrometer. 3. The ion source operated with a capillary voltage of 5.0 kV (positive-ion mode) or 4.5 kV (negative-ion mode) and a temperature of 250◦ C. Nitrogen is used as collision gas at a pressure of 10 mTorr. 4. Fragmentation transitions, declustering potentials, and collision energies should be optimized during manual loop injections of pure compounds. 5. Negative-ion multiple reaction monitoring (MRM) for 49 metabolites and 11 labeled internal standards is performed under the conditions shown in Table 4.4. 6. Data are acquired for 1.3 min after injection, and the total cycle time between injections is 2.1 min. 7. Data are processed with MRM signals averaged between 0.6 and 1.3 min and baseline subtraction of signals from 0.15 to 0.45 min. 8. Raw data are exported to an Excel spreadsheet file (Microsoft) for calculations.
Analysis of Organic Acids and Acylglycines
93
Table 4.4 Precursor (Q1), product ion (Q3) masses, and optimized voltages for the 60 compounds studied in negative-ion mode Metabolites
Q1/Q3 transition
DP (V)
CE (V) Internal standard
1 Glycolic acid
75 > 47
–30
–20
14
2 Lactic acid
89 > 43
–40
–20
14
3 3-Hydroxy-propionic acid
89 > 59
–30
–15
14
4 3-Hydroxy-butyric acid
103 > 59
–30
–15
14
5 4-Hydroxy-butyric acid
103 > 57
–15
–20
14
6 2-Hydroxy-butyric acid
103 > 57
–17
–25
14
7 Glyceric acid
105 > 75
–25
–15
14
8 Fumaric acid
115 > 71
–18
–12
14
9 Maleic acid
115 > 71
–19
–13
14
10 3-Hydroxy-isovaleric acid
117 > 59
–21
–14
15
11 2-Hydroxy-isovaleric acid
117 > 71
–31
–16
14
12 Succinic acid
117 > 73
–12
13
14 14
13 Methylmalonic acid
117 > 73
–10
–13
14 2 H3 -Methylmalonic acid 15 2 H3 -3-Hydroxy-isovaleric acid
120 > 76
–10
–13
123 > 59
–21
–15
16 Glutaric acid
131 > 87
–10
–13
28
17 Ethylmalonic acid
131 > 87
–10
–12
28
18 Methylsuccinic acid
131 > 87
–11
–13
28
19 Phosphoethanolamine
140 > 79
–20
–15
28
20 3-Methylglutaconic acid
143 > 99
–5
–9
28
21 2-Ketoglutaric acid
145 > 101
–20
–13
28
22 3-Methylglutaric acid
145 > 101
–22
–16
28
23 Adipic acid
145 > 83
–10
–18
28
24 2-Hydroxy-glutaric acid
147 > 129
–22
–13
28
25 Mevalonic acid
147 > 59
–25
–21
28
26 3-Hydroxy-glutaric acid
147 > 85
–11
–13
31
27 4-Hydroxy-phenylacetic acid
151 > 107
–8
–20
28
28 13 C6 -Adipic acid
151 > 88
–10
–18
29 Succinylacetone
157 > 99
–10
–12
46
30 3-Hydroxy-3-methylglutaric acid
161 > 99
–13
–14
31
31 2 H3 -3-Hydroxy-3-methylglutaric acid
164 > 102
–13
–14
32 Homogentisic acid
167 > 123
–34
–15
28
33 Suberic acid
173 > 111
–31
–18
28
34 N-acetylaspartic acid
174 > 88
–17
–19
35
35 2 H3 -acetylaspartic acid
177 > 89
–17
–19
36 Homovanillic acid
181 > 137
–19
–13
28
37 4-Hydroxy-phenyllactic acid
181 > 163
–30
–16
28
94
la Marca and Rizzo
Table 4.4 (continued) Metabolites 38 Sulfocysteine
Q1/Q3 transition
DP (V)
CE (V) Internal standard
200 > 136
–30
–14
28
39 Sialic acid
308 > 87
–33
–23
28
40 Uracil
111 > 42
–20
–20
41
41 15 N2 -uracil
113 > 43
–17
–20
42 Thymine
125 > 42
–22
–31
43 Thymine D4
129 > 42
–20
–31
44 Xanthine
151 > 108
–27
–25
48
45 Orotic acid
155 > 111
–13
–13
46
46 15 N2 -orotic acid
157 > 113
–13
–15
47 Uric acid
167 > 124
–54
–25
48 1,3 15 N2 -uric acid
169 > 125
–54
–25
49 Propionylglycine
130 > 74
–30
–13
50 2 H3 -propionylglycine
133 > 74
–30
–13
51 Butyrylglycine
144 > 74
–45
–15
43
48 50 50
52 Isobutyrylglycine
144 > 74
–45
–15
50
53 3-Methylcrotony lglycine
156 > 74
–45
–15
50 50
54 Tiglylglycine
156 > 75
–45
–15
55 Methylbutyry lglycine
158 > 74
–45
–15
56 Isovalerylglycine
158 > 74
–50
–15
58
57 Hexanoylglycine
172 > 74
–45
–15
58
58 2 H3 -hexanoylglycine 59 3-Phenylpropiony lglycine
175 > 74
–45
–15
206 > 74
–45
–15
58
60 Suberylglycine
230 > 74
–45
–15
58
9. Ratios of the MRM signals of the metabolites relative to the internal standards are used to construct calibration curves and calculate concentrations in the urine samples. The internal standards used for each metabolite are listed in Table 4.4. 10. Six calibrators with concentrations 0 (i.e., blank), 10, 25, 50, 100, and 250 μM are run with every batch of samples. The unenriched and enriched urine samples are also included with each batch. 11. Imprecision and analytical recovery from the enriched urine samples are determined from consecutive batches run over a period of 5 weeks. The presence of salts in the urine can lead to significant suppression of negativeion signals, which in turn affects the linearity, inter-batch variability, and recovery for metabolites quantified without their corresponding labeled internal standards. This ion
Analysis of Organic Acids and Acylglycines
95
Table 4.5 Isobaric interferences in negative ionization mode Metabolites
Q1/Q3 transition
4-Hydroxy-butyric acid
103 > 57
2-Hydroxy-butyric acid
103 > 57
Succinic acid
117 > 73
Methylmalonic acid
117 > 73
Glutaric acid
131 > 87
Ethylmalonic acid
131 > 87
Methylsuccinic acid
131 > 87
Butyrylglycine
144 > 74
Isobutyrylglycine
144 > 74
2-Ketoglutaric acid
145 > 101
3-Methylglutaric acid
145 > 101
Tiglylglycine
156 > 74
3-Methylcrotonylglycine
156 > 74
Isovalerylglycine
158 > 74
Methylbutyrylglycine
158 > 74
suppression effect is minimized using several labeled internal standards. Apart from routine ion source cleaning performed at approximately weekly intervals, no other precautions are taken to minimize ion source contamination. 12. A careful selection of appropriate MRM transitions makes it possible to measure several isomeric metabolites. In some cases, no suitable transitions to solve isomeric compounds are found (Table 4.5) (5). This condition can be solved in the future by coupling the tandem mass spectrometer with HPLC separation. 13. The primary application of the LC tandem mass spectrometer urine screening method is as a first test for suspected inborn errors of metabolism. While the tandem mass spectrometry method can be used to test all urine samples, GCMS-based organic acid analysis is typically used to confirm abnormal LC tandem mass spectrometer results or to distinguish isomers.
4. Notes 1. The 24-h collected urine should be considered a first choice for the analysis of organic acids. The majority of patients with suspicion of IEM are in neonatal age; thus, it is important to
96
la Marca and Rizzo
perform a rapid test, preferably on the first morning voiding. When possible, urine samples must be stored in a freezer at –20◦ C if a –70◦ C system is not available. In fact, poor preservation of samples can lead to (1) bacterial conversion of some organic acids to artifacts such as the conversion of all keto acids to their respective hydroxy acids, (2) increased levels of succinic acid from bacterial degradation of glutamine, and (3) an abnormal concentration of pyroglutamic acid due to conversion from glutamine. The concentration of such volatile compounds as small molecule organic acids (e.g. short-chain organic acids) can be shortened if the sample is exposed to high temperature (especially in summer). The administration of drugs should be suspended in patients undergoing organic acids analysis to avoid artifacts due to drugs or drug metabolism. The following are some examples of the interference of drugs on the analysis of organic acids. Valproic acid administration causes an abnormal excretion of 3-hydroxy-isovaleric acid, tiglylglycine, dicarboxylic acids (even saturated, e.g., suberic, adipic, and sebacid acids), 2methylbutyrylglycine, 7-hydroxy-octanoic acid, 5-hydroxyhexanoic acid, and hexanoylglycine. An increase of pivalic acid can be due to the administration of the antibiotics pivampicillin and pivmecillinam. Fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI) used to treat obsessive–compulsive disorder and depression, can cause an increment of maleic acid. A therapy with the antihyperuricemic drug allopurinol can increase orotate urinary excretion. Artifactual formation of new compounds during sample preparation can also occur. For example, during extraction with ethyl acetate, decarboxylation of keto acids can occur (14). Additionally, it is essential to pay attention to solvent contaminants, plasticizers (phthalate, adipate, and sebacate esters), glassware-cleaning agents, lubricants, resins, and bleeding from the stationary phase of the chromatographic columns. 2. IS work solution stability is only at 4◦ C or below. For example, the peak intensity of PDA-TMS is considerably larger when analyzed 1 week after preparation and storage at room temperature than when immediately analyzed. This is due to solvent evaporation at room temperature (12). 3. Bilirubine, a potential interferent, is oxidized by using potassium ferricyanide K3 Fe(CN)6 at 0.13 mmol/L. 4. Do not mix organic and aqueous phases during liquid/liquid extraction of urine with solvents. 5. Clean the injector syringe everyday to avoid encrustation, purging, and bleeding.
Analysis of Organic Acids and Acylglycines
97
6. Incorrect mass spectrometer calibration can result in abnormal qualitative and quantitative results. 7. Clean the mass spectrometer source and change the liner every 500 samples. Contamination is usually identified by an abnormal background. In a GC-MS instrument, there are sources of contamination within the gas chromatograph (bleeding septa, dirty injection port liners, air leaks, etc.) and the mass spectrometer (ion source leaks, fluid/oil, manifold dirt). Unfortunately, not all contamination can be removed through running clean carrier gas overnight. When this is the case, the instrument may need extensive cleaning. Cleaning the mass spectrometer ion source to remove contamination is critical to restore the electrostatic properties of the ion source lens. The authors suggest that the ion source be cleaned every 500 runs. Another common source of mass spectrometer contamination is from inadequate venting and maintenance of the diffusion pump. Preventive maintenance ensures that diffusion pump oil/fluids are topped to the correct levels. It is important to maintain proper fluid levels to avoid pump failure and ensure optimum performance of the vacuum system. Air leaks can occur if a seal becomes damaged or is not correctly fastened. This is another common problem for any instruments that use a vacuum and can be identified by a higher than normal vacuum manifold pressure, low relative ion abundance, and poor sensitivity. 8. The use of labeled internal standards and isotope dilution allows one to obtain a correct and absolute quantitation of organic acids, but it can be very expensive. References 1. Björkman, L., McLean, C., Steen, G. (1976) Organic acids in urine from human newborns. Clin Chem 22, 49–52. 2. Chalmers, R. A., Healy, M. J., Lawson, A. M., Watts, R. W. (1976) Urinary organic acids in man. II. Effects of individual variation and diet on the urinary excretion of acidic metabolites. Clin Chem 22, 1288–1291. 3. Kumps, A., Duez, P., Mardens, Y. (2002) Metabolic, nutritional, iatrogenic, and artifactual sources of urinary organic acids: a comprehensive table. Clin Chem 48, 708–717. 4. Pitt, J. J., Eggington, M., Kahler, S. G. (2002) Comprehensive screening of urine samples for inborn errors of metabolism by electrospray tandem mass spectrometry. Clin Chem 48, 1970–1980.
5. Rebollido, M., Cocho, J. A., Castiñeiras, D. E., Bóveda, M. D., Fraga, J. M. (2006) Aplicación de la espectrometría de masas en tándem al análisis de aminoácidos, acilcarnitinas, acilglicinas y ácidos orgánicos en muestras de orina en papel. Quím Clín 25, 64–74. 6. Chalmers, R. A., Healy, M. J., Lawson, A. M., Hart, J. T., Watts, R. W. (1976) Urinary organic acids in man. III. Quantitative ranges and patterns of excretion in a normal population. Clin Chem 22, 1292–1298. 7. Perry, T. L., Hansen, S. (1974) Artifacts and pitfalls in interpretation of gas chromatograms in Application of Gas Chromatography-Mass Spectrometry to the Investigation of Human Disease. In Proceedings of a workshop, Montreal, May 1973. McGill University-Montreal Children’s
98
8. 9. 10.
11. 12.
la Marca and Rizzo Hospital Research Institute, Montreal, Quebec, Canada, 89–102. Paterson, N. (1967) Relative constancy of 24-hour urine volume and 24-hour creatinine output. Clin Chim Acta 18, 57–58. Zorab, P. A. (1969) Normal creatinine and hydroxyproline excretion in young persons. Lancet 29, 1164–1165. Applegarth, D. A., Hardwick, D. F., Ross, P. M. (1968) Creatinine excretion in children and the usefulness of creatinine equivalents in amino acid chromatography. Clin Chim Acta 22, 131–134. Larsen, K. (1972) Creatinine assay by a reaction-kinetic principle. Clin Chim Acta 41, 209–217. Tanaka, K., West-Dull, A., Hine., D. G., Lynn, T. B., Lowe, T. (1980) Gas-
chromatographic method of analysis for urinary organic acids. II. Description of the procedure, and its application to diagnosis of patients with organic acidurias. Clin Chem 26, 847–853. 13. Tanaka, K., Hine, D. G., West-Dull, A., Nad Lynn, T. B. (1980) Gas-chromatographic method of analysis for urinary organic acids. I. Retention indices of 155 metabolically important compounds. Clin Chem 26, 1839–1846. 14. Thompson, R. M., Belanger, B. G., Wappner, R. S., Brandt, I. K. (1975) An artifact in the gas chromatographic analysis of urinary organic acids from phenylketonuric children: decarboxylation of the phenylpyruvic acid during extraction. Clin Chim Acta 61, 367–374.
Chapter 5 HPLC Analysis for the Clinical–Biochemical Diagnosis of Inborn Errors of Metabolism of Purines and Pyrimidines Giuseppe Lazzarino, Angela Maria Amorini, Valentina Di Pietro, and Barbara Tavazzi Abstract The determination of purines and pyrimidines in biofluids is useful for the clinical–biochemical characterization of acute and chronic pathological states that induce transient or permanent alterations of metabolism. In particular, the diagnosis of several inborn errors of metabolism (IEMs) is accomplished by the analysis of circulating and excreted purines and pyrimidines. It is certainly advantageous to simultaneously determine the full purine and pyrimidine profile, as well as to quantify other compounds of relevance (e.g., organic acids, amino acids, sugars) in various metabolic hereditary diseases, in order to screen for a large number of IEMs using a reliable and sensitive analytical method characterized by mild to moderate costs. Toward this end, we have developed an ion-pairing HPLC method with diode array detection for the synchronous separation of several purines and pyrimidines. This method also allows the quantification of additional compounds such as N-acetylated amino acids and dicarboxylic acids, the concentrations of which are profoundly altered in different IEMs. The application of the method in the analysis of biological samples from patients with suspected purine and pyrimidine disorders is presented to illustrate its applicability for the clinical–biochemical diagnosis of IEM. Key words: Purines, pyrimidines, HPLC, body fluids, clinical–biochemical diagnosis, inborn errors of metabolism (IEMs), head injury, neurodegeneration, ischemia and reperfusion, multiple sclerosis.
1. Introduction In the clinical biochemistry setting, the terms “purines” and “pyrimidines” identify several low molecular weight compounds deriving from nucleic acid and nucleotide catabolism. Most of the T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_5, © Springer Science+Business Media, LLC 2011
99
100
Lazzarino et al.
circulating and excreted purines and pyrimidines are uncharged, with various degrees of water solubility, and have excellent absorption coefficients in the UV region (230–300 nm). Depending on the compound considered, purines and pyrimidines have broad ranges of concentrations (from 0 to the millimolar levels) in bodily fluids of normal subjects; these levels are influenced by various factors such as age, sex, diet. Very often, those absent or present physiologically in trace amounts are subject to tremendous concentration fluctuations due to several pathologic states for which the analysis of purines and pyrimidines in urine and plasma provides a strong indication of an altered metabolic state. In fact, the determination of purines and pyrimidines could be of particular clinical relevance in a number of acute and chronic diseases, such as myocardial ischemia (1, 2), traumatic brain injury (3, 4), and neurodegenerative disorders (multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease) (5–7). Under these conditions, the determination of certain compounds of these two classes is useful to monitor changes in the metabolic status of the patient, thus giving information on the progression of the disease and the effectiveness of possible pharmacological treatments. Purine and pyrimidine concentrations in bodily fluids are also dramatically altered in various inborn errors of metabolism (IEMs). In fact, a large number of IEMs, characterized by various degrees of disability and neurological disturbances, include several enzymatic defects involving pathways of purine and pyrimidine catabolism, recovery, and de novo biosynthesis. For many of these IEMs, an early diagnosis may greatly reduce consequences for the patients but, since clinical signs are not always discriminatory, the final diagnosis is not simple and is frequently delayed. It is therefore evident that purine and pyrimidine profiling in biological fluids plays a critical role for both clinicians and IEM-affected patients (8–10). Based on the physical–chemical characteristics of those purines and pyrimidines with clinical–biochemical significance, various methods have been proposed during the last decade based on the use of high-performance liquid chromatography (HPLC) coupled with either UV-VIS (11–18) or mass spectrometric (19– 23) detectors, capillary electrophoresis (24, 25), thin-layer chromatography (TLC) (26), and gas chromatography–mass spectrometry (GC–MS) (27). We have recently described a highly sensitive, reproducible, easy to use, and low-cost ion-pairing HPLC method coupled with a diode array detector (DAD) for the determination of these compounds in biological fluids (28), suitable for the clinical– biochemical diagnosis of IEMs of purines and pyrimidines (29). This method also allows for the separation of compounds other than purines and pyrimidines and is therefore useful for the diagnosis of additional IEMs of clinical relevance (30). The method is
HPLC Analysis for the Clinical–Biochemical Diagnosis
101
characterized by minimal manipulation of biological fluids (urine, plasma/serum, cerebrospinal fluid, amniotic fluid) and allows the separation of purines (hypoxanthine, xanthine, uric acid, inosine, guanosine, adenosine, adenine, S-adenosylhomocysteine, S-adenosylmethionine, adenylosuccinate, succinylaminoimidazole carboxamide riboside, aminoimidazole carboxamide riboside) and pyrimidines (cytosine, cytidine, thymine, thyimidine, uracil, beta-pseudouridine, uridine, orotic acid), simultaneously with N-acetylated amino acids (N-acetylaspartate, N-acetylglutamate, N-acetylaspartylglutamate), dicarboxylic acids (propionic acid, malonic acid, methylmalonic acid), creatinine, reduced and oxidized glutathione, and ascorbic acid. Herein, we describe in detail how to carry out the analysis of the aforementioned compounds in biological fluids (serum and urine) of healthy subjects and of two selected patients each suffering from an IEM of purine metabolism, i.e., hypoxanthine phosphoribosyltransferase (HPRT) deficiency and adenylosuccinate lyase (ADSL) deficiency. A comprehensive list of the genetic disorders based on metabolic defects of the aforementioned compounds, for which the application of this HPLC method might be helpful in clinical diagnoses is reported in Table 5.1.
2. Materials 2.1. Chemicals and Standards
1. Tetrabutylammonium hydroxide is supplied as a 55% water solution (Nova Chimica, Milan, Italy), stored at room temperature, and light protected (see Note 1). 2. HPLC-grade methanol. 3. HPLC-grade water. 4. Monobasic potassium phosphate (KH2 PO4 ). A 1 M stock solution is prepared by dissolving the proper amount of the compound in HPLC-grade water, with stirring and moderate heating; this solution is stable for up to 1 month at 4◦ C. 5. Ultrapure standards for HPLC (Sigma, St. Louis, MO, USA). Stock solutions (1 mM final concentration) of the following compounds are prepared by dissolving the proper amount of each substance with HPLC-grade water. All solutions, with the exceptions of ascorbic acid and GSH, can be stored in aliquots and maintained at –80◦ C with no significant loss (decrease in concentration <5%) for up to 4 weeks. Ascorbic acid and GSH solutions must be prepared and used within the same day.
Analysis of succinyladenosine, adenylosuccinate, and adenosine (serum and urine) Analysis of the purines hypoxanthine, xanthine, uric acid, inosine, guanosine and of the pyrimidines uracil, uridine, thymine, thymidine, orotic acid (serum and urine) Analysis of inosine, guanosine, hypoxanthine, xanthine (serum and urine) Analysis of S-adenosyl-homocysteine (serum and urine) Analysis of thymine and uracil (serum and urine)
Adenylosuccinate lyase deficiency
Dysfunction of phosphoribosyl-pyrophosphate synthetase
Purine nucleoside phosphorylase deficiency
S-Adenosyl-homocysteine hydrolase deficiency
Dihydropyrimidinase deficiency (dihydropyrimidinuria)
Analysis of the pyrimidines uracil, uridine, thymine, thymidine, and orotic acid (serum and urine) Analysis of 5-amine-imidazole-4-carboxamide ribonucleotide and ribonucleoside (AICAR) and of inosine (serum and urine)
Isocratic separation, 100% Buffer A (25 min)
Analysis of orotic acid (serum and urine)
Orotate phosphoribosyl transferase, orotate monophosphate decarboxylase, or uridine monophosphate synthetase deficiency (orotic acidemia/uria) Uridine-5 -monophosphate hydrolase 1 deficiency
5-Amine-imidazole-4-carboxamide ribonucleotide formyltransferase and IMP cyclohydrolase deficiency
Isocratic separation, 100% Buffer A (25 min)
Analysis of malonic and methylmalonic acids (serum and urine)
Malonyl-CoA decarboxylase deficiency (malonic acidemia/uria)
Isocratic separation 100% Buffer A (25 min)
Step gradient separation (40 min)
Isocratic separation, 100% Buffer A (25 min)
Isocratic separation, 100% Buffer A (25 min)
Step gradient separation (80 min)
Step gradient separation (50 min)
Isocratic separation, 100% Buffer A (25 min)
Isocratic separation, 100% Buffer A (25 min)
Analysis of adenine and 2,8-dihydroxyadenine (serum and urine)
Adenine phosphoribosyl transferase deficiency (2,8-dihydroxyadenine urolithiasis)
HPLC conditions
Biochemical marker
Enzymatic defect
Table 5.1 Main inborn errors of metabolism that can be diagnosed using the present HPLC method
102 Lazzarino et al.
Analysis of thymine, uracil, thymidine (serum and urine)
Analysis of adenosine (serum, urine) Analysis of N-acetylaspartate (serum, urine, cerebrospinal fluid) Analysis of thymine and uracil (serum and urine) Analysis of xanthine, hypoxanthine, uric acid (serum and urine)
Thymidine phosphorylase deficiency (hepatocerebral variant of the myopathy due to mitochondrial DNA depletion or MNGIE syndrome)
Adenosine deaminase deficiency (severe combined immunodeficiency, SCID)
N-acetylaspartoacylase deficiency (Canavan disease) Dihydropyrimidine dehydrogenase deficiency (familiar pyridinemia, or pyrimidinuria, or thyminuria, or uraciluria)
Xanthine dehydrogenase deficiency (xanthinuria)
Gout due to altered PRPS1 activity
Isocratic separation, 100% Buffer A (25 min)
Isocratic separation, 100% Buffer A (25 min)
Isocratic separation, 100% Buffer A (28 min)
Step gradient separation (40 min)
Isocratic separation, 100% Buffer A (25 min)
Isocratic separation, 100% Buffer A (25 min)
Isocratic separation, 100% Buffer A (25 min)
Isocratic separation, 100% Buffer A (25 min)
Analysis of uric acid and of correlated purines (hypoxanthine, xanthine, inosine, guanosine) (serum and urine) Analysis of uric acid and of correlated purines (hypoxanthine, xanthine, inosine, guanosine) (serum and urine) Analysis of uric acid and of correlated purines (hypoxanthine, xanthine, inosine, guanosine) (serum and urine)
deficiency
Isocratic separation, 100% Buffer A (25 min)
Analysis of uric acid and of correlated purines (hypoxanthine, xanthine, inosine, guanosine) (serum and urine)
(renal
Urate transporter hypouricemia)
Hypoxanthine phosphoribosyl transferase deficiency (including Lesch–Nyhan syndrome, Kelley–Seegmiller syndrome, generic hyperuricemia, hyperuricemia with neurologic symptoms) Uromodulin deficiency (juvenile familiar hyperuricemic nephropathy)
HPLC Analysis for the Clinical–Biochemical Diagnosis 103
104
Lazzarino et al.
5a. Creatinine. 5b. Cytosine. 5c. Adenine. 5d. Adenosine. 5e. Inosine. 5f. Cytidine. 5g. Uracil. 5h. Uridine. 5i. Orotic acid. 5j. Thymine. 5k. Thymidine. 5l. Adenylosuccinate. 5m. Aminoimidazole carboxamide riboside (AICAR). 5n. Succinylaminoimidazole carboxamide riboside (SAICAR). 5o. S-adenosylhomocysteine (SAH). 5p. S-adenosylmethionine (SAM). 5q. Ascorbic acid. 5r. Reduced glutathione (GSH). 5s. Oxidized (GSSG) glutathione. 6. Ultrapure standards for HPLC (Sigma). Stock solutions (10 mM final concentration) of the following compounds are prepared by dissolving/diluting the proper amount of each substance with HPLC-grade water. These solutions can be stored in aliquots and maintained at –80◦ C with no significant loss (decrease in concentration <5%) for up to 4 weeks. 6a. N-acetylaspartate (NAA). 6b. N-acetylglutamate (NAG). 6c. N-acetylaspartylglutamate (NAAG). 6d. Propionic acid. 6e. Malonic acid. 6f. Methylmalonic acid. 7. Ultrapure standards for HPLC (Sigma). Stock solutions (1 mM final concentration) of the following compounds are prepared by dissolving the proper amount of each substance in 100 μM NaOH (see Note 2). All solutions, with the exception of uric acid, can be stored in aliquots and maintained at –80◦ C with no significant loss (decrease in concentration <5%) for up to 4 weeks. The uric acid solution must be prepared and used within the same day. 7a. Hypoxanthine. 7b. Xanthine. 7c. Uric acid. 7d. Guanosine. 8. Ultrapure beta-pseudouridine for HPLC (ICN-MP Biochemicals, Irvine, CA, USA). Stock solution (1 mM final concentration) of beta-pseudouridine is prepared by dissolving the proper amount with HPLC-grade water and can be
HPLC Analysis for the Clinical–Biochemical Diagnosis
105
stored in aliquots and maintained at –80◦ C with no significant loss (decrease in concentration <5%) for up to 4 weeks. 9. Three and 10 kDa molecular weight cut-off filters R Centrifugal Devices; Pall Gelman Laboratory, (Nanosep Ann Arbor, MI, USA). 2.2. HPLC Equipment
1. SpectraSystem P4000 HPLC pump, UV6000LP diode array detector equipped with a 5 cm light path flow cell, and refrigerated AS3000 autosampler (ThermoScientific Italia, Milan, Italy). 2. Hypersil C-18, 250 × 4.6 mm, 5-μm particle size HPLC column, and guard column (ThermoScientific Italia).
2.3. HPLC Buffers
1. Buffer A: 12 mM tetrabutylammonium hydroxide, 10 mM KH2 PO4 , 0.125% methanol; stir the solution and adjust the pH to 7.00 by adding 1 M HCl (see Note 3). 2. Buffer B: 2.8 mM tetrabutylammonium hydroxide, 100 mM KH2 PO4 , 30% methanol; stir the solution and adjust the pH to 5.50 by adding 1 M HCl (see Notes 3 and 4). 3. Filter both buffers through a Millipore filtering system equipped with acetate filters (pore diameter of 0.22 μm) to ensure proper degassing and to improve shelf life (see Note 5).
2.4. Preparation of the Standard Mixture for HPLC Separation
1. Freshly prepared standard mixtures with known concentrations are prepared daily and assayed by ion-pairing HPLC. 2. The standard mixture has a final volume of 1 mL. The following standards are used at a final concentration of 5 μM (add 5 μL of the corresponding 1 mM solution): cytosine, cytidine, creatinine, uridine, adenine, hypoxanthine, xanthine, guanosine, thymine, thymidine, and ascorbic acid; the following standards are used at a final concentration of 10 μM (add 10 μL of the corresponding 1 mM solution): uracil, beta-pseudouridine, inosine, and orotic acid; the following standards are used at a final concentration of 20 μM (add 20 μL of the corresponding 1 mM solution): uric acid, adenylosuccinate, SAH, SAM, AICAR, and SAICAR; the following standards are used at a final concentration of 25 μM (add 25 μL of the corresponding 1 mM solution): GSH and GSSG; the following standards are used at a final concentration of 50 μM (add 50 μL of the corresponding 1 mM solution): NAA, NAG, and NAAG; the following standards are used at a final concentration of 100 μM (add 10 μL of the corresponding 10 mM solution): propionic acid, malonic acid, and methylmalonic acid. 3. Adjust the final volume of the standard mixture to 1 mL with the proper volume of HPLC-grade water (see Note 6).
106
Lazzarino et al.
3. Methods 3.1. Pre-treatment of the MembraneEquipped Tubes
1. The 3 and 10 kDa molecular weight cut-off filters are equipped with regenerated cellulose membranes and require an appropriate washing treatment prior to their use with biological samples. 2. To extensively rinse the membranes, add about 0.5 mL of HPLC-grade water to each membrane followed by centrifugation at 15,000×g for 5 min at 4◦ C. This step should be repeated twice.
3.2. Preparation of Serum/Plasma Samples
1. No significant differences in concentrations of purines, pyrimidines, and other compounds between serum and plasma have been evidenced; consequently, it is preferable that serum be utilized in order to speed up the deproteinization process (see Note 7). 2. Dilute 200 μL of serum with 400 μL of HPLC-grade water R tube fitted (see Note 8) and place the sample in a Nanosep with a 10 kDa molecular weight cut-off membrane. Centrifuge the sample at 15,000×g at 4◦ C until complete passage of the liquid through the membrane (time required about 40 min). 3. In the case of plasma, the process of dilution and centrifugation is identical, but the time required for completion of the centrifugation step is increased to 50–60 min. 4. Transfer the deproteinized and ultrafiltered serum/plasma R to a Nanosep tube equipped with a 3 kDa molecular weight cut-off membrane and centrifuge again at 15,000×g at 4◦ C until complete passage of the liquid through the membrane (time required about 20 min). 5. Finally, inject the deproteinized and doubly ultrafiltered serum/plasma directly onto the HPLC column.
3.3. Preparation of Urine Samples
1. Urine samples are prepared similarly to serum/plasma samples. Dilute 100 μL of urine with 2400 μL of HPLC-grade R tube fitted with water (see Note 8) and place in a Nanosep a 3 kDa molecular weight cut-off membrane. Centrifuge the sample at 15,000×g at 4◦ C until complete passage of the liquid through the membrane (time required about 15 min) (see Note 9). 2. Inject the deproteinized and ultrafiltered urine sample directly onto the HPLC column.
HPLC Analysis for the Clinical–Biochemical Diagnosis
3.4. HPLC Equipment and Chromatographic Run Conditions
107
1. The diode array detector should be set up for data acquisition between 200 and 300 nm. Equilibrate the chromatographic column with Buffer A for 20 min at 1.2 mL/min and 10◦ C prior to the injection of any standards or biological sample.
Fig. 5.1. HPLC separation of an ultrapure standard mixture. In Panel A, the assignment of peaks to cytosine (1), creatinine (2), uracil (3), beta-pseudouridine (4), cytidine (5), hypoxanthine (6), thymine (7), xanthine (8), ascorbic acid (9), uridine (10), adenine (11), SAM (14), inosine (15), uric acid (16) guanosine (17), thymidine (18) orotic acid (19), SAH (24), AICAR (25), adenosine (26), SAICAR (28), succinyladenosine (29), and adenylosuccinate (31) was performed at 260 nm. In Panel B, the assignment of peaks to propionic acid (12), GSH (13), malonic acid (20), methylmalonic acid (21), NAA (22), NAG (23), GSSG (27), and NAAG (30) was performed at 206 nm.
0.3
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.2
0.1
0.2
Inosine
Guanosine
Adenosine
Adenine
SAH
SAM
Adenylosuccinate
SAICAR
AICAR
Cytosine
Cytidine
Thymine
Thymidine
0.1
Xanthine
Uric acid
0.1
Hypoxanthine
1
0.5
1
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
1.5
0.5
0.5
2
1
2
1
1
1
1
1
1
1
1
1
1
3
1
1
10
5
10
5
5
5
5
5
5
5
5
5
5
15
5
5
100
50
100
50
50
50
50
50
50
50
50
50
50
150
50
50
1
1
0.999
1
0.989
0.995
0.998
0.999
0.998
0.999
1
1
0.993
0.999
0.999
0.999
Final concentration Final concentration Final concentration Final concentration Final concentration Correlation in the mixture (µM) in the mixture (µM) in the mixture (µM) in the mixture (µM) in the mixture (µM) coefficient (R2 )
Table 5.2 Calibration curves and linearity of the method described
108 Lazzarino et al.
0.1
0.1
0.3
0.7
0.7
0.36
4
4
4
0.1
0.3
0.1
0.1
β-Pseudouridine
Uridine
Orotic acid
NAA
NAG
NAAG
Propionic acid
Malonic acid
Methylmalonic acid
Creatinine
GSH
GSSG
Ascorbic acid
0.5
0.5
1.5
0.5
20
20
20
1.8
3.5
3.5
1.5
0.5
0.5
0.5
1
1
3
1
40
40
40
3.6
7
7
3
1
1
1
5
5
15
5
200
200
200
18
35
35
15
5
5
5
50
50
150
50
2000
2000
2000
180
350
350
150
50
50
50
0.993
0.999
0.9999
1
0.991
0.990
0.992
0.998
0.997
0.999
1
1
1
0.999
SAH = S-adenosylhomocysteine; SAM = S-adenosylmethionine; SAICAR = succinylaminoimidazole carboxamide riboside; AICAR = aminoimidazole carboxamide riboside; NAA = N-acetylaspartate; NAG = N-acetylglutamate; NAAG = N-acetylaspartylglutamate; GSH = reduced glutathione; GSSG = oxidized glutathione.
0.1
Uracil
HPLC Analysis for the Clinical–Biochemical Diagnosis 109
110
Lazzarino et al.
Fig. 5.2. HPLC separation of deproteinized and ultrafiltered serum (Panel A) and urine (Panel B) samples from a healthy control subject. Identified purine or pyrimidine peaks follow the numbering reported in the legend to Fig. 5.1: Panel A, uracil (3), beta-pseudouridine (4), hypoxanthine (6), xanthine (8), ascorbic acid (9), uridine (10), inosine (15), and uric acid (16); Panel B, uracil (3), beta-pseudouridine (4), hypoxanthine (6), xanthine (8), and uric acid (16).
2. After sample injection, a step gradient is formed as follows: 25 min of 0% Buffer B; ramp to 20% Buffer B over 8 min; ramp to 30% Buffer B over 10 min; ramp to 45% Buffer B over 12 min; ramp to 60% Buffer B over 11 min; ramp to 85% Buffer B over 9 min; ramp to 100% Buffer B over 5 min; hold for 10 min at 100% Buffer B. This last step is lengthened to 30 min in the case of a biological sample.
HPLC Analysis for the Clinical–Biochemical Diagnosis
111
Fig. 5.3. HPLC separation of deproteinized and ultrafiltered serum (Panel A) and urine (Panel B) samples from an IEM patient suffering from partial HPRT deficiency (Kelley–Seegmiller syndrome). Only those compounds whose concentrations were changed by disease are indicated, and their identities follow the numbering reported in the legend to Fig. 5.1: Panel A and Panel B, hypoxanthine (6), xanthine (8), and uric acid (16).
Re-equilibrate the column at 100% Buffer A for 15 min before the next injection (see Note 10). 3. Maintain the flow rate and the column temperature at 1.2 mL/min and 10◦ C, respectively, for the duration of the analysis.
112
Lazzarino et al.
Fig. 5.4. HPLC separation of deproteinized and ultrafiltered serum (Panel A) and urine (Panel B) samples from an IEM patient suffering from partial ADSL deficiency. Only those compounds whose concentrations were changed by disease are indicated, and their identities follow the numbering reported in the legend to Fig. 5.1: Panel A and Panel B, SAICAR (28) and succinyladenosine (29).
4. Data are acquired and analyzed by a PC using the R software package provided by the HPLC ChromQuest manufacturer. 5. The following compounds are monitored at 260 nm: cytosine, cytidine, uracil, uridine, beta-pseudouridine, adenine,
HPLC Analysis for the Clinical–Biochemical Diagnosis
113
hypoxanthine, xanthine, inosine, guanosine, adenosine, AICAR, SAICAR, SAH, adenylosuccinate, ascorbic acid, thymine, thymidine, uric acid, and orotic acid. 6. The following compounds are monitored at 206 nm: NAA, NAG, NAAG, propionic acid, malonic acid, methylmalonic acid, GSH, and GSSG. 7. Creatinine is monitored at 234 nm. Figure 5.1 shows chromatograms of a standard mixture. 8. Calibration curves for each compound are obtained by running standard mixtures in increasing concentrations. As shown in Table 5.2, a very high linearity is observed for each compound in the concentration ranges indicated. These curves are then used to calculate the concentrations of compounds in unknown samples, as indicated below. 9. Peak assignment in deproteinized and ultrafiltered samples of biological fluids is carried out by comparing peak retention times and absorption spectra with those of freshly prepared ultrapure standards. The quantification of the different compounds in chromatographic runs of biological samples is effected by comparing their peak areas with the corresponding peak areas from chromatographic runs of standard mixtures with known concentrations. Figure 5.2 shows chromatograms of deproteinized and ultrafiltered serum (Panel A) and urine (Panel B) from a healthy control subject. Figure 5.3 illustrates chromatographic runs of deproteinized and ultrafiltrated serum (Panel A) and urine (Panel B) of an IEM patient suffering from partial HPRT deficiency (Kelley–Seegmiller syndrome), while deproteinized and ultrafiltered serum (Panel A) and urine (Panel B) of an IEM patient suffering from partial ADSL deficiency are shown in Fig. 5.4. 10. After the last chromatographic run, first wash the column with HPLC-grade water for 60 min at 1.2 mL/min followed by extensive washing with methanol/water (60/40, v/v; no less than 60 min at 1.2 mL/min at room temperature) in order to increase the column life span (see Note 11).
4. Notes 1. Tetrabutylammonium hydroxide (TBA) is utilized as the pairing reagent in both HPLC buffers; it is necessary to manage it with care because it is harmful (irritant). Highpurity TBA for HPLC applications is supplied as a very
114
Lazzarino et al.
viscous 55% solution. It is therefore recommended to pipet TBA with care and to avoid cleaning the extra liquid left on the outer wall of the pipet tip (it could alter the final concentration of TBA in the buffer solution). It is also advisable to put a reasonable amount of HPLC-grade water in a beaker and to add TBA after having cleaned the outer wall of the pipet tip. Then pipet several times to carefully rinse the inside of the pipet tip. 2. The use of NaOH is necessary because of the low solubility of the keto-tautomeric forms of these compounds in water. Prepare the 100 μM NaOH solution by dissolving a proper amount of the compound in HPLC-grade water. 3. Let the solutions stand for 5–10 min and recheck the pH; the value must be stable with no stirring at 7.00 for Buffer A and at 5.50 for Buffer B. 4. When preparing Buffer B, add methanol and water first in a beaker. Mix the solution by stirring and then add the proper amount of KH2 PO4 . Since KH2 PO4 is added from a 1 M stock solution to have a final concentration of 100 mM, the phosphate would precipitate if it were directly added to undiluted methanol. 5. In the case of Buffer A, the solution is stable for up to 4 days at 4◦ C, while in the case of Buffer B, the solution is stable for up to 4 weeks at 4◦ C. Moreover, in order to avoid any bacterial growth, it is recommended that glassware be subjected to a cycle of sterilization by autoclaving on a weekly basis. 6. After correcting the final volume of the standard mixture, it is important to check its pH value, since several purines are dissolved in 100 μM NaOH (pH can be checked with pH paper); when significantly higher than neutral, correct the pH by adding 2–5 μL of 1 M HCl. 7. This procedure avoids the use of complex, time-consuming sample manipulations, which may significantly alter the real concentrations of the various compounds in the sample. Furthermore, the method allows the direct detection of all compounds with no sample derivatization prior to HPLC analysis. 8. The sample dilution indicated is suitable for biological samples from healthy controls. In the case of patients with IEM, this dilution may result in a chromatogram with one or more peaks out of scale. In these cases, a further dilution of the sample and a new chromatographic run will be necessary in order to perform the correct quantification of the compound(s) in excess.
HPLC Analysis for the Clinical–Biochemical Diagnosis
115
9. The filtering procedure adopted for the urine preparation can also be used, with proper differences in sample dilution, for cerebrospinal or amniotic fluid preparation. In the case of cerebrospinal fluid, 200 μL of sample is diluted with 200 μL of HPLC-grade water (1:1, v/v); in the case of amniotic fluid, 200 μL of sample is diluted with 400 μL of water (1:2, v/v). 11. Since the majority of purines and pyrimidines of interest for the clinical–biochemical diagnosis of IEM are eluted isocratically during the first 25 min of the run, it is possible to perform a significantly shorter analysis with which the following compounds are separated: cytosine, creatinine, cytidine, uracil, uridine, beta-pseudouridine, adenine, hypoxanthine, xanthine, inosine, guanosine, ascorbic acid, thymine, thymidine, uric acid and orotic acid, NAA, propionic acid, malonic acid, methylmalonic acid, and GSH. When using this isocratic separation, it is possible to perform a simple column wash with methanol/water (60:40, v/v) at 1.2 mL/min for 15 min after elution of the last compound of interest. In this case, due to the high concentration of methanol in the washing solution, the reequilibration procedure should be lengthened to 25 min before a new sample is injected. 12. It is worth noting that Buffer B has a high phosphate concentration, rendering direct passage to the washing solution of methanol/water (60:40, v/v) unfeasible. If this happened, an immediate precipitation of phosphate crystals into the HPLC system would occur, with dangerous consequences for pistons, column, and tubing. An extensive wash with HPLC-grade water is therefore needed in between Buffer B and the washing solution of methanol/water (60:40, v/v).
Acknowledgments We wish to thank Sig. Salvatore Meo for his technical help in preparing the figures for this chapter. This work has been supported by research funds of the University of Catania and the Catholic University of Rome (grant D1-2004-2008).
References 1. Giardina, B., Penco, M., Lazzarino, G., Romano, S., Tavazzi, B., Fedele, F., Di Pierro, D., Dagianti, A. (1993) Effective-
ness of thrombolysis is associated with a time-dependent increase of malondialdehyde in peripheral blood of patients with acute
116
2.
3.
4.
5.
6.
7. 8.
9.
10.
11.
Lazzarino et al. myocardial infarction. Am J Cardiol 71, 788–793. Lazzarino, G., Raatikainen, P., Nuutinen, M., Nissinen, J., Tavazzi, B., Di Pierro, D., Giardina, B., Peuhkurinen, K. (1994) Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery. Circulation 90, 291–297. Cristofori, L., Tavazzi, B., Gambin, R., Vagnozzi, R., Signoretti, S., Amorini, A. M., Fazzina, G., Lazzarino, G. (2005) Biochemical analysis of the cerebrospinal fluid: evidence for catastrophic energy failure and oxidative damage preceding brain death in severe head injury: a case report. Clin Biochem 38, 97–100. Cristofori, L., Tavazzi, B., Gambin, R., Vagnozzi, R., Vivenza, C., Amorini, A. M., Di Pierro, D., Fazzina, G., Lazzarino, G. (2001) Early onset of lipid peroxidation after human traumatic brain injury: a fatal limitation for the free radical scavenger pharmacological therapy?. J Invest Med 49, 450–458. Amorini, A. M., Petzold, A., Tavazzi, B., Eikelenboom, J., Keir, G., Belli, A., Giovannoni, G., Di Pietro, V., Polman, C., D’Urso, S., Vagnozzi, R., Uitdehaag, B., Lazzarino, G. (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42, 1001– 1006. Keizman, D., Ish-Shalom, M., Berliner, S., Maimon, N., Vered, Y., Artamonov, I., Tsehori, J., Nefussy, B., Drory, V. E. (2009) Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?. J Neurol Sci 285, 95–99. Schlesinger, I., Schlesinger, N. (2008) Uric acid in Parkinson’s disease. Mov Disord 23, 1653–1657. Morris, G. S., Simmonds, H. A., Davies, P. M. (1986) Use of biological fluids for the rapid diagnosis of potentially lethal inherited disorders of human purine and pyrimidine metabolism. Biomed Chromatogr 3, 109–118. Vidotto, C., Fousert, D., Akkermann, M., Griesmacher, A., Muller, M. M. (2003) Purine and pyrimidine metabolites in children’s urine. Clin Chim Acta 335, 27–32. Duran, M., Dorland, L., Meuleman, EE., Allers, P, Berger, R (1997) Inherited defects of purine and pyrimidine metabolism: laboratory methods for diagnosis. J Inherit Metab Dis 20, 227–236. Bennet, M. J., Carpenter, K. H. (1984) Experience with a simple high performance liquid chromatography method for the anal-
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
ysis of purine and pyrimidine nucleosides and bases in biological fluids. Ann Clin Biochem 21, 131–136. Boulieu, R., Bory, C., Baltassat, P., Divry, P. (1984) Hypoxanthine and xanthine concentration determined by high performance liquid chromatography in biological fluids from patients with xanthinuria. Clin Chim Acta 142, 83–89. Di Pierro, D., Tavazzi, B., Perno, C. F., Bartolini, M., Balestra, E., Caliò, R., Giardina, B., Lazzarino, G. (1995) An ion-pairing high-performance liquid chromatographic method for the direct simultaneous determination of nucleotides, deoxynucleotides, nicotinic coenzymes, oxypurines, nucleosides, and bases in perchloric acid cell extracts. Anal Biochem 231, 407–412. Kazoka, H. (2002) Analysis of purines and pyrimidines by mixed partition-adsorption normal-phase high-performance liquid chromatography. J Chromatogr A 942, 1–10. Czauderna, M., Kowalczyk, J. (1997) Simultaneous measurement of allantoin, uric acid, xanthine and hypoxanthine in blood by highperformance liquid chromatography. J Chromatogr B 704, 89–98. Minniti, G., Caruso, U., Cerone, R., de Toni, E. (1998) Purines and pyrimidines determination in urine using high-performance liquid chromatography. Adv Exp Med Biol 431, 843–848. Katayama, M., Matsuda, Y., Shimokawa, K., Tanabe, S., Kaneko, S., Hara, I., Sato, H. (2001) Simultaneous determination of six adenyl purines in human plasma by highperformance liquid chromatography with fluorescence derivatization. J Chromatogr B Biomed Sci Appl 760, 159–163. Kojima, T., Nishina, T., Kitamura, M., Kamatani, N., Nishioka, K. (1987) Liquid chromatography with multichannel ultraviolet detection used for studying disorders of purine metabolism. Clin Chem 33, 2052–2056. Lemr, K., Adam, T., Frycak, P., Friedecky, D. (2000) Mass spectrometry for analysis of purine and pyrimidine compounds. Adv Exp Med Biol 486, 399–403. Frycak, P., Huskova, R., Adam, T., Lemr, K. (2002) Atmospheric pressure ionization mass spectrometry of purine and pyrimidine markers of inherited metabolic disorders. J Mass Spectrom 37, 1242–1248. la Marca, G., Casetta, B., Malvagia, S., Pasquini, E., Innocenti, M., Donati, M. A., Zammarchi, E. (2006) Implementing tandem mass spectrometry as a routine tool
HPLC Analysis for the Clinical–Biochemical Diagnosis
22.
23.
24.
25.
26.
for characterizing the complete purine and pyrimidine metabolic profile in urine samples. J Mass Spectrom 41, 1442–1452. Ito, T., van Kuilenburg, A. B., Bootsma, A. H., van Cruchten, A., Wada, Y., van Gennip, A. H. (2000) Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips. Clin Chem 46, 445–452. Hartmann, S., Okun, J. G., Schmidt, C., Langhans, C. D., Garbade, S. F., Burgard, P., Haas, D., Sass, J. O., Nyhan, W. L., Hoffmann, G. F. (2006) Comprehensive detection of disorders of purine and pyrimidine metabolism by HPLC with electrospray ionization tandem mass spectrometry. Clin Chem 52, 1127–1137. Friedecky, D., Adam, T., Bartak, P. (2002) Capillary electrophoresis for detection of inherited disorders of purine and pyrimidine metabolism: a selective approach. Electrophoresis 23, 565–571. Wang, S. P., Liao, C. S. (2004) Comparison of ion-pair chromatography and capillary zone electrophoresis for the assay of organic acids as markers of abnormal metabolism. J Chromatogr A 1051, 213–219. van Gennip, A. H., Grift, J., Bree-Blom, E. J., van Ketting, D., Wadman, S. K. (1979) Urinary excretion of methylated purines in
27.
28.
29.
30.
117
man and in the rat after the administration of theophylline. J Chromatogr 163, 351–362. Kuhara, T. (2002) Diagnosis and monitoring of inborn errors of metabolism using urease-pretreatment of urine, isotope dilution, and gas chromatography–mass spectrometry. J Chromatogr B Biomed Sci Appl 781, 497–517. Tavazzi, B., Lazzarino, G., Leone, P., Amorini, A. M., Bellia, F., Janson, C. G., Di Pietro, V., Ceccarelli, L., Donzelli, S., Francis, J. S., Giardina, B. (2005) Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism. Clin Biochem 38, 997–1008. Di Pietro, V., Perruzza, I., Amorini, A. M., Balducci, A., Ceccarelli, L., Lazzarino, G., Barsotti, P., Giardina, B., Tavazzi, B. (2007) Clinical, biochemical and molecular diagnosis of a compound homozygote for the 254 bp deletion-8 bp insertion of the APRT gene suffering from severe renal failure. Clin Biochem 40, 73–80. Di Pietro, V., Gambacurta, A., Amorini, A. M., Finocchiaro, A., D’Urso, S., Ceccarelli, L., Tavazzi, B., Giardina, B., Lazzarino, G. (2008) A new T677C mutation of the aspartoacylase gene encodes for a protein with no enzymatic activity. Clin Biochem 41, 611–615.
Chapter 6 Bile Acid Analysis in Various Biological Samples Using Ultra Performance Liquid Chromatography/Electrospray Ionization-Mass Spectrometry (UPLC/ESI-MS) Masahito Hagio, Megumi Matsumoto, and Satoshi Ishizuka Abstract In recent years, bile acids (BAs) have received much attention as signaling molecules as well as biosurfactants for lipophilic nutrients. To understand exact BA behavior, the precise distribution of BAs in vivo must be determined. However, to date, it has been difficult to know the precise roles of BA due to variations in BA molecules including conjugated forms. Thus, we reconsidered BA extraction methodology and introduced an ultra performance liquid chromatography/electrospray ionization-mass spectrometry (UPLC/ESI-MS) technique for BA analysis. Consequently, we established a rapid and reliable method, using UPLC/ESI-MS, for the analysis of BAs in various biological samples including liver, bile, blood, intestinal contents, and feces. This method enables us to determine the BA profile, including conjugation status, in a single 30 min run. This technique will be a useful tool for the investigation of the roles of BA metabolism in physiological and pathological conditions. Key words: Ultra performance liquid chromatography, electrospray ionization-mass spectrometry, bile acids.
1. Introduction Bile acids (BAs) are synthesized from cholesterol by various hepatic enzymes in the liver (1). They are indispensable compounds for the absorption of hydrophobic nutrients due to their amphipathic structure. BAs are absorbed mainly from the ileal epithelial cells and return to the liver through the portal vein. BAs flowing into the large intestine are converted to secondary BAs (SBAs). Normally, the amount of BA lost by fecal excretion is compensated for by neosynthesis in the liver, and the homeostasis T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_6, © Springer Science+Business Media, LLC 2011
119
120
Hagio, Matsumoto, and Ishizuka
of the BA pool is closely maintained. The polarity of each BA depends on the number and direction of hydroxyl groups, and their hydrophobicity is closely related to the ability of the forming micelle and to cytotoxicity against epithelial cells in the gut. For example, the amount of solubilized cholesterol in aqueous solution depends on BA type. Solubility of cholesterol in sodium deoxycholate solution is greater than in sodium ursodeoxycholate solution (2). The hydroxyl group in the BA molecule is thought to affect the homeostasis of epithelial cells, particularly with regard to apoptosis or cell proliferation in the large intestine (3–6). However, it is difficult to understand the precise influence of BAs on epithelial cells, as a variety of BAs exist at the same time in various tissues and intestinal contents. Furthermore, changes in BA metabolism could induce some inborn errors, such as cerebrotendinous xanthomatosis (7), Zellweger’s cerebrohepatorenal syndrome (8), defective BA conjugation (9), deficiency of various enzymes in BA biosynthesis (10), and cholestatic diseases (11). To date, gas chromatography (GC) or GC-mass spectrometry (GC-MS) techniques have been widely used for the analysis of BA composition. However, GC analysis requires many complicated steps, such as methylation or trimethylsilylation, to obtain volatile and stabilized BA molecules. Moreover, the chemicals used in these steps are usually harmful. Further, this procedure requires the deconjugation of BAs, which prevents simultaneous detection of conjugated and unconjugated BAs. Recently, HPLC has been used for composition analysis of BAs (12–14). The UPLC technique has further improved the efficiency of BA analysis in terms of time and separation ability (15).
2. Materials 2.1. Chemicals
1. BA standards (Steraloids, Newport, RI, USA). 1a. Cholic acid (5β-cholanic acid-3α,7α,12α-triol, CA) 1b. α-muricholic acid (5β-cholanic acid-3α,6β,7α-triol, αMCA) 1c. β-muricholic acid (5β-cholanic acid-3α,6β,7β-triol, βMCA) 1d. ω-muricholic acid (5β-cholanic acid-3α,6α,7β-triol, ωMCA) 1e. Chenodeoxycholic acid (5β-cholanic acid-3α,7α-diol, CDCA) 1f. Deoxycholic acid (5β-cholanic acid-3α,12α-diol, DCA) 1g. Hyodeoxycholic acid (5β-cholanic acid-3α,6α-diol, HDCA)
Bile Acid Analysis in Various Biological Samples
121
1h. Ursodeoxycholic acid (5β-cholanic acid-3α,7β-diol, UDCA) 1i. Lithocholic acid (5β-cholanic acid-3α-ol, LCA) 1j. Taurocholic acid [5β-cholanic acid-3α,7α,12α-triol-N(2-sulphoethyl)-amide, TCA] 1k. Tauro-α-muricholic acid [5β-cholanic acid-3α,6β, 7α-triol-N-(2-sulphoethyl)-amide, TαMCA] 1l. Tauro-ω-muricholic acid [5β-cholanic acid-3α,6α, 7β-triol-N-(2-sulphoethyl)-amide, TωMCA] 1m. Taurochenodeoxycholic acid [5β-cholanic acid-3α, 7α-diol-N-(2-sulphoethyl)-amide, TCDCA] 1n. Taurodeoxycholic acid [5β-cholanic acid-3α,12α-diolN-(2-sulphoethyl)-amide, TDCA] 1o. Taurohyodeoxycholic acid [5β-cholanic 6α-diol-N-(2-sulphoethyl)-amide, THDCA]
acid-3α,
1p. Taurolithocholic acid [5β-cholanic acid-3α-ol-N-(2sulphoethyl)-amide, TLCA] 1q. Glycocholic acid [5β-cholanic acid-3α,7α,12α-triol-N(carboxymethyl)-amide, GCA] 1r. Glycochenodeoxycholic acid [5β-cholanic acid-3α, 7α-diol-N-(carboxymethyl)-amide, GCDCA] 1s. Glycodeoxycholic acid [5β-cholanic acid-3α,12α-diolN-(carboxymethyl)-amide, GDCA] 1t. Glycohyodeoxycholic acid [5β-cholanic acid-3α, 6α-diol-N-(carboxymethyl)-amide, GHDCA] 1u. Glycoursodeoxycholic acid [5β-cholanic acid-3α, 7β-diol-N-(carboxymethyl)-amide, GUDCA] 1v. Glycolithocholic acid [5β-cholanic (carboxymethyl)-amide, GLCA]
acid-3α-ol-N-
2. BA internal standard: 23-nordeoxycholic acid (23-nor-5βcholanic acid-3α,12α-diol, NDCA) (Steraloids). 3. Standard mixture solution including all above BAs. A calibration curve is constructed using the standard mixture solution over the concentration range 100 nM to 50 μM. 2.2. Reagents
1. Ion-exchanged and redistilled water. 2. High-grade ethanol. 3. HPLC-grade acetonitrile. 4. HPLC-grade methanol. 5. Solvent A: acetonitrile/water (20:80, v/v) containing 10 mM ammonium acetate (NH4 Ac). 6. Solvent B: acetonitrile/water (80:20, v/v) containing 10 mM NH4 Ac (see Note 1).
122
Hagio, Matsumoto, and Ishizuka
2.3. Instruments
1. 2-mL micro tubes. 2. Ultra S Homogenizer VP-15S (Taitec Corp., Saitama, Japan). 3. Water bath. 4. Oasis HLB cartridge 1 cc/10 mg (Waters, Milford, MA). 5. Acquity UPLC system (Waters). 6. BEH C18 column (1.7 μm, 100 mm × 2.0 mm i.d.; Waters). 7. Quattro Premier XE quadrupole tandem MS (Waters) equipped with an electrospray ionization (ESI) probe.
3. Methods Biological samples including blood plasma, bile, liver, intestinal contents, and feces are lyophilized before starting extraction so as to eliminate moisture as much as possible (see Note 2). Although chloroform/methanol is generally used in lipid extractions, it is not required for BA extraction due to the amphipathic nature of BAs. 3.1. Bile Acid Extraction from Biological Samples
1. Grind lyophilized samples thoroughly. 2. Add 1 mL of ethanol (high grade) to 100 mg of the ground samples. 3. Add 50 μL of 500 μM NDCA solution (25 nmol) in methanol as an internal standard to each sample and vortex thoroughly (see Note 3). 4. Sonicate the samples (constant, 40 cycles, control 2.5, twice for 10 s) (see Note 4). 5. Heat samples at 60◦ C for 30 min in a water bath, and then heat the samples at 100◦ C for 3 min in a water bath (see Note 5). 6. After cooling down to room temperature, vortex the samples thoroughly. 7. Centrifuge the samples at 1600×g for 10 min at 4◦ C. 8. Collect the supernatants into a new tube. 9. Add 1 mL of ethanol to the precipitates. 10. Vortex thoroughly. 11. Centrifuge the samples at 11,200×g for 1 min at 4◦ C. 12. Transfer the supernatants into the tubes from Step 8.
Bile Acid Analysis in Various Biological Samples
123
13. Repeat these extraction steps (Steps 9–12) once more. 14. Evaporate the pooled extracts. 15. Store at –40◦ C until analysis. 3.2. Sample Preparation for LC-MS
1. Add 1 mL of methanol (HPLC grade) to the evaporated extract fractions and mix well (see Note 6). 2. Purify the methanol solutions using a HLB cartridge according to the manufacturer’s instructions (see Note 7). 3. Evaporate recovered eluates. 4. Add 1 mL of methanol to evaporated eluents and suspend thoroughly (see Note 8). 5. Introduce dissolved extracts to LC.
3.3. LC Settings
1. The column oven and the auto sampler are maintained at 40 and 15◦ C, respectively (see Note 9). The solvent flow rate is 400 μL/min, and the sample injection volume is 5 μL. 2. The gradient program is as follows: 5% solvent B from 0 to 5 min; linear ramp to 15% solvent B over 10 min; linear ramp to 25% solvent B over 5 min; linear ramp to 75% solvent B over 2 min. Solvent B is kept at 75% for 1 min and is then decreased linearly to 5% over 1 min. The 5% of solvent B is then maintained at 5% for 3 min. 3. The column eluent is introduced to the MS.
3.4. MS Settings
1. The capillary voltage, source temperature, and desolvation temperature are −3200 V, 120◦ C, and 400◦ C, respectively. The cone voltage is 35 V for all BAs, both conjugated and unconjugated forms. The desolvation and cone gas flow rates are 800 and 50 L/h, respectively. 2. Each BA is detected by monitoring the appropriate deprotonated molecule [M-H]– under selected ion-recording (SIR) mode. For unconjugated BAs, the m/z values of the product ions from the mono-, di-, and tri-hydroxylated forms are 375.6, 391.6, and 407.6, respectively. For taurineconjugated BAs, the m/z values of the product ions from the mono-, di-, and tri-hydroxylated forms are selected as 482.7, 498.7, and 514.7, respectively. For glycine-conjugated BAs, the m/z values of the product ions from the mono-, di-, and tri-hydroxylated forms are selected as 432.6, 448.6, and 464.6, respectively. The m/z of the NDCA internal standard is 377.5. A summary of ions monitored during MS analysis of BAs is shown in Table 6.1. A chromatogram of all detected BAs is shown in Fig. 6.1.
124
Hagio, Matsumoto, and Ishizuka
Table 6.1 Detected m/z, applied ranges of analysis, correlation coefficient of calibration curves, and accuracy of successive analysis in standard mixture and feces for bile acids SD (%) [M-H]–
Range (µM)
Correlation coefficiency
STD
Feces
Unconjugated CA
407.6
0.1–50
0.9997
3.70
5.01
αMCA
407.6
0.1–50
1.0000
3.60
3.29
βMCA
407.6
0.1–50
0.9998
4.11
3.57
ωMCA
407.6
0.1–50
1.0000
2.12
2.44
HDCA
391.6
0.1–50
1.0000
7.12
1.04
UDCA
391.6
0.1–50
0.9995
4.46
2.39
CDCA
391.6
0.1–50
0.9991
3.94
9.58
DCA
391.6
0.1–50
0.9998
1.79
1.62
LCA
375.6
0.1–50
0.9976
3.48
3.17
Taurine conjugated CA
514.7
0.1–50
0.9995
3.30
–
αMCA
514.7
0.1–50
0.9998
6.33
–
ωMCA
514.7
0.1–50
0.9992
5.26
–
HDCA
498.7
0.1–50
0.9999
1.95
–
CDCA
498.7
0.1–50
0.9997
2.78
–
DCA
498.7
0.1–50
0.9997
5.29
–
LCA
482.7
0.1–50
0.9997
3.03
–
Glycine conjugated CA
464.6
0.1–50
1.0000
3.51
–
HDCA
448.6
0.1–50
0.9999
5.88
–
UDCA
448.6
0.1–50
0.9998
3.61
–
CDCA
448.6
0.1–50
0.9999
5.52
–
DCA
448.6
0.1–50
1.0000
2.64
–
LCA
432.6
0.1–50
0.9986
7.12
–
377.5
0.1–50
0.9991
3.31
3.88
Internal standard NDCA
In this analytical protocol using UPLC/ESI-MS, these values of m/z for each BA are applied in selective ion-recording mode. We repeatedly try to adjust the dilution ratio of sample extracts to match the detected concentrations of each BA within these ranges, because, especially in biological samples, the concentration of each BA is widespread. Correlation coefficient is calculated by analyzing 0.1, 1, 5, 10, 25, and 50 μM standard mixtures (STD). The values of SD are shown as a percentage of the standard deviation against the mean value of each BA concentration in five successive analyses of STD and fecal extracts from DA rats.
Bile Acid Analysis in Various Biological Samples 100
%
TIC 7.25e6 m/z = 100 –1000
0 2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
100
22.00 6
24.00
26.00
SIR 4.27e5 m/z = 407.6, 377.5, 375.6
%
1 23
4
5
0 2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00 9
100
20.00 10
22.00
24.00
26.00
SIR 1.36e5 m/z = 391.6
8
%
7
0 2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
100
%
Relative intensity (%)
125
15
13 14
11 12
22.00 17
24.00
26.00
SIR 1.56e5 m/z = 514.7, 498.7, 482.7
16
0 2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
%
100
18 19
21
22.00 23
24.00
26.00
SIR 2.30e5 m/z = 448.6, 464.6, 432.6
22
20
0
Time 2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
22.00
24.00
26.00
Time (min)
Fig. 6.1. Selected ion-recording (SIR) chromatograms for BA standard mixture solutions (5 μM each) obtained from UPLC/ESI-MS analysis. (1) ωMCA, (2) αMCA, (3) βMCA, (4) CA, (5) NDCA, (6) LCA, (7) UDCA, (8) HDCA, (9) CDCA, (10) DCA, (11) TωMCA, (12) TαMCA, (13) THDCA, (14) TCA, (15) TCDCA, (16) TDCA, (17) TLCA, (18) GUDCA, (19) GHDCA, (20) GCA, (21) GCDCA, (22) GDCA, (23) GLCA.
3. Concentrations of the individual BAs are calculated by comparing the area under the peak of each BA with that of the internal standard NDCA (see Note 10). 4. As an illustration, a chromatogram of the jejunal contents is shown in Fig. 6.2. The concentrations of each BA in the jejunal contents and feces are shown in Table 6.2.
4. Notes 1. In preparing solvents A and B, it is preferable to dissolve NH4 Ac in water in advance and then mix acetonitrile with the water containing NH4 Ac, as NH4 Ac cannot be dissolved in acetonitrile. 2. In cases of blood plasma or bile, 100 μL of plasma or 50 μL of bile samples is lyophilized and extracted without the heating step. Especially for blood plasma, this step is advantageous in eliminating unwanted substances, such as proteins.
126
Hagio, Matsumoto, and Ishizuka 100
%
TIC 1.33e8 m/z = 100 –1000
0 2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
22.00
24.00
5
%
SIR 1.19e5 m/z = 407.6, 377.5, 375.6
3
0 2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
22.00
24.00
26.00
8
%
100
SIR 1.02e4 m/z = 391.6
9 10
7
0 2.00
4.00
6.00
8.00
10.00
12.00 14
100
%
Relative intensity (%)
26.00
4
100
14.00
16.00
18.00
20.00
22.00
24.00
SIR 8.93e5 m/z = 514.7, 498.7, 482.7
13
12
15
16
26.00
17
0 2.00
4.00
6.00
8.00
%
100
10.00 20
12.00
14.00
16.00
18.00
20.00
22.00
24.00
SIR 3.43e5 m/z = 448.6, 464.6, 432.6
19 21
18
26.00
22
0
Time 2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
22.00
24.00
26.00
Time (min)
Fig. 6.2. Chromatograms of BAs in the jejunal contents of rats using the selected ion-recording (SIR) mode. (3) βMCA, (4) CA, (5) NDCA, (7) UDCA, (8) HDCA, (9) CDCA, (10) DCA, (12) TαMCA, (13) THDCA, (14) TCA, (15) TCDCA, (16) TDCA, (17) TLCA, (18) GUDCA, (19) GHDCA, (20) GCA, (21) GCDCA, (22) GDCA.
3. It is not always necessary to add this amount of NDCA to samples, because dilution ratio of introducing samples to UPLC/ESI-MS is widespread (see Note 8). In our case, the amount of NDCA whose diluted concentration is from 10 to 25 μM is added to samples. 4. We only use sonication to make the suspensions. It is preferable to perform this step on ice. 5. As the caps on the microtubes can sometimes open during heating, we always place cap holders on the microtubes. 6. When methanol is added to the extracts, some debris might be found in the tube. If there is a large precipitant in the tube, it might be better to use the supernatant after centrifugation. 7. Although the sample for injection is normally dissolved in the same solvent as that used for cartridge equilibration, we usually dissolve the samples in methanol. Briefly, after conditioning cartridges with 1 mL of methanol, we use 1 mL of water containing 10 mM NH4 Ac as an equilibration step. Then, 1 mL of water containing 10 mM NH4 Ac is again added into the cartridge. Soon after this step, 100 μL of sample in methanol (from the solution described in Step 1 in Section 3.2) is added and gently mixed with
Bile Acid Analysis in Various Biological Samples
127
Table 6.2 Bile acid concentrations in the jejunal contents and feces Jejunum
Feces
1.52 ± 0.59
0.14 ± 0.03
Concentrations (μmol/g dry contents) Unconjugated CA αMCA
0.08 ± 0.04
0.03 ± 0.02
βMCA
0.22 ± 0.09
0.60 ± 0.17
ωMCA
0.03 ± 0.02
2.79 ± 0.80
HDCA
0.09 ± 0.04
1.96 ± 0.63
UDCA
0.03 ± 0.01
0.04 ± 0.01
CDCA
0.06 ± 0.03
<0.01
DCA
0.03 ± 0.01
0.58 ± 0.14
LCA
<0.01
0.29 ± 0.04
CA
6.63 ± 1.13
ND
αMCA
6.10 ± 1.72
ND
ωMCA
0.57 ± 0.09
ND
Taurine conjugated
HDCA
0.67 ± 0.21
<0.01
CDCA
0.35 ± 0.05
<0.01
DCA
0.31 ± 0.05
ND
LCA
ND
ND
0.47 ± 0.21
ND
Glycine conjugated CA HDCA
0.04 ± 0.03
ND
UDCA
<0.01
ND
CDCA
0.01 ± 0.01
ND
DCA
0.01 ± 0.01
<0.01
LCA
ND
ND
TBA
17.24 ± 2.41
6.45 ± 0.90
Conjugation
85.3 ± 6.1
<0.1
SBA/TBA
11.4 ± 1.6
87.2 ± 2.7
Percentages (%)
Male DA/Slc rats (6 weeks old, n = 8) (Japan SLC, Inc., Hamamatsu, Japan) had free access to a purified diet and water for 7 weeks. The diet composition was as follows (16): 52.95% dextrin, 20% casein, 10% sucrose, 7% soybean oil, 5% cellulose, 3.5% mineral mixture (AIN 93G), 1% vitamin mixture (AIN 93G), 0.3% L-cystine, and 0.25% choline chloride. TBA; total BA, SBA; secondary BA (BAs except for CA, CDCA, αMCA, and βMCA, regardless of conjugation status), ND; not detected. Values are expressed as means ± SEM.
128
Hagio, Matsumoto, and Ishizuka
the water containing 10 mM NH4 Ac on the top of the cartridge. By doing this, the sample can be applied almost wholly to water containing 10 mM NH4 Ac. 8. At this point, dilution of the extracts has to be determined independently for each sample. 9. The temperature in the auto sampler is kept at 15◦ C in a default condition in the LC. However, evaporation of methanol in samples is strictly limited because the vials are tightly covered with a cap. 10. The range of concentrations in the standard curve for each BA has to be determined individually. In five successive analyses of a standard mixture sample, the ratios of standard deviation (SD) against the mean values of BA concentrations (23 BAs) were all below 8%. In the case of a biological sample, the ratios of SD against the mean values of unconjugated BA concentrations (nine BAs) in the feces of rats were all below 10% (Table 6.1). References 1. Russell, D. W. (2003) The enzymes, regulation, and genetics of bile acid synthesis. Ann Rev Biochem 72, 137–174. 2. Ninomiya, R., Matsuoka, K., Moroi, Y. (2003) Micelle formation of sodium chenodeoxycholate and solubilization into the micelles: comparison with other unconjugated bile salts. Biochim Biophys Acta 1634, 116–125. 3. Haza, A. I., Glinghammar, B., Grandien, A., Rafter, J. (2000) Effect of colonic luminal components on induction of apoptosis in human colonic cell lines. Nutr Cancer 36, 79–89. 4. Araki, Y., Fujiyama, Y., Andoh, A., Nakamura, F., Shimada, M., Takaya, H., Bamba, T. (2001) Hydrophilic and hydrophobic bile acids exhibit different cytotoxicities through cytolysis, interleukin-8 synthesis and apoptosis in the intestinal epithelial cell lines. IEC-6 and caco-2 cells. Scand J Gastroenterol 36, 533–539. 5. Booth, L. A., Gilmore, I. T., Bilton, R. F. (1997) Secondary bile acid induced DNA damage in HT29 cells: are free radicals involved?. Free Radic Res 26, 135–144. 6. Journe, F., Durbecq, V., Chaboteaux, C., Rouas, G., Laurent, G., Nonclercq, D., Sotiriou, C., Body, J. J., Larsimont, D. (2008) Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast
7.
8.
9.
10.
11.
12.
13.
cancer from postmenopausal patients. Breast Cancer Res Treat 115, 523–535. Keren, Z., Falik-Zaccai, T. C. (2009) Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease. Pediatr Endocrinol Rev 7, 6–11. Kase, B. F. (1989) Role of liver peroxisomes in bile acid formation: inborn error of C27steroid side chain cleavage in peroxisome deficiency (Zellweger syndrome). Scand J Clin Lab Invest 49, 1–10. Hofmann, A. F., Strandvik, B. (1998) Defective bile acid amidation: predicted features of a new inborn error of metabolism. Lancet 2, 311–313. Sundaram, S. S., Bove, K. E., Lovell, M. A., Sokol, R. J. (2008) Mechanisms of disease: inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol 5, 456–468. Colombo, C., Okolicsanyi, L., Strazzabosco, M. (2000) Advances in familial and congenital cholestatic diseases. Clinical and diagnostic implications. Dig Liver Dis 32, 152–159. Shaw, R., Smith, J. A., Elliott, W. H. (1978) Bile acids LIII. Application of reverse-phase high-pressure liquid chromatography to the analysis of conjugated bile acids in bile samples. Anal Biochem 86, 450–456. Siow, Y., Schurr, A., Vitale, G. C. (1991) Diabetes-induced bile acid composition changes in rat bile determined by high performance liquid chromatography. Life Sci 49, 1301–1308.
Bile Acid Analysis in Various Biological Samples 14. Ando, M., Kaneko, T., Watanabe, R., Kikuchi, S., Goto, T., Iida, T., Hishinuma, T., Mano, N., Goto, J. (2006) High sensitive analysis of rat serum bile acids by liquid chromatography/electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal 40, 1179–1186. 15. Hagio, M., Matsumoto, M., Fukushima, M., Hara, H., Ishizuka, S. (2009) Improved
129
analysis of bile acids in tissues and intestinal contents of rats using LC/ESI-MS. J Lipid Res 50, 173–180. 16. Reeves, P. G., Nielsen, F. H., Fahey, G. C.. Jr. (1993) AIN-93 purified diets for laboratory rodents: final report of the American institute of nutrition ad hoc writing committee on the reformulation of the AIN-76a rodent diet. J Nutr 123, 1939–1951.
Chapter 7 Analysis of Glycolytic Intermediates with Ion Chromatography- and Gas Chromatography-Mass Spectrometry Jan C. van Dam, Cor Ras, and Angela ten Pierick Abstract In this chapter, we describe a method for the quantitative analysis of glycolytic intermediates using ion chromatography-mass spectrometry (IC-MS) and gas chromatography (GC)-MS as complementary methods. With IC-MS-MS, pyruvate, glucose-6-phosphate, fructuse-6-phosphate, fructose-1,6-bisphosphate, phosphoenolpyruvate, and the sum of 2-phosphoglyceraldehyde + 3phosphoglyceraldehyde can be quantified. With GC-MS using selected ion monitoring, glyceraldehyde3-phosphate, dihydroxyacetonephosphate, 2-phosphoglyceraldehyde, and 3-phosphoglyceraldehyde can be analyzed. The derivatization for GC-MS is performed in two steps. In the first step, the keto and the aldehyde groups are oximated. In the next step, a silylation with N-methyl-Ntrimethylsilyltrifluoroacetamide (MSTFA) is performed, giving TMS-MOX derivatives of the glycolytic intermediates. The derivatives are separated on a GC column and detected with MS in SIM mode. Key words: Glycolytic intermediates, anion exchange chromatography, ion suppressor, IC-MS-MS, TMS-MOX derivatives, GC-MS, isotope dilution mass spectrometry.
1. Introduction The glycolytic intermediates play an important role in many biological processes. By mapping these processes much insight has been gained on the mechanisms that play an important role in life and in the evolution of life. Although we still do not understand life itself, much can be said about the processes involved in life. Glycolysis is a main metabolic route in central carbon metabolism, and, therefore, the need to analyze the glycolytic intermediates is evident. Indeed, profiling of the glycolytic intermediates is applied T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_7, © Springer Science+Business Media, LLC 2011
131
132
van Dam, Ras, and ten Pierick
in several scientific fields, such as bio-engineering, metabolic disorders, inborn diseases, and metabolic modeling. All the glycolytic intermediates are phosphorylated compounds except pyruvate. Due to the ionic nature of these metabolites, ion chromatography (IC) is an obvious choice for the analysis. Another method which is gaining in popularity is GC-MS, in which the intermediates have to be derivatized in order to make them volatile. IC-MS/MS (multiple reaction monitoring, MRM) and GC-MS can be used as complementary techniques for the analysis of the glycolytic intermediates. In this chapter, we describe in detail the application of these two analytical methods for analysis of the glycolytic intermediates (1, 2). Most of the glycolytic intermediates can be analyzed with the IC method, with the exception of glyceraldehyde-3-phosphate (GAP) and dihydroxyacetonephosphate (DHAP). Apparently, these compounds decompose in the column due to high sodium hydroxide concentrations used in the gradient. However, GAP and DHAP can be analyzed with the GC-MS method. In the IC method, 2-phosphoglycerate (2PG) and 3-phosphoglycerate (3PG) coelute, but, due to the fact that the concentration of 3PG is approximately ten times higher than that of 2PG and that 2PG and 3PG are assumed to be in equilibrium, we measure the sum of both intermediates by using a 3PG standard. However, 2PG and 3PG can be separated and analyzed with the GC-MS method.
2. Materials 2.1. Chemicals
All glycolytic intermediates are purchased from Sigma-Aldrich (St. Louis, MO). Pyruvate is stored at 4◦ C and all other compounds at –20◦ C (see Note 1). 1. Glucose-6-phosphate (G6P; 98.5%). 2. Fructose-6-phosphate (F6P; 100%). 3. Fructose-1,6-bisphosphate (FBP; 99%). 4. Phosphoenolpyruvate (PEP; 100%). 5. 2-Phoshoglycerate (2PG; 99%). 6. 3-Phosphoglycerate (3PG; 99%). 7. Glyceraldehyde-3-phosphate (GAP; 260–320 mM). 8. Dihydroxyacetonephosphate (DHAP; >95%). 9. Pyruvate (PYR; 100%). 10. Erythritol (99%). 11. Methoxyamine-HCl (MOX; Pierce, Rockford, IL).
Analysis of Glycolytic Intermediates
12. N-methyl-N-trimethylsilyltrifluoroacetamide Pierce).
133
(MSTFA;
13. Pyridine. 14. Methanol HPLC grade. 15. HPLC solvent A: 95% water/5% methanol. 16. HPLC solvent B: 0.6 mM NaOH. 17. HPLC solvent C: 0.06 M NaOH. 18. HPLC solvent D: 0.3 M NaOH. 19. U-13 C glucose (99%, Cambridge Isotope Laboratories, Inc., Andover, MA). 2.2. Equipment
1. Milli-Q water purification system (Millipore, Billerica, MA): This system is used to produce deionized and filtered water for the preparation of solutions and eluents. 2. Heating module (Reacti-Therm III, Pierce) with aluminum heating block. Eighty-one samples can be derivatized simultaneously. 3. Centrifuge. 4. RapidVap (Labconco Corporation, Kansas City, MO).
2.3. IC-MS/MS Instrumentation
1. Waters 2795 HPLC (Waters, Milford, MA). 2. IonPac AS11 (250 mm × 4 mm) anion exchange column (Dionex, Sunnyvale, CA). 3. XTerra MS C18 (5 μm, 3.0 mm × 20 mm) guard column (Waters). 4. ASRS 300 4 mm ion suppressor (Dionex). This system removes post-column sodium ions from the eluent. 5. Two-way LabPro solvent selector valve (Rheodyne, Cotati, CA). 6. Ten-port, two-position LabPro valve (Rheodyne). 7. Quattro LC triple quadrupole mass spectrometer (Waters). 8. MassLynx 4.0 software.
2.4. GC-MS Instrumentation
1. Trace GC Ultra (Thermo Finnigan, Boston, MA). 2. Trace DSQ single quadrupole mass spectrometer (Thermo Finnigan). 3. Zebron ZB-50 column (30 m × 250 μm internal diameter, 0.25 μm film thickness; Phenomenex, Torrance, CA) 4. Straight glass liners with CarboFrit (Restek, Bellefonte, PA). 5. BTO septa (Restek). These septa are low-bleed and hightemperature resistant (400◦ C).
134
van Dam, Ras, and ten Pierick
6. Needle to puncture the PTFE septa, any injection needle will work. 7. GC vials, glass short thread vials, 32 × 11.6 mm, wide opening (Grace, Dearfield, IL). 8. Septa GC vial for freeze-drying: ultra pure PTFE thickness 0.2 mm (Grace, Dearfield, IL). 9. Septa GC vial for analysis: natural rubber red/orange/ PTFE transparent (Grace, Dearfield, IL).
3. Methods Although sampling (3) and sample handling are not part of the analysis method, it is very clear that these two subjects are very important for reliable analysis results. Storage conditions are therefore important because biological samples can easily degrade. Freezing and thawing of samples several times can also degrade samples. If you thaw a sample and only use a portion, thaw completely and mix before dividing the sample into several aliquots. Keep in mind that even a good analytical method cannot compensate for poor sampling or sample handling. The methods described here are mainly used in analyses of intracellular and extracellular metabolites from fermentations. The intracellular samples contain the entire cell matrix, with the exception of any material that is precipitated during the extraction procedure with boiling ethanol (75%). 3.1. Preparation of Standards for IC-MS/MS and GC-MS
The electrospray ionization efficiency of a metabolite is dependent on the concentrations of other coeluting metabolites and matrix components. As matrix effects – observed with electrospray ionization – are compound dependent, quantitative studies require an internal standard for each target metabolite. Otherwise, the ion suppression during electrospray could result in nonlinear responses. With isotope dilution mass spectrometry (IDMS), isotopically labeled analogues of each metabolite are used as internal standards in the sample solution and in the calibration mixtures. In most cases, these labeled materials are not easily available from commercial suppliers. However, it is possible to prepare labeled standards by growing cells on fully labeled media followed by cell extraction. For the measurement of the glycolytic intermediates, labeled isotopomers are prepared by growing microorganisms on uniformly 13 C-labeled glucose. Cells are then harvested and the metabolites extracted, giving a 13 C-labeled extract containing the whole labeled metabolome of the cell (4). The unlabeled intermediate and its isotopologue behave similarly during
Analysis of Glycolytic Intermediates
135
chromatography separation and coelute. A fixed amount of the labeled internal standard extract is added to both the calibration standards and the samples (see Note 2). After the elution of the intermediate and its isotopologue, the two compounds are detected and measured by MS. The peak area ratios are obtained by dividing the peak area of each intermediate by the peak area of its corresponding isotopologue. The peak area ratios are used for the construction of calibration curves and for quantification. Using the IDMS correction method, calibration curves are linear over a much wider range. In addition, the method also corrects for incomplete derivatization and for losses due to sample handling. In the case of GC-MS (not MS/MS), the signal of the internal standard (the 13 C analogue) should be corrected for the contribution of the naturally present labeled intermediates. 3.1.1. Preparation of 13 C Cell Extract
1. Run a yeast fermentation feeding the microorganism with U-13 C glucose and sample the fermentor. 2. Centrifuge the sample at 5000×g for 5 min and decant the liquid. Keep the cell pellet (in our fermentations, 1 mL broth contains ∼15 mg of yeast dry weight). 3. Add the cell pellet from 1 mL of yeast to 5 mL of boiling ethanol (75%). 4. Boil the sample for 3 min and then cool the sample on ice. 5. Evaporate the extract to dryness in a RapidVap. 6. Dissolve the dry extract in 500 μL water. 7. Centrifuge the extract for 5 min at 15,000×g. 8. Transfer the clear liquid to a separate tube. The is ready for use or storage.
3.1.2. Preparation of Standards
13 C
extract
1. Prepare aqueous stock solutions of 100 mM for each metabolite. 2. Prepare an aqueous mixed working solution containing the metabolites of interest by dilution of the standard stock solutions. This solution is the calibration mixture. Store aliquots of this mixture at –80◦ C (see Note 3). The concentrations of the metabolites in the calibration mixture will depend on the linear dynamic range of the IC-MS platform used, as well as the concentrations of the metabolites to be measured in the samples of interest. The concentrations of the intermediates in our calibration mixture are as follows: 150 μM PYR, 250 μM G6P, 50 μM F6P, 50 μM PEP, 100 μM 3PG, and 500 μM FBP. 3. By diluting the calibration mixture, ten standards are prepared.
136
van Dam, Ras, and ten Pierick
4. Standard 1 (0.30 μM PYR, 0.50 μM G6P, 0.10 μM F6P, 0.10 μM PEP, 0.20 μM 3PG, and 1.00 μM FBP): Pipette 2 μL of calibration mixture to a vial, add 998 μL of water, and mix the liquid. 5. Standard 2 (0.75 μM PYR, 1.25 μM G6P, 0.25 μM F6P, 0.25 μM PEP, 0.50 μM 3PG, and 2.50 μM FBP): Pipette 5 μL of calibration mixture to a vial, add 995 μL of water, and mix the liquid. 6. Standard 3 (1.50 μM PYR, 2.50 μM G6P, 0.50 μM F6P, 0.50 μM PEP, 1.00 μM 3PG, and 5.00 μM FBP): Pipette 10 μL of calibration mixture to a vial, add 990 μL of water, and mix the liquid. 7. Standard 4 (3.00 μM PYR, 5.00 μM G6P, 1.00 μM F6P, 1.00 μM PEP, 2.00 μM 3PG, and 10.00 μM FBP): Pipette 20 μL of calibration mixture to a vial, add 980 μL of water, and mix the liquid. 8. Standard 5 (7.50 μM PYR, 12.50 μM G6P, 2.50 μM F6P, 2.50 μM PEP, 5.00 μM 3PG, and 25.00 μM FBP): Pipette 50 μL of calibration mixture to a vial, add 950 μL of water, and mix the liquid. 9. Standard 6 (15.00 μM PYR, 25.00 μM G6P, 5.00 μM F6P, 5.00 μM PEP, 10.00 μM 3PG, and 50.00 μM FBP): Pipette 100 μL of calibration mixture to a vial and add 900 μL of water and mix the liquid. 10. Standard 7 (30.0 μM PYR, 50.0 μM G6P, 10.0 μM F6P, 10.0 μM PEP, 20.0 μM 3PG, and 100.0 μM FBP): Pipette 200 μL of calibration mixture to a vial, add 800 μL of water, and mix the liquid. 11. Standard 8 (45.0 μM PYR, 75.0 μM G6P, 15.0 μM F6P, 15.0 μM PEP, 30.0 μM 3PG, and 150.0 μM FBP): Pipette 300 μL of calibration mixture to a vial, add 700 μL of water, and mix the liquid. 12. Standard 9 (67.5 μM PYR, 75.0 μM G6P, 22.5 μM F6P, 22.5 μM PEP, 45.0 μM 3PG, and 225.0 μM FBP): Pipette 450 μL of calibration mixture to a vial, add 550 μL of water, and mix the liquid. 13. Standard 10 (90.0 μM PYR, 150.0 μM G6P, 30.0 μM F6P, 30.0 μM PEP, 60.0 μM 3PG, and 300.0 μM FBP): Pipette 600 μL of calibration mixture to a vial, add 400 μL of water, and mix the liquid. 14. Fill LC injection vials with 80 μL of standard or sample, add 20 μL of labeled internal standard, and mix with a vortex mixer.
Analysis of Glycolytic Intermediates
LC
AS11 column
MS
Ion suppressor MeOH 80%
137
Waste
Fig. 7.1. General set up of the LC-MS system.
pump
LC
2
solvent selector
LC
1 10
3
9 8
4 5 6 7
9 8
4
MS
solvent selector
1 10
3
waste AS11
(A)
2 guard
pump
guard
5 6 7
waste AS11
MS
(B)
Fig. 7.2. Valve switching positions A and B. In position A the sample is transferred to the analytical column (AS11) and in position B the guard column is cleaned and the chromatography performed.
3.2. IC-MS/MS
This section describes the anion exchange IC-MS/MS method for the glycolytic intermediates and is an adaptation of the method described by van Dam et al. (1). Figure 7.1 shows the general setup of the IC-MS/MS method and Fig. 7.2 gives detailed information for the column switching. The ten-port valve and the solvent selector are switched with event switches in the LC. The tubing used to connect the parts in the setup should be as short as possible to avoid extra dispersion of the intermediates in the liquid flow, which results in peak broadening and thus lower peaks and higher detection limits.
3.2.1. Ion Chromatography
1. Set the LC flow rate to 1 mL/min with the following initial conditions: A: 95%, B: 5% (see Note 4), C: 0%, and D: 0%. 2. Set the event switches as follows: event switch 1: On, event switch 2: Off, and event switch 3: On. Event switch 1 switches the ten-port valve and event switches 2 and 3 switch the solvent selector valve. 3. Due to the instability of the standards and samples, the temperature of the sample tray is set to 4◦ C. 4. Set the pump for 80% methanol – located between the AS11 column and the ion suppressor (Fig. 7.1) – to 0.7 mL/min (see Note 5).
138
van Dam, Ras, and ten Pierick
5. Set the pump for the solvent selector (Fig. 7.2) to 0.9 mL/min. 6. Start the three pumps. 7. Switch the ion suppressor on. The ion suppressor removes the sodium ions from the eluate via an electrical current (see Note 6) and replaces the sodium with hydrogen (see Note 7). After the ion suppressor (Fig. 7.1), the effluent is split by a T union, resulting in an approximate flow to the mass spectrometer of 100 μL/min. This flow reduction not only increases the observed sensitivities but also prevents quick contamination of the MS (see Note 8). 8. The chromatography is started with the column switching valve in position A (the guard column is switched in front of the AS11 column, see Fig. 7.2) and the solvent selector giving a 5% methanol solution. 9. Inject 10 μL of sample or standard in the liquid chromatograph. 10. At 1.5 min, switch the guard column to position B with event switches as follows: event switch 1: Off, event switch 2: On, and event switch 3: Off. Set the solvent selector to 80% methanol. 11. At 1.51 min, set the LC solvents to A: 95%, B: 0%, C: 5%, and D: 0%. 12. Start the sodium hydroxide gradient from 1.51 min to 17.00 min, with an exponential curve (curve 7) and to the solvent settings of A: 75%, B: 0%, C: 25%, and D: 0%. The exponential gradient improves the separation of the isomers of G6P, which are F6P, glucose-1phosphate, fructose-1-phosphate, mannose-1-phosphate, and mannose-6-phosphate. 13. From 17.00 to 22.00 min, use a linear gradient from A: 75%, B: 0%, C: 25%, and D: 0% to A: 0%, B: 0%, C: 100%, and D: 0%. This linear gradient separates PEP, 2PG+3PG, and FBP. 14. At 22.00 min, switch the solvent selector to 5% methanol with event switch 2: Off and event switch 3: On. The guard column is now reconditioned (see Note 9). 15. From 22.00 to 23.00 min, use a linear gradient from A: 0%, B: 0%, C: 100%, and D: 0% to A: 20%, B: 0%, C: 0%, and D: 80%. 16. From 23.00 to 26.00 min, maintain the conditions A: 20%, B: 0%, C: 0%, and D: 80%. This is the AS11 column cleaning step (see Note 10). 17. From 26.00 to 27.00 min, return to initial conditions using a linear gradient: A: 95%, B: 5%, C: 0%, and D: 0%.
Analysis of Glycolytic Intermediates
139
18. From 27.00 to 34.00 min, the AS11 column is reconditioned. 19. At 34.00 min, switch the guard column to position A with event switch 1: On. The LC is ready for a new injection. 3.2.2. Mass Spectrometry
1. Set the capillary voltage to –2.70 kV for negative ionization. 2. Set the source block temperature to 90◦ C. 3. Set the desolvation temperature to 250◦ C. 4. Set the nebulation gas flow to 69 L/h. 5. Set the desolvation gas flow to 620 L/h. 6. The data acquisition for the intermediates is grouped into functions. Each function contains several channels, and there is an inter-channel delay of 0.03 s between each channel. The functions used in this method are described below. 7. Function 1. Start time: 0.00 min. End time: 7.50 min. 8. PYR: MS1: 86.8 m/z, MS2: 42.8 m/z, dwell time: 0.50 s, cone (V): 18, and collision energy (eV): 12. 9.
13 C-PYR:
MS1: 89.8 m/z, MS2: 45.8 m/z, dwell time 0.50 s, cone (V): 18, and collision energy (eV): 12.
10. Function 2. Start time: 7.5 min. End time: 19.00 min. 11. G6P and F6P: MS1: 259.0 m/z, MS2: 96.8 m/z, dwell time 0.50 s, cone (V): 20, and collision energy (eV): 18. 12.
13 C-G6P
and 13 C-F6P: MS1: 265.0 m/z, MS2: 96.8 m/z, dwell time 0.50 s, cone (V): 20, and collision energy (eV): 18.
13. Function 3. Start time: 19.00 min. End time: 25.00 min. 14. PEP: MS1: 167.0 m/z, MS2: 78.7 m/z, dwell time 0.25 s, cone (V): 18, and collision energy (eV): 20. 15.
13 C-PEP:
MS1: 167.0 m/z, MS2: 78.7 m/z, dwell time 0.25 s, cone (V): 18, and collision energy (eV): 20.
16. 2PG + 3PG: MS1: 185.0 m/z, MS2: 78.7 m/z, dwell time 0.25 s, cone (V): 20, and collision energy (eV): 20. 17.
13 C-2PG
+ 13 C-3PG: MS1: 188.0 m/z, MS2: 78.7 m/z, dwell time 0.25 s, cone (V): 20, and collision energy (eV): 20.
18. Function 4. Start time: 0.00 min. End time: 25.00 min. 19. H34 SO4 : MS1: 98.8 m/z, MS2: 81.8 m/z, dwell time 0.02 s, cone (V): 40, and collision energy (eV): 20 (see Note 11). From the MRM settings, the most abundant fragment of the parent ion is used. It is clear that the most abundant fragments are mostly produced by the phosphate groups. Although this does
140
van Dam, Ras, and ten Pierick
not give selectivity, it works fine. Mass 97 m/z is the phosphate group and mass 79 m/z is the phosphate group after losing water. These fragments do not contain carbon atoms, so there will be no 13 C-labeled fragments in this case. In contrast, the pyruvate fragment is labeled giving rise to different masses for the 12 C and the 13 C intermediate fragments (see Note 12). Figure 7.3 shows representative extracted ion chromatograms (EICs) of the glycolytic intermediates using the described method. The two bottom chromatograms demonstrate the coelution of FBP and its internal reference standard (the 13 C isotopomer); all the other reference standards are measured but are not shown. The EIC of HSO4 − is added as an example of a coeluting salt, since many biological samples contain high concentrations of non-volatile salts or buffers, which may cause ionization suppression or contaminate the ion source and the mass analyzer. Therefore, non-volatile additives and buffers should be replaced by those that are volatile and MS-compatible. Aside from
%
100
4.37
PYR
0 4.00
6.00
8.00
10.00
12.00
100
14.00 16.00 15.04
%
HSO4
18.00
20.00
22.00
18.00
20.00
22.00
18.00
20.00
22.00 21.28
–
0 4.00
6.00
8.00
10.00
12.00
100
14.00
%
G6P
16.00 15.35
F6P
16.09
0 4.00
6.00
8.00
10.00
12.00
14.00
16.00
100
%
PEP
0 4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
22.00
20.58
100
%
2PG+3PG
0 4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
100
20.00
22.00 22.52
%
FBP
0 4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
100
20.00
%
13
22.00 22.46
C-FBP
0 4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
22.00
Time (min.)
Fig. 7.3. IC-MS-MS chromatogram showing extracted ion chromatograms of PYR, sulfate, G6P, and F6P (second peak; the third peak is mannose-6-phoshate), PEP, 2PG+3PG, FBP, and 13 C-labeled FBP.
Analysis of Glycolytic Intermediates
141
causing ionization suppression, high concentrations of sulfate or other salts can influence the ion chromatography due to overloading of the column. Based on the data shown in Fig. 7.3, it is clear that G6P will be easily influenced by a sulfate overloaded column. The peak shape in that case is no longer symmetrical and a retention time shift is also observed. Due to the high sulfate concentrations, ionization suppression also occurs for G6P (see Note 13). 3.3. GC-MS
Prior to derivatization, samples and standards are freeze-dried in order to remove water, because water reacts with the derivatization reagents. Two separate derivatizations – oximation and silylation – are performed prior to GC-MS analysis to increase the volatility of metabolites. In the oximation step, methoxyamineHCl reacts with the carbonyl groups of ketones and aldehydes as follows: −C=O + CH3 ONH2 → C=N−O−CH3 This reaction protects the functional groups of ketones and aldehydes and reduces the number of sugar isomers. In the silylation step, MSTFA (X−Si(CH3 )3 ) reacts with hydroxyl (–OH) and thiol (–SH) groups (in acids, amino acids, and alcohols) to form trimethylsilyl (TMS) groups on the oxygens or sulfurs: −OH + X−Si(CH3 )3 → −O−Si(CH3 )3 + HX The final derivatives are indicated as TMS-MOX derivatives. During the derivatization process, two oximated isomers are generated: syn and anti. The heights of the two isomer peaks always appear in the same ratio in the GC-MS chromatograms independent of the concentration (2). Safety precautions should be considered throughout the derivatization procedure. Use a fume hood, safety glasses, and gloves. During sample handling, open the GC vials only when they have reached room temperature and add reagents only when they are at room temperature, since moisture will react with reagents and can influence your derivatization results.
3.3.1. Derivatization
1. Fill a glass GC vial with 100 μL of sample or standard. 2. Add 20 μL of 13 C-labeled internal standard to the vial. 3. Add 20 μL of 40 μM erythritol to each GC vial for quality control of GC-MS performance (see Note 14). 4. Close the GC vials with a screw cap containing a Teflon seal. 5. Freeze the samples at –80◦ C.
142
van Dam, Ras, and ten Pierick
6. Remove the samples from the freezer after 15 min and puncture the Teflon seal twice with a needle (e.g., injection needle). 7. Freeze-dry the samples overnight. 8. Replace the punctured Teflon screw cap with a screw cap of Teflon containing natural rubber (see Note 15). Samples and standards can easily be stored when they are dry in a –80◦ C freezer. 9. Resuspend the dried samples in 50 μL of 240 mM methoxyamine-HCl in pyridine (see Note 16). 10. Place the GC vials in an aluminum heating block and incubate for 50 min at 65◦ C. Due to heating, the contents of the GC vials are mixed. 11. Remove the vials from the heating block. Cool the samples to room temperature and add 80 μL of MSTFA reagent to each standard or sample. Fresh solutions of MSTFA should be used for the silylation. 12. Incubate the GC vials again for 50 min at 65◦ C in the heating block. 13. Cool the samples to room temperature and transfer the contents of the GC vials to glass vials that can be centrifuged. 14. Centrifuge the glass vials for 1 min at 10,000×g. 15. Transfer the samples to glass inserts and place the inserts back in the previously used GC vials and close the vial with a rubber/Teflon septum. 16. For duplicate analyses, fill two inserts and put them in separate GC vials. Samples are stable for about 5 days. The contents of punctured vials will degrade soon. Ideally, the samples should be analyzed immediately after preparation. 3.3.2. GC-MS Settings
1. Operate the programmed temperature vaporization (PTV) in PTV SL mode. 2. Set the purge flow rate to 200 mL/min. 3. Set the helium carrier gas flow rate to 1 mL/min. 4. Set the temperature of the PTV to 70◦ C with a splitless time of 0.7 min. 5. Prior to injection, rinse the needle of the injector three times with isooctane. 6. After the injection of 1 μL sample or standard, raise the temperature of the PTV to 220◦ C at 10◦ C/s and hold for 5 min, then raise the temperature to 300◦ C at 14.5◦ C/s to clean the injector.
Analysis of Glycolytic Intermediates
143
7. Program the temperature gradient as follows: 70◦ C for 1 min, ramp to 76◦ C at 1◦ C/min, ramp to 150◦ C at 10◦ C/min, and finally ramp to 320◦ C at 30◦ C/min. 8. Rinse the needle of the injector five times with toluene. 9. Set the temperature of the transfer line from the GC to the MS and the ion source at 250 and 280◦ C, respectively. 10. Operate the MS in electron impact mode (EI) with 70 eV. 11. Set the mass resolution to 1 mass unit throughout the mass range of 1–1050 amu. 12. For quantitative measurements, operate the MS in selected ion monitoring (SIM) mode. 13. MS masses (m/z) for SIM analysis: GAP: 328, 13 C-GAP: 331, DHAP: 400, 13 C-DHAP: 403, 2PG: 459, 13 C-2PG: 462, 3PG: 357, 13 C-3PG: 359, G6P: 357, 13 C-G6P: 359, F6P: 217, and 13 C-F6P: 220. Due to the natural labeling of each fragment, there is a contribution of this labeling to the 13 C fragment. The 13 C fragment area therefore must be corrected for this contribution in the IDMS method. The higher the mass difference between 12 C and 13 C intermediate fragments, the lower the influence of the natural labeling on the 13 C internal standard signal. The fragments we have selected for the analysis are the optimal fragments for our instrument. Some instruments are more sensitive at higher masses. In that case, it is better to use higher masses, since the background noise is lower at higher masses and lower detection limits can be obtained (see Note 17).
4. Notes 1. The actual purities of the intermediates can be found on the manufacturers’ websites. Reference the lot numbers on the bottles to find the purities. 2. Adding the internal reference standard immediately after the sampling corrects for sample handling and degradation of intermediates during extraction and storage. 3. Store the stock solution in a –80◦ C freezer; –20◦ C is not low enough for long-term storage. The solution is stable for more than 1 year. 4. The methanol in solvent A prevents the growth of microorganisms inside the HPLC and in the tubings. Solvent B increases the pH of the injected sample above 9, so that the acids to be analyzed will be ionized. The XTerra guard column traps mainly proteins, peptides, and lipids at pH > 9. The XTerra guard column will not be damaged at this pH.
144
van Dam, Ras, and ten Pierick
Solvent B has to be replaced regularly (every 3–4 weeks) to reduce the appearance of strange peaks in front of G6P, which influence its peak shape. 5. Methanol improves the ionization in the MS. We have also evaluated the effect of adding methanol after the ion suppressor, but the best results were obtained when methanol was added before the ion suppressor. 6. The electrical current through the ion suppressor has to be optimized for the optimal signal. However, the ion suppressor lifetime is reduced at higher electrical currents. 7. The sodium concentration at the end of the chromatographic separation is 240 mM. If high sodium concentrations are introduced to the MS, one would lose almost all signals due to ionization suppression. The ion suppressor electrically removes the sodium via a membrane, and the hydroxide is neutralized by the hydrogen producing water. 8. Generally speaking, a mass spectrometer remains cleaner if you split the eluent before it enters the MS, because the load of salts and compounds is less. The MS signal arising from electrospray ionization is concentration dependent but not amount dependent, so eluent splitting does not influence the analysis result (if the flow to the MS is >10 μL/min). 9. There is an original guard column, AG11, from Dionex, but this guard column does not protect the analytical column longer than 8–10 samples when analyzing intracellular samples. After 80 sample injections, the analytical column is usually dirty and needs to be cleaned with a special procedure: fill the column with 1 M NaOH and store for 24 h at 40◦ C; wash the column with water and repeat the procedure with 1 M HCl. By using the XTerra guard column, hundreds of samples can be injected without clear performance loss of the AS11 column. 10. The concentration of sodium hydroxide should not be excessively high for a long time, because this will reduce the lifetime of the ion suppressor. On the other hand, a high concentration of sodium hydroxide is good for cleaning the analytical column. Otherwise FBP shows too much memory effect on the analytical column. The duration of this cleaning step does not significantly reduce the lifetime of the ion suppressor. 11. This molecular ion of sulfate contains the natural labeled sulfur isotope: 34 S. The reason for using this isotope is the overload of the MS detector for the 32 S sulfate. 34 S is 4% of 32 S. Note that the total dwell time in a function is ∼ 1 s. So there is one data point per second for each MRM transition.
Analysis of Glycolytic Intermediates
145
12. In analytical methods with complex samples, one prefers more selectivity, but, due to separation of isomeric intermediates, one can only expect non-isomeric intermediates to coelute. We have evaluated this and have not found any evidence for interferences. 13. All of our samples contain sulfate. The source of sulfate is the medium applied in a fermentation process. The replacement of sulfate with chloride was not successful since it produced memory effects in the LC column and suppressed ionization of all intermediates. 14. Erythritol is added as a standard to correct for the injection volume in the GC. Erythritol does not correct for discrimination in the injector. In contrast, IDMS does correct for discrimination in the injector. Note that if erythritol is a compound in your sample matrix – as it is in Penicillium chrysogenum – you cannot use it as internal standard. 15. For GC sample bottles, do not use silicon rubber instead of natural rubber caps, because silicon rubber reacts easily with the derivatization reagents. This can lead to sticky septa, a dirty needle, or even a bent needle. Storage of these dried samples has only been evaluated at –80◦ C, which did not show degradation. 16. Store the derivatization agents in a dry place. We store them in a desiccator at 4◦ C. 17. General remarks. The liner in the GC system has to be replaced (cleaned) regularly. The frequency is strongly dependent on the sample type. Some laboratories replace the liner after each injection due to the analysis of very dirty samples. In our laboratory, we mainly analyze intracellular samples – dirty samples – and we replace the liner after 30 sample injections. The MS (DSQ) which we use for the analysis is known to have fouling problems with TMS-MOX derivatives, which is observed during tuning. The design of the ion source is the main source for the fouling. Newer instruments have a better design. Check the performance of the column regularly (the frequency depends on the type of samples). Testing with a standard is in most cases sufficient. Due to dirty samples, the first part of the column becomes dirty, which is mostly seen as tailing of peaks or missing peaks in the chromatogram. The first part of the column can be cutoff and the performance can be checked. If this is not helpful, then replace the column. One of the major problems in the derivatization is moisture. If samples or solutions are coming out of the fridge or freezer, moisture can condense on the outside. Wait until they are at room temperature before opening.
146
van Dam, Ras, and ten Pierick
References 1. van Dam, J. C., Eman, M. R., Frank, J., Lange, H. C., van Dedem, G. W. K., Heijnen, S. J. (2002) Analysis of glycolytic intermediates in Saccharomyces cerevisiae using anion exchange chromatography and electrospray ionization with tandem mass spectrometric detection. Anal Chim Acta 460, 209–218. 2. Cipollina, C., ten Pierick, A., Canelas, A. B., Seifar, R. M., van Maris, A. J. A., van Dam, J. C., nd Heijnen, J. J. (2009) A comprehensive method for the quantification of the nonoxidative pentose phosphate pathway intermediates in Saccharomyces cerevisiae by GCIDMS. J Chromatogr B 877, 3231–3236.
3. Canelas, A. B., Ras, C., ten Pierick, A., Seifar, R., van Dam, J. C., van Gulik, W. M., Heijnen, J. J. (2009) Quantitative evaluation of intracellular metabolite extraction techniques for microbial metabolomics. Anal Chem 81, 7379–7389 4. Mashego, M. R., Wu, L., van Dam, J. C., Ras, C., Vinke, J. L., Van Winden, W. A., Van Gulik, W. M., Heijnen, J. J. (2004) MIRACLE: mass isotopomer ratio analysis of U-C-13-labeled extracts. A new method for accurate quantification of changes in concentrations of intracellular metabolites. Biotechnol Bioeng 85, 620–628.
Chapter 8 Analysis of the Citric Acid Cycle Intermediates Using Gas Chromatography-Mass Spectrometry Rajan S. Kombu, Henri Brunengraber, and Michelle A. Puchowicz Abstract Researchers view analysis of the citric acid cycle (CAC) intermediates as a metabolomic approach to identifying unexpected correlations between apparently related and unrelated pathways of metabolism. Relationships of the CAC intermediates, as measured by their concentrations and relative ratios, offer useful information to understanding interrelationships between the CAC and metabolic pathways under various physiological and pathological conditions. This chapter presents a relatively simple method that is sensitive for simultaneously measuring concentrations of CAC intermediates (relative and absolute) and other related intermediates of energy metabolism using gas chromatography-mass spectrometry. Key words: Citric acid cycle, CAC intermediates, GC-MS, metabolomics, mass spectrometry.
1. Introduction In mammalian cells, the citric acid cycle (CAC) is a series of enzyme-catalyzed chemical reactions that result in the generation of reducing equivalents (NADH/NAD+ , FADH2 /FADH) that fuel oxidative phosphorylation (mitochondrial cellular respiration), as well as carbon dioxide (1). The CAC links key metabolic pathways, such as glycolysis (2), gluconeogenesis (3, 4), and anaplerosis/cataplerosis (5–7), and provides precursors for many compounds including fatty acids and some amino acids. This chapter presents a qualitative method that is sensitive for simultaneously measuring concentrations of CAC intermediates (relative and absolute) and other related intermediates of energy metabolism using gas chromatography-mass spectrometry (GC-MS) and stable isotope technologies. This approach has T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_8, © Springer Science+Business Media, LLC 2011
147
148
Kombu, Brunengraber, and Puchowicz
been utilized for over two decades in laboratories conducting classical metabolomics, often in parallel with other biochemical analyses that use GC-MS techniques (2, 8, 9). With major advancements in GC-MS technology (increased sensitivity and throughput), database information from the National Institute of Standards and Technology (NIST), and cost-effectiveness, this approach has become more popular to researchers and thus prompted a new generation of scientists interested in metabolomics as a tool for the identification of unexpected correlations between apparently related and unrelated pathways of metabolism (10, 11). We describe a quantification method for assaying concentration profiles of (water-soluble) CAC metabolites as measured against a mixture of stable isotope reference compounds, such as [U-13 C6 ]citrate, [U-13 C4 succinate], and 3-hydroxy[2 H4 ]glutarate (12). Briefly, our approach utilizes the rapid reaction of silylating reagent with alcohols, acids, and amines to form silyl derivatives. Commercially, silylating reagents are available as combinations to accelerate the reaction, as well as to react with the hindered group. We use either a mixture of N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) and trimethylchlorosilane (TMCS) to form a TMS derivative or a mixture of N-Methyl-N-(t-butyldimethylsilyl)trifluoroacetamide (MTBSTFA) and t-butyldimethylchlorosilane (TBDMS) to form a TBDMS derivative (see Note 1). The resultant TMS and TBDMS derivatives of these metabolites/intermediates can be performed on plasma, tissue extracts, organ perfusates, or cell media preparations. As previously described (slightly modified method) (12), the assay involves (i) spiking the sample with one or more internal standards, (ii) homogenization with Folch’s solvent or an acid–methanol mixture and then centrifugation, (iii) evaporation of extract and derivatization with either trimethylor t-butyldi-silyl, and (iv) identification of the m/z of each analyte using ammonia-positive chemical ionization (CI) or electron impact ionization (EI) GC-MS. To analyze compounds containing “keto groups,” such as α-ketoglutarate and oxaloacetate, we also describe derivatization of TMS-methoxylamine, which requires a few additional preparatory steps. This chapter does not present mass isotopomer distribution analysis (MIDA) or the use of labeling patterns of intermediates to determine fluxes or turnover, as this approach often requires the use of low isotopomer background derivatizing agents (3, 4).
2. Materials 2.1. Chemicals and Materials
1. Chloroform. 2. Methanol.
Analysis of the Citric Acid Cycle Intermediates
149
3. Glacial acetic acid (≥99.7%). 4. Selected internal standards: [13 C6 ]citric and [13 C4 ]succinic acids (98%) (Isotec, Miamisburg, OH); (RS)-3-hydroxy[2 H4 ]glutarate was prepared as previously described (13). R 5. Regisil + 10% TMCS (TMS; Regis Technologies, Morton Grove, IL). Store in a refrigerator (4◦ C) in a desiccator.
6. N-Methyl-N-(t-butyldimethylsilyl)trifluoroacetamide (MTBSTFA + t-BDMCS; TBDMS; Regis Technologies, Morton Grove, IL). Store in a refrigerator (4◦ C) in a desiccator. 7. 10 N sodium hydroxide solution. Store at room temperature. 8. Methoxylamine–HCl solution (MOX; 100 mM): To prepare MOX solution, weigh 83.52 mg of methoxylamine hydrochloride in a conical tube and add 10 mL of water. Adjust the pH to 8–10 using 10 N sodium hydroxide solution (2). Prepare MOX solution fresh on the day of analysis (Caution: corrosive; avoid contact with skin and eyes; avoid breathing; and wear protective clothing) (see Note 2). 9. Chloroform/methanol mixture (2:1, v/v). This mixture is stable at room temperature and can be used for 1 month. This mixture is used in extraction method A, which is slightly modified from Yang et al. (12). 10. Methanol/water mixture (3:2, v/v). This mixture is stable at room temperature and can be used for 1 month. 11. Acid–methanol mixture: 5% acetic acid in methanol/water (1:1, v/v). This solution is stable at room temperature and can be used for 1 month. This mixture is used in extraction method B (14, 15). 12. Heating block capable of heating up to 70◦ C. 13. Turbovap evaporator (Caliper Life Sciences, Hopkinton, MA). 14. Speedvac vacuum Bellefonte, PA).
concentrator
(Thermo
Scientific,
15. Omni General Laboratory Homogenizer (Kennesaw, GA). 16. Disposable centrifuge tube, polypropylene (15 mL; Fisher Scientific, Fair Lawn, NJ). 17. Disposable culture tube, borosilicate glass (13 × 100 mm; Fisher Scientific). 18. Wide opening glass crimp vial (2 mL; Agilent Technologies, Santa Clara, CA). 19. Glass vial insert (250 μL; Agilent Technologies). 20. Aluminum crimp cap with PTFE/rubber septa (11 mm; Agilent Technologies).
150
Kombu, Brunengraber, and Puchowicz
2.2. GC-MS
1. Mass spectrometer: Agilent 5973 mass spectrometer, linked to a model 6890 gas chromatograph equipped with an autosampler (Agilent Technologies, Santa Clara, CA). 2. Carrier gas: helium (1 mL/min) with a pulse pressure of 40 p.s.i.g. 3. Column: VF-5MS EZ guard capillary column (60 m × 0.25 mm inner diameter) with guard column (10 m) (Varian Technologies, Palo Alto, CA). 4. Chemical ionization gas (CI mode): Ammonia
3. Methods 3.1. Tissue Preparation
3.1.1. Method A: Chloroform/Methanol Extraction Procedure
The tissues are extracted by two methods, either using chloroform/methanol (method A) (12) or using 5% acetic acid in methanol/water (method B) (14, 15). Method A is advantageous for simultaneously analyzing CAC intermediates, as well as cholesterol and fatty acids from the same tissue as the chloroform phase contains these lipids. Method B is specifically useful for CAC intermediates as it completely extracts these water-soluble acids from the tissue. Both methods can be used on tissues such as liver, brain, muscle, and kidney. 1. Weigh about 0.2–0.5 g of powdered frozen (–80◦ C) tissue in a pre-weighed/tarred, 15 mL disposable centrifuge tube previously chilled over dry ice and record the tissue weight. (Caution: dry ice is extremely cold and can cause frost bite. Wear protective gloves and goggles while handling.) 2. After weighing, spike the powdered frozen tissue with the selected internal standards (~50 nM of [13 C6 ]citrate, ~30 nM of [13 C4 ]succinate, and ~30 nM of (RS)-3-hydroxy[2 H4 ]glutarate; see Note 3). 3. Using an Omni homogenizer, homogenize the tissue with 6 mL of pre-cooled (–25◦ C) chloroform/methanol (2:1, v/v) for 5 min on a dry ice–acetone bath (caution: dry ice is extremely cold and can cause frost bite. Wear protective gloves and goggles while handling) (see Note 4). 4. To break the phases, add 2 mL of ice-cold water to the same tube and re-homogenize for 5 min at –25◦ C. 5. Centrifuge the slurry at 670×g for 20 min at 4◦ C. 6. Collect the upper methanol/water phase in a disposable culture tube; if necessary, filter to remove tissue fragments. 7. For complete extraction of analytes, a second extraction is suggested: to the lower organic chloroform phase, add
Analysis of the Citric Acid Cycle Intermediates
151
3 mL of pre-cooled (–20◦ C) methanol/water (3:2, v/v) and vortex for 5 min. 8. Repeat steps 5 and 6 (see Note 5). 9. Combine the two upper methanol/water phase extracts obtained from steps 6 and 8. 10. To the combined extract, add methoxylamine–HCl solution to a final concentration of 200 μM (see Note 6). 11. Adjust the pH to 8.0 with 10 N sodium hydroxide to complete the derivatization process. 12. Evaporate the extract completely under vacuum overnight using a Savant vacuum centrifuge (see Note 7). 13. Add 100 μL of TMS (or TBDMS) to the completely dried residue using a transfer pipette (caution: TMS and TBDMS derivatizing agents are volatile, toxic, carcinogenic, and corrosive. Use protective measures like gloves and hood) (see Notes 8 and 9). 14. Heat the mixture at 70◦ C for 50 min on a heating block; this process yields TMS (or TBDMS) and methoxamates/TMS (or TBDMS) derivatives of the analytes (see Note 10). 15. Allow the sample to cool to room temperature (caution: avoid moisture). 16. Transfer the derivatized mixture to a wide open glass crimp vial with glass vial insert and cap tightly. 17. Inject the mixture on to the GC-MS for analysis (see Note 11; see Section 3.3). 18. For quantification of analytes, prepare stock solutions with known amounts of standards in water. Prepare a serial dilution. Treat the standards the same way the samples are treated. The amounts of selected internal standards need to be the same as that added to the samples. This enables the amounts of analytes in the sample to be quantified as absolute or relative amounts. For the derivatization procedure, follow Section 3.1.2, steps 10–17. 19. Plot a standard curve of the peak areas (standards against internal standards, relative to known amounts of the added standards) (12). 20. Calculate the absolute or relative concentrations of analytes of interest as identified during electron ionization runs (see Section 4). 3.1.2. Method B: Acidified Methanol/Water Extraction Procedure
1. Weigh about 0.2–0.5 g of powdered frozen (–80◦ C) tissue in a pre-weighed/tarred, 15 mL conical “homogenizing” tube previously chilled over dry ice and record the tissue
152
Kombu, Brunengraber, and Puchowicz
weight. (Caution: dry ice is extremely cold and can cause frost bite. Wear protective gloves and goggles while handling.) 2. After weighing, spike the powdered frozen tissue with the selected internal standards (~50 nM of [13 C6 ]citrate, ~30 nM of [13 C4 ]succinate, and ~30 nM of (RS)-3-hydroxy[2 H4 ]glutarate; see Note 3). 3. Using an Omni homogenizer, homogenize the tissue with 5 mL of 5% acetic acid in methanol/water (1:1, v/v) extraction buffer (chilled on ice) for 2 min on ice bath. 4. Centrifuge the homogenate at 670×g for 30 min at 4◦ C. Decant the supernatant into a glass test tube and save on ice and process immediately or freeze the supernatant at –80◦ C until derivatization procedure (see Notes 12 and 13). 5. For the derivatizing procedure, pipette 100–200 μL of the supernatant collected in step 3 or use all of the supernatant collected in step 3 and follow Section 3.1.1, steps 10–20. 3.2. Plasma and Organ Perfusate Preparation
1. Thaw the plasma or perfusate on ice at 4◦ C. 2. Once thawed, immediately aliquot 0.1 mL of the perfusate or plasma and spike with the selected internal standards (~50 nM of [13 C6 ]citrate, ~30 nM of [13 C4 ]succinate, and ~30 nM of (RS)-3-hydroxy-[2 H4 ]glutarate, see Note 3). The reserve can be stored in a deep freezer at –80◦ C for further analysis. 3. To derivatize analytes containing keto groups, add methoxylamine–HCL solution to a final concentration of 200 μM, cap tightly, and heat the mixture at 60◦ C for 3 h. 4. Then add 1 mL of cold acetonitrile/methanol (7:3, v/v) and vortex for 30 s. 5. Centrifuge at 670×g for 20 min at 4◦ C. 6. After centrifugation, collect the supernatant and follow the procedure in Section 3.1.1, steps 12–20.
3.3. GC-MS Assays
1. Following the sample preparation procedures above (see Section 3.1.1, step 16), the derivatized samples can be analyzed either in CI mode (12) or in EI mode (2). The parameters described here are for CI mode and the parameters for EI mode are given in parenthesis. 2. On the Agilent 5973 mass spectrometer linked to a model 6890 gas chromatograph, set the injector temperature at 270◦ C (EI: 250◦ C) and the transfer line at 280◦ C (EI: 300◦ C). 3. Set the ion source and the quadrupole at 150◦ C.
Analysis of the Citric Acid Cycle Intermediates
153
Table 8.1 Chemical and electron ionization mass spectra of the TMS or TBDMS derivatives of CAC and related intermediates PCI-MOX-TMSa Analyte
Retention time
Succinate Fumarate
m/z to monitor
8.55
280
EI-TMSb
EI-TBDMSb
m/z to monitor
m/z to monitor
247
331, 289, 215
9.04
278
245
329, 287, 245
Oxaloacetate
10.46
323
290
–
Malate
10.72
368
335, 245, 233
419, 403, 287
α-ketoglutarate
11.86
337
304, 275
431, 446
Citrate
14.48
481
465, 375, 347
459, 431, 357
Glutamate
–
–
348, 246, 230
432, 330, 272
Glutamine
–
–
347, 245, 229
431, 329, 271
For the internal standards, the m/z of [13 C6 ]citrate yields M+6 citrate, [13 C4 ]succinic acid yields M+4 succinate, and 3-hydroxy-[2 H4 ]glutarate yields 437, 304, and 260 as TBDMS derivatives. a Retention times correspond to the CI method as described in Section 3.1.1 (12). b For EI methods, the retention times are relative according to the GC gradient program (this method uses hydroxylamine instead of MOX) (2) and the m/z of the major fragments for each analyte are given and confirmed by NIST. The m/z ions are selected based on the spectral characterization (fragmentation pattern) of the particular derivative as well as their intensities. The intensites of these ions may differ depending on the mass spectrometer used.
4. The GC temperature program is as follows: start at 80◦ C, hold for 1 min, increase by 10◦ C/min to 320◦ C, hold at 320◦ C for 5 min. (EI: start at 80◦ C, increase by 5◦ C/min to 250◦ C followed by an increase by 50◦ C/min to 300◦ C, hold at 300◦ C for 5 min). 5. Adjust the ammonia pressure to optimize peak areas. 6. The retention times and m/z values monitored using the CI method are listed in Table 8.1 and Fig. 8.1.
3.4. Calculations
1. The raw mass spectrometric areas are used to calculate the analytical parameter (area of analyte)/(area of reference compound). This parameter is not a relative concentration; thus, to calculate relative concentrations, use the following equation: Relative concentration = average[(area of analyte)/ (area of reference compound)]i /average [(area of analyte)/ (area of reference compound)]c where i is the intervention/experimental group and c is the control group.
154
Kombu, Brunengraber, and Puchowicz
Fig. 8.1. Positive chemical ionization chromatograms of metabolites extracted from a liver perfused with 5 mM lactate (adapted from Yang et al. (12)). In addition to m/z spectra, the retention times and relative peak heights are also used to characterize and reference each metabolite. For example, apart from the analytes listed in Table 8.1, the TMS derivatives of related metabolites such as glycine, aspartate, glucose, pyruvate, phosphoenolpyruvate, dihydroxyacetone phosphate, glyceraldehyde-3-phosphate, 2-phosphoglycerate, 3-phosphoglycerate, fructose-6-phosphate, and glucose6-phosphate can be simultaneously analyzed by introducing appropriate ions and retention times in the scan table of the mass spectrometer software (panel A: 1 μL split 10:1; panel B: 2 μL splitless, see Note 13).
2. Absolute concentrations are calculated against a standard curve that contains the same amount of internal standard(s) as added to the samples. Preparation of standard curve: prepare graded amounts of known standards and add a constant amount of internal standard to each of the prepared standards (reference compound). Run the standards on the GC-MS along with the samples under the same conditions. Calculate the ratio of the peak height or area for standards and samples to that of the internal standard. Using the standard curve, the concentrations per sample can be calculated
Analysis of the Citric Acid Cycle Intermediates
155
(9). The mass spectrometer software has the function to build the calibration curves and calculate the concentrations based on the input to the software.
4. Notes 1. The advantage of TBDMS derivatization is that these derivatives are more stable to moisture and reduce the risk of enol silyl ether formation (9, 16). The advantage of the trifluroacetamide groups in these reagents is their volatility, low reactivity, and specificity to react only with alcohols when there is a carboxyl group in the same molecule (16). 2. Instead of MOX, hydroxylamine can be substituted. 3. The estimated amount of internal standards used depends on tissue type. For example, α-ketoglutarate content is greater in liver than in brain. For accuracy, it is very important to add internal standards at the initial processing step, otherwise volume additions or losses would need to be accounted for and the final concentration calculations adjusted. 4. During the 5-min extraction, the tube is partially immersed in acetone kept at –25◦ C by periodic addition of dry ice. 5. The chloroform phase can be used for analyzing fatty acids and cholesterol (12). 6. This step is to protect/stabilize the keto group by derivatizing with MOX. Steps 10 and 11 can be omitted if the analytes of interest do not contain keto groups, as this step is essential for stabilizing the keto group. 7. To shorten the processing time, heat at 50◦ C for 3 h and then dry under nitrogen at 50◦ C using a Turbovap. Take care not to overheat as it will lead to degradation of analytes. The reagents in Section 3.1.1, step 13 are highly moisture sensitive and thus the sample should be completely dry before proceeding. 8. Make a small hole in the cap with a 22 gauge needle to avoid pressure buildup and popping of the cap. 9. TMS and TBDMS derivatizing reagents react readily with glass and plastics. While drawing the reagent using the syringe, it may block it. It is better to use a transfer pipette. If a glass syringe is used, wash immediately with methanol and designate the syringe for these reagents. 10. If moisture or alcohol (protic solvent) is present, the reagents will first react with them to form a white residue.
156
Kombu, Brunengraber, and Puchowicz
Avoid opening the reagent bottle frequently and, once opened, do not use it after a month or two. These reagents are volatile; avoid over heating to prevent complete dryness. Switch on the heating block at least an hour earlier before placing the tubes to get the block equilibrated at 70◦ C. 11. The injection volume and split flow may need to be adjusted according to the intensity of the individual analyte of interest. For example, pyruvate is less intense compared to malate, thus requiring more injection volume without a split flow. 12. To ensure the glass test tube does not break upon freezing, make sure that the volume in the test tube is less that 50% of the height and store on a slight angle in –80◦ C freezer. 13. In some procedures, the first fraction is used for other assays such as for acyl-CoA profiles (14, 15).
Acknowledgments This work was supported, in whole or in part, by National Institutes of Health Roadmap Grant R33DK070291 and Grant R01ES013925. This work was also supported by a grant from the Cleveland Mt. Sinai Health Care Foundation. We acknowledge the Mouse Metabolic Phenotyping Center (MMPC) at Case Western Reserve University where many of these procedures were developed. References 1. Krebs, H. A. (1940) The citric acid cycle and the szent-gyorgyi cycle in pigeon breast muscle. Biochem J 34, 775–779. 2. Des, R. C., Fernandez, C. A., David, F., Brunengraber, H. (1994) Reversibility of the mitochondrial isocitrate dehydrogenase reaction in the perfused rat liver. Evidence from isotopomer analysis of citric acid cycle intermediates. J Biol Chem 269, 27179–27182. 3. Yang, L., Kasumov, T., Kombu, R. S., Zhu, S. H., Cendrowski, A. V., David, F., Anderson, V. E., Kelleher, J. K., Brunengraber, H. (2008) Metabolomic and mass isotopomer analysis of liver gluconeogenesis and citric acid cycle: II. Heterogeneity of metabolite labeling pattern. J Biol Chem 283, 21988–21996.
4. Yang, L., Kombu, R. S., Kasumov, T., Zhu, S. H., Cendrowski, A. V., David, F., Anderson, V. E., Kelleher, J. K., Brunengraber, H. (2008) Metabolomic and mass isotopomer analysis of liver gluconeogenesis and citric acid cycle. I. Interrelation between gluconeogenesis and cataplerosis; formation of methoxamates from aminooxyacetate and ketoacids. J Biol Chem 283, 21978–21987. 5. Reszko, A. E., Kasumov, T., Pierce, B. A., David, F., Hoppel, C. L., Stanley, W. C., Des, R. C., Brunengraber, H. (2003) Assessing the reversibility of the anaplerotic reactions of the propionyl-CoA pathway in heart and liver. J Biol Chem 278, 34959–34965.
Analysis of the Citric Acid Cycle Intermediates 6. Brunengraber, H., Roe, C. R. (2006) Anaplerotic molecules: current and future. J Inherit Metab Dis 29, 327–331. 7. Kasumov, T., Sharma, N., Huang, H., Kombu, R. S., Cendrowski, A., Stanley, W. C., Brunengraber, H.. (2009) Dipropionylcysteine ethyl ester compensates for loss of citric acid cycle intermediates during post ischemia reperfusion in the pig heart. Cardiovasc Drugs Ther 23, 459–469. 8. Beylot, M., Soloviev, M. V., David, F., Landau, B. R., Brunengraber, H. (1995) Tracing hepatic gluconeogenesis relative to citric acid cycle activity in vitro and in vivo. Comparisons in the use of [3-13 C]lactate, [2-13 C]acetate, and alpha-keto[3-13c]isocaproate. J Biol Chem 270, 1509–1514. 9. Schwenk, W. F., Berg, P. J., Beaufrere, B., Miles, J. M., Haymond, M. W. (1984) Use of t-butyldimethylsilylation in the gas chromatographic/mass spectrometric analysis of physiologic compounds found in plasma using electron-impact ionization. Anal Biochem 141, 101–109. 10. Weckwerth, W., Fiehn, O. (2002) Can we discover novel pathways using metabolomic analysis?. Curr Opin Biotechnol 13, 156–160. 11. Katz, J., Wals, P., Lee, W. N. (1993) Isotopomer studies of gluconeogenesis and the krebs cycle with 13c-labeled lactate. J Biol Chem 268, 25509–25521.
157
12. Yang, L., Kasumov, T., Yu, L., Jobbins, K., David, F., Previs, S., Kelleher, J., Brunengraber, B. (2006) Metabolomic assays of the concentration and mass isotopomer distribution of gluconeogenic and citric acid cycle intermediates. Metabolomics 2, 85–94. 13. Chang, H. C., Maruyama, H., Miller, R. S., Lane, M. D. (1966) The enzymatic carboxylation of phosphoenolpyruvate. 3. Investigation of the kinetics and mechanism of the mitochondrial phosphoenolpyruvate carboxykinase-catalyzed reaction. J Biol Chem 241, 2421–2430. 14. Deng, S., Zhang, G. F., Kasumov, T., Roe, C. R., Brunengraber, H. (2009) Interrelations between C4 ketogenesis, C5 ketogenesis, and anaplerosis in the perfused rat liver. J Biol Chem 284, 27799–27807. 15. Zhang, G. F., Kombu, R. S., Kasumov, T., Han, Y., Sadhukhan, S., Zhang, J., Sayre, L. M., Ray, D., Gibson, K. M., Anderson, V. A., Tochtrop, G. P., Brunengraber, H. (2009) Catabolism of 4-hydroxyacids and 4-hydroxynonenal via 4-hydroxy-4phosphoacyl-CoAS. J Biol Chem 284, 33521–33534. 16. Watson, D. (1993) Chemical Derivatization in Gas Chromatography. In: Baugh, P., Ed.. Gas Chromatography: A Practical Approach, Oxford University Press, New York, NY, 133–153.
Chapter 9 Quantification of Pentose Phosphate Pathway (PPP) Metabolites by Liquid Chromatography-Mass Spectrometry (LC-MS) Amber Jannasch, Miroslav Sedlak, and Jiri Adamec Abstract The pentose phosphate pathway plays an important role in several cellular processes including biosynthesis and catabolism of five-carbon sugars and generation of reducing power through NADPH synthesis. Although the pentose phosphate metabolic reaction network has been mapped in substantial detail, the comprehensive quantitative analysis of the rates and regulation of individual reactions remains a major interest for various biofields. Here we describe a simple method for comprehensive quantitative analysis of pentose phosphate pathway intermediates. The method is based on Group Specific Internal Standard Technology (GSIST) labeling in which an experimental sample and corresponding internal standards are derivatized in vitro with isotope-coded reagents in separate reactions, then mixed and analyzed in a single LC-MS run. The use of co-eluting isotope-coded internal standards and experimental molecules eliminates potential issues with ion suppression and allows for precise quantification of individual metabolites. Derivatization also increases hydrophobicity of the metabolites enabling their effective separation using reversed-phase chromatography. Key words: Group Specific Internal Standard Technology (GSIST), isotope coding, metabolomics, pentose phosphate pathway (PPP), sugar derivatives.
1. Introduction The pentose phosphate pathway (PPP) is a critical metabolic pathway for generation of NADPH and for fermentation of five-carbon sugars. Overall, 10 intermediates are involved in the PPP (Fig. 9.1). Whilst glucose-6-phosphate, 6-phosphoglucono-δ-lactone, 6-phosphogluconate, and ribulose5-phosphate represent the oxidative phase of the PPP, erythrose4-phosphate, fructose-6-phosphate, glyceraldehyde-3-phosphate, T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_9, © Springer Science+Business Media, LLC 2011
159
160
Jannasch, Sedlak, and Adamec
Fig. 9.1. Intermediates involved in pentose phosphate pathway (PPP).
ribose-5-phosphate, sedoheptulose-7-phosphate, and xylulose-5phosphate are part of the non-oxidative phase. Like any other biochemical study, precise quantification of PPP metabolites is the first and key element for understanding of fundamental cellular processes and for developing successful kinetic models. Recently, several methods for comprehensive quantification of PPP intermediates have been published. Most of the methods are based on separation of metabolites using either gas chromatography (GC) (1–3) or liquid chromatography (LC) (4–6) and their detection by mass spectrometry (MS). A major concern with LC-MS quantification is a well-known phenomenon called ion suppression, in which the ion intensities of specific compounds depend on the co-eluting matrix compositions that affect ionization efficiencies of the analytes. Although the use of corresponding stable isotope standards can solve this issue, only limited numbers of these standards are commercially available and “in-house” or outsourced synthesis is usually very expensive and unrealistic. Another problem related to LC-MS methods is that
Quantification of PPP Metabolites by LC-MS
161
sugars are best separated on anion exchange chromatography, requiring MS-incompatible solvents. To circumvent these obstacles, we have developed a simple method based on Group Specific Internal Standard Technology (GSIST) labeling (7–9). In GSIST, an experimental sample and corresponding internal standards are derivatized in vitro with isotope-coded reagents in separate reactions and then mixed and analyzed in single LC-MS run. Because both the internal standard and corresponding molecule from the experimental sample co-elute, their ionization efficiency is the same, and precise concentrations can be calculated for the ratio between light (sample) and heavy (internal standard of known concentration) forms of the metabolite. Derivatization of sugars also changes the physical properties of the molecules and allows for their effective separation using MS-compatible reversed-phase chromatography (6).
2. Materials 2.1. Cell Growth and Extraction
1. Glucose solution: 50% (w/v) glucose in Milli-Q water. 2. YPD medium: 10 g Bacto yeast extract (BD Diagnostic Systems, Sparks, MD), 20 g Bacto peptone (BD Diagnostic Systems), 40 mL glucose solution, and 960 mL Milli-Q water. Glucose solution must be autoclaved separately. 3. Quenching solution: 60% (v/v) analytical grade methanol; 70 mM HEPES, pH 7.5. 4. Cell wash solution: 60% (v/v) analytical grade methanol. 5. Ethanol solution: 75% (v/v) ethanol in Milli-Q water. 6. Shaker (New Brunswick, Edison, NJ). 7. Nephelo flask with three baffles (300 mL) equipped with a sidearm (BellCo Glass, Vineland, NJ). 8. Klett colorimeter clinical model 800-3 equipped with red filter KS-66 (Scienceware Bel-Art Products, Pequannock, NJ). 9. 50 mL Oak Ridge centrifugation tube FEP (Nalgene, Rochester, NY). 10. Cryostat bath HAAKE Phoenix II P1 (Thermo Fisher Scientific, Waltham, MA). 11. AVANTI J-30I centrifuge equipped with JA-25.50 rotor (Beckman Coulter, Brea, CA). 12. Two microprocessor-controlled 280 Precision Water bathes (Thermo Fisher Scientific, Waltham, MA).
162
Jannasch, Sedlak, and Adamec
2.2. Sample and Standard Derivatization
1. Eppendorf tubes (VWR International, West Chester, PA). 2. Light labeling reagent: Prepare 6 M 12 C6 -aniline solution (pH 4.5) by mixing 5.500 mL of aniline with 2.250 mL of water and 2.250 mL of concentrated hydrochloric acid (HCl). Vortex well and measure pH. If necessary adjust pH with HCl. The solution can be stored at 4◦ C for up to 2 months. 3. Heavy labeling reagent: Prepare 6 M 13 C6 -aniline solution (pH 4.5) by mixing 250 mg of 13 C6 -aniline (Cambridge Isotopes, Andover, MA) with 88 μL of water and 88 μL of concentrated hydrochloric acid (HCl). Vortex well and measure pH. If necessary adjust pH with HCl. The solution can be stored at 4◦ C for up to 2 months. 4. EDC solution: N-(3-dimethylaminopropyl)-N ethylcarbodiimide hydrochloride (200 mg/mL; SigmaAldrich, St. Louis, MO) dissolved freshly in Milli-Q water (see Note 1). 5. Triethylamine (TEA). 6. Standards: 10 mM stock solutions in Milli-Q water: a. Erythrose-4-phosphate (E4P, ≥61%; Sigma-Aldrich) b. Fructose-6-phosphate (F6P, ≥98%; Sigma-Aldrich) c. Glucose-6-phosphate (G6P, 100%; Sigma-Aldrich) d. Glyceraldehyde-3-phosphate (GAP, 260–320 mM; Sigma-Aldrich) e. 6-Phosphogluconate (6PG, ≥98%; Sigma-Aldrich) f. Ribose-5-phosphate (R5P, ≥99%; Sigma-Aldrich) g. Ribulose-5-phosphate (RBU5P, ≥96%; Sigma-Aldrich) h. Sedoheptulose-7-phosphate (S7P, ≥98%; Glycoteam GMbH, Germany) i. Xylulose-5-phosphate (X5P, ≥90%; Sigma-Aldrich) 7. Standard test solutions: Dilute individual standard stock solutions 100× with Milli-Q water (0.1 mM final concentration). 8. Internal standard (IS) working solution: Combine 5 μL of each standard stock solution and 955 μL of Milli-Q water (final concentration CS = 50 μM each) (see Note 2).
2.3. LC-MS Procedure
1. LC-MS system: 1100 series HPLC (Agilent Technologies, Santa Clara, CA) coupled to an Agilent MSD-TOF (time of flight) mass spectrometer (Agilent Technologies) (see Note 3). 2. Analytical column: Zorbax Eclipse XDB-C8 (2.1 × 150 mm, 3.5 μm particle size; Agilent Technologies). 3. Solvent A: 5 mM tert-butylamine (TBA) aqueous solution adjusted to pH 5.0 with acetic acid. 4. Solvent B: 5 mM TBA in 100% acetonitrile.
Quantification of PPP Metabolites by LC-MS
2.4. Metabolite Quantification
163
1. Agilent MassHunter Workstation software – Qualitative Analysis v. B01.03 (Agilent Technologies) (see Note 3). 2. SigmaPlot 11.0 or any other software capable of basic statistical analysis
3. Methods The GSIST approach for simultaneous quantification of PPP metabolites is based on work by Yang et al. (6) and consists of two important segments, including metabolite extraction and metabolite analysis. Whilst metabolite analysis is universal and can be applied to any biological source, the extraction protocol described here was optimized for yeast (10, 11). Experiments with other types of cells, tissues, or whole organisms require modification in the extraction protocol before PPP intermediates can be determined. The list of methods for quenching (arrest) of metabolic activity and subsequent metabolite extraction for prokaryotic microorganisms (bacteria) and eukaryotic microorganisms (yeast and filamentous fungi) can be found in the review by Mashego et al. (12). Plant, animal, and human tissue is generally quickly frozen in liquid nitrogen, then grinded, and metabolites are extracted by organic solvents (13–16). Another important step in this method is derivatization of PPP metabolites in the sample(s) and corresponding standards through the reaction of aniline with carbonyl, phosphoryl, or carboxyl functional groups. The labeling and mixing schema is illustrated in Fig. 9.2. The LC-MS analysis described here assumes the use of an Agilent 1100 series HPLC coupled to an Agilent MSD-TOF (time of flight) mass spectrometer; however, any other LC-MS system can be employed. Precise quantification requires metabolite standards. Although no standard is available for 6-phosphoglucono-δ-lactone, semi-quantification (not described here) can be achieved using 13 C-labeled fructose6-phosphate standard as a structural analogue (6). All other intermediates are commercially available and monoisotopic masses corresponding to their light and heavy derivatized forms are summarized in Table 9.1. Some of the metabolites such as glucose6-phosphate and fructose-6-phosphate share the same molecular mass and cannot be differentiated by MS. For this reason, it is necessary to determine the retention times of individual derivatized standards before analyzing real samples. The concentration of individual intermediates is simply calculated from the intensity
164
Jannasch, Sedlak, and Adamec
Fig. 9.2. Determination of PPP metabolites using GSIST – labeling and mixing schema.
ratios between corresponding light and heavy ions (Fig. 9.3) and usually expressed in moles per gram of cells dry weight. 3.1. Cell Growth and Extraction
1. Inoculate yeast Saccharomyces cerevisiae (ATCC 4124) from an agar plate into 5 mL of YEPD medium and incubate in a shaker at 30◦ C and set to 200 rpm overnight. 2. Transfer overnight culture into 100 mL of YPD media in a 300 mL flask equipped with a sidearm for easy determination of optical density (O.D.) by a Klett colorimeter.
Quantification of PPP Metabolites by LC-MS
165
Table 9.1 Labeling pattern of PPP intermediates m/z value Compound
12 C
Erythrose-4-phosphate
349.09
Fructose-6-phosphate
labeling
13 C
labeling
Labeling pattern
MS species
361.13
Bi-
[M-H]–
334.07
340.09
Mono-
[M-H]–
Glucose-6-phosphate
409.12
421.16
Bi-
[M-H]–
Glyceraldehyde-3-P
319.09
331.13
Bi-
[M-H]–
6-Phosphogluconate
425.11
437.15
Bi-
[M-H]–
Ribose-5-phosphate
379.11
391.15
Bi-
[M-H]–
Ribulose-5-phosphate
304.06
310.08
Mono-
[M-H]–
Sedoheptulose-7-phosphatea
NA
NA
NA
NA
Xylulose-5-phosphate
304.06
310.08
Mono-
[M-H]–
a Sedoheptulose-7-phosphate was not included in the original study (6) and labeling pattern must be obtained experimentally.
Continue incubation in the shaker until optical density reaches ∼500 K.U. (generally 1 A540 unit = 500 K.U.). 3. At this point, add 24 mL of glucose (50% w/v) and continue growth under identical conditions for an additional 3 h. 4. Take two 5 mL aliquots. Filter one aliquot using a preweighed filter paper (WFB ) under vacuum. Wash the filtered cells with 10 mL Milli-Q water and dry the filter with cells at 80◦ C for 5 h (see Note 4). Weigh dry filter with cells (WFA ), subtract weight of the filter, and record the value as “dry weight” (WD ) (see Note 5). 5. Spray another aliquot into a 50 mL centrifugation tube containing 26 mL of quenching solution kept at –45◦ C in a cryostat bath for 3 min (see Note 6). 6. Centrifuge the mixture at 500×g for 5 min with temperature set to –20◦ C (see Note 7). 7. Discard supernatant and resuspend the cell pellet in 5 mL of cell washing solution at –45◦ C. Repeat centrifugation and discard supernatant. Keep the tubes containing the washed pellet at –45◦ C in the cryostat bath (see Note 8). 8. Place the tubes into a 90◦ C water bath, immediately overlay with 5 mL of boiling ethanol solution, vortex, and keep the samples in the water bath for 3 min. 9. Transfer the tubes directly into a –80◦ C freezer.
166
Jannasch, Sedlak, and Adamec
Fig. 9.3. Data analysis and interpretation. (a) Extracted ion chromatograms of 13 C6 -labeled fructose-6-phosphate (m/z = 340.1), indicating the time segment covering the entire chromatographic peak. (b) MS spectra corresponding to selected chromatographic area. Concentration is calculated from intensity ratio of light (IE ) and heavy (IS ) forms of aniline-labeled fructose-6-phosphate.
3.2. Sample Derivatization and Mixing
1. Transfer a 100 μL aliquot from each standard test solution (0.1 mM) into a new Eppendorf tube.
3.2.1. Determination of Retention Times of Individual Metabolites
3. Add 10 μL of light labeling reagent (6 M 12 C6 -aniline solution) and vortex slowly at room temperature.
2. Add 10 μL of EDC solution to each sample (see Note 1).
4. After 2 h, add 2–5 μL TEA (see Note 9). 5. Centrifuge at 13,500×g for 2 min and transfer supernatant into an auto-sampler vial. 6. Analyze each standard by the LC-MS procedure described below. 7. Visualize the results using extracted ion chromatograms and record retention times for individual standards.
Quantification of PPP Metabolites by LC-MS
3.2.2. Sample Labeling
167
1. Remove extracted samples from –80◦ C (Step 8 of Section 3.1) and reduce the volume (≤100 μL) using nitrogen gas bubbling through a needle immersed into the sample at room temperature (at this point, the samples can be stored at –80◦ C until ready to analyze). 2. Pre-weigh one Eppendorf tube for each sample (WTB ). 3. Add 0.5 mL of Milli-Q water to the sample, vortex each sample for 3 min (see Note 10). To repellet solids, centrifuge at 13,500×g for 10 min at 4◦ C. 4. Transfer supernatants to pre-weighed Eppendorf tubes, then reweigh tubes with the samples (WTA ). This value (WD ) will be taken into account during the data evaluation. 5. Transfer 100 μL of each sample into a new Eppendorf tube (see Note 11). 6. In a separate tube, prepare one 100 μL aliquot of IS working solution for each sample. 7. Add 10 μL of EDC solution to both the samples and IS working solution (see Note 1). 8. Add 10 μL of light labeling reagent (6 M 12 C6 -aniline solution) to the samples and vortex slowly at room temperature for 2 h. 9. Add 10 μL of heavy labeling reagent (6 M 13 C6 -aniline solution) to the IS working solution and vortex slowly at room temperature for 2 h (see Note 12). 10. Add 2–5 μL of TEA (see Note 9) and centrifuge at 13,500×g for 2 min. 11. Mix 50 μL of light labeled samples with 50 μL of the heavy labeled internal standards and vortex the mixture for 1 min (see Notes 2 and 13). 12. Transfer to an auto-sampler vial and analyze by the LC-MS procedure described below.
3.3. LC-MS Procedure
1. Set the following HPLC gradient with the flow rate at 0.3 mL/min: a. Set an elution gradient from 5 to 70% Solvent B over 25 min. b. Increase to 100% Solvent B over 2 min. c. Wash the column with 100% Solvent B for 3 min. d. Decrease to 5% Solvent B over 1 min. e. Re-equilibrate the column with 5% Solvent B for 9 min.
168
Jannasch, Sedlak, and Adamec
2. Set the mass spectrometer parameters as follows (see Note 14): a. Use electrospray ionization (ESI) in negative mode. b. Set the mass range to 150–1000 m/z. c. Set the dry temperature and gas flow to 300◦ C and 8 L/min, respectively. d. Set the capillary fragmentor voltages to 4000 and 165 V, respectively. 3. Place vials with sample into auto-sampler with temperature set to 10◦ C. 4. Inject 20 μL for each sample. 3.4. Data Analysis and Quantification
1. Open acquired LC-MS data with Agilent MassHunter Workstation – Qualitative Analysis software. 2. For each metabolite, visualize the results with the Extracted Ion Chromatogram function (Fig. 9.3a). Use m/z of heavy derivatized standards as indicated in Table 9.1. 3. Identify peaks corresponding to individual standards. If more peaks appear for a single m/z, then determine the appropriate peak using retention time. 4. For each compound, select the chromatographic segment covering the entire peak and open the corresponding MS spectra (m/z vs. intensity) in a new panel (Fig. 9.3b). 5. Record intensities of light (IE ) and heavy (IS ) forms of the ions (Fig. 9.3) as indicated in Table 9.1. 6. Determine metabolite concentration in extract: CE [M] = (IE /IS ) × CS [M] 7. Calculate volume of extracted sample: VE [mL] = WTB [g]–WTA [g] 8. Determine amount of metabolite in extract: NE [mol] = (VE /1000) × CE 9. Calculate dry weight of cells: WD [g] = WFB [g]–WFA [g] 10. Normalize the results per gram of cell dry weight: CDW [mol/g] = NE /WD
4. Notes 1. Make a fresh EDC solution in water before the beginning of each experiment. Do not reuse solutions from past experiments.
Quantification of PPP Metabolites by LC-MS
169
2. This concentration can be altered to fit each experiment. The goal is to spike an approximately equal amount of internal standard as real analyte present in each sample. This may need to be determined experimentally. Final concentrations (CS ) of individual IS are used for determination of corresponding metabolite concentrations in sample extract. 3. Any LC-MS system and software capable of data visualization and quantification can be used. 4. Drying time usually depends on the cell type and the cell amount. Typically, the filter is weighted in 1 h intervals until a constant weight is reached. 5. It is recommended to create a calibration curve for the relationship between O.D. (Klett unit) and dry weight ([g]/L). In that case, Step 4 of Section 3.1. is not necessary and dry weight can be determined directly from O.D. 6. Manual sampling is suitable if samples are taken in longer intervals (hours). If samples must be taken in shorter intervals (seconds or minutes), a rapid sampling procedure should be used (17). 7. The centrifugation speed could be increased if the pellet gets disturbed during the discarding of supernatant. However, the centrifugation speed should be kept as low as possible to allow quick pellet resuspension by the washing solution. 8. The rotor must be pre-cooled at –30◦ C in a freezer for at least 2 h. After spinning, the rotor should be placed back at –30◦ C to cool down for the next sample. Tubes containing 60% (v/v) methanol solution must be pre-cooled to –45◦ C in the cryostat bath for 2 h. Quick sample handling is critical because temperature in the samples should not rise above –20◦ C. 9. TEA is added to stop the reaction and increase the stability of derivatized products by adjusting pH to ∼8. 10. Be sure to reconstitute the entire pellet into the water solution. It may take more than the allotted time to do so. 11. Freeze the remaining 400 μL of sample at –80◦ C. It should remain viable for 1 week after the freeze date. 12.
13 C
6 -aniline is supplied as a liquid solution. Transfer the liquid content into a new tube before adding water and HCl.
13. Depending on the number of samples, the appropriate amount of standard solution must be labeled to allow for 50 μL to be mixed with 50 μL of each sample. The reaction can be scaled linearly from the indicated volumes.
170
Jannasch, Sedlak, and Adamec
14. If QQQ mass spectrometer is available selected ion monitoring (SIM) or multiple reaction monitoring (MRM) modes can be used. Due to the differences in instruments, optimal MS conditions must be determined experimentally.
Acknowledgments This work was supported by grants from the US Department of Energy Biomass Program (GO17059-16649) and the National Science Foundation (DBI-0421102). References 1. Cipollina, C., ten Pierick, A., Canelas, A. B., Seifar, R. M., van Maris, A. J. A., van Dam, J. C., Heijnen, J. J. (2009) A comprehensive method for the quantification of the non-oxidative pentose phosphate pathway intermediates in Saccharomyces cerevisiae by GC-IDMS. J Chromatogr B 877, 3231–3236. 2. Koek, M. M., Muilwijk, B., van der Werf, M. J., Hankemeier, T. (2006) Microbial metabolomics with gas chromatography/mass spectrometry. Anal Chem 78, 1272–1281. 3. Strelkov, S., von Elstermann, M., Schomburg, D. (2004) Comprehensive analysis of metabolites in Corynebacterium glutamicum by gas chromatography/mass spectrometry. Biol Chem 385, 853–861. 4. Luo, B., Groenke, K., Takors, R., Wandrey, C., Oldiges, M. (2007) Simultaneous determination of multiple intracellular metabolites in glycolysis, pentose phosphate pathway and tricarboxylic acid cycle by liquid chromatography-mass spectrometry. J Chromatogr A 1147, 153–164. 5. Wamelink, M. M., Struys, E. A., Huck, J. H., Roos, B., van der Knaap, M. S., Jakobs, C., Verhoeven, N. M. (2005) Quantification of sugar phosphate intermediates of the pentose phosphate pathway by LC-MS/MS: application to two new inherited defects of metabolism. J Chromatogr B 823, 18–25. 6. Yang, W.-C., Sedlak, M., Regnier, F. E., Mosier, N., Ho, N., Adamec, J. (2008) Simultaneous quantification of metabolites involved in central carbon and energy metabolism using reversed-phase liquid
7.
8.
9.
10.
11.
12.
13.
chromatography–mass spectrometry and in vitro 13c labeling. Anal Chem 80, 9508–9516. Yang, W. C., Adamec, J., Regnier, F. E. (2007) Enhancement of the LC/MS analysis of fatty acids through derivatization and stable isotope coding. Anal Chem 79, 5150–5157. Yang, W. C., Regnier, F. E., Adamec, J. (2008) Comparative metabolite profiling of carboxylic acids in rat urine by CEESI MS/MS through positively pre-charged and (2)H-coded derivatization. Electrophoresis 29, 4549–4560. Yang, W. C., Regnier, F. E., Sliva, D., Adamec, J. (2008) Stable isotope-coded quaternization for comparative quantification of estrogen metabolites by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B 870, 233–240. De Koning, W., van Dam, K. A. (1992) A method for the determination of changes of glycolytic metabolites in yeast on a subsecond time scale using extraction at neutral ph. Anal Biochem 204, 118–123. Gonzalez, B., Francois, J., Renaud, M. (1997) A rapid and reliable method for metabolite extraction in yeast using boiling buffered ethanol. Yeast 13, 1347–1355. Mashego, M. R., Rumbold, K., De Mey, M., Vandamme, E., Soetaert, W., Heijnen, J. J. (2007) Microbial metabolomics: past, present and future methodologies. Biotechnol Lett 29, 1–16. Denkert, C., Budczies, J., Weichert, W., Wohlgemuth, G., Scholz, M., Kind, T., Nies-
Quantification of PPP Metabolites by LC-MS porek, S., Noske, A., Buckendahl, A., Dietel, M., et al. (2008) Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover. Mol Cancer 7, 72. 14. Parab, G. S., Rao, R., Lakshminarayanan, S., Bing, Y. V., Moochhala, S. M., Swarup, S. (2009) Data-driven optimization of metabolomics methods using rat liver samples. Anal Chem 81, 1315–1323. 15. Weckwerth, W., Wenzel, K., Fiehn, O. (2004) Process for the integrated extraction, identification and quantification of metabolites, proteins and RNA to reveal their co-
171
regulation in biochemical networks. Proteomics 4, 78–83. 16. Wu, H., Southam, A. D., Hines, A., Viant, M. R. (2008) High-throughput tissue extraction protocol for NMR- and MSbased metabolomics. Anal Biochem 372, 204–212. 17. Lange, H. C., Eman, M., van Zuijlen, G., Visser, D., van Dam, J. C., Frank, J., de Mattos, M. J., Heijnen, J. J. (2001) Improved rapid sampling for in vivo kinetics of intracellular metabolites in saccharomyces cerevisiae. Biotechnol Bioeng 75, 406–415.
Chapter 10 High-Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS)-Based Drug Metabolite Profiling Ian D. Wilson Abstract The identification of drug metabolites in biofluids such as urine, plasma, and bile, as well as in in vitro systems, is an important step in drug discovery and development. Mass spectrometry, particularly when combined with high-performance liquid chromatography (HPLC-MS), can enable detailed structural information to be obtained on the metabolites of a drug or xenobiotic as a result of metabolism. The successful identification of drug metabolites by HPLC-MS-based techniques requires careful optimisation of a number of factors. First, the chromatographic separation should provide good resolution of the individual xenobiotic metabolites present in the sample. There is also the need to minimise the interference caused by the presence of endogenous metabolites, which may interfere with MS detection. Ideally, untreated samples should be profiled to reduce the likelihood of missing important metabolites due to losses during sample processing, but, depending upon the matrix, some degree of sample cleanup/extraction and concentration of the metabolites may be required using liquid–liquid or liquid– solid extraction. Second, the MS conditions must be carefully selected in order to maximise the potential of detecting the separated metabolites, which may have a very different character to the parent compound. The use of radiolabelled drugs in metabolism experiments greatly aids in the detection (and quantification) of metabolites, directing the investigator towards peaks that need to be characterised by MS. The presence of characteristic isotope patterns from either the incorporation of stable isotopes (e.g. 13 C, 15 N) or naturally occurring isotope patterns from substituents on the molecule (e.g. 35/37 Cl, 79/81 Br) can also provide a useful handle on the drug and its metabolites for the purposes of detection and spectrometric interpretation. This chapter provides guidelines for, and examples of, HPLC-MS-based drug metabolite profiling. Key words: Mass spectrometry, metabolite profiling, metabolite identification, liquid chromatography.
T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_10, © Springer Science+Business Media, LLC 2011
173
174
Wilson
1. Introduction Mass spectrometry represents, together with nuclear magnetic resonance (NMR) spectroscopy, a vital component of strategies for the detection and structural elucidation of the biotransformation products of drugs and other xenobiotics. Identification can be performed by obtaining mass spectra via direct analysis of metabolites that have been isolated in a pure form from the biological matrix by the infusion of solutions of the pure metabolite or from desorption from probes inserted into the ion source of the mass spectrometer (MS). However, in modern practice it is more usual to use a hyphenated technique such as highperformance liquid chromatography (HPLC-MS) with the column eluent directly flowing into the mass spectrometer via special interfaces (1). Ideally, in such an analysis, the metabolites are resolved both from each other and from matrix components by the separation technique and are presented to the MS in sufficient quantity to enable a diagnostic mass spectrum to be obtained. HPLC, and the more recently introduced variant of ultra highperformance liquid chromatography (UHPLC or UPLC) (2), provides a high-resolution separation method that can be directly interfaced with the mass spectrometer and that can be optimised to separate the xenobiotic metabolites from each other and from interferences such as endogenous metabolites and dose vehicles (e.g. polyethylene glycol, PEG). For this type of work, a reversedphase separation with gradient elution is generally used, based on either a “generic” gradient for routine/high-throughput profiling or a more optimised “bespoke” separation tuned to maximise the separation for the particular compound under study. The decision on the choice of generic or bespoke separation will depend upon the required outcomes of the study, but, irrespective of these, the generic separation represents a good starting point to obtain metabolic profiles, and this separation can be further optimised to give a more comprehensive profile if required. If the compound is available in a radiolabelled form (14 C and 3 H are the most common labels), online detection (HPLC-RAD) using a suitable radioactivity (or radio) detector can provide a useful means of both highlighting and quantifying the presence of the metabolites for MS (HPLC-MS-RAD) (3–5). The ability of radiodetectors to detect and quantify the compound-related metabolites is also of value in helping to overcome some of the inherent difficulties associated with MS-based approaches. The main difficulties associated with MS are that, in the absence of authentic standards of the metabolite, it can only be used as a qualitative technique. This is because ionisation efficiency is compound dependent and can vary widely between parent and metabolite and indeed metabo-
HPLC-MS-Based Drug Metabolite Profiling
175
lite and metabolite. The presence of a radiolabel that provides an “absolute” measure of the amount of material present in a peak can enable a relative response to be determined and, in extreme circumstances, can highlight the presence of metabolites that have been missed by the MS because the optimal ionisation conditions have not been used. The approach does of course depend upon the retention of the radiolabel in all of the metabolites. Some caution has therefore to be exercised in this respect as placing the radiolabel in a metabolically labile position, or very extensive metabolism that results in the cleavage of large molecules into several parts, may mean that not all of the metabolites retain the label. Clearly, where no label is available, care must be taken not to overinterpret the result of a metabolite profiling study. Having performed HPLC-MS comparison of the mass spectra of the detected metabolites with that of the parent compound, combined with the fragmentation patterns seen in the spectra and knowledge of the potential routes of metabolism, then enables structural elucidation to be attempted. Depending upon the mass spectrometer used, and the amount of material available, a range of MS-based experiments can be undertaken to provide further confidence in the preliminary examination of the spectra. The MS experiments that can be performed, depending upon the mass spectrometer, include techniques such as MS/MS, MSn , MSe , neutral losses (1), with the aim of building up a sufficient body of mass spectral evidence to propose potential metabolite structures. In addition, the data can be searched, either manually or automatically, via bespoke software applications such as mass defect filtering, for the additions (or losses) in mass expected for typical metabolic reactions such as hydroxylations, reductions, oxidations, and conjugations etc (1). In order to obtain a mass spectrum, it is essential to first ionise the molecule. In HPLC-MS, it is most common to use electrospray ionisation (ESI). To obtain the most comprehensive determination of the metabolic profiles, it may be necessary to employ both positive and negative ESI and, depending upon the mass spectrometer used, this may either be performed in one run or require re-running of the sample in a second. In the first instance, the most important information available from the mass spectrum is the molecular ion from which the molecular mass of the metabolite can be obtained. In some cases, depending upon the complexity of the parent compound, it may be possible to derive the structure of the metabolite simply from this information (e.g. addition of 16 mass units to a simple aromatic compound would immediately suggest hydroxylation). If the MS used has the ability to generate accurate mass data (e.g. Time-of-Flight, Orbitrap, and FT-ICR instruments), empirical atomic formulae can be derived, which can also help to confirm or refute potential structures. The next level of interpretation of the spectra comes from looking at
176
Wilson
–80 Da –SO3
100
248
O
Relative Intensity
HN
+O + SO3
F
%
m/z 248 168
249 250
173 212
108 150 167 74 80 93 97 117125
0 50
75
100
125
150
208 175
200
247 251 302 338 230 278290 294 328 346 368382 388 417
225
250
275
300
325
350
375
400
425
455 479 450
475
497
501 m/z
500
m/z Fig. 10.1. Negative ion mass spectrum of a probable hydroxysulphate metabolite of the acetanilide of 2-fluoroaniline showing a fragment ion 80 amu lower in mass (m/z 168) than the parent (m/z 248), consistent with the loss of SO3 characteristic of a sulphate metabolite.
fragmentation patterns obtained from the molecule wherein the loss of diagnostic ions can point directly to structural features. The ions detected in the mass spectrum may show which parts of the xenobiotic remain unchanged by metabolism, and, conversely, which have changed, and may provide strong indications as to what those changes are. An example is given in Fig. 10.1 for a metabolite of 3-fluoroaniline, where the characteristic loss of 80 amu, corresponding to loss of SO3 from the M– H– ion is seen. This provides a clear indication that the metabolite contains a sulphate moiety, strongly suggesting a ring hydroxysulphate as a metabolite of the original aniline. In fact, careful examination of the profile found two other metabolites with the same characteristics representing further positional isomers with essentially the same mass spectrum. This highlights a difficulty with MS in such circumstances in that it may not be possible, based on MS data alone, to obtain a definitive structure without additional spectroscopic data of the type provided by NMR spectroscopy (see Chapter 18) or the synthesis of an authentic standard. Obtaining suitable NMR spectra can be performed in a number of ways, including the semi-preparative isolation of the metabolite or, more efficiently, by online HPLC-NMR (6) (see Chapter 18) or using the multiple hyphenation of HPLC-NMR-MS (7).
HPLC-MS-Based Drug Metabolite Profiling
177
The biological matrix being investigated must also be taken into account when considering metabolite profiling and identification by HPLC-MS. Some matrices, such as urine (or bile), may be injected directly into the HPLC system and, providing the metabolites are present in sufficient amount, profiles are relatively easily obtained. In the case of plasma, or serum, or in vitro metabolism samples, however, direct injection of the sample is more problematic as the proteins present in the matrix will denature and cause the rapid failure of the HPLC column. Protein removal, generally by solvent precipitation, is therefore mandatory before HPLC-MS is undertaken. It is also usually the case that the concentrations of metabolites present in plasma may be very low compared to other sample types, and it may also be necessary to perform some further sample cleanup and concentration (e.g. HPLC with fraction collection). For solid samples such as tissues or faeces, a solvent extraction is also mandatory prior to profiling as these samples cannot be analysed directly by HPLCMS. A difficulty with any extraction procedure is that the recovery of the xenobiotic metabolites is uncertain and can only really be determined when a radiolabel is incorporated into the compound, in which case the recovery can be determined using liquid scintillation counting (LSC). In the absence of a radiolabel, caution should always be exercised in interpreting the metabolite profile obtained from such extracts as significant metabolites may be extracted with different efficiencies (or not at all) leading to a bias in the HPLC-MS data. The procedures described here cover the use of HPLC and UPLC-MS-based metabolite identification exemplified using both generic and “bespoke” reversed-phase gradients with and without the use of radiolabelled xenobiotics.
2. Materials 2.1. Freeze-Drying of Samples or Large Volumes of Sample Extracts
1. Freeze-dryer (e.g. Edwards Modulya 4 K or VirTis Sentry 2.0).
2.2. Solid–Liquid Extraction
1. Biological fluid/sample (e.g. plasma/serum, urine, or bile or in vitro incubation), dry or freeze-dried or dried and powdered faeces.
2. Glass vials with screw top neck. 3. Liquid nitrogen (–196◦ C) or solid carbon dioxide (Cardice, –140◦ C) to freeze the sample.
2. HPLC-grade methanol (MeOH).
178
Wilson
3. HPLC-grade acetonitrile (ACN). 4. Centrifuge (e.g. Megafuge 1.0R, Heraeus instruments, Newport Pugnell, UK). 5. Solvent evaporator or freeze-dryer. 2.3. Plasma or Serum Protein/In Vitro Incubation Precipitation
1. Organic solvent (e.g. HPLC-grade ACN, MeOH). 2. Vortex mixer. 3. Centrifuge. 4. Solvent evaporator or freeze-dryer.
2.4. Liquid Scintillation Counting (LSC)
1. Biological fluid, extract, or HPLC fraction. 2. Scintillant, e.g. Ultima GoldTM (PerkinElmer Life Sciences, Boston, MA). 3. Scintillation Counter (Packard Instruments, Chicago, IL).
2.5. High-Performance Liquid Chromatography (HPLC)
1. HPLC column (appropriate for analyte, e.g. C18 Symmetry, 250 × 4.6 mm, 5 μm particle size, Waters Corporation, Watford, UK or Hichrom RPB, 4.6 × 150 mm, 5 μm particle size, Hichrom Ltd., Theale, UK). 2. HPLC system (e.g. PerkinElmer 200 series HPLC pump fitted with an autosampler, Packard Instruments, Chicago, IL) plus a UV (Jasco UV-VIS 2075 UV 74) or radioactivity detector, if the compound is radiolabelled (e.g. Packard R Radiomatic 500TR series flow scintillation FLO-ONE analyser fitted with a 500 μL liquid flow cell (Packard Instruments)). 3. Ultima-FloTM M scintillant (Packard) for radiolabelled compounds. 4. Mobile phases: HPLC-grade water and ACN or MeOH. 5. Buffers of choice: e.g. HPLC-grade ACN or MeOH and aqueous phase, pH adjusted with analytical-grade formic acid (e.g. 0.1% formic acid, v/v) and/or buffered with analytical-grade ammonium formate (e.g. 10 mM) (see Note 1).
2.6. Ultra-Performance Liquid Chromatography (UPLC)
1. UPLC column (appropriate for analyte, e.g. Acquity UPLCTM BEH C18 column, 2.1 mm × 100 mm, 1.7 μm particle size). 2. AcquityTM UPLC-pump and UV detector (Waters Corporation). 3. Fraction collector capable of collecting samples into 96-well plates or glass vials (e.g. Gilson FC 204). 4. Mobile phases: As for HPLC.
HPLC-MS-Based Drug Metabolite Profiling
2.6.1. Mass Spectrometry
179
1. Mass spectrometer, e.g. Waters Q-TofTM micro or LCT PremierTM orthogonal acceleration time-of-flight mass spectrometer (oa-TOFMS) equipped with an electrospray ion source (Waters Corporation). 2. A LockSprayTM interface to provide accurate mass measurements (Waters). 3. Leucine enkephalin (50 fmol/μL, in 50:50 ACN:H2 O, 0.1% formic acid) (SigmaAldrich).
3. Methods 3.1. Freeze-Drying
Freeze-drying (also termed lyophilisation) can be used to concentrate biofluid samples and reduce large volumes of biofluids, extracts, in vitro incubations, or HPLC fractions to dryness. 1. Biofluids may be freeze-dried directly; however, the removal of organic solvent residues from samples, such as extracts or HPLC fractions, prior to freeze-drying is essential to prevent damage to the freeze-dryer. 2. Freeze small aliquots (ca. 1–5 mL) of biofluids or biofluid extracts in liquid nitrogen (–196◦ C) or solid carbon dioxide (Cardice, –140◦ C) in screw neck glass vials placed at a slight angle. 3. Operate freeze-dryer according to instruction manual. 4. Redissolve dried samples in an appropriate volume of the starting HPLC eluent (see Note 2).
3.2. Solid–Liquid Extraction
Solid–liquid extraction is used to obtain metabolites from solid material (e.g. faeces, tissues), freeze-dried biofluids (e.g. plasma/serum, urine, or bile), or freeze-dried in vitro incubation samples, which cannot be directly injected into the LC-MS system. 1. Homogenise or reduce the sample to a powder (freezedry first if necessary) and mix thoroughly with aliquots of organic solvent (e.g. 1–5 mL MeOH/g). 2. Centrifuge at 4◦ C for 10 min at 1800×g, then carefully remove the supernatant without disturbing the solid material. 3. Repeat the process several times and combine the supernatant fractions. 4. If the compound is radiolabelled, determine the extraction recovery using LSC.
180
Wilson
5. Evaporate the supernatant and redissolve in the starting HPLC eluent (see Note 2). 3.3. Plasma or Serum Protein/In Vitro Incubation Precipitation
Protein precipitation is designed to remove proteins, which would otherwise degrade the chromatographic performance of the system, from the sample while minimising potential losses of metabolites. 1. Protein precipitation is most easily achieved by taking aliquots of plasma/serum or in vitro incubations and mixing with cold (–20◦ C) ACN (1:3, v/v) or MeOH (1:3 v/v), vortexing, and then centrifuging at 4◦ C for 10 min at 1800×g (see Note 3). 2. Transfer the supernatant to a separate vial. 3. Re-suspend the precipitated protein and re-extract with the organic solvent, then repeat the centrifugation step. 4. Combine the supernatants and evaporate the solvent. 5. Reconstitute the sample in the starting HPLC mobile phase (see Note 2). 6. If the compound is radiolabelled, determine the extraction recovery using LSC.
3.4. Liquid Scintillation Counting
The amount of radioactivity present in samples such as biofluids, in vitro incubation media, and sample extracts can be determined by scintillation counting. 1. Take 100 μL of the sample (smaller amounts may be taken if sample size is limited) and place in a glass or plastic scintillation vial. 2. Add 900 μL of water (or make up to 1 mL if less than 100 μL of sample was used). 3. Mix with 10 mL of Ultima GoldTM scintillant. 4. Determine radioactivity present using a Packard Scintillation Counter according to the manufacturer’s instructions.
3.5. HPLC-MS Metabolite Profiling
These instructions assume the use of a suitable liquid chromatograph, a C18-bonded reversed-phase chromatography column, a suitable gradient HPLC system with a UV detector, and a Waters Q-TofTM Micro or LCT Premier orthogonal acceleration time-of-flight mass spectrometer (oa-TOFMS) equipped with an electrospray source capable of operating in both posR itive and negative ion mode and controlled using Waters MassLynxTM software. However, HPLC-MS metabolite profiling and identification can be performed with a wide range of different instruments from different manufacturers and this methodology should be easily modified according to the available instrumentation.
HPLC-MS-Based Drug Metabolite Profiling
181
1. Prior to performing HPLC-MS metabolite profiling, the performance of the HPLC system should be checked to ensure suitability. The flow rate, back pressure, analyte retention, and chromatographic peak shape should be examined and compared with the expected results. 2. Prior to analysis of the samples by HPLC-MS, the performance of the mass spectrometer should be checked to be within the manufacturer’s specifications for factors such as sensitivity and mass accuracy to ensure that valid data will be obtained. 3. Before attempting to detect and characterise metabolites, the chromatographic and mass spectrometric properties of the parent compound itself should be determined so that the subsequent analysis can be optimised both for the separation and detection of biotransformation products. Usually, metabolism will result in the introduction of polar (e.g. hydroxylations) or ionic (e.g. sulphates, glucuronides) groups into the parent compound. As a consequence of the increase in polarity brought about by metabolism in general in gradient reversed-phase chromatographic systems, metabolites will elute before the parent compound. Therefore, the chromatographic retention of the parent drug should be maximised by adjusting the gradient conditions such that it elutes towards the end of the chromatographic run. 4. A suitable starting point (a “generic” gradient) for method development would be HPLC separation on a Hichrom RPB 4.6 × 150 mm (5 μm) column or C18 Symmetry 250 × 4.6 mm (5 μm) column, at a solvent flow rate of 1 mL/min using a combination of 0.1% aqueous formic acid as “solvent A” and ACN-containing 0.1% formic acid as “solvent B”. A gradient profile of 0–5 min at 0% B followed by a linear increase to 50% B from 5 to 45 min and a further linear increase to 90% B at 50 min to wash the column. The column should then be returned to 0% B at 60 min and allowed to re-equilibrate for a further 5 min before the next sample is analysed. 5. The mass spectrometric properties of the parent molecule, such as the optimum ionisation conditions (positive or negative ESI) and fragmentation properties (including the presence of diagnostic fragments or isotope patterns), provide essential information for the detection and characterisation of metabolites enabling metabolic modifications to be detected and interpreted (see refs. 1, 8, 9). 6. Providing that the performance of the HPLC-MS system is acceptable, proceed to develop a suitable method for
182
Wilson
metabolite profiling with the injection of an aliquot of the sample (typically an injection of 10–50 μL is acceptable) (see Note 4). 7. Method development strategies will be affected by the presence or absence of a radiolabel in the parent compound. In the absence of a radiolabel, inject aliquots of the samples (including pre-dose control biofluid samples/preincubation in vitro samples), and, using a linear gradient from low percentages of organic modifier up to 100% over 30–50 min, monitor UV and total ion current traces for evidence of the unchanged parent compound and metabolites (Fig. 10.2). 8. The data can be examined for the presence of ions characteristic of well-known metabolic changes to the parent compound (such as addition of 16 amu to the parent molecular ion indicating hydroxylation), which may be indicative of the presence of a metabolite. This can either be done manually or by using bespoke software (so called data-dependent acquisition, DDA, see refs. 1 and 9). 9. The HPLC-MS data may also be examined for characteristic fragments/isotopic patterns from the parent that might also be expected to be present in metabolites (see Note 5).
Fig. 10.2. Traces showing (a) the UV, (b) total ion current (TIC), and (c) extracted ion chromatograms for the major metabolite (m/z 270) obtained using gradient reversedphase HPLC on rat urine obtained following the administration of 4-bromoaniline (see ref. 12). Chromatographic conditions were Hypersil BDS C18 column (250 × 4.6 mm i.d) (Thermo Scientific, Warrington, UK) packed with 5 μm particles. The mobile phases used to form the gradient were 0.01 M ammonium formate in D2 O (pD 7.0) (solvent A) and ACN (solvent B) at 1 mL/min. The gradient started with 100% A for 10 min increasing, in a linear gradient, to 30% B at 35 min followed by a second linear gradient to 50% B at 45 min.
HPLC-MS-Based Drug Metabolite Profiling
183
10. In addition to increases in mass, the data can be examined for losses characteristic of particular biotransformations (e.g. a fragment showing the loss of 176 amu from the parent compound for glucuronides or 80 amu for a sulphate, observed either directly in the MS spectrum or from a precursor ion in an MS/MS experiment) (see refs. 1, 9, and 10) (Figs. 10.1 and 10.3). 11. If the MS instrument used is capable of generating “exact” masses, then these can be used to provide elemental compositions for putative metabolites, which can aid in metabolite identification by supporting or eliminating metabolic possibilities. 12. MS/MS, MSn , or MSe experiments can be used on putative metabolites to aid in structure elucidation. 13. On the basis of the results obtained from these initial profiling studies, it may be necessary to modify the solvent gradient used for the chromatographic separation to improve the retention or resolution of metabolites. Repeat until the optimum separation is obtained (software such as “Drylab”
100
240
O HN
Relative Intensity
Cl
F
%
+O + C6H8O6
242
m/z 378/380 243
0 50
– 176 Da – C6H8O6
378
380 202 160 244 162 175 222 238 381 292 187 213 256 273 308320 348 376 390 85 97 113 117 147 75 100 125 150 175 200 225 250 275 300 325 350 375 400
436 425 450
478 m/z 475 500
m/z Fig. 10.3. Negative ion mass spectrum of a metabolite of 2-chloro-4-fluoroaniline detected using UPLC-ToF-MS (negative ESI mode) in urine following the administration of the aniline to bile-cannulated rats. The [M-H]– ion at m/z of 378/380 is consistent with N-acetylation, hydroxylation, and glucuronidation to give a hydroxy-2-chloro-4-fluoroacetanilide-Oglucuronide. The presence of the glucuronide is supported by the neutral loss of 176 Da from the parent ion to leave a fragment at 200/202. The ion seen in the spectrum at m/z 240/242 results from co-elution with another metabolite (hydroxy-2-chloro-4-fluoroaniline sulphate), which elutes as a broad peak. The presence of the chlorine isotope pattern is useful for selectively detecting metabolites of the parent 2-chloro-4-fluoroaniline.
184
Wilson
can be used to aid this optimisation step) (see ref. 11) (Fig. 10.4). 14. If step 12 is required, repeat steps 7–11 using the final optimised separation. 15. If a radiolabel is incorporated into the molecule, then the chromatographic optimisation of the metabolite separation can be performed on the basis of resolving the peaks detected using the radiodetector (see ref. 3). This can be performed online with the HPLC-MS or offline as the optimisation of the metabolite separation is based solely on the presence of the radioactive isotope (see Note 6). 16. If a radioactivity detector is not available, then fraction collection can be performed and a chromatogram reconstructed following offline fraction collection and LSC (see Note 7 and ref. 3–5). For good peak resolution using
N
O
N
100 75
100
50 25 0 0
Intensity/cps
S
20 40 Time (mins)
60
75 g
4.0e6
50 b d a
f
% Acetonitrile
Mobile phase B (%)
N
7.5e6
O
N
N
25
e c
0 0.0
10
20
30
40
Time/mins
Fig. 10.4. A generic HPLC gradient separation performed using a Prominence Sil-20A/C auto sampler and a Sil-20 AB binary pump (Shimadzu, Milton Keynes, UK), with the separation performed on a Synergi 150 × 4.6 mm, 4 μm POLARRP 80 Å column (Phenomenex, Macclesfield, UK). MS detection was performed using a Sciex API4000 QTrap mass spectrometer (Applied Biosystems, Warrington, UK) in positive ESI. The initial mobile phase conditions were 90:10:0.1 aqueous:ACN:formic acid (v/v/v). The gradient profile is shown on the figure (also see inset). The flow rate used was 1 mL/min. Metabolite key: a, b = hydroxy-O-glucuronides, d, g = hydroxylated metabolites, e = di-glucuronide, f = parent AZD5438 (structure in inset). See also Fig. 10.5 (from ref. 13, with permission).
HPLC-MS-Based Drug Metabolite Profiling f
100
g
Intensity/ cps
b
75
50
4.0e6
c
d
e
% Acetonitrile
8.2e6
185
25 a
0.0
5
10
0
14
Time/ mins
Fig. 10.5. An optimised UPLC separation for the sample shown in Fig. 10.4 using an Acquity UPLC system (Waters Corporation, Massachusetts, USA), with the separation obtained on an Acquity 2.1 × 100 mm, 1.7 μm column (Waters Corporation). MS detection was performed using a Sciex API4000 QTrap mass spectrometer (Applied Biosystems) in positive ESI. The initial mobile phase was the same as that used for the conventional chromatographic system (see Fig. 10.4 caption), and the gradient profile is shown in the figure. The flow rate employed was 0.66 mL/min. Key, as for Fig. 10.4 (from ref. 13, with permission).
offline fraction collection, a minimum of 2 fractions/min should be collected. 17. Where a radiolabel is available, it is good practice to perform a run on the optimised system, where the total eluent from the column is collected and the recovery of the radiolabel after injection of the sample is determined. This ensures that all of the metabolites are eluted from the column and that the resulting metabolite profile is complete. 18. When an optimised separation of the metabolites based on the radiolabel has been obtained, then steps 7–11 can be performed as for the unlabelled compounds. 3.6. UPLC-MS
As indicated above, the use of UPLC provides a more efficient chromatographic system for metabolite resolution. These instructions assume the use of a Waters Acquity UPLCTM system together with separations performed on a 2.1 × 100 mm BEH C18 column (1.7 μm particle size) (see Note 8) and a Q-tofTM Micro or LCT PremierTM mass spectrometer equipped with an electrospray ion source with a LockSprayTM interface, referenced to leucine enkephalin, to provide accurate mass measurements (50 fmol/μL, in 50:50 ACN:H2 O, 0.1% formic acid). 1. Perform steps 1–3 from Section 3.5. 2. A suitable starting point (a “generic” gradient) for method development for UPLC is based on the use of a 2.1 ×
186
Wilson
100 mm Acquity UPLCTM BEH C18 column (1.7 μm particle size) with the gradient formed from 0.1% (v/v) formic acid in water as solvent A and 0.1% formic acid (v/v) in ACN as solvent B at an eluent flow of 600 μL/min. 3. A suitable gradient profile of 100% A over 0–1 min, rising thereafter via a linear gradient to 50% B at 7 min, 90% B at 15 min, then returning to 100% A and remaining there for 18 min before the next injection. As for HPLC, the UPLC method should be optimised for good retention of the parent compound to ensure retention of the metabolites (Fig. 10.5). 4. When an optimised separation has been obtained, then steps 4–11 from Section 3.5 can be performed until an optimised separation for metabolite characterisation has been obtained. 5. If a radiolabel is present, then method development can also be undertaken using this as a means of detecting the metabolites (see Notes 6 and 7 and refs. 3–5). However, on-flow radiodetection can be problematic with UPLC and fraction collection may be necessary (4 fractions/min). 3.7. Metabolite Structural Elucidation and Identification
Very powerful MS-based techniques may be unable to provide definitive identification directly from samples because the metabolites are present only in trace quantities, ionise poorly, give little fragmentation, or may be one of several possible isomers. In such circumstances, it may be necessary to isolate larger quantities of material for further MS-based studies or for NMR spectroscopy, including HPLC-NMR or HPLC-NMR-MS if available (Fig. 10.6) (see Chapter 18). 1. Larger quantities of material for investigation can be obtained by fraction collection of the required peak(s) using the developed HPLC system and a fraction collector with a number of injections of the sample at the maximum amount on column that does not lead to the unacceptable deterioration of the separation. 2. Following purification of sufficient material for further studies by collection of fractions, these should be freeze-dried to provide a sample for further investigation (see Note 9). 3. If the collection of the metabolite is intended for NMR spectroscopic studies to complement the HPLC-MS investigations, then the sample should be redissolved in a suitable deuterated solvent (see Chapter 18). 4. If MS (and NMR) studies are inconclusive, then it may be necessary to use synthetic methods to obtain a pure standard(s) of the putative metabolite for comparison of HPLC and spectroscopic properties in order to obtain a definitive identification.
HPLC-MS-Based Drug Metabolite Profiling
187
Fig. 10.6. Spectra obtained via HPLC-NMR-MS showing the MS (lower) and 1 H NMR (upper) spectra for an N-oxanillic acid metabolite obtained using gradient reversedphase HPLC on rat urine obtained following the administration of 4-bromoaniline. The NMR spectrum was obtained in stopped flow mode (see Chapter 18). Chromatographic conditions were Hypersil BDS C18 column (250 × 4.6 mm i.d) (Thermo Scientific) packed with 5 μm particles. The mobile phases used to form the gradient were 0.01 M ammonium formate in D2 O (pD 7.0) (solvent A) and ACN (solvent B) at 1 mL/min. The gradient started with 100% A for 10 min increasing, in a linear gradient, to 30% B at 35 min followed by a second linear gradient to 50% B at 45 min (see ref. 12).
4. Notes 1. Avoid non-volatile buffers, such as sodium phosphate, as these can lead to rapid deterioration of the performance of the mass spectrometer. Similarly, avoid pH modifiers, such as trifluoroacetic acid (TFA), as these will tend to suppress the ionisation of the analytes resulting in poor sensitivity (particularly in negative ion mode for TFA). Formic acid and ammonium formate, both of which are volatile, generally provide a good compromise where pH modification of the mobile phase is needed to obtain or optimise retention. 2. Ideally, the sample should be dissolved in the solvent that forms the initial mobile phase used for the HPLC solvent gradient in order to ensure the best possibility for retention on the column. Injection of large volumes of sample
188
Wilson
dissolved in solvents containing a high proportion of organic solvent should be avoided, if at all possible, as this may result in poor retention on the column, low sample loading capacity, or poor peak shape. 3. While both ACN and MeOH can be used to provide efficient removal of proteins, it is generally preferable to use ACN, especially where acyl (or ester) glucuronides may be present. This is because the presence of methanol can result in transesterification reactions whereby the acyl glucuronide is converted to the methyl ester, resulting in the loss of information and the potential for mis-identification of the metabolite. 4. The amount of sample that can be injected onto a HPLC column should be carefully optimised with respect to the column dimensions, to avoid overloading and to provide sufficient material for detection by the various detectors being used (radio, UV and MS). Care should also be taken to ensure that the loop size chosen is compatible with the injection volume. If there is evidence of column overloading the sample volume injected should be reduced. 5. Characteristic losses from the parent molecule can be a useful aid to finding metabolites but this approach cannot be relied upon to find all of the compound-related material. This is because metabolism on the part of the molecule that results in the formation of this characteristic fragment will mean that it is no longer observed in the fragments from such metabolites. Thus, while the presence of the fragment provides good evidence for the presence of a metabolite, the absence of the fragment does not necessarily indicate that a new peak in the sample that was not seen in the pre-dose/control is not a metabolite. Over-reliance on this approach of searching for common fragments alone may lead to metabolites being missed. 6. Two types of radiodetectors are available, using flow cells based on either solid or liquid scintillants. Radiodetectors using solid scintillants may be connected inline with the UV and MS systems. Instruments using liquid scintillants cannot be connected inline because of the need to avoid the introduction of large amounts of the scintillant into the ion source of the mass spectrometer. The use of liquid scintillant-based systems requires flow splitting and careful calibration of the lengths of tubing, etc., to ensure that the relationship between the retention time of peaks in the radiodetector flow cell and ion source of the MS are known. The main reason for using flow cells based on liquid scintillants is higher sensitivity compared to the solid scintillants.
HPLC-MS-Based Drug Metabolite Profiling
189
7. Fraction collection can provide a means of producing radiochromatograms in the absence of an online radiodetector or, alternatively, where the amounts of radioactivity are too low for online detection. Fractions can be collected into vials for conventional determination using scintillation counters or into coated 96-well plates for determination using systems such as “TopCount” (this utilises a yttrium silicate embedded “LumaPlate” for fraction collection and can be used to rapidly determine the radioactivity in each well thereby reducing the overall time taken for determining the profile (see ref. 5) (TopCount NXT and LumaPlates, Perkin Elmer LAS, Buckinghamshire, UK). Fraction collection has the disadvantage that it is relatively slow compared to online monitoring. 8. The use of UPLC provides much more efficient chromatography than conventional HPLC, potentially resulting in much better resolution of metabolite peaks. This improved chromatographic efficiency can be used to advantage in two ways: either reducing run times from 30–50 to 10–15 min without loss of resolution or by obtaining much greater resolution of metabolites (from each other and from endogenous compounds or contaminants such as PEG) in the case of extensive and complex metabolism. 9. If further MS or NMR studies are to be performed on isolated metabolites, then care should be taken to ensure that the collection and subsequent sample handling conditions are suitable for preserving unstable metabolites such as acyl glucuronides (e.g. see Note 3). References 1. Ma, S., Chowdhury, S. K. (2008) Application of liquid chromatography/mass spectrometry for metabolite identification, in (Zhang, D., Zhu, M., Humphreys, W. G., eds.), Drug Metabolism in Drug Design and Development, pp. 319–368. Wiley, New Jersey. 2. Johnson, K. A., Plumb, R. (2005) Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS. J Pharm Biomed Anal 39, 805–810. 3. Zhu, M., Zhao, W., Humphreys, W. G. (2008) Applications of liquid radiochromatography techniques in drug metabolism studies, in (Zhang, D., Zhu, M., Humphreys, W. G., eds), Drug Metabolism in Drug Design and Development, pp. 319–368. Wiley, New Jersey.
4. Athersuch, T. J., Sison, R. L., Kenyon, A. S. J., Clarkson-Jones, J. A., McCormick, A. D., Wilson, I. D. (2008) Evaluation of the use of UPLC-tof/MS with simultaneous [14 C]radioflow detection for drug metabolite profiling: application to propranolol metabolites in rat urine. J Pharm Biomed Anal 48, 151–157. 5. Dear, G. J., Patel, N., Kelly, P. J., Webber, L., Yung, M. J. (2006) Topcount coupled to ultra-performance liquid chromatography for the profiling of radiolabeled drug metabolites in complex biological samples. J Chromatogr B 884, 96–103. 6. Lindon, J. C., Nicholson, J. K., Wilson, I. D. (1996) Direct coupling of chromatographic separations to NMR spectroscopy. Prog Nucl Magn Res 29, 1–49.
190
Wilson
7. Scarfe, G. B., Wright, B., Clayton, E., Taylor, S., Wilson, I. D., Lindon, J. C., Nicholson, J. K. (1999) Quantitative studies on the urinary metabolic fate of 2-chloro-4trifluoromethylaniline in the rat using 19 FNMR spectroscopy and directly coupled HPLC-NMR-MS. Xenobiotica 29, 77–91. 8. Duckett, C. J., Lindon, J. C., Walker, H., Abou-Shakra, F., Wilson, I. D., Nicholson, J. K. (2006) Metabolism of 3-chloro4-fluoroaniline in rat using [14 C]radiolabelling, 19 F-NMR spectroscopy, HPLC-MS/MS, HPLC-ICPMS and HPLCNMR. Xenobiotica 36, 59–77. 9. Anari, M. R., Sanchez, R. I., Bakhtiar, R., Franklin, R. B., Baillie, T. A. (2004) Integration of knowledge-based metabolic predicitions with liquid chromatography datadependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinvar. Anal Chem 76, 823–832. 10. Levesen, K., Schiebel, H. M., Behnke, B., Dotzer, R., Dreher, W., Elend, M.,
Thiele, H. (2005) Structure elucidation of phase II metabolites by tandem mass spectrometry: an overview. J Chromatogr A 1067, 55–72. R (2000) Chromatography Optimisa11. Drylab tion Software, version 3.0.09, Molnar-Institut für Angewandte Chromatographie, Berlin, Germany. 12. Scarfe, G. B., Nicholson, J. K., Lindon, J. C., Wilson, I. D., Taylor, S., Clayton, E., Wright, B. (2002) Identification of the urinary metabolites of 4-bromoaniline and 4bromo-[carbonyl-13 C]-acetanilide in the rat. Xenobiotica 32, 325–337. 13. Shillingford, S., Bishop, L., Smith, C. J., Payne, R., Wilson, I. D., Edge, A. M. (2009) Application of high temperature LC to the separation of AZD5438 (4- (1isopropyl-2-menythyl-1 H-imidazol-5-yl)N-4(methylsulphonyl))phenyl]pyrimidin-2amine) and its metabolites: comparison of UPLC and HTLC. Chromatographia 70, 37–44.
Chapter 11 Gas Chromatography-Mass Spectrometry (GC-MS)-Based Metabolomics Antonia Garcia and Coral Barbas Abstract Metabolic fingerprinting, the main tool in metabolomics, is a non-targeted methodology where all detectable peaks (or signals), including those from unknown analytes, are considered to establish sample classification. After pattern comparison, those signals changing in response to a specific situation under investigation are identified to gain biological insight. For this purpose, gas chromatographymass spectrometry (GC-MS) has a drawback in that only volatile compounds or compounds that can be made volatile after derivatization can be analysed, and derivatization often requires extensive sample treatment. However, once the analysis is focused on low molecular weight metabolites, GC-MS is highly efficient, sensitive, and reproducible. Moreover, it is quantitative, and its compound identification capabilities are superior to other separation techniques because GC-MS instruments obtain mass spectra with reproducible fragmentation patterns, which allow for the creation of public databases. This chapter describes well-established protocols for metabolic fingerprinting (i.e. the comprehensive analysis of small molecules) in plasma and urine using GC-MS. Guidelines will also be provided regarding subsequent data pre-treatment, pattern recognition, and marker identification. Key words: Pattern recognition, urine, plasma, multivariate analysis, silylation, volatile compounds, gas chromatography-mass spectrometry.
1. Introduction Gas chromatography coupled to mass spectrometry (GC-MS) has been regarded as the gold standard for analysing many compounds (lipids, drug metabolites, and environmental contaminants), as well as for forensic science. One of the advantages of GC-MS is that identification of detected species is based on both a retention time and a mass spectrum (a compound’s specific fragmentation pattern). Compounds produce reproducible T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_11, © Springer Science+Business Media, LLC 2011
191
192
Garcia and Barbas
fragmentation patterns when ionized by a fixed electron voltage (usually –70 eV). Thus, the fragmentation spectra obtained by GC-MS are not instrument dependent and allow for the creation of databases and the sharing of data between users, making the technique particularly valuable. In addition, GC-MS allows for quantitative detection of analytes. In classical methods, measuring either a single compound or a set of chemically related substances (such as short chain fatty acids or amino acids), there are clearly established protocols for sample treatment and for quantification using the appropriate standards. In the last few years (1), a new analytical strategy has evolved for obtaining a global view of the metabolic status of an organism. “Metabo(l/n)omics” is an approach capable of generating a comprehensive data set of metabolites. This is not only a new terminology but a new approach to the analytical problem with very different analytical requirements. In an “omics” methodology, the expectation is that the response pattern(s) of numerous analytes, both known and unknown, is reflective of a biological condition, and the comprehensive nature of the data set enables evaluation of systemic response. The broader scope of the analysis forces compromises in method development (e.g. sample extraction, cleanup, derivatization, chromatography) and requires flexibility in accuracy criteria for specific metabolites. On the one hand, GC-MS is far from the ideal of metabolomics; not only is it limited to compounds that either are volatile or can be made volatile through the derivatization process, but also all nonvolatile compounds must be carefully removed from the sample before analysis, which requires demanding sample treatment. However, on the other hand, it is clear that no single analytical platform is capable of detecting the whole set of metabolites in a biological sample. 1 H-NMR, capable of measuring intact samples and, in principle, ideal, is limited by a bias towards analytes with medium to high concentrations. In contrast, GC-MS is highly sensitive and reproducible and permits working with standard libraries for identification of detected species (2); it is widely used, although only a certain subset of compounds will be analysed. This chapter describes and explains guidelines for metabolite fingerprinting of plasma and urine by GC-MS. It gives experimental details on basic steps such as sample collection, storage, protein precipitation, extraction, concentration, derivatization, data acquisition, raw data processing, and data transformation. In general, procedure descriptions are as straightforward and comprehensive as possible and have been optimized and validated from previously described protocols in our laboratory. With this method, organic acids, amino acids, mono- and di-saccharides, sterols, and other compounds can be detected in the same analysis.
Gas Chromatography-Mass Spectrometry (GC-MS)-Based Metabolomics
193
2. Materials 2.1. Chemicals
1. Standard compounds (Sigma, St. Louis, MO, or Aldrich, Steinheim, Germany): 2-aminobutyric acid, 2-hydroxybutyric acid, 2-hydroxyisobutyric acid, 2ketoglutaric acid, 3-hydroxybutyric acid, 4-hydroxybutyric acid, 4-hydroxyproline, 5-hydroxy-3-indolacetic acid, alanine, asparagine, aspartic acid, cholesterol, citric acid, creatinine, ethylene diamine tetraacetic acid (EDTA) disodium salt, estearic acid, fructose, fumaric acid, glucitol, gluconic acid, glucose, glutamic acid, glutamine, glutaric acid, glyceric acid, glycine, glycolic acid, hexanoic acid, isoleucine, lauric acid, leucine, linoleic acid, malic acid, methyl estearate (IS), methionine, myo-inositol, myristic acid, oleic acid, ornithine, oxalacetate, oxalate, palmitic acid, phenylalanine, pyroglutamate, proline, pyruvic, sarcosine, serine, sodium lactate, succinate, threonine, tryptophan, tyrosine, urea, uric acid, and valine. These standards are of analytical grade except where stated otherwise. Stock solutions of the reference compounds should be prepared at 25 mM either in Milli-Q water or in methanol. Standard solutions should be kept at –80◦ C. Before analysis, the solutions should be thawed and diluted (1:100) with methanol. These compounds are only necessary for confirming the identification of detected metabolites, and the list can be modified as necessary by the researcher. 2. Urease (Sigma-Aldrich, Poole, UK): 600 units/mL (0.0085 g/mL) in Milli-Q water. 3. Pentadecanoic methanol.
acid
(Sigma-Aldrich):
6
mg/mL
in
4. C18:0 methyl ester (Sigma): 1000 ppm stock solution diluted to 10 ppm with heptane. 5. N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) plus 1% trimethylchlorosilane (TMCS; Pierce Chemical Co, Rockford, IL, USA). 6. O-Methoxyamine hydrochloride (Sigma): 15 mg/mL in pyridine. This solution can be stored in the freezer for 2 weeks. 7. Silylation-grade pyridine. 8. Analytical-grade heptane. 9. HPLC-grade methanol. 10. HPLC-grade acetone.
194
Garcia and Barbas
11. HPLC-grade acetonitrile. 12. Ultrapure water can be produced by a Milli-Q Reagent Water System (Millipore, MA, USA) or similar (see Notes 1 and 2). 2.2. Samples
1. Plasma 2. Urine: First-void urine samples are preferred compared to spot urine samples because the influence of lifestyle factors (e.g. diet, physical exertion, stress) on the metabolic urinary profiles is relatively minimized and normalized in the case of first-void urine (3).
2.3. Equipment
1. Centrifuge. 2. Microcentrifuge (Hettich, Tuttlingen, Germany). 3. Speedvac concentrator (Thermo Fisher Scientific, Waltham, MA). 4. 0.22 μm filters (Millipore, Billerica, MA). 5. 3 mL Vacuette plastic tubes containing 4.5 mg of EDTA·K3 for plasma collection (Greiner Bio One, Brazil). 6. 2 mL GC-HPLC glass vials with 200 μL conical narrow opening inserts. 7. Ultrasonic bath. 8. Digitheat 80 L stove (Selecta, Barcelona, Spain). 9. Vortex mixer.
2.4. GC-MS Equipment
1. 3900 Series GC (Varian, Palo Alto, CA). Electronic Flow Control provides constant flow separation. 2. CP-8400 AutoSampler (Varian). 3. Saturn 2110T Series MS ion trap (Varian). D Alternative mass spectrometers, such as quadrupole, time-of-flight, or triple quadrupole, can be used. 4. National Institute of Standards and Technology (NIST) mass spectra library. 5. GC capillary column: VF-5 ms, 30 m × 0.25 mm ID, 0.25 DF, (Varian).
2.5. Software
1. Matlab version 7.0 (MathWorks, Natick, MA). 2. MassTransit version 3.0 (Palisade Corporation, Ringoes, NJ). This is a Microsoft Windows application for reading, displaying, and converting GC-MS data files between different instrument vendor formats. 3. SIMCA P+ version 12 (Umetrics, Umeå, Sweden). This software is used for multivariate analysis of data.
Gas Chromatography-Mass Spectrometry (GC-MS)-Based Metabolomics
195
3. Methods 3.1. Metabolite Fingerprinting in Plasma Samples
3.1.1. Plasma Preparation
Blood plasma is a heterogeneous mixture of lipoprotein particles, proteins, small organic molecules, and ions, which together undergo a variety of possible molecular interactions including metal complexation, chemical exchange processes, micellar compartmentation of metabolites, enzyme-mediated biotransformations, and small molecule–macromolecular binding (4). The low molecular weight compounds, in particular, are chemically diverse and vary widely in concentrations and stabilities and are commonly noncovalently bound to proteins (5). The following analytical procedure is based on two methods previously described (4, 6). The whole process consists of three steps: deproteinization, ketone functional group protection by methoximation, and derivatization to increase the volatility of the metabolites. Deproteinization removes the analytical interference due to proteins; albumin is the most abundant blood protein with a typical concentration of 34–50 g/L (7). After deproteinization, samples should be dried to permit the action of derivatizating agents. Methoximation utilizes CH3 ONH2 in pyridine to stabilize carbonyl moieties by suppressing keto–enol tautomerism and the formation of multiple acetal- or ketal-structures. It also helps to reduce the numbers of derivatives of reducing sugars and generates only two forms of the –N=C< derivative, syn and anti. Silylation involves replacement of active hydrogen atoms with an alkylsilyl group, for example, –SiMe3 . Functional groups that present a problem with volatility – hydroxyl (–OH), carboxyl (–COOH), amine (–NH2 ), thiol (–SH), and phosphate (–PO4 3– ) – can be derivatized by silylation reagents. Importantly, while the (–OH) and (–COOH) groups react simultaneously and very fast, the hydrogen atoms of the (–NH2 ) groups react more slowly (1) and can yield multiple derivatives of some compounds. Silylation thus increases the volatility and thermal stability of polar metabolites (8).
1. Collect fresh blood in the EDTA-treated tubes. 2. Centrifuge anticoagulated blood quickly at 1000×g for 10 min at 4◦ C. 3. Collect the supernatant and freeze the plasma at –80◦ C in 100 μL aliquots. 4. Prior to further manipulation, plasma samples must be thawed, vortex-mixed, and filtered through a 0.22 μm filter before use (see Notes 3–6).
196
Garcia and Barbas
3.1.2. Plasma Deproteinization
1. On ice, pipette 40 μL of plasma to a 650 μL Eppendorf, vortex-mix it with 120 μL of cold acetonitrile for 2 min and let stand for 5 min. Maintain the ratio of acetonitrile to sample at 3:1 to guarantee the precipitation of the proteins. 2. Centrifuge the sample at 15,400×g for 10 min at 4◦ C with the microcentrifuge. 3. Transfer 100 μL of the supernatant to a GC vial equipped with a 200 μL insert and evaporate to dryness by speedvac at 30◦ C. Check to assure the vial is completely dry.
3.1.3. Methoximation
1. Add 10 μL of O-methoxyamine hydrochloride (15 mg/mL) in pyridine to each GC vial and mix vigorously for 1 min. 2. Ultrasonicate the samples three times for 10 s and vortex again for 2 min. 3. Cover the GC vials in aluminium foil and incubate at room temperature for 16 h (see Notes 7 and 8) in the dark.
3.1.4. Derivatization
1. Add 10 μL of BSTFA with 1% TMCS as catalyst to each sample, then vortex-mix for 5 min. 2. Place the GC vials in an oven for 1 h at 70◦ C for silylation. 3. Add 100 μL of heptane containing 10 ppm of C18:0 methyl ester (IS) to each GC vial and vortex-mix for 2 min before GC analysis (see Note 9).
3.2. Metabolite Fingerprinting in Urine Samples
3.2.1. Urine Preparation
Due to the fact that the urine contains metabolic signatures of many biochemical pathways, this biofluid is ideally suited for metabolomic analysis. However, the urine metabolome is highly variable with respect to the composition and quantity of compounds in response to diet, medication, and metabolic state. Therefore, metabolic fingerprinting in urine can be quite challenging. Urease is used to deplete urea, which can cause major chromatographic interference and mask many low-intensity metabolite peaks. Finally, since most compounds identified in urine are also present in blood plasma, the protocol of urine extraction and derivatization is based on that of plasma. 1. Thaw frozen urine samples at room temperature (25 ± 3◦ C) (see Notes 16–18). 2. Add 30 units (50 μL) of urease to 200 μL of urine and incubate at 37◦ C in a stove for 30 min to decompose and remove excess urea.
Gas Chromatography-Mass Spectrometry (GC-MS)-Based Metabolomics
197
3. Add 800 μL methanol to urine samples to precipitate urease and other proteins and add 10 μL pentadecanoic acid (6 mg/mL) as internal standard. 4. Vortex-mix the samples for 5 min and then centrifuge at 15,400×g for 10 min at 4◦ C. 5. Transfer 200 μL of the supernatant to a GC vial and then evaporate to dryness by speedvac at 30◦ C. Check to assure the vial is completely dry. 3.2.2. Methoximation
1. Add 30 μL of O-methoxyamine hydrochloride (15 mg/mL) in pyridine to each GC vial and mix vigorously for 10 min. 2. Ultrasonicate the samples three times for 10 s and vortex again for 2 min. 3. Cover the GC vials in aluminium foil and incubate at room temperature for 16 h in the dark (see Notes 7 and 8).
3.2.3. Derivatization
1. Add 30 μL of BSTFA with 1% TMCS as catalyst to each sample, then vortex-mix for 5 min. 2. Place the GC vials in an oven for 1 h at 70◦ C for silylation. 3. Add 40 μL of heptane to each GC vial and vortex-mix for 10 min before GC analysis (see Note 9).
3.3. GC-MS Analysis
1. Inject 1 μL (splitless) or 2 μL (split ratio of 1:10) of derivatized urine or plasma samples, respectively, into the GC-MS system. 2. Set the helium carrier gas flow rate to 1 mL/min through the column. 3. Set the injector temperature to 250◦ C. 4. Programme the temperature gradient as follows: set initial oven temperature at 50◦ C, hold for 1 min, and then increase temperature at the rate of 3.3◦ C/min to a final temperature of 340◦ C. 5. Set the detector transfer line, trap, and manifold temperatures to 280, 200 and 60◦ C, respectively. 6. Operate the electron ionization source at –70 eV. 7. Operate the mass spectrometer in scan mode only over a mass range of 50–650 m/z at a rate of 5 spectra s–1 (see Notes 10–15).
3.4. Data Analysis
Check the quality of individual chromatograms. In addition to visual inspection, establishing the internal standard signal over a certain value could be a good quality control criterion. The main steps in data analysis are summarized in Fig. 11.1.
198
Garcia and Barbas
DATA ANALYSIS
1,0 0,8 0,6
'c4p' 'c1p' 'c2p' 'c5p'
t[2]
'd1p'
0,0
'c7p' 'd7p'
0
R2X
R2X
R2X Q2
Q2
Q2
'c8p' 'c14p' 'c11p'
Comp[3]
'c15p'
Comp[2]
0,2
10
Comp[1]
0,4
Before multi alignment
'd16p' 'd5p' 'd3p'
After multi alignment
'd19p' 'd15p'
–10 'c3p'
'd8p'
–02
–10
0 t[1]
10
20
MULTIVARIATE ANALYSIS
DATA PRE-TREATMENT Glucose
CONTROL
DIABETIC
MARKER IDENTIFICATION
Fig. 11.1. Scheme of steps in data analysis.
3.4.1. Data Pre-processing
Data can be pre-processed as defined peaks or with the total profile of data points. In any case, the appropriate software should be employed. In our laboratory data treatment was performed as follows: 1. Export each chromatogram with the total ion chromatogram (TIC) signal as TXT format to Excel or ASCII. These last formats can be opened with the MATLAB program. 2. Generate a matrix of data with one column per sample (include all the samples of the metabolomic experiment) and one row per MS signal. 3. Delete the zero signals at the beginning and at the end of the chromatogram. It is very important to keep the same number of data points per sample/column to configure the matrix of data. 4. Simultaneously, export each MS file to MATLAB format with MassTransit (9). Each new file contains the intensity of each m/z fragment detected in any scan per sample. During a standard chromatogram, more than 3500 scans are performed. The new matrix is obtained with the intensity of the sorted m/z fragments in columns and the different samples in rows. 5. The matrix of data is submitted first to baseline correction and then to multialignment by comparing the mass spectra
Gas Chromatography-Mass Spectrometry (GC-MS)-Based Metabolomics
199
in points to be aligned. Finally, normalization by dividing by the internal standard peak is applied. R 1. Load the chromatographic matrix of clean data to Matlab or SIMCA for multivariate data analysis, for example, principal components analysis (PCA), principal least squaresdiscriminant analysis (PLS-DA), or orthogonal projection to latent structure-discriminant analysis (OPLS-DA).
3.4.2. Multivariate Statistical Tools
2. Once samples cluster according to the pathology or problem under study and chemometric models are adequately validated, identify signals accounting for the classification in the loading plot as a variable number. The next step in the analytical process is transforming a variable number in an identified metabolite. Critical to this process is the reliance on both retention time index and spectral databases. Both of these are publicly available through web-based platforms, which have been recently reviewed by Tohge et al. (10) (see chromatogram (TIC) of a plasma sample is shown in Fig. 11.2. Most
3.4.3. Metabolite Identification
kCounts 700
IDENTIFIED COMPOUNDS (A) 32
600 16 500
45
400
31 14
300
22 21
200 1 100
4 5
10
6 7
10
41
50 48
12 23
11
28
24 25
30
33
36 35 38 37
43 42
46
44
49
47
40
19
17
15
kCounts 700
39
18 15
2
29
27
34
13
3 0
26
20
9 8
20
25
30
minutes 40
35
70
54
IDENTIFIED COMPOUNDS (B)
600
*
500 61 400
*
67
59 300
* 60
65 66
200
52 0
51
40
62
45
78
77
*
73 71
63 64 57 55 56 58
*
75
*
53
100
*
*
74 68 69
50
72
76
55
60
65
70 minutes
Fig. 11.2. Plasma fingerprint obtained with GC-MS. For conditions see the text. Numbers correspond to compounds identified that are described in Table 11.1.
50. Unknown 51. Citrate (standard confirmed) 52. Isocitrate (standard confirmed)
24. Glycerate
25. Unknown
26. Serine II (standard confirmed)
48. Ornithine (standard confirmed) 49. Dehydrated citrate
22. Glycine II (standard confirmed)
21. Threonine I (standard confirmed) + proline (standard confirmed)
23. Succinate (standard confirmed)
46. Lysine 47. Xylitol
20. Isoleucine (standard confirmed)
44. Asparagine (standard confirmed) 45. Unknown
19. Unknown + glycerol (standard confirmed)
17. Urea (standard confirmed)
18. Serine I (standard confirmed)
42. Unknown 43. Laurate (standard confirmed)
16. Valine II (standard confirmed)
41. Glutamate (standard confirmed) + phenylalanine II (standard confirmed)
15. 2-Aminobutyrate (standard confirmed)
37. Creatinine (standard confirmed)
11. Oxalate I (standard confirmed)
40. Ketoglutarate (standard confirmed) + phenylpyruvate (standard confirmed)
36. Phenylalanine I (standard confirmed)
10. Oxalate I (standard confirmed)
14. Silica derivative
35. 2,3,4-tri-OH-butyrate I
9. 2-OH-butyric (standard confirmed)
38. 2,3,4-tri-OH-butyrate II
34. Aspartate I (standard confirmed)
8. Glycine I (standard confirmed)
39. Unknown
33. 4-OH-proline (standard confirmed)
7. Unknown
13. 3-OH-butyrate (standard confirmed)
32. Methionine (standard confirmed) + pyroglutamate (standard confirmed) + glutamine (standard confirmed)
6. Alanine I (standard confirmed)
12. Silica derivative
30. Malic acid (standard confirmed) 31. Butylhydroxytoluene
5. Valine I (standard confirmed)
3. Oxalacetic acid
4. Glycolate (standard confirmed)
28. Alanine II (standard confirmed) 29. Aminomalonate
2. Lactate (standard confirmed)
27. Threonine II (standard confirmed)
1. Pyruvate (standard confirmed)
List of identified compounds in human plasma by GC-MS
78. Cholesterol (standard confirmed)
77. Unknown
76. EDTA (standard confirmed)
75. Trimethylsilyl Estearate
74. 11-trans-octadecenoate
73. 11-cis-octadecenoate
72. Linoleate (standard confirmed)
71. Tryptophan (standard confirmed)+5-OHindoleacetic (standard confirmed)
70. Unknown
69. Internal standard – Octadecanoic methyl ester
68. Urate (standard confirmed)
67. Myoinositol (standard confirmed)
66. Palmitate (standard confirmed)
65. Glucose derivative
64. Inositol
63. Gluconate (standard confirmed)
62. Glucose + glucopyranose
61. Unknown
60. Tyrosine (standard confirmed)
59. Glucitol (standard confirmed)
58. Glucose
57. Glucose
56. Fructose II (standard confirmed) + glucose
55. Fructose I (standard confirmed)
54. Myristic acid (standard confirmed)
53. Galactofuranose
Table 11.1 Compounds identified in plasma either by the library or by the corresponding standard in plasma fingerprints 200 Garcia and Barbas
Gas Chromatography-Mass Spectrometry (GC-MS)-Based Metabolomics
201
of the peaks in the chromatograms can be identified as endogenous metabolites by the NIST mass spectra library and many were compared with pure standards, as an additional confirmation. For that purpose, standards prepared as described in Section 2.1 and subjected to the derivatization procedure were analysed either individually or in groups with very different characteristics, and a customized database was developed including retention time and mass spectra. A candidate compound should match both criteria to be confirmed. In the case of isobaric and closely eluting compounds, the standard was also spiked into the sample for confirmation. Identifications are listed in Table 11.1. Finally, a metabolomics experiment should not be a list of compounds increasing or decreasing with the situation under study; therefore, the last step should be the search for the biological interpretation of those changes.
4. Notes 1. Never prepare a new reactant solution during the experiment. Think about the total number of samples, and the total volume of any solution required, and prepare each reactant solution once. 2. Pyridine is a hazardous solvent. Take appropriate precautions. 3. When designing a metabolomics study in humans, control subjects are a main challenge. Study carefully how to select the appropriate controls, matching in age and sex, and also ensure that samples are withdrawn, stored, and processed simultaneously. 4. Plasma samples can be established at withdrawal with citric acid, instead of EDTA. However, this makes the measurement of endogenous citrate impossible. 5. Samples thawed more than twice are not recommended. 6. It is very important to consider variables involved in sample collection, for example, the handling and storage of samples, the types of collection tubes and anticoagulants. The profile may change and disturb the biomarker pattern. Commercially available blood collection tubes contain multiple components that may appear as interfering or confounding peaks during the MS analysis. Silicones are commonly used as lubricants for stoppers or coatings for the internal surface of tubes. Polymeric surfactants, such as polyvinylpyrrolidones or polyethylene glycols, may be added to influence surface wetting (11). For those reasons,
202
Garcia and Barbas
changes in collection tubes during a metabolomics study are never recommended. 7. After the methoximation period, the solution in all the vials must be clear with no solid suspension material. If the sample cannot be analysed immediately, it must not be kept in a refrigerator or freezer but only in a dark place. Otherwise, humidity can hydrolyse it. 8. Total evaporation of solvent prior to methoximation is needed because this reaction will be slower in aqueous media. Minimize the variation between samples with complete drying. 9. During derivatization, some compounds yield different derivatives depending on which acid hydrogen is substituted by the trimethylsilyl group. Each trimethylsilyl group adds +72 Da to the molecule. 10. Use vials with glass insert tubes already included, because the cap closes more tightly. Check if any solvent could be lost during the procedure. 11. In GC-MS-based metabolomics, a method for monitoring the quality of the results and the overall analytical procedure is required. In that way, as the experiment starts, a large volume of a homogeneous sample must be aliquoted to be used in quality control (QC) samples and frozen at –80◦ C. On the day of analysis, one or several aliquots are thawed and deproteinized and derivatized along with the rest of the samples. 12. In normal planning, the operator prepares 12 samples plus 2 quality controls every day. The sequence in the GC could be one injection of blank solution containing 10 ppm IS in heptane (this is to check the blank profile and for conditioning the column to the temperature programme); one QC sample; six unknown samples randomly organized; one QC sample; and finally repeat the sequence except the injection of the blank solution. 13. For standardizing the GC-MS data acquisition process and minimizing biases that cannot be corrected through the use of an internal standard, the metabolomic profiles obtained must be within the linear range of the GC-MS equipment’s operation, and the sequence of analysis must be randomized as much as possible to analyse samples coming from all the groups. In addition, check if the instrument detector is working properly for every analysis day and ensure that all the chromatographic profiles are filtered from any artefacts and adducts. 14. A pre-column of around 10 m length, same diameter, and same film thickness is recommended to preserve the analytical column and the detector.
Gas Chromatography-Mass Spectrometry (GC-MS)-Based Metabolomics
203
15. Running the first 8 min with the filament switched off is recommended when the solvent and any excess of derivatizating reagents appear, in order to extend filament performance in the mass detector. 16. Urine concentrations can be very different, as in the case of streptozotocin diabetic rats and their controls; urinary creatinine may be used as a correction factor. Adjust sample dilution to the same creatinine value before starting the fingerprinting assay. 17. Boric acid, a common preservative in urine collection, interferes with urease activity giving variable urea concentrations and precipitates as insoluble salt during the derivatization process. 18. Urine is commonly treated with urease to reduce the risk of column overloading, peak distortions, or matrix effects (12); urea produces a huge peak at around 19 min more than 5 min wide. Kind et al. (13) observed when comparing urine analysis with and without urease treatment that many other metabolites, including acotinic acid, hypoxanthine, and the tricarboxylic acid (TCA) intermediates, were modified. However, in our experience, alignment when urea is present was impossible, even cutting the section of the peak. Therefore, the risk in using urease treatment is necessary. 19. Looking at the profile, the major component in plasma is glucose with a regulated concentration of 5 mM in humans, in order to provide energy to all organs, especially to the brain. 20. There are software tools that assist in a semi-automated peak identification; however, some limitations for the optimum assignation are chromatographic drift, very similar chemical structures of molecules in biologically significant classes (e.g. mono- or disaccharides), the vast number of peaks of yet unknown origin, the occurrence of peaks that are products of the GC column bleeding, and multiple derivatives of particular metabolites that are produced at different derivatization times.
Acknowledgements The authors acknowledge Joanna Teul for her careful experimental work and funding support from the Comunidad de Madrid, S-GEN-0247-2006 and Ministry of Science and Technology (MCIT) CTQ2008-03779.
204
Garcia and Barbas
References 1. Kanani, H., Chrysanthopoulos, P. K., Klapa, M. I. (2008) Standardizing GC– MS metabolomics. J Chromatogr B 871, 191–201. 2. Pasikanti, K. K., Ho, P. C., Chan, E. C. Y. (2008) Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J Chromatogr B 871, 202–211. 3. Lenz, E. M., Bright, J., Wilson, I. D., Morgan, S. R., Nash, A. F. (2003) A 1 H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J Pharm Biomed Anal 33, 1103–1115. 4. Daykin, C. A., Foxall, P. J. D., Connor, S. C., Lindon, J. C., Nicholson, J. K. (2002) The comparison of plasma deproteinization methods for the detection of low-molecularweight metabolites by 1 h nuclear magnetic resonance spectroscopy. Anal Biochem 304, 220–230. 5. Wu, S. L., Amato, H., Biringer, R., Choudhary, G., Shieh, P., Hancock, W. S. (2002) Targeted proteomics of low-level proteins in human plasma by LC/msn: using human growth hormone as a model system. J Proteome Res 21, 253–262. 6. Jiye, A., Trygg, J., Gullberg, J., Johansson, A. I., Jonsson, P., Antti, H., Marklund, S. L., Moritz, T. (2005) Extraction and
7. 8.
9. 10.
11.
12. 13.
GC/MS analysis of the human blood plasma metabolome. Anal Chem 77, 8086–8094. Tietz, N. W. (1986) Textbook of Clinical Chemistry, Saunders, Philadelphia, PA. p. 590. Halket, J. M., Waterman, D., Przyborowska, A. M., Patel, R. K. P., Fraser, P. D., Bramley, P. M. (2005) Chemical derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS. J Exp Bot 56, 219–243. Palisade Corporation web page. http://www.palisade.com. Accesed May 2009. Tohge, T., Fernie, A. R. (2009) Webbased resources for mass-spectrometry-based metabolomics: a user’s guide. Phytochemistry 70, 450–456. Luque-Garcia, J. L., Neubert, T. A. (2007) Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J Chromatogr A 1153, 259–276. Kuhara, T. (2005) Metabolomics: The Frontier of Systems Biology, Springer, Tokyo. Kind, T., Tolstikov, V., Fiehn, O., Weiss, R. H. (2007) A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 363, 185–195.
Chapter 12 The Use of Two-Dimensional Gas Chromatography–Time-of-Flight Mass Spectrometry (GC×GC–TOF-MS) for Metabolomic Analysis of Polar Metabolites Kimberly Ralston-Hooper, Amber Jannasch, Jiri Adamec, and Maria Sepúlveda Abstract Metabolites produced by an organism can be quite extensive, and one analytical technique alone is not capable of their comprehensive detection and identification. The majority of environmental metabolomic studies have implemented proton nuclear magnetic resonance (1 H-NMR) spectroscopy with little attention given to mass spectrometry (MS) techniques. In this chapter, an analytical technique is outlined that incorporates two-dimensional gas chromatography–time-of-flight MS (GC×GC–TOF-MS) for the identification and quantification of polar metabolites. Key words: Two-dimensional gas chromatography, time of flight, mass spectrometry.
1. Introduction The use of metabolomics in environmental sciences as a tool to help understand the impacts of different stressors on organisms has substantially increased over the past few years (1–5). As with any scientific field, there are numerous analytical technologies available for metabolome analysis (6). Overall, proton nuclear magnetic resonance (1 H-NMR) spectroscopy has been the most popular choice for environmental metabolomic studies (7–10). Limitations of NMR-based metabolomic techniques include their relatively low sensitivity that results in an examination of a limited T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_12, © Springer Science+Business Media, LLC 2011
205
206
Ralston-Hooper et al. Methanol:Chloroform Extraction
Methanol (Polar Metabolites)
Dry Sample
Chloroform (Non-Polar Metabolites) LC/TOF-MS Analysis
See Chapter 15 for more details
Derivatize Sample
GCxGC/TOF-MS Analysis
Metabolite IdentificationMatched against NIST database (SV > 750)
Fig. 12.1. Flowchart of sample preparation steps used for GC×GC–TOF-MS analysis.
number of metabolites (11, 12). Alternatively, mass spectrometry (MS) coupled with a separation technique such as gas chromatography (GC) has been successfully utilized for metabolome analysis in other fields such as human disease and plant metabolism (13, 14) but has not been extensively used for environmental metabolomic studies. For example, GC×GC–TOF-MS has been used successfully for characterizing metabolite profiles of complex biological mixtures (15–17), as well as to study metabolomic profiles of atrazine-exposed invertebrates (18). Since the number of metabolites produced by an organism is quite extensive, one instrument or technique will not be able to detect and identify all metabolites. Using multiple analytical techniques such as GC×GC–TOF-MS and 1 H-NMR can be extremely advantageous. Both these instruments coupled with bioinformatics or multivariate analysis of complex datasets could be beneficial in biomarker identification. In this chapter, a method utilizing MS– metabolomic techniques is outlined (see Fig. 12.1).
2. Materials 2.1. Extraction Solvents
1. Chloroform (>99.9% HPLC grade). 2. Methanol (>99.9% HPLC grade). 3. 18.2 M cm water (see Note 1).
The Use of Two-Dimensional Gas GC×GC–TOF-MS for Metabolomic Analysis
2.2. Derivatization Agents
207
1. Anhydrous pyridine (99.8% purity). 2. O-Methylhydroxylamine hydrochloride (>98% purity Fluka, St. Louis, MO): 20 mg/mL anhydrous pyridine (see Note 2). 3. N-Methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide (MSTFA) (>98.5% GC grade; Thermo Fisher Scientific, Waltham, MA) (see Note 3).
2.3. Equipment
1. Axygen 1.7-mL microtubes (Axygen Scientific, Inc., Union City, CA). 2. Sawtooth stainless steel tissue homogenizer TH-01 (Omni, Marietta, GA). 3. Sonicator (Ultrasonic Power Corporation, Freeport, IL). 4. Sevant SpeedVac Concentrator SPD 131DDA (Thermo Electron Corporation, Milford, MA). R R III and ChromaTOF , 5. GC×GC–TOF-MS Pegasus Leco Corporation, V. 2.32 (Leco Corporation, St. Joseph, MI).
6. First-dimension column: Restek Rtx-5 (10 m, 0.18 mm i.d., 0.2 μm d.f.). 7. Second-dimension column: DB-17 (1.1 m, 0.18 mm i.d., 0.18 μm d.f.). R 8. Statistical Analysis Software, SAS , V. 9.1.3 (http://www. sas.com/technologies/analytics/statistics/stat/index.html).
9. R statistical software, R Development Core Team, V. 2.10.0 (http://www.r-project.org). 10. PLS_ Toolbox Advanced Chemometrics, V. 3.5, R Central, (http://software.eigenvector.com/ Matlab toolbox/3_5/index.html). 11. National Institute of Standards and Technology (NIST) database (http://www.nist.gov/srd/index.htm).
3. Methods 3.1. Sample Preparation
1. Samples that have been stored at –80◦ C are prepared for metabolomic analysis (see Note 4). 2. Weigh samples (either whole organisms or tissues) to the nearest 0.001 g (see Note 5) and add to a clean centrifuge tube. Add 300 μL cold methanol and 150 μL chilled water to each sample.
208
Ralston-Hooper et al.
3. Homogenize samples for 20 s using a sawtooth stainless steel homogenizer. 4. Sonicate the samples using 10 1-s bursts (see Note 6). 5. Add 450 μL of chloroform to each sample. 6. Thoroughly vortex the samples for approximately 30 s. 7. Centrifuge the samples at 3000×g for 20 min. 8. After centrifugation, two distinct solvent phases will be observed (see Note 7). 9. Using a glass transfer pipette, collect each phase and place in a clean centrifuge tube. 10. Evaporate extraction solvents using a SpeedVac. Methanol fractions (polar metabolites) will be prepared for GC×GC– TOF-MS analysis (see Section 3.2), while chloroform fractions (non-polar metabolites) can be prepared for LC– TOF-MS analysis (but will not be discussed in detail here; please see Chapter 15 for more details). 3.2. Derivatization
1. To the methanol fractions, add 30 μL of Omethylhydroxylamine hydrochloride solution per 10 mg of sample (see Note 8). 2. Shake samples for 30 min at 60◦ C. 3. Add 45 μL MSTFA per 10 mg of sample (see Note 8). 4. Allow samples to react for 1 h at 60◦ C. 5. Transfer samples to clean, labeled GC autosampler vials and immediately inject onto the GC×GC–TOF-MS (see Section 3.3 for instrumental conditions).
3.3. GC×GC–TOF-MS Instrumental Conditions
1. Injection volume: 2 μL. 2. Inlet temperature: 280◦ C. 3. Carrier gas: helium. 4. Flow rate: 1 mL/min. 5. Injection type: split mode (ratio = 20). 6. Temperature profile 1: 10◦ C/min from 50 to 300◦ C; 5 min hold at 300◦ C. 7. Temperature profile 2: 10◦ C/min from 75 to 325◦ C; 5 min hold at 325◦ C. 8. Second-dimension separation time: 4 s. 9. Ion source temperature: 200◦ C. 10. Detector voltage: 1600 V. 11. Filament bias: –70 V. 12. Mass range: 50–900 u. 13. Acquisition rate: 50 spectra/s.
The Use of Two-Dimensional Gas GC×GC–TOF-MS for Metabolomic Analysis
3.4. Peak Merging, Alignment, and Normalization
209
1. Chromatographic peaks are merged and aligned using R MSort software. Since retention times and fragment spectra of chromatographic peaks are expected to differ across individual runs, we use “in-house” software to align, match, and compare metabolite peaks from various samples (19). R software include Three major functionalities of MSort peak entry merging, alignment, and contaminant elimination. Multiple peak entries of the same chromatographic R are recognized and peak generated from ChromaTOF merged so that one peak entry represents one chromatographic peak. The merged peaks are then aligned based on their retention times and spectrum similarity of fragment ions. Window sizes used during peak merging and alignment included 1% window for first dimension, 5% for second dimension, and a cutoff correlation coefficient value of 0.95. 2. Data are normalized using R statistical software (19). To allow for multi-experiment analyses, it is important to normalize data to make samples comparable. This normalization step aims to quantitatively filter overall peak intensity variations due to experimental errors such as varying amounts of samples loaded onto the GC×GC–TOF-MS. In order to make all samples comparable, peaks were normalized using a constant mean approach where the total ion current was assumed equal across samples. Normalized peaks were then subjected to statistical significance tests and pattern recognition.
3.5. Statistical Analysis
1. Two-tailed t-tests are used to detect significant differences in metabolite concentration (peak areas) when comparing two groups. If more than two groups are to be compared, analysis of variance (ANOVA) is employed using SAS. 2. Since multiple hypothesis testing was conducted, the associated p-values were adjusted to correct for multiple comparisons using the false discovery rate (FDR) or the expected proportion of errors among the rejected hypothesis using SAS (20). 3. Metabolite pattern recognition is carried out using principal component analysis (PCA) performed with PLS toolbox.
3.6. Metabolite Identification
1. Polar metabolites analyzed via GC×GC–TOF-MS are identified by matching mass spectra against the NIST library resulting in a similarity value (SV). An SV value >750 is considered a positive identification since approximately 75% of collected spectra match the NIST library spectra (17).
210
Ralston-Hooper et al.
4. Notes 1. 18.2 M cm water (which will be referred to as “water” throughout the text) should be used to prepare all solutions unless otherwise noted. 2. O-Methylhydroxylamine hydrochloride is a possible mutagen, so take necessary precautions, e.g., avoid breathing dust and minimize exposure by using the appropriate personal protection equipment (face shield, lab coat, gloves, MSHA/NIOSH-approved respirator). This compound is also hygroscopic, so store in a sealed container in a cool, dry place. For best results, O-methylhydroxylamine hydrochloride solution should be made fresh prior to use. 3. MSTFA is extremely sensitive to moisture and should be handled and stored accordingly. All glassware and syringes, as well as the samples of interest, should be carefully dried because water could interfere with derivatization efficiency. 4. In order to prevent sample degradation, samples must be immediately flash frozen and stored at –80◦ C until analysis. Samples are to be kept on ice during the extraction procedure until Step 7. 5. Sample weights (typically wet weights) are used for sample normalization during the derivatization step prior to GC×GC–TOF-MS analysis. 6. A sonicating water bath may also be used. Place samples in a 37◦ C water bath and sonicate for 3 min. 7. The top phase is methanol and contains polar metabolites. The bottom phase is chloroform and contains non-polar metabolites. 8. The 30 μL of O-methylhydroxylamine hydrochloride solution and 45 μL of MSTFA are added per 10 mg of sample and need to be adjusted according to initial sample weight.
Acknowledgments We would like to thank the Agriculture and Research Program and the Department of Forestry and Natural Resources at Purdue University for supporting the senior author with a 4-year research assistantship towards her PhD. We also thank the Center for the Environment, Purdue University for financially supporting this work.
The Use of Two-Dimensional Gas GC×GC–TOF-MS for Metabolomic Analysis
211
References 1. Viant, M. R. (2007) Metabolomics of aquatic organisms: the new “omics” on the block. Mar Ecol Prog Ser 332, 301–306. 2. Samuelsson, L. M., Larsson, D. G. J. (2008) Contributions from metabolomics to fish research. Mol Biosyst 4, 974–979. 3. Lin, C. Y., Viant, M. R., Tjeerdema, R. S. (2006) Metabolomics: methodologies and applications in the environmental sciences. J Pestic Sci 31, 245–251. 4. Viant, M. R. (2008) Recent developments in environmental metabolomics. Mol Biosyst 4, 980–986. 5. Bundy, J., Davey, M., Viant, M. (2009) Environmental metabolomics: a critical review and future perspectives. Metabolomics 5, 3– 21. 6. Dunn, W. B., Ellis, D. I. (2005) Metabolomics: current analytical platforms and methodologies. Trends Anal Chem 24, 285–294. 7. Ekman, D. R., Teng, Q., Jensen, K. M., Martinovic, D., Villeneuve, D. L., Ankley, G. T., Collette, T. W. (2007) NMR analysis of male fathead minnow urinary metabolites: a potential approach for studying impacts of chemical exposures. Aquat Toxicol 85, 104– 112. 8. Ekman, D., Keun, H., Eads, C., Furnish, C., Murrell, R., Rockett, J., Dix, D. (2006) Metabolomic evaluation of rat liver and testis to characterize the toxicity of triazole fungicides. Metabolomics 2, 63–73. 9. Viant, M. R., Pincetich, C. A., Tjeerdema, R. S. (2006) Metabolic effects of dinoseb, diazinon and esfenvalerate in eyed eggs and alevins of chinook salmon (Oncorhynchus tshawytscha) determined by 1 H NMR metabolomics. Aquat Toxicol 77, 359–371. 10. Samuelsson, L. M., Förlin, L., Karlsson, G., Adolfsson-Erici, M., Larsson, D. G. J. (2006) Using NMR metabolomics to identify responses of an environmental estrogen in blood plasma of fish. Aquat Toxicol 78, 341–349. 11. Keun, H. C., Beckonert, O., Griffin, J. L., Richter, C., Moskau, D., Lindon, J. C., Nicholson, J. K. (2002) Cryogenic probe 13 C NMR spectroscopy of urine for metabonomic studies. Anal Chem 74, 4588–4593. 12. Wang, Y., Bollard, M. E., Keun, H., Antti, H., Beckonert, O., Ebbels, T. M.,
13. 14.
15.
16.
17.
18.
19.
20.
Lindon, J. C., Holmes, E., Tang, H., Nicholson, J. K. (2003) Spectral editing and pattern recognition methods applied to highresolution magic-angle spinning 1 H nuclear magnetic resonance spectroscopy of liver tissues. Anal Biochem 323, 26–32. Houten, S. M. (2009) Metabolomics: unraveling the chemical individuality of common human diseases. Ann Med 41, 402–407. Lisec, J., Steinfath, M., Meyer, R. C., Selbig, J., Melchinger, A. E., Willmitzer, L., Altmann, T. (2009) Identification of heterotic metabolite QTL in Arabidopsis thaliana RIL and IL populations. Plant J 59, 777–788. Hope, J. L., Sinha, A. E., Prazen, B. J., Synovec, R. E. (2005) Evaluation of the dotmap algorithm for locating analytes of interest based on mass spectral similarity in data collected using comprehensive two-dimensional gas chromatography coupled with time-offlight mass spectrometry. J Chromatogr A 1086, 185–192. Welthagen, W., Shellie, R., Spranger, J., Ristow, M., Zimmermann, R., Fiehn, O. (2005) Comprehensive two-dimensional gas chromatography–time-of-flight mass spectrometry (GC×GC–TOF) for high resolution metabolomics: biomarker discovery on spleen tissue extracts of obese NZO compared to lean C57BL/6 mice. Metabolomics 1, 65–73. Mohler, R. E., Dombek, K. M., Hoggard, J. C., Young, E. T., Synovec, R. E. (2006) Comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry analysis of metabolites in fermenting and respiring yeast cells. Anal Chem 78, 2700– 2709. Ralston-Hooper, K., Hopf, A., Oh, C., Zhang, X., Adamec, J., Sepúlveda, M. S. (2008) Development of GC×GC/TOF-MS metabolomics for use in ecotoxicological studies with invertebrates. Aquat Toxicol 88, 48–52. Oh, C., Huang, X., Regnier, F. E., Buck, C., Zhang, X. (2008) Comprehensive twodimensional gas chromatography/time-offlight mass spectrometry peak sorting algorithm. J Chromatogr A 1179, 205–215. Benjamini, Y., Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57, 289–300.
Chapter 13 LC-MS-Based Metabolomics Sunil Bajad and Vladimir Shulaev Abstract Metabolomics involves qualitative and/or quantitative analysis of hundreds of metabolites in a complex sample. As most of the metabolites are polar in nature (for example, amino acids, nucleotides, carboxylic acids), their chromatographic separation and analysis present a difficult challenge. Recently, hydrophilic interaction chromatography (HILIC) has become a useful tool for analysis of such polar molecules. In this chapter, we present a simple HILIC LC-MS/MS method for targeted multiple reaction monitoring (MRM)-based relative quantitation of hundreds of polar metabolites in a complex sample. The method uses an aminopropyl column with acetonitrile as weak solvent and 20 mM ammonium acetate buffer (pH 9.4) as strong solvent. The method does not use any ion pairing reagent making it suitable for analysis in both positive and negative ionization mode using a simple LC-MS/MS instrument setup. The method has been thoroughly tested, validated, and applied to a variety of samples such as bacteria, yeast, plants, human body fluids, and cell cultures. Key words: Metabolomics, metabolite profiling, LC-MS/MS, chromatography, MRM, HILIC.
1. Introduction Metabolomics aims at quantitative analysis and/or qualitative profiling of large numbers of cellular metabolites. It complements other “omics” disciplines, like proteomics and transcriptomics, to obtain a holistic view of the living systems. Liquid chromatography-mass spectrometry (LC-MS)based metabolomics experiments can be performed using targeted analysis, non-targeted profiling, or metabolic fingerprinting approaches (1, 2). While targeted analysis is based on measuring a set of known metabolites for which chemical structures are identified and authentic standards are available, non-targeted profiling aims at identification and quantitation of all peaks in T.O. Metz (ed.), Metabolic Profiling, Methods in Molecular Biology 708, DOI 10.1007/978-1-61737-985-7_13, © Springer Science+Business Media, LLC 2011
213
214
Bajad and Shulaev
the chromatogram even if the chemical structure of many compounds remains unknown. Similarly, the metabolic fingerprinting approach considers the whole metabolite profile as a fingerprint or pattern, which can be used for sample classification using one of the available multivariate statistical analysis or pattern recognition algorithms. Many cellular metabolites are highly polar in nature and their analysis using chromatography combined with mass spectrometry is a significant analytical challenge. To address this analytical challenge, hydrophilic interaction chromatography (HILIC) was proposed to separate and quantitate various classes of polar metabolites that are poorly retained on the reversed-phase chromatographic matrix (3, 4). HILIC can efficiently separate many classes of highly polar metabolites, including amino acids, nucleotides, nucleosides, nucleotide phosphates, carboxylic acids, and vitamins. The sensitivity and selectivity of the HILIC separation can be greatly enhanced by employing the multiple reaction monitoring (MRM) function of tandem quadrupole mass spectrometers (4, 5). We describe here a procedure for targeted MRM-based relative quantitation of hundreds of polar metabolites in a complex sample. The method uses an aminopropyl column with acetonitrile as weak solvent and 20 mM ammonium acetate buffer (pH 9.4) as strong solvent. The method does not use any ion pairing reagent making it suitable for analysis in both positive and negative ionization mode using a simple LC-MS/MS instrument setup. This method can be used to profile over a hundred cellular metabolites in a single chromatographic separation. The method has been thoroughly tested, validated, and applied to a variety of samples such as bacteria, yeast, plants, human body fluids, and cell cultures.
2. Materials 2.1. Sample Collection and Processing
1. Dry ice. 2. LC-MS-grade methanol. 3. LC-MS-grade water. 4. Benchtop refrigerated (–10◦ C minimum temperature) microcentrifuge (Beckman Coulter, Inc., Brea, CA). The rotor should accommodate up to 2.0 mL microcentrifuge tubes and have a maximum speed of 15,000×g. 5. Ultrasonic cleaner (Fisher Scientific, Pittsburg, PA). 6. Microcentrifuge tubes: 2.0 and 1.7 mL. 7. Plastic falcon tubes: 50 mL. 8. Plastic falcon tubes: 15 mL.
LC-MS-Based Metabolomics
215
9. Uniformly labeled (13 C, 15 N) internal standards: alanine, deoxyadenosine, glutamate, succinate, thymidine, threonine, UMP, AMP, ATP, and TTP (Medical Isotope Inc., Pelham, NH; Sigma, St. Louis, MO). 10. Methanol–water mixture, 50:50 v/v: In a clean glass container, mix 50 mL of LC-MS-grade water and 50 mL of LC-MS-grade methanol. Store at 4◦ C. 11. Quenching solvent: In a clean glass container, mix 40 mL of LC-MS-grade water and 60 mL of LC-MS-grade methanol. Prepare 5 aliquots of 20 mL each in 50 mL plastic tubes. Store at –80◦ C. 12. Extraction buffer: In a clean glass container, mix 20 mL of LC-MS-grade water and 80 mL of LC-MS-grade methanol. Prepare 5 aliquots of 20 mL each in 50 mL plastic tubes. Store at –4◦ C. 13. Internal standard stock solutions (2 mg/mL): Prepare 4 mg/mL solutions of individual internal standards in LC-MS-grade water. Dilute 1:1 with LC-MS-grade methanol. Store 100 μL aliquots at –80◦ C (during preparation, keep the solutions on ice at all times). 14. Internal standard mixture: In a 15 mL plastic tube, mix 0.5 mL each from the stock solutions of alanine, glutamate, threonine, AMP, and UMP and 1.5 mL each from the stock solutions of succinate, deoxyadenosine, thymidine, ATP, and TTP. Store 50 μL aliquots at –80◦ C (during preparation, keep the solutions on ice at all times). 15. Extraction buffer with internal standards (to be prepared on the day of sample processing): For each 1 mL of extraction solvent, add 10 μL of internal standard mixture to 990 μL of extraction solvent. This results in final internal standard concentrations of 1 μg/mL for alanine, glutamate, threonine, AMP, and UMP and 3 μg/mL for succinate, deoxyadenosine, thymidine, ATP, and TTP. 16. Quality control standard: Extraction solvent with internal standards can be used as a quality control sample. 2.2. Hydrophilic Interaction Chromatography (HILIC)
1. Ammonium acetate stock solution: Weigh 38.5 g of ammonium acetate and transfer it to a clean 500 mL cylinder. Make up the volume to 500 mL with LC-MS-grade water. This results in a 1 M ammonium acetate stock solution. Transfer the solution to a clean glass solvent bottle and store at 4◦ C. 2. Ammonium hydroxide stock solution: Add 92 mL of LCMS-grade water to a clean 250 mL glass solvent bottle. Add 100 mL of ammonium hydroxide (25% v/v, see Note 1 for additional information on ammonium hydroxide volume
216
Bajad and Shulaev
calculation) from the original bottle to the water and mix. This results in a 3.26 M ammonium hydroxide stock solution. Transfer the solution to a clean glass solvent bottle and store at 4◦ C. 3. LC-MS-grade acetonitrile. 4. LC-MS-grade water. 5. LC solvent A: In a clean 1 L solvent bottle, add 960 mL of LC-MS-grade water. With a glass pipette, add 20 mL of 1 M ammonium acetate solution and 20 mL of 3.26 M ammonium hydroxide solution and mix. With a glass pipette, remove 50 mL and transfer to a 50 mL falcon tube, then replace with 50 mL of acetonitrile. 6. LC solvent B: LC-MS-grade acetonitrile. 7. Luna NH2 aminopropyl column, 250 mm × 2.1 mm, 5 μm (Phenomenex, Torrance, CA). 8. Luna NH2 aminopropyl guard column, 4 mm × 2.1 mm (Phenomenex, Torrance, CA). 2.3. LC-MS/MS Instrumentation
1. Shimadzu LC10Avp (Shimadzu Scientific Instruments, Columbia, MD), High Performance Liquid Chromatography system equipped with an autosampler capable of operating at 4◦ C. 2. TSQ Quantum Ultra (Thermo Scientific, San Jose, CA) triple quadrupole mass spectrometer.
3. Methods 3.1. LC-MS/MS Analysis
1. Create a LC method with the following gradient: 0 min→ 95% B, 25 min→10% B, 30 min →10% B, 30.1 min → 95% B, 37 min → 95% B. Flow rate →0.3 mL/min. Column temperature→25◦ C (see Note 2). 2. Set the ESI voltage to 4000 V in positive ionization mode or –3500 V in negative ionization mode. 3. Set the sheath gas to 40 psi. 4. Set the auxiliary gas to 10 psi. 5. Set the collision gas to 1.5 mTorr (see Note 3). 6. If the triple quadrupole instrument to be used is a TSQ Quantum Ultra or advanced model from Thermo Scientific (Waltham, MA), then previously optimized MRMs (4) can be used (Table 13.1).
90
112 113 115 116
C3 H8 NO2 + C4 H5 O3 – C5 H14 NO+ C3 H5 O4 – C3 H8 NO3 + C4 H6 N3 O+
C4 H5 N2 O2 +
C4 H3 O4 –
C5 H10 NO2 + C4 H5 O4 – C4 H8 NO3 – C5 H12 NO2 + C4 H10 NO3 + C3 H8 NO2 S+ C6 H4 NO2 – C6 H7 N2 O+ C2 H6 NO3 S– C5 H7 N2 O2 + C5 H15 N4 + C4 H3 O5 – C4 H6 NO4 – C6 H14 NO2 +
Putrescine
Alanine
Uracil
Fumarate
Proline
(Iso)leucine
Aspartate
Oxaloacetate
Agmatine
Thymine
Taurine
Nicotinamide
Nicotinate
Cysteine
Homoserine
Valine
Threonine
Succinate
Cytosine
Serine
Glycerate
Choline
132
132
131
131
127
124
123
122
122
120
118
118
117
106
105
104
101
89
C4 H13 N2 +
Glycine
Acetoacetate
76
C2 H6 NO2 +
Metabolite
parent mass
12 C
Parent ion formulab
Table 13.1 MS/MS parametersa
138
136
135
136
132
126
129
128
125
124
123
122
121
121
119
117
116
109
108
109
105
93
93
78
parent mass
13 C
11
17
12
16
17
16
20
14
27
30
11
12
10
11
11
23
17
13
15
19
21
11
11
16
Collision energy (eV)
86
88
87
72
110
80
80
78
59
44
55
74
73
70
71
70
95
60
75
60
57
44
72
30
product mass
12 C
91
91
90
76
115
80
85
83
61
46
59
76
76
74
74
73
99
62
77
63
60
46
76
31
Product mass
13 C
C5 H12 N+
C3 H6 NO2 –
C 3 H3 O 3 –
C4 H10 N+
C5 H4 NO2 +
SO3 –
C 5 H6 N +
C 5 H4 N –
C 2 H3 S +
C 2 H6 N +
C 4 H7 +
C2 H4 NO2 –
C 3 H5 O 2 –
C 4 H8 N +
C 3 H3 O 2 –
C3 H4 NO+
C 4 H3 N 2 O +
C2 H6 NO+
C 2 H3 O 3 –
C3 H10 N+
C 3 H5 O –
C 2 H6 N +
C4 H10 N+
CH4 N+
Product ion formulac
LC-MS-Based Metabolomics 217
133 133
136 137 137 139 140
146 147 147
C 4 H5 O 5 –
C5 H13 N2 O2 + C 5 H6 N 5 + C4 H10 NO2 S+ C7 H6 NO2 –
C 5 H5 N 4 O +
C 7 H5 O 3 –
C 2 H4 O 5 P –
CH3 NO5 P– C6 H12 N3 O+ C 5 H5 O 5 – C7 H20 N3 +
C5 H11 N2 O3 +
C6 H15 N2 O2 + C5 H10 NO4 + C5 H12 NO2 S+ C 5 H6 N 5 O + C 7 H5 O 4 – C 5 H5 N 4 O 2 + C 5 H3 N 2 O 4 – C6 H10 N3 O2 + C 5 H5 N 2 O 4 – C 4 H7 N 4 O 3 +
Malate
Ornithine
Hypoxanthine
p-Hydroxybenzoate
Acetylphosphate
Carbamoyl-phosphate
Glutamine
Lysine
Allantoin
Dihydroorotate
Histidine
Orotate
Xanthine
2,3-Dihydroxybenzoate
Guanine
Methionine
Glutamate
Spermidine
α-Ketoglutarate
Histidinol
p-Aminobenzoate/ anthranilate
Homocysteine
159
157
156
155
153
153
152
150
148
145
142
136
136
133
C 4 H9 N 2 O 3 +
Asparagine
Adenine
12 C parent mass
Parent ion formulab
Metabolite
Table 13.1 (continued)
163
162
162
160
158
160
157
155
153
153
152
153
150
148
141
141
144
142
143
140
141
138
137
137
parent mass
13 C
11
12
12
13
16
17
18
10
15
15
15
13
11
18
22
22
21
19
16
10
24
12
12
17
Collision energy (eV)
99
113
110
111
110
109
110
133
84
84
84
112
101
95
79
79
93
110
92
90
119
70
115
74
product mass
12 C
102
117
115
115
114
115
114
138
88
89
88
119
105
100
79
79
99
114
98
93
124
74
119
76
Product mass
13 C
C3 H3 N2 O2 +
C4 H5 N2 O2 –
C5 H8 N3 +
C4 H3 N2 O2 –
C4 H4 N3 O+
C6 H5 O2 –
C4 H4 N3 O+
C5 H9 O2 S+
C4 H6 NO+
C5 H10 N+
C4 H6 NO+
C7 H14 N+
C4 H5 O3 –
C5 H7 N2 +
PO3 –
PO3 –
C6 H5 O–
C4 H4 N3 O+
C6 H6 N–
C3 H8 N5 +
C5 H3 N4 +
C4 H8 N+
C4 H3 O4 –
C2 H4 NO2 +
Product ion formulac
218 Bajad and Shulaev
163 166
169 170 171 173 173 173 174 175 175 175 179 179 180 182
C 9 H7 O 3 –
C9 H12 NO2 + C7 H4 NO4 – C 3 H4 O 6 P – C3 H6 O6 P–
C8 H12 NO3 +
C 3 H8 O 6 P –
C6 H13 N4 O2 –
C 7 H9 O 5 –
C 6 H5 O 6 –
C6 H12 N3 O3 –
C 4 H7 N 4 O 4 – C5 H7 N2 O5 –
C7 H15 N2 O3 +
C 9 H7 O 4 –
C6 H11 O6 –
C6 H14 NO5 +
C4 H8 NO5 S– C9 H12 NO3 + C 3 H6 O 7 P – C3 H9 NO6 P+ C 6 H7 O 7 –
Carnitine
Phenylpyruvate
Phenylalanine
Pyridoxine
Glycerol-3-phosphate
Arginine
Shikimate
Trans-aconitate
Citrulline
Allantoate
Carbamoyl-L -aspartate
N-α-acetylornithine
Hydroxyphenylpyruvate
Myo-inositol
Glucosamine
Homocysteic acid
Citrate
3-Phosphoserine
3-Phosphoglycerate
Tyrosine
Dihydroxy-acetonephosphate
Phosphoenolpyruvate
191
186
185
182
167
166
162
C7 H16 NO3 +
Metabolite
Quinolinate
parent mass
12 C
Parent ion formulab
Table 13.1 (continued)
197
189
188
191
186
186
185
188
182
180
179
180
179
180
179
174
178
172
170
173
175
172
169
parent mass
13 C
13
10
15
37
21
10
15
11
14
12
12
13
10
18
12
13
22
38
41
12
28
11
18
Collision energy (eV)
111
88
97
77
80
162
161
107
115
132
132
131
129
93
131
79
134
79
79
122
103
91
103
product mass
12 C
116
91
97
83
80
168
167
114
120
136
135
136
134
99
136
79
142
79
79
128
111
98
107
Product mass
13 C
C5 H3 O3 –
C3 H6 NO2 +
H2 PO4 –
C 6 H5 +
SO3 –
C6 H12 NO4 +
C6 H9 O5 –
C7 H7 O–
C5 H9 NO2 +
C4 H6 NO4 –
C3 H6 N3 O3 –
C5 H11 N2 O2 –
C5 H5 O4 –
C6 H5 O–
C5 H11 N2 O2 –
PO3 –
C8 H8 NO+
PO3 –
PO3 –
C6 H4 NO2 –
C 8 H7 +
C 7 H7 –
C4 H7 O3 +
Product ion formulac
LC-MS-Based Metabolomics 219
195 199 205
C6 H11 O7 –
C 4 H8 O 7 P –
C11 H13 N2 O2 + C 6 H9 O 8 – C5 H10 O7 P– C9 H16 NO5 – C7 H15 N2 O4 S+ C10 H9 O6 – C9 H13 N2 O5 + C5 H10 O8 P– C10 H13 N2 O5 – C9 H11 N2 O6 – C9 H14 N3 O5 + C10 H17 N2 O3 S+ C10 H14 N5 O3 + C10 H13 N4 O4 + C6 H12 O9 P– C6 H15 NO8 P+ C6 H15 NO8 P+ C12 H17 N4 OS+ C10 H14 N5 O4 + C10 H14 N5 O4 + C10 H13 N4 O5 +
2-Dehydro-D-gluconate
Gluconate
Erythrose-4-phosphate
Tryptophan
Inosine
Deoxyguanosine
Adenosine
Thiamine
Glucosamine-6-P
Glucosamine-1-P
D-hexose-phosphate
Deoxyinosine
Deoxyadenosine
Biotin
Cytidine
Uridine
Thymidine
D-rib(ul)ose-5-phosphate
Deoxyuridine
Prephenate
Cystathionine
Pantothenate
Deoxyribose-phosphate
269
268
268
265
260
260
259
253
252
245
244
243
241
229
229
225
223
218
213
209
193
C 6 H9 O 7 –
Metabolite
D-glucarate
parent mass
12 C
Parent ion formulab
Table 13.1 (continued)
279
278
278
277
266
266
265
263
262
255
253
252
251
234
238
235
230
227
218
215
216
203
201
199
parent mass
13 C
14
15
27
17
15
15
40
12
20
18
12
19
15
48
11
15
11
19
33
16
16
17
15
12
Collision energy (eV)
137
152
136
122
126
162
79
137
136
227
112
200
125
79
113
91
134
146
79
85
146
97
129
103
product mass
12 C
142
157
141
128
132
168
79
142
141
237
116
208
130
79
117
97
138
153
79
89
155
97
134
107
Product mass
13 C
C5 H5 N4 O+
C5 H6 N5 O+
C5 H6 N5 +
C6 H8 N3 +
C6 H8 NO2 +
C6 H12 NO4 +
PO3 –
C5 H5 N4 O+
C5 H6 N5 +
C10 H15 N2 O2 S+
C4 H6 N3 O+
C8 H10 NO5 –
C5 H5 N2 O2 –
PO3 –
C4 H5 N2 O2 +
C6 H3 O–
C4 H8 NO2 S+
C7 H16 NO2 –
PO3 –
C4 H5 O2 –
C9 H8 NO+
H2 PO4 –
C5 H5 O4 –
C4 H7 O3 –
Product ion formulac
220 Bajad and Shulaev
300 307 308
C9 H12 N2 O8 P–
C9 H15 N3 O7 P+ C10 H18 N3 O6 S+ C10 H19 O7 P2 – C10 H16 N2 O8 P+ C9 H15 N3 O8 P+ C9 H14 N2 O9 P+ C10 H11 N5 O6 P– C10 H15 N5 O6 P+ C6 H13 O12 P2 – C12 H21 O11 –
Guanosine
dUMP
dCMP
Riboflavin
Orotidine-phosphate
Xanthosine-5-phosphate
GMP
IMP
dGMP
AMP
Thiamine-phosphate
Trehalose
Fructose-1,6-bisphosphate
dAMP
cyclic-AMP
UMP
CMP
dTMP
Geranyl-PP
Reduced glutathione
N-acetyl-glucosamine-1phosphate
C12 H18 N4 O4 PS+ C10 H15 N5 O7 P+ C10 H15 N5 O7 P+ C10 H14 N4 O8 P+ C10 H15 N5 O8 P+ C10 H14 N4 O9 P+ C10 H12 N2 O11 P– C17 H21 N4 O6 +
284
C10 H14 N5 O5 + C10 H13 N4 O6 + C8 H15 NO9 P–
6-Phospho- D-gluconate
377
367
365
364
349
348
348
345
341
339
332
328
325
324
323
313
308
285
275
C6 H12 O10 P–
Metabolite
Xanthosine
parent mass
12 C
Parent ion formulab
Table 13.1 (continued)
394
377
375
374
359
358
358
357
353
345
342
338
334
333
333
323
318
317
316
308
295
294
281
parent mass
13 C
24
16
11
19
19
36
21
13
18
28
21
31
12
16
17
18
19
16
16
32
20
33
11
Collision energy (eV)
243
323
97
152
137
135
136
122
179
97
136
134
97
112
81
79
162
112
195
79
153
135
97
product mass
12 C
255
332
102
157
142
140
141
128
185
97
141
139
102
116
86
79
167
116
200
79
158
140
97
Product mass
13 C
C12 H12 N4 O2 +
C9 H12 N2 O9 P–
C5 H5 O2 +
C5 H6 N5 O+
C5 H5 N4 O+
C5 H3 N4 O+
C5 H6 N5 +
C6 H8 N3 +
C6 H11 O6 –
H2 PO4 –
C5 H6 N5 +
C5 H4 N5 –
C5 H5 O2 +
C4 H6 N3 O+
C5 H5 O+
PO3 –
C5 H8 NO3 S+
C4 H6 N3 O+
C5 H8 O6 P–
PO3 –
C5 H5 N4 O2 +
C5 H3 N4 O+
H2 PO4 –
Product ion formulac
LC-MS-Based Metabolomics 221
386
C9 H14 N3 O10 P2 – C5 H12 O14 P3 – C15 H23 N6 O5 S+
dCDP
dGTP
ATP
dATP
UTP
CTP
TTP
dUTP
dCTP
5-Methyl-THF
FMN
7,8-Dihydrofolate
GDP
Folate
IDP
dGDP
APS
ADP
UDP
CDP
dTDP
S-adenosyl-L-methionine
PRPP
C10 H15 N2 O11 P2 – C9 H14 N3 O11 P2 – C9 H13 N2 O12 P2 – C10 H14 N5 O10 P2 – C10 H13 N5 O10 PS– C10 H14 N5 O10 P2 – C10 H13 N4 O11 P2 – C19 H20 N7 O6 + C10 H14 N5 O11 P2 – C19 H22 N7 O6 + C17 H20 N4 O9 P– C20 H26 N7 O6 + C9 H15 N3 O13 P3 – C9 H14 N2 O14 P3 – C10 H16 N2 O14 P3 – C9 H15 N3 O14 P3 – C9 H14 N2 O15 P3 – C10 H15 N5 O12 P3 – C10 H15 N5 O13 P3 – C10 H15 N5 O13 P3 –
385
C14 H21 N6 O5 S+
S-adenosyl-L-homocysteine
506
506
490
483
482
481
467
466
460
455
444
442
442
427
426
426
426
403
402
401
399
389
381
C15 H27 O7 P2 –
trans, trans-farnesyl diphosphate
Metabolite
parent mass
12 C
Parent ion formulab
Table 13.1 (continued)
516
516
500
492
491
491
476
475
480
472
463
452
461
437
436
436
436
412
411
411
414
394
395
399
396
parent mass
13 C
28
21
27
33
32
31
25
28
19
19
30
19
16
14
25
20
24
15
29
29
13
18
25
19
21
Collision energy (eV)
159
408
159
159
159
159
159
159
313
213
178
159
295
159
159
346
134
305
159
159
250
291
159
136
79
product mass
12 C
159
418
159
159
159
159
159
159
328
218
185
159
309
159
159
356
139
314
159
159
260
296
159
141
79
Product mass
13 C
HO6 P2 –
C10 H12 N5 O9 P2 –
HO6 P2 –
HO6 P2 –
HO6 P2 –
HO6 P2 –
HO6 P2 –
HO6 P2 –
C15 H17 N6 O2 +
C5 H10 O7 P–
C7 H8 N5 O+
HO6 P2 –
C14 H11 N6 O2 +
HO6 P2 –
HO6 P2 –
C10 H13 N5 O7 P–
C5 H4 N5 –
C9 H10 N2 O8 P–
HO6 P2 –
HO6 P2 –
C10 H12 N5 O3 +
C5 H9 O10 P2 –
HO6 P2 –
C5 H6 N5 +
PO3 –
Product ion formulac
222 Bajad and Shulaev
522 565 579 602 606 613
C10 H15 N5 O14 P3 –
C15 H23 N2 O17 P2 –
C15 H21 N2 O18 P2 – C16 H24 N5 O15 P2 – C10 H16 N5 O17 P4 –
C17 H26 N3 O17 P2 –
C20 H33 N6 O12 S2 + C21 H26 N7 O14 P2 – C21 H28 N7 O14 P2 –
C21 H36 N7 O13 P2 S+ C21 H27 N7 O17 P3 – C21 H29 N7 O17 P3 – C21 H37 N7 O16 P3 S+ C27 H34 N9 O15 P2 + C23 H39 N7 O17 P3 S+ C24 H41 N7 O17 P3 S+ C25 H41 N7 O18 P3 S+ C24 H39 N7 O19 P3 S+ C25 H41 N7 O19 P3 S+ C27 H43 N7 O20 P3 S–
ITP
GTP
UDP-D-glucose
UDP-D-glucuronate
UDP-n-acetyl-D-glucosamine
Oxidized glutathione
Dephospho-CoA
910
868
854
852
824
810
786
768
744
742
688
664
662
937
893
878
877
848
833
813
789
765
763
709
685
683
633
623
612
604
594
580
532
517
parent mass
13 C
a Reproduced from Bajad et al. (4) with permission. Copyright Elsevier Science. b Charge on the ion indicates ionization mode used for the metabolite. c The chemical formulas for product ions have not been confirmed for all metabolites.
3-hydroxy-3-methylglutarylCoA
Succinyl-CoA
Malonyl-CoA
Acetoacetyl-CoA
Propionyl-CoA
Acetyl-CoA
FAD
CoA
NADPH
NADP+
NADH
NAD+
Guanosine 5 -diphosphate, 3 -diphosphate
588
507
C10 H14 N4 O14 P3 –
Metabolite
ADP-D-glucose
parent mass
12 C
Parent ion formulab
Table 13.1 (continued)
43
38
26
34
33
28
24
37
34
18
25
31
19
33
26
22
22
24
23
23
19
Collision energy (eV)
408
361
347
345
317
303
348
261
408
620
348
408
540
231
385
504
346
403
323
424
409
product mass
12 C
418
376
361
360
331
316
358
272
418
635
358
418
555
239
394
514
356
412
332
434
419
Product mass
13 C
C10 H12 N5 O9 P2 –
C15 H25 N2 O6 S+
C14 H23 N2 O6 S+
C15 H15 N2 O5 S+
C14 H25 N2 O4 S+
C13 H23 N2 O4 S+
C10 H15 N5 O7 P+
C11 H21 N2 O3 S+
C10 H12 N5 O9 P2 –
C15 H20 N5 O16 P3 –
C10 H15 N5 O7 P+
C10 H12 N5 O9 P2 –
C15 H20 N5 O13 P2 –
C8 H11 N2 O2 S2 +
C9 H11 N2 O11 P2 –
C10 H13 N5 O13 P3 –
C10 H13 N5 O7 P–
C9 H13 N2 O12 P2 –
C9 H12 N2 O9 P–
C10 H12 N5 O10 P2 –
C10 H11 N4 O10 P2 –
Product ion formulac
LC-MS-Based Metabolomics 223
224
Bajad and Shulaev
7. To add MRMs for additional metabolites, the auto MRM generation tool of Xcalibur software, common to Thermo Scientific Mass Spectrometers, can be used. (If the instrument is from another manufacturer, then optimization of MRMs is required, see Note 4.) 8. Run the representative sample or standard mixture of metabolites several times in positive and negative ionization mode with 60 MRMs in each run to obtain the retention times for the metabolites of interest. 9. Once the retention times are obtained, divide the run time into four to five time segments. In a time segment, insert the MRMs of the metabolites eluting in that particular time segment. Use 50–100 ms transition time/SRM and a scan width of 1 m/z (see Note 5). 10. Insert MRMs corresponding to the internal standards in the same time segments as the corresponding 12 C metabolites. Use alanine, glutamate, deoxyadenosine, UMP, and AMP in positive ionization mode and succinate, threonine, thymidine, ATP, and TTP in negative ionization mode. 3.2. Extraction of Metabolites
1. Centrifuge 50 mL of Escherichia coli culture (optical density A650 of ∼ 0.3) at 5000×g for 4 min. 2. Remove the supernatant and immediately add 300 μL of cold (–75◦ C) extraction buffer. 3. After mixing, keep on dry ice for 15 min. 4. Transfer to a 1.7 mL microcentrifuge tube and centrifuge at 14,000 ×g for 3 min at 4◦ C. 5. Collect supernatant in a fresh tube and then repeat extraction with 200 μL of ice cold methanol-water mixture, 50–50 v/v. 6. Perform a third round of extraction with water bath sonication for 15 min in ice-cold water. 7. Combine the extracts.
3.3. Sample Analysis
1. Label the LC vials and keep them on wet ice for at least 10 min. 2. Centrifuge the processed extracts at 10,000×g for 5 min at 4◦ C before transferring them to the LC vials to remove particulate matter. 3. Transfer the samples to LC vials, then place the vials in the LC autosampler set at 4◦ C (it is important to keep the samples at 4◦ C or below at all times before and during analysis as some sensitive metabolites such as NADH, NADPH, and ATP degrade over time). We have found that samples are stable for 24 h in an autosampler set at 4◦ C.
LC-MS-Based Metabolomics
225
4. Create a sample analysis sequence with the first run as a blank followed by a quality control standard followed by the experimental samples. It is important to run a blank sample before each sequence to obtain reproducible retention times. If the sequence is stopped in the middle of the sequence, then a blank injection is required to reequilibrate the column in order to obtain the same retention times as obtained before stopping the sequence. Else, the first sample will show very different chromatography. 5. Insert an appropriate number of blank samples in between the experimental samples to avoid carryover (a blank after every three samples is good practice even for very complex samples). The sequence should end with a quality control sample followed by a blank sample (see Note 6). A representative chromatogram is shown in Fig. 13.1. 3.4. Data Analysis
1. Using one representative data file, create a data processing method which includes assignment of name, expected retention time, internal standard, and peak integration parameters to each metabolite with the Xcalibur quantitative method. 2. The method should also include automated results output to Microsoft Excel for further data processing and graphing. 3. Using this method, process all the raw data in a batch mode. 4. This generates a report in Microsoft Excel with each metabolite as a row and metabolite peak area, internal standard peak area, metabolite/internal standard peak area ratio, and retention time as columns. 5. Further processing can be done in Microsoft Excel as required, for example, to calculate the relative ratios of metabolite peak areas in control and experimental samples, as well as the mean, standard deviation, relative standard deviation, etc. 6. Representative relative quantitation data obtained by analyzing stationary phase and exponential phase E. coli cultures is shown in Fig. 13.2.
4. Notes 1. The concentration of ammonium hydroxide (MW: 35 g; specific gravity: 0.9 g) in the bottle is 25% v/v. 2. The gradient can be changed appropriately if a column with different dimensions than indicated in this method is
Bajad and Shulaev
Adenosine
Lysine
4.0x105
2.0x105
Glutamate
Tryptophan
6.0x105
Succinyl-CoA
Glucosamine-6P
8.0x105
AMP
1.0x106
Glutamine
226
X 10
0.0
6.0x104
25
30
35
NAD
Trehalose
Hexose-phosphate
4.0x104
2.0x104
20
Citrate
Thymidine
8.0x104
15
Dihydroorotate
10
5
(a)
ATP
dGTP
0.0
(b)
5
10
15
20 25 Retention time (min)
30
35
Fig. 13.1. A representative chromatogram obtained by injecting metabolite standards in positive ionization mode (top panel ) and negative ionization mode (bottom panel). Reproduced from Bajad et al. (4) with permission. Copyright Elsevier Science.
used. For example, a 150 mm × 2.1 mm, 3 μm column can also be used with careful modification of the gradient. Lowering solvent B to 80% at the start of the gradient will result in faster elution of nucleotide phosphates, CoAs, and organic acids. However, nucleotide bases/nucleosides are not sufficiently retained and co-elute with lipids. So, a
LC-MS-Based Metabolomics
227
2
P-Value >0.01 1
0
−1
−2
−3
Histidine Phenylalanine cyclic-AMP Tryptophan (Iso)leucine Lysine S-adenosyl-L-methionine Tyrosine Methionine NAD+ TMP Phosphoenolpyruvate NADP+ Arginine ATP ADP Citrate dTDP Aspartate AMP TTP alpha-ketoglutarate FAD 3-Phosphoglycerate GMP CDP Threonine Oxidized Glutathione UMP CTP CMP Riboflavin Ornithine Glutamate D-rib(ul)ose-5-P UTP Acetyl-CoA Proline Valine Alanine Citrulline Glutamine Fumarate D-Hexose-P UDP-N-Acetyl-D-glucosamine UDP-D-glucose Malate Glucosamine-6-Phosphate 2,3-Dihydroxybenzoic Acid Succinate Fructose-1,6-bis-P IMP
Log10([Stationary culture signal]/[Exponential culture signal])
P-Value <0.01
Compounds
Fig. 13.2. Representative data obtained using the described LC-MS/MS method. The figure shows differences in the metabolome of stationary phase and exponentially growing Escherichia coli cells. Reproduced from Bajad et al. (4) with permission. Copyright Elsevier Science.
lower starting organic percentage should be used only if the focus of the analysis is quantitation of phosphorylated or acidic compounds. Methanol cannot be substituted for acetonitrile as it produces broad peak shapes. 3. These parameters are for the TSQ Quantum Ultra. For other instruments, source optimization is required which can be done by using a mixture of standard metabolites. 4. Purchasing all the metabolite standards and creating MRMs is costly and time consuming. Therefore, we suggest optimization of instrument specific parameters for published MRMs using an experimental sample. For example, on an ABI 4000 triple quadrupole or advanced model, the declustering potential can be simultaneously optimized for 100 s of MRMs by running samples at three different declustering potentials and choosing the value that gives the best signal.
228
Bajad and Shulaev
5. Without dividing the LC run time into time segments, only 60 metabolites can be monitored. Hence, the LC run time needs to be divided into time segments, each containing MRMs for the metabolites eluting in that time segment (4). The best approach is to run the representative sample several times with 60 MRMs in each run to obtain the retention times for the metabolites of interest. Once the retention times are obtained, it is easy to divide the run time into segments and insert the appropriate MRMs. 6. For a new analytical column, it is important to wash the column with 100% acetonitrile for 30 min to remove the shipping solvent (hexane). During this washing step, do not connect the column outlet to the MS inlet. After this step, condition the column in the starting solvent and then run two blank samples before starting the actual sample analysis. References 1. Halket, J. M., Waterman, D., Przyborowska, A. M., Patel, R. K., Fraser, P. D., Bramley, P. M. (2005) Chemical derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS. J Exp Bot 56, 219–243. 2. Shulaev, V. (2006) Metabolomics technology and bioinformatics. Brief Bioinform 7, 128–139. 3. Tolstikov, V. V., Fiehn, O. (2002) Analysis of highly polar compounds of plant origin: combination of hydrophilic interaction chro-
matography and electrospray ion trap mass spectrometry. Anal Biochem 301, 298–307. 4. Bajad, S. U., Lu, W., Kimball, E. H., Yuan, J., Peterson, C., Rabinowitz, J. D. (2006) Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. J Chromatogr A 1125, 76–88. 5. Bajad, S., Shulaev, V. (2007) Highly-parallel metabolomics approaches using LC-MS for pharmaceutical and environmental analysis. Trends Analyt. Chem 26, 625–636.
Chapter 14 Capillary Electrophoresis–Electrospray Ionization-Mas